



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup>:</b> <b>C07H 21/04, C07K 14/47, C12N 1/21,</b> <b>15/12, 15/64, C12P 21/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/35937</b> <b>(43) International Publication Date:</b> 22 June 2000 (22.06.00)
<b>(21) International Application Number:</b> PCT/US99/29950 <b>(22) International Filing Date:</b> 16 December 1999 (16.12.99)  <b>(30) Priority Data:</b> 60/112,809           17 December 1998 (17.12.98)   US 60/113,006           18 December 1998 (18.12.98)   US  <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Ter- race #316, Gaithersburg, MD 20878 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, Va 22020 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). DUAN, D., Roxanne [US/US]; 5515 North- field Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; 437 West Side Drive,		Apt. 102, Gaithersburg, MD 20878 (US). LAFLEUR, David, W. [US/US]; 3142 Quesada Street, NW, Wash- ington, DC 20015 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place, #24, Gaithersburg, MD 20878 (US). FLORENCE, Kimberly [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US).  <b>(74) Agents:</b> HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> 47 HUMAN SECRETED PROTEINS		
<b>(57) Abstract</b> <p>The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## 47 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and  
5 polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,

proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
5 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
10 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded  
15 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The  
20 invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**



The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as

disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain  
5 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the  
10 nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the  
15 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As  
20 shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

25 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to

sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x

- 5 Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

- Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily
- 10 accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M  $\text{NaH}_2\text{PO}_4$ ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml
- 15 salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

- Note that variations in the above conditions may be accomplished through the
- 20 inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,
- 25 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, **PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES**, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); **POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS**, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., *Meth Enzymol* 182:626-646 (1990); Rattan et al., *Ann NY Acad Sci* 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does  
5 exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to  
10 the polypeptide of the present invention.)

#### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

15 The translation product of this gene shares sequence homology with Maguin-1 and Maguin-2 (see GenBank Accessions: AAD04568 and AAD04567; all references available through this accession are hereby incorporated herein by reference; for example Yao, I., et al., J. Biol. Chem. 274:11889-96 (1999). Maguin-1 and -2 are proteins which interact with membrane-associated guanylate kinases  
20 (MAGUK's). MAGUK proteins constitute a relatively new family of proteins identified as structural components of epithelial tight junctions, neuromuscular junctions, neuronal synapses, and also as cell signaling proteins in multicellular organisms. The combined data from recent biochemical and genetic analyses of membrane-associated guanylate kinases suggest that certain tight junction proteins  
25 can play an important roles in cell signaling pathways. MAGUKs are also localized at the plasma membrane of other cell types, including erythrocytes, where they

contribute to cell shape maintenance. MAGUKs function mainly by binding directly to the cytoplasmic termini of transmembrane proteins as well as to other signal transduction proteins. They appear to hold together elements of individual signaling pathways, thereby contributing to the efficiency and specificity of signaling interactions while simultaneously maintaining the structural specializations of the plasma membrane. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Maguin-1 and Maguin-2 proteins. Such activities include, but are not limited to, establishing and maintaining cell structural integrity and participating in cell-signal transduction pathways. Other activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in colon cancer and to a lesser extent in embryonic tissues and testis. This gene has also been found to be expressed in both central and peripheral nervous system tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers of colon. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the colon and gastrointestinal track, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an

individual not having the disorder. The tissue distribution also indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 62 as residues: Pro-55 to Gly-66, Phe-92 to Leu-103. Polynucleotides encoding said polypeptides are also provided.



The tissue distribution diagnosis and treatment of colon cancers or cancers of Gastrointestinal system. In addition, the gene product can be used directly or as a therapeutic target for gastrointestinal ailments or diseases, including congenital disorders, infections, diverticular diseases, inflammatory bowel diseases, radiation enterocolitis, neoplasms, malabsorption, ulcers etc.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1752 of SEQ ID NO:11, b is an integer of 15 to 1766, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 2

Preferred polypeptides of the invention comprise the following amino acid sequence: AAPDGGTMSSSGGAPGASASSAPPAQEEG (SEQ ID NO: 113).

Polynucleotides encoding these polypeptides are also provided. The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 43 - 59 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 60 to 108 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in uterine cancer and neuroblastoma, and to a lesser extent in fetal brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, uterine cancer and neuroblastoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, neurological, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 63 as residues: Arg-87 to Leu-100. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in uterine cancer and neuroblastoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and/or treatment of uterine cancer and neuroblastoma, as well as cancers of other tissues where expression has been indicated. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the

"Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain degenerative disorders, such as spinal muscular atrophy (SMA). Alternatively, this gene product may be involved in the pattern of cellular proliferation that accompanies early embryogenesis. Thus, aberrant expression of this gene product in tissues - particularly adult tissues - may correlate with patterns of abnormal cellular proliferation, such as found in various cancers. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2653 of SEQ ID NO:12, b is an integer of 15 to 2667, where both a and b correspond to the positions of nucleotide  
10 residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

The translation product of this gene shares sequence homology with K-glypican/glypican-4 (GPC4), which is thought to be important in the control of cell  
15 division and growth regulation.

This gene is expressed primarily in macrophages and monocytes, and to a lesser extent in fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, Simpson-Golabi-Behmel Syndrome (SGBS), immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorder. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing  
25 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and

nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, nervous, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having  
5 such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 64 as residues: Lys-40 to Ala-47, Glu-70 to Tyr-75, Leu-77 to Phe-83, Arg-101 to Glu-107, Asn-115 to Leu-120, Lys-192 to Leu-197, Gln-234 to  
10 Val-244, Gln-280 to Phe-286. Polynucleotides encoding said polypeptides are also provided.

The glypican family of heparan sulfate proteoglycans comprises four vertebrate members, glypican, cerebroglycan, OCI-5, and K-glypican, and the *Drosophila* protein, daily. These molecules share highly conserved protein structural  
15 features that sharply distinguish them from the syndecans, the other major class of cell surface heparan sulfate proteoglycans. Typically, members of the glypican family are expressed in the developing nervous system, with one member (cerebroglycan) being restricted to that tissue. Although the functions of the vertebrate members of this family are not known, in *Drosophila*, the effects of mutations in the daily gene  
20 suggest a role for members of the glypican family in regulating cell cycle progression during the transition of neural cells from proliferation to neuronal differentiation. It is likely that proteoglycans of the glypican family also play other important roles in neural development. The OCI-5 gene is mutated in patients with the Simpson-Golabi-Behmel Syndrome (SGBS), an X-linked disorder characterized by pre- and postnatal  
25 overgrowth, and various visceral and skeletal dysmorphisms. Some of these dysmorphisms could be the result of deficient growth inhibition or apoptosis in

certain cell types during development. The homology of this gene to the glypican family and the tissue distribution of this gene would suggest an important role for the product of this gene in the immune system, particularly as a signalling or cell adhesion molecule -- involved in; cell migration; cell proliferation; angiogenesis; chondrogenesis; oncogenesis; haematostasis; wound healing; and/or organ regeneration. Other immunologically related conditions implicating this gene product might include: immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, inflammation, anemias (leukemia) and other hematopoietic disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2156 of SEQ ID NO:13, b is an integer of 15 to 2170, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

The translation product of this gene shares sequence homology with yeast longevity-assurance protein and human GDF-1 embryonic growth factor, which is thought to be important in rejuvenizing old cells and increasing the yeast cell life span. The translation product of this gene could function as a cell

growth/differentiation factor, and/or could function as an embryonic development factor, such as a TGF-beta family member in humans.

Preferred polypeptides of the invention comprise the following amino acid sequence:

- 5 RRRRNQDRPQLXKKFCEASWRFLFYLSFVGGLSVLYHESWLWAPVMCWD  
 RYPNQTLKPSLYWWYLLELGFYLSLLIRLPFDVKRKDFKEQVIHHFVAVILMT  
 FSYSANLLRIGSLVLLHDSDDLLEACKMVNYMQYQQVCDALFLIFSFFVFFY  
 TRLVLFPTQILYTTYYESISNRGPFFGYFFNGLL (SEQ ID NO: 114),  
 RRRRNQDRPQLXKKFCEASWRFLFYLSFVGGLSVLYHESWLWAPV (SEQ  
 10 ID NO: 115),  
 MCWDRYPNQTLKPSLYWWYLLELGFYLSLLIRLPFDVKRKDFKEQVIH (SEQ  
 ID NO: 116),  
 HFVAVILMTFSYSANLLRIGSLVLLHDSDDLLEACKMVNYMQYQQ (SEQ  
 ID NO: 117), and/or  
 15 VCDALFLIFSFFVFFYTRLVLFPTQILYTTYYESISNRGPFFGYFFNGLL (SEQ  
 ID NO: 118). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in human prostate cancer and breast tissue, and to a lesser extent in liver, heart, brain, adipose tissue, hepatoma and macrophages.

- Therefore, polynucleotides and polypeptides of the invention are useful as  
 20 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, cancer or neoplasia of various tissue origins. Similarly, polypeptides  
 and antibodies directed to these polypeptides are useful in providing immunological  
 probes for differential identification of the tissue(s) or cell type(s). For a number of  
 25 disorders of the above tissues or cells, particularly of the breast and prostate tissues,  
 expression of this gene at significantly higher or lower levels may be routinely

detected in certain tissues or cell types (e.g., breast, prostate, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 65 as residues: Lys-23 to Ile-31, Asp-34 to Glu-43. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast tissue and prostate cancer tissue, and homology to longevity assurance protein or GDF-1, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of tumors, espacially breast cancer and prostate cancer, as well as cancers of other tissues where expression has been indicated. The expression in the prostate tissue may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. Likewise, the expression in the breast tissue may indicate its uses in breast neoplasia and breast cancers, such as fibroadenoma, pipillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.



Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1176 of SEQ ID NO:14, b is an integer of 15 to 1190, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

The translation product of this gene shares sequence homology with sialyl transferase, which is thought to be important in post translational modification of proteins, for example, in modifying the surface and functional response of secreted and cell surface proteins.

Preferred polypeptides of the invention comprise the following amino acid sequence: KTYVLPSPGLSIRPPGREVPGSHPPAPALETAAAPRLLRDS (SEQ ID NO: 119) and

KTYVLPSPGLSIRPPGREVPGSHPPAPALETAAAPRLLRDS  
SMKAPGRLVLIIL  
CSVVFSAVYILLCCWAGLPLCLATCLDHHFPTGSRPTVPGPLHFSGYSSVPDG  
KPLVREPCRSCAVVSSSGQMLGSGLGAEIDSAECVFRMNQAPT  
VGFEADVGG  
RSTLRVVSHTSVPLLLRNYSHYFQKARDTLYMVWGQGRHMDRVLGGRTYR  
TLLQLTRMYPGLQVYTFTERMMA YCDQIFQDETGKNRRQSGSFLSTGWFTMI  
LALELCEEIVVYGMVSDXYCREKSHPSVPYHYFEKGRLDECQMYLAHEQAP  
RSAHRFITEKAVFSRWAKKRPIVFAHPSWRTE (SEQ ID NO: 120).

Polynucleotides encoding these polypeptides are also provided. Preferred polynucleotides of the invention comprise the following nucleic acid sequence:

ACATGGTGTGGGGCCAGGGCAGGCACATGGACCGGGTGCTCGGCGGCCG  
CACCTACCGCACGCTGCTGCAGCTCACCAGGATGTACCCCGGCCTGCAGG  
5 TGTACACCTTCACGGAGCGCATGATGGCCTACTGCGACCAGATCTTCCAG  
GACGAGACGGGCAAGAACCGGAGGCAGTCGGGCTCCTTCCTCAGCACCG  
GCTGGTTCACCATGATCCTCGCGCTGGAGCTGTGTGAGGAGATCGTGGTC  
TATGGGATGGTCAGCGACACTACTGCAGGGAGAAGAGCCACCCCTCAGTG  
CCTTACCACTACTTTGAGAAGGGCCGGCTAGATGAGTGTGAGATGTACCT  
10 GGCACACGAGCAGGCGCCCCGAAGCGCCACCGCTTCATCACTGAGAAG  
GCGGTCTTCTCCCGCTGGGCCAAGAAGAGGCCCATCGTGTTGCCCCATCC  
GTCCTGGAGGACTGAGTAGCTTCCGTCGTCCTGCCAGCCGCCATGCCGTTG  
CGAGGCCTCCGGGATGTCCCATCCCAAGCCATCACACTCCACAAAAACAT  
TTAATTTATGGTTCCTGCCCTCTGCCACGTGCTGGGTGGACCTAAGGTTCT  
15 TCCCACCCATTCTGGCGACACTTGGAGCCATCTCAGGCCCCTCCACTCCCT  
GAGTAATTCATGGCATTTGGGGGCTCACCCACCTCCAGGTCTGTCAAGT  
GGCCTTTGTCC  
CTGGGGCTGATGGCCCCCAACTCACCAGCATCATGACCTTGTGCCAGTCCT  
GGTCCTCCCTCCCCAGCCGCCCTACCACCTTTTGGTGCCACACTTCTCAG  
20 GCTGGCCGCCCTGGTTGGGGCAGCCGAGAGCCTGGGGTTCATTGGTGAAG  
GGGCCTTGGAGTTGTGACTGCCGGGGCCGTATCAGGAACGTACGGGTAAA  
CGTGTGTTTTCTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAA (SEQ ID NO:121 ). Polypeptides encoded by these polynucleotides are also  
provided.

The gene encoding the disclosed cDNA is thought to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in breast, brain and in fetal tissues including fetal lung, liver and spleen, 8 week embryos and 9 week embryos, and to a lesser extent in placenta, colon, a variety of blood cells and ovarian tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, developmental, and hematopoietic diseases and/or disorders, particularly hematologic malignancies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the blood and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., blood, immune, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 66 as residues: Pro-43 to Thr-49, Asn-135 to Asp-145, Gln-197 to Ser-207. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in blood and immune tissues and the homology to sialyl transferases indicates that polynucleotides and polypeptides corresponding to this

gene are useful for diagnosing and treating diseases of the blood, including abnormal proliferation of blood and immune system precursors. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

Also provided is a kit for detecting tumors in which expression of this protein occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1721 of SEQ ID NO:15, b is an integer of 15 to 1735, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 6

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

TRNKIWSSTRGGGRSRTSGSPGLQEFGTRSHLAAVHMAAWVFPLLSVIHTXL  
PQASPEIWVTQSEGGDQGVACEXVGGVLSTLDRIELCFLSDRASSGCXDKXP  
15 QTGVLFLGAGICHEGVGRAGSSRALSPGPAXAVFPSFPCAFPGPSCVCLCPRL  
SWXXYRSQGPWSYWIRATLMASCHCSYL (SEQ ID NO: 122). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly neurological and behavioral disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be

5 routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1260 of SEQ ID NO:16, b is an integer of 15 to 1274, where both a and b correspond to the positions of nucleotide

10 residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares sequence homology with the Diff-33 protein, which is thought to be important in spermatogenesis and overexpression in

15 tumors (see Genbank Accession No: gnl|PID|e1310269).

Preferred polypeptides of the invention comprise the following amino acid sequence:

FLGVLVSIIMLSPGVESQLYKLPWVCEEGAGIPTVLQGHIDCGSLLGYRAVYR  
(SEQ ID NO: 123),

20 PGAGRPKPGAAAMGACLGACSLSCASCLCGSAPCILCSCCPASRXSTVSRLLI  
FTFFLFLGVLVSIIMLSPGVESQLYKLPWVCEEGAGIPTVLQGHIDCGSLLGYR  
AVYRMCFATAAFFFFFTLLMLCVSSSRDPRAAIQNGFWFFKFLILVGXTVGAF  
YIPDGSFTNIWFYFGVVGSLFILIQLVLLIDFAHSWNQRWLKAEECDSRAW  
YAGLFFFTLLFYLLSIAAVALMFMYYTEPSGCHEGKVFISLNLTCVCVSIAA  
25 VLPKVQDAQPNSGLLQASVITLYTMFVTWSALSSIPEQKCNPHLPTQLGNETV  
VAGPEGYETQWWDAPSIVGLIIFLLCTLFISLRSSDHRQVNSLMQTEECPPML

DATQQQQQVAACEGRAFDNEQDGVTSYSFFHFCLVLASLHVMMTLTNW  
YKPGETRKMISTWTA VWVKICASWAGLLLYLWTLVAPLLLRNRDFS (SEQ  
ID NO: 125) and/or

PGAGRPKPGAAAMGACLGACSLSCASCLCGSAPCILCSCCPASRXSTVSRLI

- 5 FTFFL (SEQ ID NO: 124). Polynucleotides encoding these polypeptides are also provided. The polypeptide of this gene has been determined to have transmembrane domains at about amino acid positions 225-246, 64-80, 106-122, 141-157, 35-51, 335-351, and 292-308 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene
- 10 shares structural features to type IIIa membrane proteins. The translation product of this gene appears to be a novel 7TM G-coupled receptor.

This gene is expressed primarily in prostate, testicular tumors, cheek carcinoma and kidney cancer, tumors of various tissues and to a lesser extent in liver and breast.

- 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancers, breast cancers and cancers of various origins. Similarly, polypeptides and antibodies directed to these polypeptides are useful in
- 20 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate, kidney and breast tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., prostate, kidney, breast, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
- 25 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression



level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 68 as residues: Ser-21 to Arg-26. Polynucleotides encoding said polypeptides are also provided.

5           The tissue distribution in prostate tissue, and the homology to Diff-33, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of neoplasia or cancers of various origins, particularly prostate, kidney, cheek, testicles and breast cancers, as well as other tissues where expression has been observed. Additionally, the abundant expression level in the  
10   prostate tissue may be utilized for the treatment of other disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia; prostatic hyperplasia and prostate neoplastic disorders, adenocarcinoma, transitional cell carcinoma, ductal carcinoma, and squamous cell carcinoma. Furthermore, its potential involvement in spermatogenesis may be utilized  
15   for contraceptive development, or as a remedy for male infertility. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

          Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
20   related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
25   formula of a-b, where a is any integer between 1 to 1907 of SEQ ID NO:17, b is an

integer of 15 to 1921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

5 Preferred polypeptides of the invention comprise the following amino acid sequence: RCSSIFTPWKLTTLSSFLHHHPGAQRSKLLSIFSPSPRTLTLTYR (SEQ ID NO: 126). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by  
10 the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

RCSSIFTPWKLTTLSSFLHHHPGAQRSKLLSIFSPSPRTLTLTYRMGPSSCLLLILI  
PLLQLINLGSTQCSLDSVMDKKIKDVLNSLEYSPSPISKKLSCASVKSQGRPSS  
CPAGMAVT GCACGYGCGSWDVQLETTCHCQCSVVDWTTARCCHLT (SEQ

15 ID NO: 127). Polynucleotides encoding these polypeptides are also provided

This gene is expressed primarily in both normal and malignant colon tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
20 not limited to, gastrointestinal diseases and/or disorders, particularly colon cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal and immune systems, expression of this gene at significantly higher or  
25 lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, immune, cancerous and wounded tissues) or bodily fluids (e.g.,

lymph, serum, plasma, bile, chyme, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 69 as residues: Lys-59 to Ser-66. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in normal and cancerous colon tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of colon cancer, as well as cancer of other tissues where expression has been observed. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

Also provided is a kit for detecting tumors in which expression of this protein occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 678 of SEQ ID NO:18, b is an integer of 15 to 692, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

15 This gene is expressed primarily in activated T-cells

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 70 as residues: Gly-34 to Thr-48, Gln-58 to Glu-64, Arg-77 to Thr-92, Pro-132 to Ser-138, Glu-155 to Thr-165,  
5 Pro-172 to Lys-177. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating inflammatory conditions resulting from the activation of T-cells. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other  
10 processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including  
15 arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in T cells also  
20 strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1486 of SEQ ID NO:19, b is an integer of 15 to 1500, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The translation product of this gene was found to have homology to the conserved myeloid upregulated protein from *Mus musculus* (See Genbank Accession No. gnl|PID|e347937 (AJ001616)), which is thought to be important in the regulation of myeloid cells, particularly during progression through differentiation.

Preferred polypeptides of the invention comprise the following amino acid sequence: SVSTTRSFSVDSSAKTAAMPVTVTRTTTTTTTTSSSGLGSP (SEQ ID NO: 128), STCVAFSLVASVGAWTG (SEQ ID NO: 129), MFTWCFCF (SEQ ID NO: 130), ILIVEL (SEQ ID NO: 131), FPLSWRNFPIFACYAALFCLS (SEQ ID NO: 132), SIIYPTTYVQFL (SEQ ID NO: 133), RDHAIAAT (SEQ ID NO: 134), AYATEVAWTRARPGEITGYMATVPGLLKV (SEQ ID NO: 135), ETFVACIIFAFI (SEQ ID NO: 136), ALEWCVAVY (SEQ ID NO: 137), and/or CTNVLPIPPF (SEQ ID NO: 138). Polynucleotides encoding these polypeptides are also provided. The polypeptide of this gene has been determined to have seven transmembrane domains at about amino acid position 18 - 34, 51 - 67, 80 - 96, 114 - 130, 152 - 168, 184 - 200, and/or 217 - 233 of the amino acid sequence referenced in Table I for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins, or alternatively to G-protein coupled receptors.

The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in eosinophils, and to a lesser extent, in  
5 adipose, thymus, heart, cartilage and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders. Similarly, polypeptides and  
10 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, adipose, metabolic, cardiovascular,  
15 endothelial, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention  
20 comprise immunogenic epitopes shown in SEQ ID NO: 71 as residues: Arg-136 to Glu-141, Phe-240 to Gly-245. Polynucleotides encoding said polypeptides are also provided.

The expression of this gene in eosinophils, combined with the homology to the conserved myeloid upregulated protein indicates the protein or fragments thereof  
25 may play a potential role in the treatment/detection of immune disorders such as such as arthritis, asthma, immune deficiency diseases such as AIDS, and leukemia, in

addition to eosinophil specific disorders including eosinophilia, eosinopenia, and eosinophilic granuloma. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

10           The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein (i.e., inhibit the myeloid differentiation potential of the protein, inhibit a signalling pathway integral to myeloid differentiation, etc.). Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

20           Also provided is a kit for detecting tumors in which expression of this protein occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the



bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
5 that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
15 formula of a-b, where a is any integer between 1 to 2122 of SEQ ID NO:20, b is an integer of 15 to 2136, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

20 This gene is expressed primarily in colon, and to a lesser extent in Soares breast 3NbHBst, bone marrow, ulcerative colitis, breast lymph node, thymus, tonsils, Soares ovary tumor NbHOT, rectum, weizmann olfactory epithelium, Hodgkin's Lymphoma II, tongue tumour, adult small intestine, and tongue normal.

Therefore, polynucleotides and polypeptides of the invention are useful as  
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, colon cancer and ulcerative colitis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and tumor systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., colon, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 72 as residues: Leu-40 to Gly-47. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in colon and gastrointestinal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of colon cancer, as well as cancers of other tissues where expression has been indicated. Furthermore, the tissue distribution in gastrointestinal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sach's disease, phenylketonuria, galactosemia, porphyrias, and Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1533 of SEQ ID NO:21, b is an  
 5 integer of 15 to 1547, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The translation product of this gene shares sequence homology with  
 10 ribonuclease/angiogenin inhibitor [Homo sapiens].

Preferred polypeptides of the invention comprise the following amino acid sequence:

GLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPE  
 VVPVELLCMPSPASQGD LHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVH  
 15 FPVAGSYRWPNTGLCFVMREAVTVEIEFCVWDQFLGEINPQH SWMVAGPLL  
 DIKAEPGAVEAVHLP HFVALQGGHVDTS LFQVAHFKEEGMLLEKPARVELH  
 HIVLENPSFSPLGVLLKMIHNALRFIPVTSVLLYHRVHP EEVTFHLYLIPSDCS  
 IRKELELCYRSPGEDQLFSEFYVGH LGSGIRLQVKDKKDETLVWEALVKPGD  
 LMPATTLIPPARISVPSPLDAPQLLHFVDQYREQLIARVTSVEVVDK LHGQV  
 20 LSQEQYERVLAENTRPSQMRKLFSLSQSWDRKCKDGLYQALKETHPHSLWN  
 SGRRAAKRDSCHSAAEVSTLALDP (SEQ ID NO: 139),  
 GLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPE  
 VVPVELLCMP (SEQ ID NO: 140),  
 SPASQGD LHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVHFPVAGSYRWP  
 25 NTGLCFVMRE (SEQ ID NO: 141),  
 AVTVEIEFCVWDQFLGEINPQH SWMVAGPLL DIKAEPGAVEAVHLP HFVALQ

GGHVDTSLFQV (SEQ ID NO: 142),  
 AHFKEEGMLLEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPVTSVLL  
 YHRVHPPEEVTFH (SEQ ID NO: 143),  
 LYLIPSDCSIRKELELCYRSPGEDQLFSEFYVGHLGSGIRLQVKDKKDETLVW  
 5 EALVKPGDLMPA (SEQ ID NO: 144),  
 TTLIPPARISVPSPLDAPQLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQ  
 YERVLAENTRP (SEQ ID NO: 145), and/or  
 SQMRKLFSLSQSWDRKCKDGLYQALKETHPHSLWNSGRRAAKRDSCHSAAE  
 VSTLALDP (SEQ ID NO: 146). Polynucleotides encoding these polypeptides are  
 10 also provided.

This gene is expressed primarily in breast lymph node and to a lesser extent in eosinophils, tonsils, Soares\_NhHMPu\_S1, KMH2, and resting T-cell.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
 15 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and tumor systems, expression of this gene  
 20 at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., breast, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
 25 individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 73 as residues: Thr-49 to

Arg-54, Leu-147 to Asp-153. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast cancer tissue, and the homology to ribonuclease/angiogenin inhibitor [Homo sapiens], indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of breast cancer, as well as cancers of other tissues where expression has been indicated. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2643 of SEQ ID NO:22, b is an integer of 15 to 2657, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed primarily in LNCAP prostate cell line, and to a lesser extent in Soares fetal liver spleen 1NFLS.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostatic cancer. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive and tumor systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain

5 tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of prostatic cancer, as well as cancers in other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

20 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2452 of SEQ ID NO:23, b is an integer of 15 to 2466, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

This gene is expressed primarily in activated neutrophils, and healing groin wound.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 75 as residues: Ser-19 to Met-38, Lys-53 to Asp-60, Asn-66 to Arg-73. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune tissues and healing groin wounds indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of immune system disorders and wound healing disorders. Furthermore, the tissue distribution in healing groin wounds indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders involving the vasculature. Elevated expression of this gene product in healing groin wounds indicates that it may play vital roles in the regulation of endothelial cell function; secretion; proliferation; or angiogenesis.

Alternately, this may represent a gene product expressed at the healing groin wound which is then transported to distant sites of action on a variety of target organs. Expression of this gene product by hematopoietic cells also indicates involvement in the proliferation; survival; activation; or differentiation of all blood cell lineages. This

5 gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the

10 above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the

15 differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to

20 its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically



excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2481 of SEQ ID NO:24, b is an integer of 15 to 2495, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

When tested against U937 and K-562 cell lines, supernatants removed from cells containing this gene activated both the GAS (gamma activating sequence), as well as, the ISRE (interferon-sensitive responsive element ) promoter element. Thus, it is likely that this gene activates promyeloid or leukemic cells, or more generally, immune, hematopoietic, or other cells, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. ISRE is also a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

The translation product of this gene shares sequence homology with the rat SCAMP 37 and its human and mouse counterparts which are thought to be important

in Golgi/secretory granule formation and routing, particularly to the cell membrane  
(See Genbank Accession No. |S37395|S37395). In specific embodiments,  
polypeptides of the invention comprise the following amino acid sequences:

SEQLPTIAQIHPAEAMFL (SEQ ID NO: 147), YSSPACQHDQAPLLPLDVT

5 (SEQ ID NO: 148),

APHRSGAAHSSARCGLSAAERPRQFRTKRCGQATGPAGNIMAEKVNNFPPLP

KFIPLKPCFYQDFEADIPPQHVSMTKRLYYLWM (SEQ ID NO: 149),

GAAHSSARCGLSAAERPRQF (SEQ ID NO: 150),

ATGPAGNIMAEKVNNFPPLPKFI (SEQ ID NO: 151), and/or IPPQHVSMTKRLY

10 (SEQ ID NO: 152). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of  
the open reading frame upstream of the predicted signal peptide are contemplated by  
the present invention. Specifically, polypeptides of the invention comprise the  
following amino acid sequence: HHGRESEQLPTIAQIHPAEAMFLPRLRGRYSS

15 PACQHDQAPLLPLDVTSSFSFMAFFFTFMAQLVISIIQAVGIPGWGVCGWIA  
TISFFGTNIGSAVVMLI

PTVMFTVMAVFSFIALSMVHKFYRGSGGSFSKAQEEWTTGAWKNPHVQQA  
AQNAAMGAAQGAMNQPTQY SATPNYTYSNEM (SEQ ID NO: 153).

Polynucleotides encoding these polypeptides are also provided.

20 The gene encoding the disclosed cDNA is believed to reside on chromosome  
15. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 15.

This gene is expressed primarily in cerebellum, and to a lesser extent in the  
cortical regions of the brain, as well as, amygdala, retina and pituitary gland.

25 Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural disorders, particularly aberrant sensory, growth, and function disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the

5 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and neuroendocrine system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, secretory, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or

10 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 76 as residues: Ser-79 to Trp-85, Thr-87 to His-94, Asn-112 to Tyr-118. Polynucleotides encoding said

15 polypeptides are also provided.

The tissue distribution in various brain tissues, combined with the detected ISRE and GAS biological activities, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of brain defects and tumors, in addition to sensory, memory and cognitive conditions. Representative uses

20 are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflammatory conditions such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette

25 Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and

infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, disorders of the cardiovascular system, or disorders of the immune or hematopoietic systems, including growth or proliferative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3230 of SEQ ID NO:25, b is an integer of 15 to 3244, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The translation product of this gene was found to have homology to the glutathione peroxidase of *Schistosoma mansoni* (See Genbank Accession No. >gi|160998), which is thought to be involved in the regulation of vital cellular processes, particularly of metabolic origin.

5 Preferred polypeptides of the invention comprise the following amino acid sequence: ARESSN (SEQ ID NO: 154),  
RNCTKSLDHPTSACWLFPDNQFGESEPRPSKEVESFARKNYGVTFPIFHKIKIL  
GSEGEPAFRFLVDSSKKEPRWNFWKYLVNPEGQVVKFWRPEEPIEVIRPDIAA  
LVRQVIKKKEDL (SEQ ID NO: 155), ACWLFPDNQFGESEPRPSKEVESF (SEQ  
10 ID NO: 156), EGEPAFRFLVDSSKKEPRWNFW (SEQ ID NO: 157), and/or  
KFWRPEEPIEVIRPDIAALV (SEQ ID NO: 158). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in  
15 linkage analysis for chromosome 5.

This gene is expressed primarily in spinal cord, chondrosarcoma, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, or skeletal disorders, particularly osteoporosis and osteosarcoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
25 particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural,

skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
5 having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 77 as residues: Lys-10 to Arg-15. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution spinal cord, chondrosarcoma, and osteoblast tissue and cells indicates that polynucleotides and polypeptides corresponding to this gene are  
10 useful for diagnosis and treatment of skeletal disorders, such as osteoporosis and osteosarcoma. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "Infectious Disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Moreover, the expression of this gene product would suggest a role in the detection and treatment of disorders and  
15 conditions afflicting the skeletal system, in particular bone cancer or growth conditions, as well as, disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint  
20 abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to  
25 its use as a nutritional supplement. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1348 of SEQ ID NO:26, b is an integer of 15 to 1362, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

The translation product of this gene shares good sequence homology with oligodendrocyte-specific secreted protein 17 and with clostridial enterotoxin cell surface receptors which are thought to be important in clostridial attachment. The physiological roles or endogenous human ligands for these receptors are not known.

This gene is expressed primarily in testes tumor, fetal and infant lung and to a lesser extent in amygdala and some other organs and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, bacterial infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

tissues or cells, particularly of the pulmonary and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution and homology to CPE receptors indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of infectious diseases and immune defense disorders.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1367 of SEQ ID NO:27, b is an integer of 15 to 1381, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

This gene is expressed primarily in synovial sarcoma, hemangiopericytoma, and placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a



biological sample and for diagnosis of diseases and conditions which include, but are not limited to, synovial sarcoma, hemangiopericytoma, and placental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, immune, placental, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 79 as residues: Pro-27 to Ala-43, Pro-46 to Pro-55, Arg-63 to Gln-79, Glu-95 to Tyr-102, Thr-111 to Asn-124, Pro-141 to Asp-151, Pro-162 to Cys-168, Ala-206 to Ser-215. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in synovial sarcoma and hemangiopericytoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and/or treatment of synovial sarcomas and hemangiopericytomas. In addition, the expression of this gene product in synovium indicates a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal

dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is
- 10 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2513 of SEQ ID NO:28, b is an integer of 15 to 2527, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 19

Preferred polypeptides of the invention comprise the following amino acid sequence:

- VLNGKILVDISNNLKINQYPESNAEYLAHLVPGAHVVKAFNTISAWAL (SEQ
- 20 ID NO: 159),
- QSGALDASRQVFVCGNDSKAKQRVMDIVRNGLGLTPMDQGSLMAAKEI (SEQ ID NO: 160), VLNGKILVDISNNLKINQYPESNAEYLAHLVPGAHVVKAFNTISAWALQSGALDASRQVFVCGNDSKAKQRVMDIVRNGLGLTPMDQGSLMAAKEI
- 25 NRIFPITALTLLALVYSLVLLLPFYNCTEXTKYRRFPDWDHWMLCRKQLGL VALGFAFLXLXXLVIPIRYVVRXRLGNLTVTQXILKKENPFSTSSAWLSDSY

VALGILGFFLFVLLGITSLPSVSNVNWREFRVQSKLGYLTLILCTAHTLVYG  
 GKRFLSPSNLRWYLPAAAYVLGLIIPCTVLVIKFVLIMPCVDNTLTRIRAGKGT  
 QNTRKSIEWKINI (SEQ ID NO: \_ ) and/or

EKYPLQLFPMWRFPFYLSAVLCVFLFFYCVRDVIYPYVYEKKDNTFR (SEQ  
 5 ID NO: 161) or a fragment of one of the above-listed sequences. Polynucleotides  
 encoding these polypeptides are also provided.

This gene is expressed primarily in human placenta.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 10 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, developmental and endocrine disorders. Similarly, polypeptides and  
 antibodies directed to these polypeptides are useful in providing immunological  
 probes for differential identification of the tissue(s) or cell type(s). For a number of  
 disorders of the above tissues or cells, particularly of the endocrine system and  
 15 developing tissues expression of this gene at significantly higher or lower levels may  
 be routinely detected in certain tissues or cell types (e.g., endocrine, developing,  
 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,  
 synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
 individual having such a disorder, relative to the standard gene expression level, i.e.,  
 20 the expression level in healthy tissue or bodily fluid from an individual not having the  
 disorder.

The tissue distribution in placenta indicates that polynucleotides and  
 polypeptides corresponding to this gene are useful as a hormone, a growth factor, for  
 the induction of abortion or spontaneous abortions, for hyperplastic abnormalities, as  
 25 a factor(s) involved in circulation, in nutrient transport, as a preventative of multiple  
 gestation, to detect or treat gestational trophoblastic diseases, such as hydatidiform

mole, as well as to detect placental trophoblastic tumors and choriocarcinomas. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2067 of SEQ ID NO:29, b is an integer of 15 to 2081, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

The translation product of this gene shares sequence homology with human hepato-cellular carcinoma oncogene which may be used to produce recombinant oncoprotein and antibodies for screening and diagnosis of hepatic tumors.

- 5 Preferred polypeptides of the invention comprise the following amino acid sequence: KKTNKTCTYY (SEQ ID NO: 162). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in primary dendritic cells.

- Therefore, polynucleotides and polypeptides of the invention are useful as
- 10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, in addition to proliferative conditions, such as hepatic carcinoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential
- 15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine/ immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, bile, synovial
- 20 fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- The tissue distribution in primary dendritic cells, combined with the homology to human hepato-cellular carcinoma oncogene indicates that polynucleotides and
- 25 polypeptides corresponding to this gene are useful for diagnosis and treatment of hepatic carcinoma. Representative uses are described in the "Immune Activity" and

"Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin indicates the natural gene product may be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:30, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

Preferred polypeptides of the invention comprise the following amino acid sequence: RAPPSSVYQNQQARAQLXDFC (SEQ ID NO: 163). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is thought to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in fetal spleen and liver and to a lesser extent in a variety of other tissues of the immune system, such as neutrophils and monocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatoblastoma, leukemias, lymphomas, liver metabolic diseases and other conditions that are attributable to the differentiation of hepatocyte progenitor

cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and immune system, expression of this gene at significantly higher or lower

5 levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the

10 disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 82 as residues: Gln-73 to Ser-83, Pro-116 to Gln-122, Met-130 to Tyr-136, Phe-146 to Thr-153. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in liver indicates that polynucleotides and polypeptides

15 corresponding to this gene are useful for the detection and treatment of liver disorders and cancers, as well as other immune disorders and conditions (e.g. hepatoblastoma, jaundice, hepatitis, leukemias, lymphomas, AIDS, arthritis, asthma, liver metabolic diseases and other conditions that are attributable to the differentiation of hepatocyte progenitor cells). Furthermore, this gene product may be involved in the regulation of

20 cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as

25 an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease,



sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1790 of SEQ ID NO:31, b is an integer of 15 to 1804, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with LAK-4p, which is thought to be important in T-cell activation.

When tested against SK and Reh cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the

Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in ovarian cancer, and to a lesser extent in breast cancer and prostate tissue.

5           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer of the reproductive systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
10 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal  
15 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 83 as residues: Phe-4 to Ala-10, Gln-142 to Pro-150, Glu-156 to Glu-161,  
20 Leu-177 to Ala-190. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution and homology to LAK-4p indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of disorders of developing and growing systems, and cancers, including cancer of the reproductive system(s), as well as other tissues where  
25 expression has been indicated. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1447 of SEQ ID NO:32, b is an integer of 15 to 1461, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

The translation product of this gene shares distant homology to the mouse HC1 ORF (Genbank Accession No:g1333929).

Preferred polypeptides of the invention comprise the following amino acid sequence: TTCYLNTYMFNINTYIKFTCILNTYVKYIQCIYICTQY (SEQ ID NO: 164). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in activated neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
5 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 84 as residues: Thr-24 to Lys-29. Polynucleotides encoding said polypeptides are also provided.

10 The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the immune system. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Furthermore, this gene product may be involved in  
15 the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be  
20 also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell  
25 types. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1100 of SEQ ID NO:33, b is an integer of 15 to 1114, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

This gene is expressed primarily in breast cancer tissue, testes, and macrophages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and immune disorders, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,

breast milk, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in breast cancer tissue, as well as in testes, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of reproductive system cancers, as well as cancers of other tissues where expression has been observed. Furthermore, the tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are  
10   useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is  
15   believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone  
20   formation, and kidney function, to name a few possible target indications. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

          Also provided is a kit for detecting tumors in which expression of this protein  
25   occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of

detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2221 of SEQ ID NO:34, b is an integer of 15 to 2235, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

Preferred polypeptides of the invention comprise the following amino acid sequence: CRNSARAPIKNLNPLPTQKHCVFL (SEQ ID NO: 165). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in B-cell lymphoma, and to a lesser extent in human tonsils, fetal bone, and 8 week human embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly cancers of blood forming cells, particularly in B cell lymphomas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 86 as residues: Ile-69 to Pro-74. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lymphomas indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating B cell lymphomas or other disorders of blood forming cells. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.



Also provided is a kit for detecting tumors in which expression of this protein occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein.

Furthermore, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1839 of SEQ ID NO:35, b is an integer of 15 to 1853, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

Preferred polypeptides of the invention comprise the following amino acid sequence: TRPKKEAGRISTVELQK (SEQ ID NO: 166). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in retina and multiple sclerotic tissue.

- 5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular or visual disorders, particularly degenerative conditions, such as multiple sclerosis. Similarly, polypeptides and antibodies directed to these
- 10 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., muscle, visual, retinal, and cancerous and wounded tissues) or bodily
- 15 fluids (e.g., lymph, serum, plasma, urine, aqueous humor, vitreous humor, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes
- 20 shown in SEQ ID NO: 87 as residues: Leu-33 to Trp-38, Pro-64 to Lys-69. Polynucleotides encoding said polypeptides are also provided.

- The tissue distribution in multiple sclerotic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of degenerative muscle conditions, such as multiple sclerosis.
- 25 Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various muscle disorders, such as

active site domain containing proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with proteases. Such activities are known in the art, some of which are described elsewhere herein. The following publication was referenced above and is hereby  
5 incorporated herein by reference: Dufour E., Biochimie 70:1335-1342 (1988).

This gene is expressed primarily in fetal heart.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10 not limited to, developmental, cardiovascular, or growth disorders, particularly atherosclerosis or congestive heart failure. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory system, expression of this  
15 gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, cardiovascular, growth, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression  
20 level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 88 as residues: Leu-23 to Asp-34, Cys-97 to Pro-106, Ser-202 to Gly-208, Pro-251 to Gly-257. Polynucleotides encoding said polypeptides are also provided.

25 The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

atherosclerosis, and congestive heart failure. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Moreover, the expression within fetal tissue indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein may be useful in the treatment, detection, and/or prevention of a variety of vascular disorders, which include, but are not limited to microvascular disease, emboism, stroke, aneurysm, or vascular leak syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 971 of SEQ ID NO:37, b is an integer of 15 to 985, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

muscular dystrophy, cardiomyopathy, fibroids, myomas, and rhabdomyosarcomas. The protein would also be useful for the treatment, detection, and/or prevention of visual diseases and/or disorders, particularly macular degeneration. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or

5 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

10 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1451 of SEQ ID NO:36, b is an integer of 15 to 1465, where both a and b correspond to the positions of nucleotide

15 residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 27

Preferred polypeptides of the invention comprise the following amino acid sequence: HERRHEAAGPAAP (SEQ ID NO: 167),

20 MVPNQRPEPCALPHSSKLPKSKPPHDHTSCGHS LCPCAS RTEAPGRP WGLLCR  
LHLHGRTEHSVCVAGQGSDSAKAAAHPSVQGEWNPHAGHL PFLPDPSLPLH  
VLVLWPPAGTKPAPSTLQHPILLQRGQCLPRSSDLLVLSA VQEGSPAL (SEQ  
ID NO: 168), CALPHSSKLPKSKPPHDHTSC (SEQ ID NO: 169),  
EAPGRP WGLLCRLHLHGRTEHSVC (SEQ ID NO: 170),

25 QGSDSAKAAAHPSVQGEWNPHAGHL (SEQ ID NO: 171), and/or  
APSTLQHPILLQRGQCLPRSSDL (SEQ ID NO: 172). Polynucleotides encoding

these polypeptides are also provided. The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 119 - 135 and 182 - 198 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene  
5 shares structural features to type IIIa membrane proteins.

Included in this invention as preferred domains are eukaryotic thiol (cysteine) proteases histidine active site domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Eukaryotic thiol proteases (EC 3.4.22.-) [1] are a family of proteolytic enzymes which contain an active site cysteine.  
10 Catalysis proceeds through a thioester intermediate and is facilitated by a nearby histidine side chain; an asparagine completes the essential catalytic triad. The consensus pattern is as follows: Q-x(3)-[GE]-x-C-[YW]-x(2)-[STAGC]-[STAGCV], [C is the active site residue].

Preferred polypeptides of the invention comprise the following amino acid  
15 sequence: SVHAVLATGSG (SEQ ID NO: 173). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the eukaryotic thiol (cysteine) proteases histidine active site domain of the sequence referenced in Table I for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid  
20 residues of this referenced sequence. The additional contiguous amino acid residues may be N-terminal or C-terminal to the eukaryotic thiol (cysteine) proteases histidine active site domain. Alternatively, the additional contiguous amino acid residues may be both N-terminal and C-terminal to the eukaryotic thiol (cysteine) proteases histidine active site domain, wherein the total N- and C-terminal contiguous amino  
25 acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to eukaryotic thiol (cysteine) proteases histidine

This gene is expressed primarily in apoptotic and activated T cells, and to a lesser extent in bone marrow, tonsils, brain and retina.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory, immune and nervous system defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 89 as residues: Tyr-52 to Glu-62. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune tissues such as T-cells, bone marrow, etc., indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of neuroendocrine, infectious, and inflammatory and general immune disorders. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor

marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 705 of SEQ ID NO:38, b is an integer of 15 to 719, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

## **20 FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

This gene is expressed primarily in uterus and fetal liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, blood and urigenital conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

PZ035PCT



differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hemopoietic and urigenital systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., uterus, liver/spleen, cancerous and  
5 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal liver/spleen and uterus indicates that  
10 polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of immune, hemopoietic and urogenital disorders. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of  
15 lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and  
20 psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1255 of SEQ ID NO:39, b is an integer of 15 to 1269, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The translation product of this gene shares sequence homology with F20D12.3 gene product [*Caenorhabditis elegans*].

Preferred polypeptides of the invention comprise the following amino acid sequence:

- 15 TRPVSCLTAGVLNPELGYDALLVGTQTNLLAYDVYNNSDLFYREVADGANA  
 IVLGTLGDISSPLAIIGGNALQGHNHEGSDLFWTVTGDNVNSLALCDFDGDG  
 KKELLVGSEDFDIRVFKEDEIVAEMTETEIVTSLCPMYGSRFGYALSNGTVGV  
 YDKTSRYWRIKSKNHAMSIHVFDLNSDGVNELITGWSNGKVDARS DRTGEVI  
 FKDNFSSAIAGVVEGDYRMDGHIQLICCSVDGESKLG (SEQ ID NO: 174),  
 20 TRPVSCLTAGVLNPELGYDALLVGTQTNLLAYDVYNNSDLFYREVADGANA  
 I (SEQ ID NO: 175),  
 VLGTLGDISSPLAIIGGNALQGHNHEGSDLFWTVTGDNVNSLALCDFDGDG  
 K (SEQ ID NO: 176),  
 KELLVGSEDFDIRVFKEDEIVAEMTETEIVTSLCPMYGSRFGYALSNGTVGVY  
 25 D (SEQ ID NO: 177), KTSRYWRIKSKNHAMSIHVFDLNSDGVNELITGWSNG  
 (SEQ ID NO: 178), and/or

KVDARSDRTGEVIFKDNFSSAIAGVVEGDYRMDGHIQLICCSVDGESKLG

(SEQ ID NO: 179). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in Soares\_total\_fetus\_Nb2HF8\_9w, and to a lesser extent in Soares\_fetal\_lung\_NbHL19W and Soares infant brain 1NIB.

5           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
10 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., fetal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
15 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          The tissue distribution in fetal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of  
20 developmental disorders. Furthermore, expression within fetal tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, fetal development also involves decisions involving cell differentiation and/or apoptosis in pattern  
25 formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2514 of SEQ ID NO:40, b is an integer of 15 to 2528, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

Preferred polypeptides of the invention comprise the following amino acid sequence:  
HASGRGAGGGGGGGGRDPAGQVGTARSGCGRCRAGLGPPEPPASSPPSVGR  
MCAR (SEQ ID NO: 180). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in Soares adult brain N2b4HB55Y, and to a lesser extent in larynx tumor, Soares retina N2b5HR, and endometrial stromal cells-treated with estradiol.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies

directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain  
5 tissues or cell types (e.g., brain, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention  
10 comprise immunogenic epitopes shown in SEQ ID NO: 92 as residues: Thr-6 to Tyr-13, Leu-70 to Glu-75, Arg-106 to Pro-114, Lys-142 to Gly-151, Ser-217 to Gly-224, Pro-237 to Gln-244, Lys-308 to Thr-319, Thr-330 to Ser-336, Tyr-370 to Asp-380, Lys-414 to Arg-420, Glu-456 to Trp-461, Ala-477 to Arg-484. Polynucleotides encoding said polypeptides are also provided.

15 The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of neurodegenerative disorders and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning  
20 disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1678 of SEQ ID NO:41, b is an integer of 15 to 1692, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

This gene is expressed primarily in rejected kidney tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, kidney rejections, and renal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal system and organ rejection, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in rejected kidney tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of kidney rejections. Furthermore, the tissue distribution in kidney tissue indicates that this gene or gene product is useful in the treatment and/or detection of kidney diseases

5 including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed

10 against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of

15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1591 of SEQ ID NO:42, b is an

20 integer of 15 to 1605, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

The translation product of this gene has homology to the SIR2 protein of

25 *Candida albicans* (See Genbank Accession No.gi|3005095 (AF045774)), which is thought to be involved in silencing, cell cycle progression and chromosome stability.

Such proteins also are known to metabolize NAD and may have protein ADP-Ribosyltransferase activity. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with SIR2 and SIR2-like proteins. Such activities are known in the art, some of which are described elsewhere herein. The protein of the present invention was recently published by another group confirming the homology to the SIR2 protein family and activities specific to SIR2 proteins (Biochem. Biophys. Res. Commun. 260 (1), 273-279 (1999); which is hereby incorporated herein by reference).

Preferred polypeptides of the invention comprise the following amino acid sequence:

TTSPSWATSLLRGCQAKGPTKSRLMSSRGTELRTASVKLAGSTSREVPRMS  
SRSAMGKSTTCSKNLWGSGSQRTQCRASQRRCPGSGEPCLPSRQPECPLG  
RVFGRLCRWQRQRFHELQPALRQGCPTLKFKPKRSVAAASEMSTQGQEHNF  
WAWQDSSLKPIDVLRVEPQKQPLVMKQPEKVVS DVGLVVSRVQLLGQSEKG  
LGVVKEEWEFKNGLGVREIVLLEVAVQATPRRSEVWNATGCADAGPHHDH  
HPLAGSGPNQLSYILQGKLPLVTAASTSNNT (SEQ ID NO: 181),  
LLRGCQAKGPTKSRLMSSRGTELRTA (SEQ ID NO: 182),  
MGKSTTCSKNLWGSGSQRTQCRA (SEQ ID NO: 183),  
GSGEPCLPSRQPECPLGRVFGRLCR (SEQ ID NO: 184),  
PTLKFKPKRSVAAASEMSTQGQEH (SEQ ID NO: 185),  
WQDSSLKPIDVLRVEPQKQPLVMKQP (SEQ ID NO: 186),  
VAVQATPRRSEVWNATGCADAGP (SEQ ID NO: 187),  
DWLLSVSFAAVFFSVSIKGGRRSISFSVGASSVVGSGGSSDKGKLSLQDVAELI  
RARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFF  
HNP KPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERGVL  
PSPEVVLLALRAHLGGGSNTSLWLEFQCRASLPQSWLKLMEPLPLPPAQSAK



- DPSQGR T FGLT ( SEQ ID NO: 188), GGRRSISFSVGASSVVGSGGSS (SEQ ID NO: 189), KLSLQDVAELIRARACQRVVVMV (SEQ ID NO: 190), YSNLQQYDLPYPEAIFELPFFFH (SEQ ID NO: 191), LYPGNYKPNVTHYFLRLLHDKGLL (SEQ ID NO: 192),
- 5 LPSPEVVLLALRAHLGGGSNTSLWLEF (SEQ ID NO: 193), RDGRQGSPLPGLHRRCEARHCVLWEPLPQRFLHVVDFPMADLLLILGTSLE VEPFASL TEAVRSSVPRLINRDLVGPLAWHPRS RDVAQLGDVVHGVESLVE LLGWTEEMRDLVQRETGKLDGPKD (SEQ ID NO: 194), LPGLHRRCEARHCVLWEPLPQRFL (SEQ ID NO: 195),
- 10 VVDFPMADLLLILGTSLEVEPFASL (SEQ ID NO: 196), LVGPLAWHPRS RDVAQLGDVVH (SEQ ID NO: 197), VESLVELL GWTEEMRDLVQRETG (SEQ ID NO: 198), ISVSGIPASKLVEAHGTFASATCTVCQRPFGED IRADV MADRVPRCPVCTGVVKPDIVFFGSRCPRGSCCMWLISPWQICSSLGP
- 15 PWRWSLLPA (SEQ ID NO: 199), EAHGTFASATCTVCQRPFGEDIRADV MADRV (SEQ ID NO: 200), and/or FFGSRCPRGSCCMWLISPWQICSSLG (SEQ ID NO: 201). Polynucleotides encoding these polypeptides are also provided.

- The gene encoding the disclosed cDNA is believed to reside on chromosome
- 20 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

This gene is expressed primarily in retina, and to a lesser extent, in the developing embryo, in fetal liver-spleen and brain.

- Therefore, polynucleotides and polypeptides of the invention are useful as
- 25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, vision, developmental, immune and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune,

5 developmental, and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., vision, developmental, immune, neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, vitreous humor, aqueous humor, synovial fluid and spinal fluid) or another tissue or cell sample taken from an

10 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 94 as residues: Gln-95 to Phe-103. Polynucleotides encoding said polypeptides are also provided.

15       The tissue distribution of this gene in retina, the developing embryo, in fetal liver-spleen, and in brain tissue indicates a role in the treatment and/or detection of vision defects including blindness, hyperopia, myopia, retinal detachment, retinitis pigmentosa, retinoblastoma and retinopathy; in the treatment/detection of immune disorders including such as arthritis, asthma, immune deficiency diseases such as

20 AIDS, and leukemia; in addition to behavioral and nervous disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of

25 cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions

involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2446 of SEQ ID NO:43, b is an integer of 15 to 2460, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

The translation product of this gene shares sequence homology with glycosyl transferases, which are enzymes important for post-translational protein glycosylation, as well as sugar and nucleotide metabolism.

This gene is expressed primarily in colon cancer, macrophages and dendritic cells and to a lesser extent in various other transformed cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and inflammatory conditions and tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the gastrointestinal and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 95 as residues: Pro-4 to Trp-12. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in colon cancer indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of gastrointestinal and immune disorders and neoplasms. Furthermore, the tissue distribution in gastrointestinal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sach's Disease, phenylketonuria, galactosemia, porphyrias, and Hurler's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 1503 of SEQ ID NO:44, b is an integer of 15 to 1517, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

10 This gene is expressed primarily in stromal-osteoclastoma, and to a lesser extent in Osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, osteoarthritis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell  
20 types (e.g., skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention  
25 comprise immunogenic epitopes shown in SEQ ID NO: 96 as residues: Pro-17 to His-22, Ser-29 to Ser-39. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in osteoclasts and osteoblasts indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of osteoarthritis and related skeletal disorders. Furthermore, elevated levels of expression of this gene product in osteoclastoma and osteoblastoma

5 indicates that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3066 of SEQ ID NO:45, b is an integer of 15 to 3080, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

## 20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

Preferred polypeptides of the invention comprise the following amino acid sequence:

TRPLSPTFSKLWAAGVTVCTDFSMCVCGCMYECVCFVCLCIYRGM RVPWV  
CTLDIPLYILCVLTWTHSVYLYCVYTHVQPICPYIGVCVYYVCTLSTYGCVCV  
25 PLSPYLGERENVCVCVSMYGCVDILCLYLECRYMDVHVLVCVVRTHLPLC

VCACVYLCPCIGGVCTLLVYVWGSTCSL (SEQ ID NO: 202). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed in rejected kidney, bone marrow, osteoarthritis, and cells of the immune system.

5           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly osteoarthritis and lymphoma. Similarly, polypeptides and antibodies directed to these

10 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., skeletal, immune, cancerous and wounded tissues) or bodily

15 fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 97 as residues: Ile-

20 44 to Glu-50. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in rejected kidney and immune system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of dysfunctions of the immune system, as well as organ rejection(s). Furthermore, the expression observed predominantly in hematopoietic

25 cells also indicates that the polynucleotides or polypeptides are important in treating and/or detecting hematopoietic disorders, such as graft versus host reaction, graft

versus host disease, transplant rejection, myelogenous leukemia, bone marrow fibrosis, and myeloproliferative disease. The polypeptides or polynucleotides are also useful to enhance or protect proliferation, differentiation, and functional activation of hematopoietic progenitor cells (e.g., bone marrow cells), useful in treating cancer patients undergoing chemotherapy or patients undergoing bone marrow transplantation. The polypeptides or polynucleotides are also useful to increase the proliferation of peripheral blood leukocytes, which can be used in the combat of a range of hematopoietic disorders, including immunodeficiency diseases, leukemia, and septicemia. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2190 of SEQ ID NO:46, b is an integer of 15 to 2204, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

This gene is expressed in tonsils, adipocytes, neutrophils, monocytes, and brain.



Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, central nervous system and immune system disorders, cancer.

- 5 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,
- 10 central nervous system, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention
- 15 comprise immunogenic epitopes shown in SEQ ID NO: 98 as residues: Thr-19 to Thr-25. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in central nervous system and immune system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of neurodegenerative and immune system disorders as

20 well as cancers of these tissues, in addition to cancers of other tissues where expression has been observed. Furthermore, the tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette

25 Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors,

including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Additionally, the tissue distribution in immune tissues indicates that

5 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of

10 cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as

15 an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as,

20 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of

25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1984 of SEQ ID NO:47, b is an integer of 15 to 1998, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 38**

The gene encoding the disclosed cDNA is thought to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in  
10 linkage analysis for chromosome 19.

This gene is expressed primarily in tissues and cells of endothelial origin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, cardiovascular/pulmonary disorders, such as atherosclerosis, restenosis, thrombosis, cystic fibrosis pulmonary fibrosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this  
20 gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., vascular, endothelial, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or  
25 bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 99 as

residues: His-34 to Leu-42, Arg-52 to His-57, Gln-74 to Leu-79, Gly-91 to Gly-97.

Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cardiovascular diseases such as heart disease, and respiratory or pulmonary disorders such as  
5 athesma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stroke, angina, thrombosis hypertension, inflammation and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
15 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2055 of SEQ ID NO:48, b is an integer of 15 to 2069, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

Preferred polypeptides of the invention comprise the following amino acid sequence:

ASLIFSSPLSPLLTSPSSSICSVRPLGIVMITCFHSRCHLKQRPASPNGVFQQRA

25 (SEQ ID NO: 203),

AHLSPTAALHVAQGESLSTDVECRVPGLMLTLLAVHQQILVG (SEQ ID NO:

204), LPVQVGWSLCNTDGPKLLCGRQGLMLLTGHHHCQASKHKSQGL (SEQ ID NO: 205), and/or

ASLIFSSPLSPLLTSPSSSICSVRPLGIVMITCFHSRCHLKQRPASPNGVFQQRAA  
HLSPTAALHVAQGESLSTDVECRVPGLMLTLLAVHQQILVGLPVQVGWSLC

5 NTDGPKLLCGRQGLMLLTGHHHCQASKHKSQGL (SEQ ID NO: 206).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample  
20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 100 as residues: Thr-49 to Asn-55, Cys-86 to His-107. Polynucleotides encoding said polypeptides are also  
25 provided.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 910 of SEQ ID NO:49, b is an integer of 15 to 924, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed primarily in fetal spleen and liver, and to a lesser extent in T-cells and primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hepatoblastoma, leukemias, lymphomas, liver metabolic diseases and other conditions that are attributable to the differentiation of hepatocyte progenitor cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., liver, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 101 as residues: Lys-34 to Glu-39, Ile-47 to Ser-53, Pro-106 to Leu-111, Pro-140 to Gly-146, Glu-195 to Gly-204, Leu-281 to Thr-288, Glu-291 to Arg-297, Tyr-302 to Ile-308. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers, as well as other immune disorders and conditions (e.g. hepatoblastoma, jaundice, hepatitis, leukemias, lymphomas, AIDS, arthritis, asthma, liver metabolic diseases and other conditions that are attributable to the differentiation of hepatocyte progenitor cells).

Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. This is particularly supported by the expression of this gene product in fetal liver, which is a primary site of definitive hematopoiesis. Expression of this gene product in T cells and primary dendritic cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2506 of SEQ ID NO:50, b is an integer of 15 to 2520, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.



**FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

This gene is expressed primarily in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as

5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

10 tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

15 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 102 as residues: Gly-31 to Thr-51. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in T-cells indicates that polynucleotides and

20 polypeptides corresponding to this gene are useful for the detection and/or treatment of immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as,

25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as

an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3323 of SEQ ID NO:51, b is an integer of 15 to 3337, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 42

In specific embodiments, polypeptides of the invention comprise the following amino acid sequence

VEAEWLQDVGLSTLISGDEEEDGKALLSTLRTQAAAVQKRYHTYTQTMRK  
KDKQSIRDVRDIFGVSESPPRDTCGNHTNQLDGTKEERELPRVIKTSGSMPDD  
ASLNSTTSLSDASQDKEGSFAVPRSDSVAILETIPVLPVHSNGSPEPGQPVQNAI  
SDDDFLEKNIXPEAEELSFEVSYSEMVTEALKRNKCLKKSEIKKEDYVLTKFNX  
QKTRFGLT (SEQ ID NO: 207),

VEAEWLQDVGLSTLISGDEEEDGKALLSTLTRTQAAAVQKRYHTYTQTMR  
(SEQ ID NO: 208),

KKDKQSIRDVRDIFGVSESPPRDTCGNHTNQLDGTKEERELPRVIKTSGSMPD  
D (SEQ ID NO: 209),

5 ASLNSTTLSDASQDKEGSFAVPRSDSVAILETIPVLPVHSNGSPEPGQPQVQN  
(SEQ ID NO: 210), and/or

AISDDDFLEKNIXPEAEELSFEVSYSSEMVTEALKRNKLKKSEIKKEDYVLTKF  
NXQKTRFGLT (SEQ ID NO: 211). Polynucleotides encoding these polypeptides are  
also provided.

10 This gene is expressed with a limited tissue distribution; primarily in testes,  
and to a lesser extent in embryo and adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, disorders of the reproductive systems and developing systems.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
developing and reproductive systems, expression of this gene at significantly higher  
20 or lower levels may be routinely detected in certain tissues or cell types (e.g., testes,  
reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
from an individual having such a disorder, relative to the standard gene expression  
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
25 having the disorder. Preferred polypeptides of the present invention comprise

immunogenic epitopes shown in SEQ ID NO: 103 as residues: Pro-27 to Ser-37, Ser-94 to Arg-99. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in testes and embryonic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

5 diagnosis and treatment of disorders of the reproductive and developing systems. Furthermore, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male

10 infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body.

15 Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Many polynucleotide sequences, such as EST sequences, are publicly

20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

25 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:52, b is an

integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

5 Preferred polypeptides of the invention comprise the following amino acid sequence: LAQTVTDMPLTGTNHDRQGHLRLSGTTYLLA (SEQ ID NO: 212). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in white blood cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic disorders, particularly T-cell and B-cell leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the  
15 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample  
20 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in white blood cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of T-  
25 cell and B-cell leukemia. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system

disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of hematopoietic cell

5 lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an

10 agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host

15 diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of

20 various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 720 of SEQ ID NO:53, b is an integer of 15 to 734, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### 10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

The translation product of this gene shares sequence homology with human atrial natriuretic peptide factor (ANF) gene which is thought to be important in diagnosis of a form of hereditary hypertension.

Preferred polypeptides of the invention comprise the following amino acid  
15 sequence: LSFLELDSECS (SEQ ID NO: 213). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in CD43 positive white blood cells, and to a lesser extent in endothelial cells, colon, and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as  
20 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, or vascular disorders, particularly hypertension. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the  
25 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or

lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, vascular, gastrointestinal, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells, combined with the homology to the human atrial natriuretic peptide factor (ANF) gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis of hypertension. Moreover, the protein is useful for the detection, treatment, and/or prevention of a variety of vascular disorders, which include, but are not limited to the following, microvascular disease, atherosclerosis, stroke, aneurysm, or embolism, in addition to cardiovascular disorders. Based upon the tissue distribution of this protein, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

Also provided is a kit for detecting tumors in which expression of this protein occurs. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, to raise



antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is
- 10           cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1168 of SEQ ID NO:54, b is an integer of 15 to 1182, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

This gene is expressed primarily in induced neutrophils.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
- 20           biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system disorders, cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression
- 25           of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids

(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune system disorders and cancers of the immune system, as well as cancers of other tissues where expression has been observed. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or  
10 other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including  
15 arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also  
20 strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

          Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
25 related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1852 of SEQ ID NO:55, b is an  
 5 integer of 15 to 1866, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 46

The translation product of this gene shares sequence homology with the  
 10 hippocampal cholinergic neurotrophic peptide (HCNP), in addition to the phosphatidylethanolamine binding protein (See Genbank Accession No. gi|406292) which are thought to be important in normal neurological functions of the hippocampus. Members of this family of proteins are thought to play integral roles in signalling, sensory perception, and may be associated with the modulation/detection  
 15 of pain or similar stimuli.

Preferred polypeptides of the invention comprise the following amino acid sequence:

WWSLETRMRTARVPMRPSWTRTPSFARALKFSTQSWGTLAARLFLIVTTTDR  
 RSPPGWKPIVKFPGAVDGATYNPGDGGSRCP (SEQ ID NO: 214),  
 20 MRTARVPMRPSWTRTPSFAR (SEQ ID NO: 215),  
 PGWKPIVKFPGAVDGATYNPG (SEQ ID NO: 216),  
 SSSRGPWTAQPIILVMVDPDAPSRAEPRQRFWRHWLVTDIKGADLKKGKIQQ  
 QELSA YQAPSPPAHSGFHR YQFFVYLQEGKVISLLPKENKTRGSWKMDRFLN  
 RFHLGEPEASTQFMTQNYQDSPTLQAPRERASEPKHKNQAEIAAC (SEQ ID  
 25 NO: 217), PIILVMVDPDAPSRAEPRQRFWRH (SEQ ID NO: 218),  
 KIQGQELSA YQAPSPPAHSGFHR (SEQ ID NO: 219),

ISLLPKENKTRGSWKMDRFL (SEQ ID NO: 220), PEVPMGWT (SEQ ID NO: 222), and/or QELSAYQAPSPPAHSGF (SEQ ID NO: 221). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptides of the invention comprise the following amino acid  
5 sequence:

MRLVTAALLLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFY  
PELGNIGCKVVPDCNNYRQKITSWMEADSQVPGGRGRRNL (SEQ ID NO:  
223). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in parathyroid tumor, prostate, and brain.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, endocrine, or reproductive disorders, particularly neurodegenerative disorders and dementia eg. Alzheimer's and Parkinson's disease.

15 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, endocrine,  
20 reproductive, prostatic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present  
25 invention comprise immunogenic epitopes shown in SEQ ID NO: 107 as residues:

Asp-23 to Cys-30, Asp-63 to Ile-71, Pro-97 to Trp-110. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and parathyroid, combined with the homology to the hippocampal cholinergic neurotrophic peptide, HCNP; indicates that

5 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of neurodegenerative disorders and dementia; e.g., Alzheimer's and Parkinson's disease. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative

10 Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered

15 behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates that it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the gene or gene product may also play a role in

20 the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Polynucleotides and polypeptides corresponding to this gene are useful in the regulation of signalling pathways, particularly pathways involving G-protein coupled receptors or pathways involving calcium activation. In addition, the protein is useful

25 for the detection, treatment, and/or prevention of reproductive disorders, such as infertility. The protein may be useful as a contraceptive. The protein is also useful for

the modulation of pain stimuli. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1014 of SEQ ID NO:56, b is an integer of 15 to 1028, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 47**

Preferred polypeptides of the invention comprise the following amino acid sequence:

PILWGNRVPMEPQKCHPAGWHGLGQAEAGDQDGRWRPGLPQKRPPAGA  
GQAWLSCHRHMVERGVPCPPWGGGTRALVYSDAG (SEQ ID NO: 224),  
20 PMEPQKCHPA GWHGLGQAEAGDQDG (SEQ ID NO: 225),  
AGAGQAWLSCHRHMVERGVPCPPWGGGT (SEQ ID NO: 226),  
SPXTHVQGQTGMYVIWGLGGGLPRGHPLLGPPWDPFCGETGCPWSLRNA  
TRLVGMAWRRQRQETKMAGGGQAYHNGRDLPLGPGRPGSAATGIWWRG  
GYPAHLGVVAPELLSIQTLVWGLG PLTGDRASVGEF (SEQ ID NO: 227),  
25 WGLGGGLPRGHPLLGPPWDPFCG (SEQ ID NO: 228),  
QRQETKMAGGGQAYHNGRDLPLGPGR (SEQ ID NO: 229), and/or

HLGVVAPPELLSIQTLVWGLG (SEQ ID NO: 230). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in  
5 linkage analysis for chromosome 17.

This gene is expressed primarily in ovary, neutrophils, and dendritic cells, and to a lesser extent, in various regions of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, reproductive, or neural diseases or disorders, particularly female fertility disorders and neurodegenerative conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
15 disorders of the above tissues or cells, particularly of the immune system and female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, hematopoietic, neural, development, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
20 tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder. Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 108 as residues: Arg-4 to Cys-13. Polynucleotides encoding said polypeptides are also provided.

25 The tissue distribution of this gene in ovary, neutrophils, dendritic cells, and brain indicates a role for the gene product in the treatment and/or detection of

reproductive disorders and/or immune disorders such as arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, in addition to neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorders. The protein may also be useful in the treatment/prevention/detection of endocrine disorders. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1840 of SEQ ID NO:57, b is an integer of 15 to 1854, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.



Table 1

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of 5' NT Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HLICQ90	203517 12/10/98	pCMVSPORT 1	11	1766	1	1766	249	249	62	1	29	30	206
2	HNTSM04	203499 12/01/98	pSport1	12	2667	1	2667	147	147	63	1	20	21	108
3	HMCAL59	203517 12/10/98	Uni-ZAP XR	13	2170	1	2170	52	52	64	1	24	25	286
4	HMACO04	203517 12/10/98	Uni-ZAP XR	14	1190	406	1190	576	576	65	1	20	21	85
5	HMAHY59	203499 12/01/98	Uni-ZAP XR	15	1735	50	1735	293	293	66	1	35	36	302
6	HFXLL52	203499 12/01/98	Lambda ZAP II	16	1274	1	1274	111	111	67	1	17	18	149
7	HKABY55	203517 12/10/98	pCMVSPORT 2.0	17	1921	234	1921	336	336	68	1	48	49	357

116

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HCQCF36	203499 12/01/98	Lambda ZAP II	18	692	1	692	200	200	69	1	23	24	111
9	HTADO22	203499 12/01/98	Uni-ZAP XR	19	1500	1	1500	259	259	70	1	21	22	183
10	HHFHD92	203499 12/01/98	Uni-ZAP XR	20	2136	1	2136	192	192	71	1	36	37	253
11	HNGFW58	203517 12/10/98	Uni-ZAP XR	21	1547	1	1547	279	279	72	1	28	29	99
12	HOEFV61	203517 12/10/98	Uni-ZAP XR	22	2657	1	2657	64	64	73	1	13	14	180
13	HPIAQ68	203517 12/10/98	Uni-ZAP XR	23	2466	1	2466	20	20	74	1	22	23	62
14	HNFFY60	203499 12/01/98	Uni-ZAP XR	24	2495	1	2495	65	65	75	1	26	27	73
15	HWBAS39	203499 12/01/98	pCMVSPORT 3.0	25	3244	1	3197	279	279	76	1	20	21	130

117

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
16	HE8EW79	203499 12/01/98	Uni-ZAP XR	26	1362	1	1362	20	20	77	1	46	47	107
16	HE8EW79	203499 12/01/98	Uni-ZAP XR	58	1349	1	1349	8	8	109	1	46	47	209
17	HTTDF41	203517 12/10/98	Uni-ZAP XR	27	1381	1	1381	66	66	78	1	16	17	125
17	HTTDF41	203517 12/10/98	Uni-ZAP XR	59	1072	9	1072	62	62	110	1	16	17	215
18	HSSGJ45	203499 12/01/98	Uni-ZAP XR	28	2527	1	2509	33	33	79	1	31	32	218
18	HSSGJ45	203499 12/01/98	Uni-ZAP XR	60	2508	1	2508	25	25	111	1	31	32	276
19	HLWBY76	203517 12/10/98	pCMVSPORT 3.0	29	2081	1	2081	432	432	80	1	28	29	232
20	HDPBN34	203499 12/01/98	pCMVSPORT 3.0	30	1262	1	1262	32	32	81	1	19	20	121

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
21	HMSHY73	203517 12/10/98	Uni-ZAP XR	31	1804	81	1094	100	100	82	1	33	34	154
22	HPRBF19	203517 12/10/98	Uni-ZAP XR	32	1461	1	1461	63	63	83	1	31	32	190
23	HNFJE06	203499 12/01/98	Uni-ZAP XR	33	1114	31	1114	354	354	84	1	17	18	72
24	HCHCF61	203499 12/01/98	pSport1	34	2235	17	2235	33	33	85	1	25	26	42
25	HBJLH40	203499 12/01/98	Uni-ZAP XR	35	1853	1	1853	74	74	86	1	30	31	74
26	HDPMV72	203499 12/01/98	pCMVSPORT 3.0	36	1465	1	1465	54	54	87	1	39	40	125
27	HEMFA84	203499 12/01/98	Uni-ZAP XR	37	985	1	985	42	42	88	1	17	18	257
28	HTOHW95	203517 12/10/98	Uni-ZAP XR	38	719	1	719	77	77	89	1	32	33	121

119

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HUNAH63	203517 12/10/98	pBluescript SK-	39	1269	1	1269	91	90	1	23	24	87
30	HISBT59	203517 12/10/98	pSport1	40	2528	1	2514	142	91	1	27	28	82
31	HNTAS52	203517 12/10/98	pCMVSPORT 3.0	41	1692	1	1692	167	92	1	32	33	508
32	HRACM44	203499 12/01/98	pCMVSPORT 3.0	42	1605	1	1605	175	93	1	22	23	47
33	HFPE577	203499 12/01/98	Uni-ZAP XR	43	2460	1	2460	57	94	1	22	23	119
34	HUSXU29	203517 12/10/98	pSport1	44	1517	172	1517	321	95	1	28	29	289
35	HOHBB49	203517 12/10/98	pCMVSPORT 2.0	45	3080	1	3080	148	96	1	19	20	48
36	HRABX31	203499 12/01/98	pCMVSPORT 3.0	46	2204	1	2204	197	97	1	43	44	117

120

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
37	HROBD68	203499 12/01/98	Uni-ZAP XR	47	1998	1	1998	122	122	98	1	22	23	48
38	HMHBE18	203517 12/10/98	Uni-ZAP XR	48	2069	1	2069	29	29	99	1	24	25	123
39	HNHDY21	203517 12/10/98	Uni-ZAP XR	49	924	1	924	208	208	100	1	26	27	131
40	HOEBZ89	203517 12/10/98	Uni-ZAP XR	50	2520	1	2520	19	19	101	1	21	22	333
41	HYAAJ71	203517 12/10/98	pCMVSPORT 3.0	51	3337	1	3337	190	190	102	1	31	32	62
42	HTEKS16	203517 12/10/98	Uni-ZAP XR	52	1947	21	1845	176	176	103	1	25	26	99
43	HCUFX40	203499 12/01/98	ZAP Express	53	734	1	734	115	115	104	1	29	30	86
44	HCWDL75	203499 12/01/98	ZAP Express	54	1182	97	1182	351	351	105	1	27	28	82

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
45	HNHKJ57	203499 12/01/98	Uni-ZAP XR	55	1866	1	1866	158	158	106	1	37	38	44
46	HCMSS06	203499 12/01/98	Uni-ZAP XR	56	1028	91	1028	153	153	107	1	22	23	227
46	HCMSS06	203499 12/01/98	Uni-ZAP XR	61	952	2	952	75	75	112	1	25	26	86
47	HIBCE35	203499 12/01/98	Other	57	1854	227	1830	409	409	108	1	36	37	65

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.



The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid  
5 position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently  
10 accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety  
15 of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain  
20 sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater  
25 than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of

5 plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can

10 also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be

15 isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or

20 species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may

25 be isolated and identified by making suitable probes or primers from the sequences

provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly  
5 produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below).  
10 It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an  
15 isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or  
20 recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or  
25 alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides

encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

### **Signal Sequences**

- 5           The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also
- 10 encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases,
- 15 cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.
- 20           Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the
- 25 information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of

predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

5           In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis  
10 of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence  
15 shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present  
20 invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of  
25 directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID

NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

5

### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

10 The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many  
15 regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the  
20 nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

25 Polynucleotides which hybridize to these nucleic acid molecules under stringent

hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 5 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% 10 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% 15 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified 20 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best 25 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined

using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

- 10           If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.
- 25           For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the



subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%,

90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence; whichever is shorter.

15           If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score

is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal  
5 residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10  
10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100  
15 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not  
20 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter  
25 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred.

Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over

the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500  
5 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of  
10 a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and  
15 otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make  
20 phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in  
25 different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions

where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

5           The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant  
10       molecules can then be tested for biological activity.

          As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino  
15       acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of  
20       the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

          Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the  
25       genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound,

such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are  
5 deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the  
10 aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid  
15 sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide  
20 to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is  
25 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

5           In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ  
10 ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA  
15 sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g.,  
20 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750,  
25 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500,



1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller  
5 by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also  
10 encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a  
15 part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90,  
20 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the  
25 mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the

carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

- 5 Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and  
10 alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are  
15 specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological  
20 activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide  
25 demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete)

polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the

invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another  
5 embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related  
10 biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

### **Epitopes and Antibodies**

15 The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in  
20 ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence  
25 encoding an epitope of the invention, and polynucleotide sequences which hybridize

to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes

include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more  
5 of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., *Cell* 37:767-778 (1984); Sutcliffe et al., *Science* 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe  
10 et al., *supra*; Wilson et al., *supra*; Chow et al., *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle et al., *J. Gen. Virol.* 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for  
15 eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very  
20 least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-  
25 2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide

to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent  
5 such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100  $\mu$ g of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at  
10 intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods  
15 well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins  
20 (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-  
polypeptide and various domains of the constant regions of the heavy or light chains  
25 of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the

immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be  
5 more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For  
10 example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine  
15 residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the  
20 techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;  
25 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol.



Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

### 15 Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules

that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

5           Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s)  
10 alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human,  
15 murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described  
20 infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a  
25 heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol.

147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920;  
5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they  
5 recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind  
10 polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at  
15 least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding  
20 epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the  
25 above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific

antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation

(e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,

Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);  
Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference  
herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited  
5 to, to purify, detect, and target the polypeptides of the present invention, including  
both in vitro and in vivo diagnostic and therapeutic methods. For example, the  
antibodies have use in immunoassays for qualitatively and quantitatively measuring  
levels of the polypeptides of the present invention in biological samples. See, e.g.,  
Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory  
10 Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may  
be used either alone or in combination with other compositions. The antibodies may  
further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus  
or chemically conjugated (including covalently and non-covalently conjugations) to  
15 polypeptides or other compositions. For example, antibodies of the present invention  
may be recombinantly fused or conjugated to molecules useful as labels in detection  
assays and effector molecules such as heterologous polypeptides, drugs,  
radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438;  
WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

20 The antibodies of the invention include derivatives that are modified, i.e., by  
the covalent attachment of any type of molecule to the antibody such that covalent  
attachment does not prevent the antibody from generating an anti-idiotypic response.  
For example, but not by way of limitation, the antibody derivatives include  
antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation,  
25 phosphorylation, amidation, derivatization by known protecting/blocking groups,  
proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

- 5           The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal
- 10 antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and
- 15 potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be

20 produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not

25 limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).



F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,

including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using  
5 methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and  
10 antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule  
15 in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*  
20 *Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule.  
25 Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,  
5 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP  
10 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods  
15 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the  
25 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.

The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the

nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence  
5 encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is  
10 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable  
15 to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

20 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A  
25 Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John

Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes

from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived  
5 from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature  
10 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

15

#### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

20 Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an  
25 antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the



antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be

5 used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or

10 light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or

15 light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain

20 thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the

25 antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently

purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding  
5 sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such  
10 fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin  
20 promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric  
25 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region

E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk. Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the

5 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

10 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,

15 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which

20 possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell

25 line such as, for example, CRL7030 and Hs578Bst.

- For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.
- A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science

260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci.*

USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any  
5 method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or  
10 fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80,  
15 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be  
20 used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g.,  
25 Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS

89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins



consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having

5 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A

10 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

15 identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

20 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which

25 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include

paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and  
5 puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-  
10 dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological  
15 response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth  
20 factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g.,  
25 angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports  
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld  
10 et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,  
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can  
25 be used as a therapeutic.

### Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular  
5 marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and  
10 include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual  
15 disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

### 20 Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent  
25 assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by  
5 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1%  
10 Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in  
15 SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding  
20 immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein  
25 sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-

fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody. e.g., an anti-human  
5 antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For  
10 further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable  
15 compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the  
20 well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs  
25 known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One  
5 example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by  
10 scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

### 15        Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include,  
20 but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression  
25 and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment



and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

#### Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY  
5 (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters  
10 operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the  
15 antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

20 Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

25 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be

accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct  
5 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,  
10 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for  
15 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,  
20 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral  
25 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which

facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection  
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,  
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.  
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and  
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598: Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the

therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

10

#### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),

25



construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion  
5 or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route,  
10 including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical  
15 compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,  
20 including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et  
25 al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such  
5 compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term  
10 "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline  
15 solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired,  
20 can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as  
25 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation  
5 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the  
10 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the  
15 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.  
20 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

25 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body  
5 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,  
10 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With  
15 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier  
20 thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting  
25 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody

assay labels are known in the art and include enzyme labels, such as. glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5           One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which  
10 specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that  
15 detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

20           It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99}\text{mTc}$ . The labeled antibody or antibody fragment will then preferentially  
25 accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of

Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patent using positron emission-tomography. In



yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

### Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by  
5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of  
10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of  
20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting  
10 surface-bound anti-antigen antibody.

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a  
15 second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

20 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics  
25 of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the

polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling  
5 of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in  
10 chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)  
15 Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion  
20 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,  
25 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for

example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

- 5           Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.
- 10          As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)
- 15           Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

- 20           The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

- 25           The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate,

such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech,

Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ,pGAPZ, pGAPZalph,  
5 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated  
10 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

15 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most  
20 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical  
25 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,

insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1*



regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially  
5 as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a PSF-2 protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

10 Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like,  
15 including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the  
20 yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding  
25 sequence), and/or to include genetic material (e.g., heterologous polynucleotide

sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences  
5 via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935  
10 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*,  
15 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the  
20 common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-  
25 amino acids, designer amino acids such as  $\beta$ -methyl amino acids.  $\alpha$ -methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random

positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein

5 (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules.

10 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl

15 group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific

20 embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides

25 corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and

fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the

invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one  
5 instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the  
10 heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as  
15 described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another  
20 embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

25 Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper

polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

5 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide

10 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are

15 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-

25 Flag® antibody.



The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent

5 Number 5,478,925, which is herein incorporated by reference in its entirety).

Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by

10 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,

15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic

20 engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are

25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic

polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described  
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

10

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

15

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

20

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids  
25 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping  
5 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.  
10 This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to  
15 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

20 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins  
25 University Welch Medical Library) .) Assuming 1 megabase mapping resolution and

one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

- 5 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide  
10 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

- Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using  
15 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

- Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the  
20 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

- In still another embodiment, the invention includes a kit for analyzing samples  
25 for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe

containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand  
5 containing a 31'-mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present  
10 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the  
15 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard  
20 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for  
5 obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a  
10 solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms  
15 (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention  
20 that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,  
25 thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose

derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).

5 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is  
10 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia  
15 cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb  
20 proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of  
25 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.



In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more  
5 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a  
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR  
25 Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene

expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and  
5 technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-  
10 radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

15 A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the  
20 subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.  
25 In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which  
involves (a) assaying the expression of a polypeptide of the present invention in cells  
5 or body fluid of an individual; (b) comparing the level of gene expression with a  
standard gene expression level, whereby an increase or decrease in the assayed  
polypeptide gene expression level compared to the standard expression level is  
indicative of a disorder. With respect to cancer, the presence of a relatively high  
amount of transcript in biopsied tissue from an individual may indicate a  
10 predisposition for the development of the disease, or may provide a means for  
detecting the disease prior to the appearance of actual clinical symptoms. A more  
definitive diagnosis of this type may allow health professionals to employ  
preventative measures or aggressive treatment earlier thereby preventing the  
development or further progression of the cancer.

15 Moreover, polypeptides of the present invention can be used to treat, prevent,  
and/or diagnose disease. For example, patients can be administered a polypeptide of  
the present invention in an effort to replace absent or decreased levels of the  
polypeptide (e.g., insulin), to supplement absent or decreased levels of a different  
polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair  
20 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor  
suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to  
reduce the activity of a membrane bound receptor by competing with it for free ligand  
(e.g., soluble TNF receptors used in reducing inflammation), or to bring about a  
desired response (e.g., blood vessel growth inhibition, enhancement of the immune  
25 response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can  
5 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also  
10 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

### 15 Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present  
20 invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

25 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a

polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; 5 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters 10 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, 15 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the 20 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, 25 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye,



gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

- 5           The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

          In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10   invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15   84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

- 20           Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25   available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to

produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

- 5 The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.
- 10 SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
- 15 then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980); Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.
- 20
- 25

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports  
5 on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,  
10 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding  
15 polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

20 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by  
25 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,

the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which  
5 include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can  
10 be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for  
15 many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt  
20 to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,  
25 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein

incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other  
5 varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of  
10 infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*,  
15 using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is  
20 limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell  
25 integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found

in Sambrook et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper  
5 viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its  
10 genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO  
15 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

20 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting  
25 sequence will be sufficiently near the 5' end of the desired endogenous



polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR.

Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

10 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 15 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The 20 promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor 25 alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

5 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

10 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available  
15 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
20 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting  
25 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
15 Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise  
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of

polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and  
5 birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits, sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present  
10 invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

15

### **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation,  
20 differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases,  
25 disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present

invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used

to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the

present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

## 25 Hyperproliferative Disorders

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:



hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

- 5           One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

          Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally  
10   proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

          Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention  
15   to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to  
20   be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating  
25   cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule,

chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said  
5 external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the  
10 destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in  
15 the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature  
20 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating  
25 and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in

the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to

5 abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at

10 the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

15 Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as

20 decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

25 The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a

mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may  
5 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

20 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or  
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and

therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those  
5 with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in  
10 combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).  
15 Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments  
20 thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related  
25 apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs  
5 or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

10 Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4  
15 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions  
20 containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic  
25 and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and  
5 immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### Cardiovascular Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the invention  
10 may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and  
15 Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such  
20 as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac  
25 arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular

hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, 5 rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial 10 block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic 15 junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve 20 insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, 25 endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.



Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis,

Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

5           Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

10           Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura,  
15           allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art,  
20           including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the  
25           art. Polypeptides of the invention may be administered as part of a *Therapeutic*,

described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

#### Anti-Angiogenesis Activity

5           The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive  
10           processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization  
15           including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-  
20           203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

25           The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the

polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a

catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in  
5 treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy,  
10 retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial  
15 angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided  
20 for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar  
25 or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result

in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or  
5 diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the  
10 polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris  
15 neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step  
20 of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it  
25 also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of

diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),  
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in  
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-  
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent  
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing  
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the

cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should



be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist  
5 and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or  
10 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be  
15 treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example,  
20 diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals,  
25 arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma

fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis. birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (*Helicobacter pylori*),

5     Bartonellosis and bacillary angiomatosis.

          In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or  
10    agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

          Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch  
15    granulomas.

          Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal  
20    surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic  
25    compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the

invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

5           Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic  
10   compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied  
15   after hepatic resections for malignancy, and after neurosurgical operations.

          Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may  
20   be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

          The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive  
25   Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator

Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition  
5 metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium  
10 metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten  
15 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its  
20 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and  
25 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan  
5 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;  
10 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;  
15 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

20

#### Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as  
25 follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer,

melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic

cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

10 Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as 15 that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

### Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft. Ollier-



Thiersch graft, omentoplastic graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

5           It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as  
10   sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

15           The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or  
20   polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

          The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial  
25   thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The

polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or  
5 agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large  
10 intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production  
15 of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

20 Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to  
25 prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from

smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

## 25 Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which

5 result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)

10 ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of

15 the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex

20 virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a

25 portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic

acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus  
5 erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive  
10 multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with  
15 cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell  
20 injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell  
25 injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous

system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary  
5      Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### **Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present  
10      invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively,  
15      polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or  
20      polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae  
25      (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae),

Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a

5 variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox,

10 hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or

15 antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or

20 agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to,

25 include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium,



- Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis. Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic
- 5 E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g.,
- 10 Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to:
- 15 bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,
- 20 meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.
- Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used
- 25 to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention

are used to treat, prevent, and/or diagnose: tetanus, Diptheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, 5 Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium 10 ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used totreat, prevent, 15 and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering 20 an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

25

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or

conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, 5 Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### Chemotaxis

10 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then 15 fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system 20 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

25 It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules

could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

5

### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
10 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural  
15 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

20 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially  
25 containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

5        Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a  
10        standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

15        Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for  
20        example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides  
25        can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

5 As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein  
10 microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be  
15 employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol.  
20 Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide  
25 sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the

invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the



compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this  
5 procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured.  
10 Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase,  
15 ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays  
20 can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the  
25 invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a

biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are  
5 directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,  
10 any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional  
15 embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

In another embodiment, the invention provides a method of delivering  
20 compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one  
25 embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention

(including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double  
5 stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in  
10 association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used  
15 according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed  
20 antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or  
25 mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which  
5 modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by  
10 using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids  
15 expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any  
20 other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically  
25 labeled. Following incubation, free agent is separated from that present in bound

form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

20

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered

25

(see, for example, O'Connor, *Neurochem.*, 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988).

Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for

5 example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary  
10 DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide.

15 A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS  
20 HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide  
25 is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense

RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or  
5 a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard  
10 in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early  
15 promoter region (Bernoist and Chambon, Nature, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A., 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., Nature, 296:39-42 (1982)), etc.

20 The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,  
25 forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation

may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

- 5 One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

- Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA.
- 15 Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six
- 20 nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

- The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-
- 25 stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization,



- etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

- The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs

5 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well

10 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to

15 increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo.

20 DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of

25 the ribozyme to destroy endogenous messages and inhibit translation. Since

ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

**Other Activities**

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide  
5 may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore,  
10 facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the  
15 invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

20 The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

25 The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

5 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue,  
10 pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present  
15 invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

20 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

## 25 **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

5        Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

10       Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

15       Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as  
20       defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

25       Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.



Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
5 sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human  
10 cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological  
15 sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
20 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences  
25 comprises determining the extent of nucleic acid hybridization between nucleic acid

molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1;  
and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA  
Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit  
Number shown for said cDNA clone in Table 1.

5           The method for diagnosing a pathological condition can comprise a step of  
detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at  
least two nucleotide sequences, wherein at least one sequence in said panel is at least  
95% identical to a sequence of at least 50 contiguous nucleotides in a sequence  
selected from said group.

10           Also preferred is a composition of matter comprising isolated nucleic acid  
molecules wherein the nucleotide sequences of said nucleic acid molecules comprise  
a panel of at least two nucleotide sequences, wherein at least one sequence in said  
panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a  
sequence selected from the group consisting of: a nucleotide sequence of SEQ ID  
15 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence  
encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
and contained in the deposit with the ATCC Deposit Number shown for said cDNA  
clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA  
molecules.

20           Also preferred is an isolated polypeptide comprising an amino acid sequence  
at least 90% identical to a sequence of at least about 10 contiguous amino acids in the  
amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

          Also preferred is a polypeptide, wherein said sequence of contiguous amino  
acids is included in the amino acid sequence of SEQ ID NO:Y in the range of  
25 positions beginning with the residue at about the position of the First Amino Acid of

the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least

one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of:  
an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone

Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said  
5 polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone  
10 identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of  
15 making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making  
20 an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and  
25 said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein



encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HLICQ90	11	791828	T91236, T86019, T99745, H26993, H30177, H42449, H78217, H90333, N62729, N75483, AA430026, AA430235
2	HNTSM04	12	826718	None
3	HMCAL59	13	827295	None
4	HMACO04,H OEBE74	14	829265	T68728, T68746, T68794, T68813, T89540, R72283, R72320, H19329, H38021, H38246, H70681, H95507, AA025779, AA025778, AA025920
5	HMAHY59,H ARMD18	15	826003	R06989, R28538, R71873, R71880, R71897, R77885, R77978, H30007, H30008, R88696, R90942, H49957, H50479, H63845, H63846, N74299, N93977, W05209, AA428961, AA429078
6	HFXLL52	16	793766	None
7	HKABY55	17	821607	T40555, R16077, R15713, R66066, R67665, R72008, R72007, R72471, R72869, R72882, R73342, R73357, H00901, H00902, H02520, R93337, N94336, AA010655, AA010656, AA047596, AA130587, AA130551
8	HCQCF36	18	827281	None
9	HTADO22	19	827319	None
10	HHFHD92	20	799537	None
11	HNGFW58	21	833074	None
12	HOEFV61	22	833079	None
13	HPIAQ68	23	833082	None
14	HNFFY60	24	826715	None
15	HWBAS39	25	823926	R21399, R52101, R52196, R55654, H09798, H22862, H41225, R90791, R90894, H84247, H84246, H87060, H92415, AA018825, AA173352
16	HE8EW79	26	567372	None
16	HE8EW79	58	905372	None
17	HTTDF41	27	827309	None
17	HTTDF41	59	824557	None
18	HSSGJ45	28	905739	None
18	HSSGJ45	60	826722	None
19	HLWBY76	29	797609	N30680

20	HDPBN34	30	665433	N47245
21	HMSHY73	31	784862	T49414, R17179, H02748, R84902, H66713, N44946, W19836, W47291
22	HPRBF19	32	753282	None
23	HNFE06	33	826289	None
24	HCHCF61	34	826773	None
25	HBJLH40	35	828130	None
26	HDPMV72	36	637584	None
27	HEMFA84	37	608198	None
28	HTOHW95	38	590745	None
29	HUNAH63	39	567435	None
30	HISBT59	40	833086	None
31	HNTAS52	41	833077	None
32	HRACM44	42	827301	None
33	HFPE577	43	748229	None
34	HUSXU29	44	824407	None
35	HOHBB49	45	833080	None
36	HRABX31	46	827300	None
37	HROBD68	47	827306	None
38	HMHBE18	48	753236	None
39	HNHDY21	49	609901	None
40	HOEBZ89	50	828177	None
41	HYAAJ71	51	826754	None
42	HTEKS16	52	775586	None
43	HCUFX40	53	711241	None
44	HCWDL75	54	825939	H70608, AA053601
45	HNHKJ57	55	827299	None
46	HCMSS06	56	912881	H83784, H83927, W32197, W32232, W33189, W37255, AA192426, AA192427, AA194737, AA661735, AA688029, AA902491, AA903899, F19507, F20527, AA854779, AI218954, AI659751
46	HCMSS06	61	815654	H83784, H83927, W32197, W32232, W33189, W37255, AA192426, AA192427
47	HIBCE35	57	823743	T40292, T41126, T41157

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being

15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention

does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional  
5 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample  
10 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ  
15 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular  
20 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection  
25 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the  
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and  
the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the  
desired cDNA using the deposited cDNA plasmid as a template. The polymerase  
chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction  
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is  
10 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25  
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR  
(denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation  
at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated  
thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and  
15 the DNA band with expected molecular weight is excised and purified. The PCR  
product is verified to be the selected sequence by subcloning and sequencing the  
DNA product.

Several methods are available for the identification of the 5' or 3' non-coding  
portions of a gene which may not be present in the deposited clone. These methods  
20 include but are not limited to, filter probing, clone enrichment using specific probes,  
and protocols similar or identical to 5' and 3' "RACE" protocols which are well  
known in the art. For instance, a method similar to 5' RACE is available for  
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et  
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a  
population of RNA presumably containing full-length gene RNA transcripts. A

primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

- 5           This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
- 10   to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
- 15   used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

20   **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

25   **Example 3: Tissue Distribution of Polypeptide**



Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with  $P^{32}$  using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

#### **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

5           A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15 sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20 expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid  
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The

cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

5           Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from  
10   QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
15   washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
20   NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
25   mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

- 5 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

- 10 DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or  
15 *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

20 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 25 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5           The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10           The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

          Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
15           the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

          To clarify the refolded polypeptide solution, a previously prepared tangential  
20           filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a  
25           stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are  
5 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the  
10 polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS  
15 contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

#### **Expression System**

20 In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")  
25 is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5           Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-  
10   39 (1989).

          Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does  
15   not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20           The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

          The plasmid is digested with the corresponding restriction enzymes and  
25   optionally, can be dephosphorylated using calf intestinal phosphatase, using routine

procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue

5 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

10 Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a  
15 microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is  
20 then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life  
25 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of



a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then  
5 resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's  
10 medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  
15 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
20 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
25 mediates the initiation of transcription of mRNA, a protein coding sequence, and

signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
5 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
10 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

15 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
20 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker  
25 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,

the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

- 5           Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,  
10   with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

- Specifically, the plasmid pC6, for example, is digested with appropriate  
15   restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.

- 20   Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

- The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%  
25   agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG

domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

**Human IgG Fc region:**

GGGATCCGGAGCCCAAATCTTCTGACAAAACACACATGCCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
5 CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
10 ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
15 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

20 The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
method, a preparation of the secreted protein is prepared and purified to render it  
25 substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells,

and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of  
5 further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub>  
10 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced  
15 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson  
20 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**



The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution  
5 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered  
10 Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x  
15 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods  
20 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be  
25 transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates  
 5 off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in  
 10 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 15 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 20 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 25 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
5 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
10 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end  
15 of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
20 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
25 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

**Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

5	<u>Ligand</u>	<u>JAKs</u>				<u>STATs</u>	<u>GAS(elements) or ISRE</u>
		<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
10	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrophic)	?	+	?	?	1,3	
15	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
20	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP
	>>Ly6)(IgH)						
25	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
30	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS

SUBSTITUTE SHEET (RULE 26)

Growth hormone family

	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
5	EPO	?	-	+	-	5	GAS(B-
	CAS>IRF1=IFP>>Ly6)						

Receptor Tyrosine Kinases

	EGF	?	+	+	-	1,3	GAS (IRF1)
10	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

SUBSTITUTE SHEET (RULE 26)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)



Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final  
5 concentration of  $10^7$  cells/ml. Then add 1 ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with  
10 supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being  
15 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

20 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

25 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul

samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
5 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
10 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.  
15 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
20 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

25 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter  
5 molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and  
10 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-  
15 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding  
20 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and  
16. However, many other promoters can be substituted using the protocols described  
25 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-

2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

5 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP  
10 activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
15 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing  
20 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
25 RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life

KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

- 5           The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described  
10   growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example  
11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml  
interferon gamma can be used which is known to activate U937 cells. Over 30 fold  
15   induction is typically observed in the positive control wells. SEAP assay the  
supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are  
20   activated through many different signal transduction pathways. One of these genes,  
EGR1 (early growth response gene 1), is induced in various tissues and cell types  
upon activation. The promoter of EGR1 is responsible for such induction. Using the  
EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12  
25   cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or  
differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

- 5           The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

- 10           5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

- Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1  
15   promoter.

          To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

- 20           PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and  
25   resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

apoptosis (NF- KB appears to shield cells from apoptosis). B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)



Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
5 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

10

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

15

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

20

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25

#### **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- 5           Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- Cool the samples to room temperature for 15 minutes. Empty the dispenser  
10       and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at  
15       each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5

21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

---

**Example 18: High-Throughput Screening Assay Identifying Changes in Small**

**Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small  
5 molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane  
potential. These alterations can be measured in an assay to identify supernatants  
which bind to receptors of a particular cell. Although the following protocol  
describes an assay for calcium, this protocol can easily be modified to detect changes

in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small  
5 molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for  
10 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four  
15 times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are  
20 washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as  
25 fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an  
5 extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

10 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is  
15 unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
20 receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine  
25 kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the

following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane

bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4  
5 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by  
10 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

15 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the  
20 components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction  
25 mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for  
5 one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
10 tyrosine kinase activity.

**Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine  
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,  
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are  
25 then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against



Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

5           A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

10           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
15           procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

20    **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
25    is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for

30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical

Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

5

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide  
10 is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with  
15 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample  
20 containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.  
25 The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

**Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01

mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An  
5 intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments,  
10 gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and  
15 intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal  
20 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

25 Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable

polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

- 5           Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric  
10   acid (EP 133,988).

- Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)).
- 15   Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small  
20   (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

- In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see Langer, supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.*  
25   14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage  
5 injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

10 Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's  
15 solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as  
20 phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or  
25 arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar

alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will  
5 be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container  
10 having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml  
15 vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the  
20 invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

25 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the



Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either

concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through  
5 separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like  
10 molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No.  
15 WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904),  
20 DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms  
25 CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination  
5 with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but  
10 are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents,  
15 nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that  
20 may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™,  
25 FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™,

KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, 5 DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic 10 *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with 15 GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another 20 specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent 25 an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered  
5 in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered  
10 with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-  
15 sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other  
20 immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™  
25 (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucorticosteroids, and RAPAMUNE™ (sirolimus). In a specific

embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations.

5 Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.

In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation  
10 therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-  
15 inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone,  
20 guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to,  
25 antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-

FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate);  
5 hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g.,  
10 dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another  
15 embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are  
20 administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3,  
25 IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).



In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, 5 FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

10 **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the 15 invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering 20 to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on 25 administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising  
5 administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of  
10 decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation  
15 of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a  
20 subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed  
25 to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS,

penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge.

- 5 The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

- 10 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine  
15 sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene  
20 of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.

- 25 The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the

polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary  
5 phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the  
10 supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10<sup>6</sup> cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to  
15 construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an  
20 Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-  
25 digested pUC18 plasmid.

<211> 1866  
 <212> DNA  
 <213> Homo sapiens

<400> 55  
 ggcacgagac aacattttatt accaatccgt gaactctgga catccccaaa gagcatttct 60  
 aggaaattgg cttcctcttt cccttgggac agttggacat cttagctgct ccccgagcccc 120  
 tgcaatgtcc atgttccagg agccttgata ggtaaatg aggcccaatg tcctgcagggt 180  
 ggcatttccc atcagtagcc atcgggtgtgt ccgccctagt tgttggtctc tgttcattct 240  
 gtttagactg ctaccatta tgatcagcca accaggctgt aacagttgtt aaatattttg 300  
 aatgtcaccg ctggcatttg ccaaagtttt cttatggagt accggattca caagattgtc 360  
 ataaaacaaa gaaaaataag cttgcaaacy gatgaatcat ctaggctctg agaagtcttg 420  
 caagaaagat tttgtttacc tgtgtttaac tcaatatatg ccaaagtat tgaatcacat 480  
 atgaaaagtc ctccctaccc ttctcccttt ttcagtttca agaaatactg tacctactac 540  
 catgctgtgg aactagtgtc tgggaaacat catcttcgaa aggaaatgga cttctactaa 600  
 ccacattggt ctgtgtctga aagtcccaat ctctctatag acaaagatgc tgatgaagat 660  
 ggcttttaaaa ggaacatttg gaaagtgcc atatttggtt aacagatgga ttatatattga 720  
 aactctggtt tctccacttg gccctccaca aattatttaa atggtcatat gctcagtttc 780  
 ttcactctga agacagggtt agcgttacct cctttgcagg attgctgtga ggattctaga 840  
 ggtaaaagat gtaaaatggt ttatcacagt gcctggcgaga tggcaaacac tcaagaagag 900  
 ttagctgtta gcatccagta ttacaggaac cctgaggacc atacaagggtg accttaaggc 960  
 tacctgttct catggacatc acagtctggt tagacagaca acatagacct gtggaactat 1020  
 agccaccatc gaagaaaaga ctaaactgag gctggaggaa aacaatggca ttggaatggt 1080  
 tggaagtcgc ttcataaaat tgggtgtgatt gggtgagccc tgacacaaag acatttactt 1140  
 ccttctatcc ttttaaaaat aatggcctcc tgttgaatgg tagttgccaa gaactagggg 1200  
 gaagtacagt agaaagttaa tgtttaatgg ctacggaatt ttagtttggg aagatgaaaa 1260  
 aaacttctgg agatggatga tggattgat tacataacat tgtgaatgca tgtaatgcca 1320  
 ctcaattgta ttcttaaaaa tggttaaaaat gatcaatttt ctgaagtgtg ctataaccaca 1380  
 gtttaaaaaa attaaataat aattaccttg ttatcaaaag gggctaatta gctcactccc 1440  
 ttcactccat acaaatttat atcattggtt taagactaca tctcccagaa catgctggtc 1500  
 ccttttcagc ttaggtgttc catttcttct tccttctagg gtttctcttc tttaccagcc 1560  
 aagcctccag atgggtatttc agtcactcag ccaaacacct tcattgcagt cttttccccc 1620  
 ttctccccc gttcacttaa aaataaattg tcttttttcg taactccaga cagaacatga 1680  
 agcactctct ctctctctct tttacgctgc cactgaattc taagtacaca attatgcagg 1740  
 gaatgtcttt agattcacca gcttgagaac ttttaaacat taagctctga atcagataac 1800  
 agctttctac tcaagaacag ctttgcactg tacctaagta aaagctaac ttatatataa 1860  
 aaaaaa 1866

<210> 56  
 <211> 1028  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1022)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1026)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1027)  
 <223> n equals a,t,g, or c

ctgcagtcct	catttgtctt	cccaaaaaaa	aaaaagaatt	tttttttttt	taaggaatcc	360
ttccttgact	cctaaagact	cctaaggatg	ctgaggcctc	ctcagcatga	tttccatata	420
cttactttct	ctgttggact	gcagacaact	tgaaagcagg	aactttggca	gtgtttcccc	480
agcaccagca	tcatgcctgg	tccatagtag	ctaccaataa	aaaagtaagc	atcatgaacc	540
caaaaaaaaa	aaaaaaaaaa	tcgagagtac	ttctagagcg	gccgcggggc	atcgatttcc	600
acccgggtgg	gggtaccagg	aagtgtaccc	aattcgccct	atagtgaagc	gtattacaat	660
tcatgggcgt	cgggtttana	ngtcgtgact	gggnaaacct	gggggttanc	caacttaaac	720
gccttggagg	anat					734

&lt;210&gt; 54

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1119)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1128)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1131)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1147)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 54

tcaaaacaag	ataaagttaa	aaaaaaaaaa	aaaacagtga	cccttttgca	taagccagaa	60
gagcagtgcc	ttgcttcctg	tgaaaaatgc	ttggcagtta	gcctgtgtaa	ttatttagca	120
atcatgttaa	tagatgttta	agaataatgg	aactggagct	gtactgagcc	aaggatggaa	180
atgaagacat	gtgagactat	tttttcttca	tccaccgata	ctcttcagtt	acaaggattt	240
aattttaaag	ggttttaatt	aaatggaatc	cagaagcttt	ggacgctcca	gtttttcttc	300
ttagagacaa	accctagctc	agtttcctgg	agcttgactc	agaatgcagc	atggtactcc	360
ggactgacag	tgtgccagct	ttattcaact	atctctctac	cttttggtt	gcatttattt	420
cagggtctgg	tgacattttg	accttatgta	caaagatggc	cgatacgatt	atttttcatc	480
atatattaca	gaaaatacta	ctcttgaaaa	atactctgag	aaatatgttc	tatggtcaga	540
taagtgttgg	aaacagtga	ttattgttcc	tcctttgcag	aatcacaatg	cactgttagc	600
taattaaaga	ctctcagatg	tcccaactgga	aagaatcatg	tttagctttg	tttaacctag	660
catttcccaa	acttattaga	gcataaaact	ttgtttttgt	ttttttttta	ataagatagg	720
tagctatttc	cttagaacac	agtttgggaa	actttttgtt	catttgtttt	aataagatac	780
cttaggtagc	tatttcctta	gaacacgagc	cgggtgcagt	ggctcacgcc	tgtaatccca	840
gcactttggg	aggcccaggc	gggcggatca	cctgaggtca	ggagatcgag	atcatccggc	900
ccaacatggt	gaaaccccg	ctctactaaa	aagacaaaaa	ttagccagcc	atggtggcag	960
gcacctgtag	tcctagctac	tgtggaggct	gaggcaggag	aatcacttga	acccgggatg	1020
gggagggtgc	agtgagctga	gatggcgcca	ctgtactcca	gcctgggcca	cgagcaaaaa	1080
ctccttcaaa	aaaaaaaaaa	aaaaactcga	gagtacttnt	agagcggncc	ngggcccatc	1140
gattttncac	ccgggtgggg	taccaggtaa	gtggacccaa	tt		1182

&lt;210&gt; 55



gactgccttt	tttgawgcct	ttgggaattc	rrctgaaaag	gaaccaaacc	agagaaagta	780
aaaggacsag	acaatgggat	ttttggagtt	ccacttacag	tcctcctgga	cggtgaccga	840
aagaaagacc	ctggagtga	agttccccct	ggtattacaa	aaattttttg	agaaagttga	900
ggaatcaggt	ctggaatctg	aaggaatttt	tcgactttca	ggatgtactg	ctaaagtcaa	960
gcaataccgt	gaagaacttg	atgccaagtt	taatgctgat	aaatttaa	gggacaaaat	1020
gtgccataga	gaagctgcag	taatgttgaa	agcgtttttc	agagaactac	ccacctctct	1080
cttcctctgtg	gaatatatac	ctgccttcat	cagtctaatg	gaaagagggc	ctcacgtcra	1140
agtacagttt	caagccttac	acmterkgst	catggcgctg	cctggatgcc	aacagagatg	1200
cagctcaggc	cctcatgaca	ttcttcaata	aagtgattgc	caatgaatca	aaaaaccgaa	1260
tgagtctgtg	gaacatttct	acagtgatgg	caccgaacct	tttsttcagt	agaagcaaac	1320
actctgatta	tgaagaatta	ctgttagcaa	acaytgccgc	ccacatcatc	cgcctaatgc	1380
ttaagtacca	gaagattttg	tggaagggtc	cgtcttttwt	taatcactca	agtaagaaga	1440
atgaatgaag	ccacgatgct	attgaagaag	cagctcccaa	gtgtcaggaa	gctgctcagg	1500
aggaagaccc	tcgagcggga	gactgcaagc	cccaagactt	caaagggtact	gcaaaaatca	1560
ccctcgccaa	gacgaatgtc	tgacgtgccg	gaaggagtca	tacgggtcca	tgctccactt	1620
ccttccaagg	tgtccatggc	cattcaactc	aacaatcaaa	ccaaagccaa	agacatatgt	1680
gcaaaatttc	aatatgaaaa	cagtcattgt	tcatacagaat	gtattaagat	tcagaaccaa	1740
aggttatatg	aaattggagg	aaatatagga	gagcattgct	tggtatccaga	tgcttatata	1800
ttggatgtat	atcgtataaa	tcctcaagca	gaatgggtga	ttaaacccca	accaagttct	1860
taaaaatatcc	tcgagagagc	tgctatcatg	tattatatgc	caaaaagatc	ctacattttg	1920
gtagggaaaa	amaaactgt	gtctgac				1947

&lt;210&gt; 53

&lt;211&gt; 734

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (678)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (681)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (694)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (709)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (732)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 53

ggcacagcat	gcccttgact	ggcacaaacc	gtgacagaca	tgcccttgac	tggcacaaac	60
catgacagac	aaggccacct	cctcagaagc	ggaacaacct	attatctttt	ggcaatggga	120
gctaacttca	ctgttttctt	acaatacctg	gtttttccta	tctttgggtt	ccttttgatt	180
atctctcatc	catctcagcc	actattctcc	tccctccctt	tgtgtctaca	acacccatt	240
ttaccaagtc	tcccatttaa	cctccccatc	cttttctttt	ccttaaagtc	tcatatgata	300

gacggagtct	tgctcggtcg	cccaggctgg	agtgcagtta	aatgaaaaaa	cgtaccacaga	1080
cagagggttct	aaaacagcac	caaaatatta	atttaaatgag	tggagawtag	ttttctttat	1140
caacactaca	atthttctttt	cttttttttt	tttttttttt	ttttgagacg	tagtctcact	1200
ctgtcgcctca	ggctggagtg	cagtggcaca	atctcggctc	actgcaagct	ccgcctcccg	1260
ggttcacacc	attctcctgc	ctcagcctcc	caagtagctg	ggactacagg	tgccccaccac	1320
cacgcccagc	taatgttctg	tatttttagt	agagatgggg	tttctactgtg	ttatctagga	1380
tggctcgatc	tcctgacctc	gtgatctgcc	cgctcggcct	cccaaagtgc	tgggaattaca	1440
ggtgtgagcc	acattgcccg	gcccattttat	gktgktttta	tccatctaac	cagccaccat	1500
atattgtgtg	cttcccatgt	accacaacac	attctgagaa	cttgccacac	atgctctact	1560
ttcgtcttca	catcaacaat	gtgaatctta	agctgtgctg	aattttgtcc	aaaatgactc	1620
agataggaaa	aggcagaata	aggaatacat	tccagttgtc	tccaaagtcc	acctttttct	1680
aagtgtcaca	ttatattgtc	cttgccactg	gcacacagct	taaataaaaag	tcaaaccatg	1740
agaagccata	gaaagtaata	tcagagtaca	ggtgagaagt	tgcacttaca	taaatgatca	1800
ttcaagactt	cctggagaag	gcacgagttg	tcctttggag	tgaccaagac	tcacttccaa	1860
gtagaaaagct	cagtaatttt	gcttgagaga	tagcatggaa	agggcccgat	cttcagagtg	1920
tggttgactt	gaatttgagc	tctatcttca	tctatttcta	cccatgtgcc	tctggacatc	1980
ttacttaacc	tctctgaatc	ttcatcttgt	cattgtgaga	aacctgattg	acttgttgtta	2040
aagattaaac	aaatcatgaa	acacatctag	tccaaaactg	atactatagt	agacatttaa	2100
caagtgtatg	ttgatttaat	tcaagtctct	aggtttatag	aagacaatgg	caaaattatta	2160
attaatcagc	ttctccagtt	tgtgcgtttg	agaagggtaa	gccaaaggag	gactttgttt	2220
tcatacttca	tattgcatcg	tttgtcataa	aaattacaca	tttatacaag	cgcgcacaca	2280
cacacacaca	cacaggcaca	aacactcaga	catgagccac	aatccacaat	gaaggagtgc	2340
ttagagtgtc	taggcacccat	aataaaacttt	cacataaagt	acagcagtag	cattcttaat	2400
taaaatctct	aaagtactct	tgttgttgac	aatatcrcca	cccaaagcca	tatttacctt	2460
gttaattatt	caagttgcag	tgaataagaa	acaatgcccc	ggcttcccat	aaaatttcca	2520
aaaattaaac	cagggaaatg	ggcaataaat	gtcatttgaa	atggaaactga	tgccagttaa	2580
ttacaagaca	actgtaaaat	aatggggcat	gaggttcttc	aacaatgcct	aattagtaac	2640
tatatgggca	tttccttgga	aaaaatggca	attacacggt	gcaaacactt	agcagtcac	2700
atcaaaggcc	cttaaccaat	attagctaatt	taatcttccc	tacaacactc	cagcaggagg	2760
cagcacaagt	cctcattgag	ggagggagaa	kggaagccaa	aagatgaaat	ggaaaatcct	2820
cttctgctca	gcactgttaa	agaacaattt	gacactcgca	gcctagaagc	actcaggagg	2880
gattcccagr	ccaagagaga	gagttttcct	taatgataag	gttaatgtgg	tgaacacctta	2940
gcttctctct	gatttgctgc	catggctcac	atccttgctg	tccycgagaa	ctccccacac	3000
caaattgctg	ttgcaggcac	acatgcactc	ttgcgcttat	caaccctttt	ctctttttct	3060
cagcaagaag	gcttttgacc	tcaaatatat	aaaaccaatg	gggggagaa	gaagctatgc	3120
ctctttccac	aaagccaagc	ttgttatatt	ataacatgat	ccacagcttt	tgatttcaac	3180
ttaatgtatg	agatctggaa	ttatttcaga	agtatgattg	attttgatca	ggtgaagata	3240
ttttaaaaga	agtgaattat	ctcttatgtt	acttaattta	atccacatta	aagatttatg	3300
acaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	cggcgcgc			3337

&lt;210&gt; 52

&lt;211&gt; 1947

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

gttgaagcag	aatggctgca	agatgtgggt	ttatcaactc	tgatctcagg	tgatgaagag	60
gaagatggca	aagccttgct	ctccacattg	actcgaaccc	aagcagctgc	cgtgcaaaag	120
agataccata	cctataccca	aaccatgagg	aaaaaggata	agcaatctat	cagggatgtc	180
agagacattt	ttggagtcag	tgaatctcct	cctcgtgata	cctgtggcaa	ccacactaat	240
cagctggatg	gcaccaagga	agaaagagag	cttccaagag	ttatcaagac	aagtggttcc	300
atgccagatg	atgcttctct	caacagtact	accctgtctg	acgcatccca	ggataaagaa	360
gggagttttg	cgggtcccag	gagtgcactc	gtggctatac	ttgagaccat	tccagtctta	420
ccagttcatt	ccaatggatc	accggagcct	ggacagccag	ttcagaatgc	gataagtgat	480
gatgattttc	tggaaaagaa	cattycacca	gargctgaag	agctgtcatt	tgaagtgtct	540
tattcagaaa	tggttacgga	ggctctaaaa	agaaataaac	ttaagaaatc	agagattaag	600
aaagaagact	atgttttaac	taaatttaat	gktcagaaaa	ccagatttgg	cttaacttga	660
agcaggagat	ctgkctgctg	aagacatgaa	gaaaatccgs	catctctcty	tgawtgaatt	720

gctattgccg	gaaactggga	gcgcaagagg	cctgtctggg	tgatgctcat	ggccaactcc	540
ctgactgaag	tggacattaa	gtcccgtgga	gtgctgtct	tagacctgtt	ccttgcccag	600
gaggctgagc	ggctgaggaa	acagactggg	gcagtggaaa	aggtggaaga	gcagtgccat	660
ccattgaatg	ggttgaactt	ttcacaggtc	atctttgctt	tgaaccagac	cctcctgcag	720
caggaaaagcc	tgcgagcagg	cagtcttcag	atccccata	cgacggagga	tctcatcaaa	780
cactataaact	gcggggacct	cagctccgtc	atcctcagcc	atgacagctc	ccaggttccc	840
aattttatta	atgccacgct	accacctcag	gagcgcac	ctgctcagga	gattgacagc	900
tacttacgcc	gggagctgat	ctacaagcgg	aatgagagaa	tagggaaagc	ggtgaaggcc	960
cttttgagg	agttccctga	caaaggcttc	ttctttgcct	ttggagctgc	ttcacagtag	1020
ccttgaaaat	caggagcctt	gaactacagt	agctgtgaaa	actgtttgcc	taatgggtac	1080
tggaggggac	agaattgggt	caaagtccct	ccaaagctcc	atccttaaa	aatcatcact	1140
atttgacatg	tccaatagtt	ccctgaaatt	tccattccca	agcttgtctt	catttgacct	1200
gactcagagc	ttgctctgtg	tgaatagccc	tattcttagg	gtgtgtgttg	aaaacaatca	1260
gtagcagctg	tttaacatca	tagttgctgg	aaatagcaat	attaattgaa	gcttacaagg	1320
ggctgcccac	aaaacttaaa	agcaaaatcc	catagggggg	atagaaaagc	tctaaaatat	1380
tcctagagag	tcacatgcat	gagaagagct	gtgcacatgc	ccaggaaaga	cctgagaagg	1440
tcctaattctc	tcacctctgg	ctgatcttga	ggctctgtgt	aagcagagt	tgaagctaa	1500
ggcaaaagtc	taaattgcct	gttgaagcat	caaatacatg	cccccact	cacacagccc	1560
ctctgcaaa	gttgggaaac	ttgcaaggaa	tttaaggaaa	tctctgttca	gtcattagcc	1620
agccactaaa	ctaactgagc	agatccttca	gtgatcacac	acaacaaaga	atacagactt	1680
tacagactta	gtcctagaaa	atcactacac	aaacagcaac	acaatgcac	ctgggactaa	1740
gggagaggag	atgagttcca	gagttgggtat	attattttaa	tgtctagttt	tcaataaaaa	1800
caattataag	acacagagca	aaactagaaa	gtatggccca	taccagga	aaaacaagca	1860
accaatagaa	gctgtccttg	aggaagttaa	tatcttgagc	ttactagaaa	atgacttta	1920
cactagtatt	tataaatatg	ttcaaaaaac	taaaagaggc	cagggtgcga	ggctcacgcc	1980
tataatccca	gcactttggg	aggctgaagc	aggtgggtca	cctgaggtca	ggagtgtgag	2040
accagcctga	ccaatatggc	aaaaccctat	ctctactaat	aatacaaaaa	ttagccaggc	2100
gttgtggcgc	acacctgtaa	tcccagctac	ttgggaggct	gaagcaggag	aactgcttga	2160
aactgggagg	aagaggttgc	agtaagctga	gatcacacca	ctgtactcca	gcctgggcca	2220
caagagtga	actccatctc	caaaaaaaaa	aaaaaaaaaa	aaaaccctaa	aattaaccat	2280
atctaaagaa	ttaaaggaaa	gtttgagaac	aatatctcac	caatacagaa	tatcaataaa	2340
aatataaaaa	ttatttttaa	agaaccaa	aggaattctg	gaatttaaa	tgtaggaa	2400
gaaatgaaaa	attcactacg	ggggctgaac	agtagatttg	aactggcaga	agaagaatca	2460
acatacatga	agatagggtg	attgagatga	ttcagtatga	gaaagaaaaa	aaaaaaaaaa	2520

&lt;210&gt; 51

&lt;211&gt; 3337

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ggttgatttc	ccctcaactt	tccacaggta	tcttaaaagc	tttgcctact	catcccttct	60
ctgacttagg	atttgagcat	ctttctgtta	tgctgttgcc	ccactcctat	tgaataactc	120
ctcttcttaa	gaaagttttt	ctagactaat	gtctagatta	aacttctttt	ctttgacaat	180
aatgatgcca	tgacttggac	aaaatgcccc	ttgctcttgg	gtcctgtttt	cttcacccag	240
tgtctcetta	ttggactcct	tgtgcctctc	cttggctggg	gaaatcagaa	tacacagtgg	300
tatcccactt	ctaagatgcc	tgatctgaag	gacagtaaaa	caactgacct	ttgccagcat	360
gtaaaacaca	tggtttaact	agtcctccag	gaacaacamt	gagcaatcct	gacctgggac	420
tactttactc	ggccatctcc	tacttgagat	gctccttgtc	tctctgttca	aggacacctt	480
ttctgagcct	ttcttgaaca	agagtggagg	accgataggc	gattaaaactg	tccttgacac	540
aacttttagag	cttcwactga	gaatctagaa	gagagttagat	ggaaaaatat	ttttccctcc	600
cctccaaatg	caaggataat	cttacacgag	tccaggagga	aggctcattc	cacactaagt	660
gttctgaatc	aaaaagatga	acaaaaataca	gtgccattct	tcaaggrrctt	cacagtctac	720
aggaaaggw	tatagttaaa	caaataactg	cagaattgga	aattggagct	gatgtgctta	780
gaagtgtttt	gaacaagggg	catgactgtg	actctctctg	cttttgcaag	cttcaggaaa	840
acctttactc	acagttgaaa	atacagagcc	tcagggtgaa	gccctaactt	cccacagcag	900
atggggctta	tgaggaggaa	gaagtagacg	catggaccag	tcctgttatg	aagacaagtt	960
tcatggtgct	actgtgtctc	catgagctcc	tatggcccag	aagctggcat	cctgtgagtg	1020

tcttttgggca	agggttaagcc	tttactgcat	agcagaccac	acagaagggt	gtggggccacc	1020
agagaattttt	ggtaaaaaatt	tggcctctg	ccttgagctt	ctaaatctct	gtatccgtca	1080
gatctctgtg	gttacaagaa	acagccactg	accctgggtca	ccagaggctg	caattcaggc	1140
cgcaagcagc	tgcctggggg	gtgtccaagg	agcagagaaa	actactagat	gtgaacttga	1200
agaaggttgt	cagctgcagc	cactttctgc	cagcatctgc	agccactttc	tgccagcatc	1260
tgcagccagc	aagctgggac	tggcaggaaa	taaccacaaa	aagaagcaaa	tgcaatttcc	1320
aacacaagg	ggaagggatg	cagggggagg	cagcgctgca	gttgctcagg	acacgctcct	1380
ataggaccaa	gatggatg	acccaagacc	caggaggccc	agctgctcag	tgcaactgac	1440
aagttaaaaa	ggtctatgat	cttgagggca	gacagcagaa	ttcctcttat	aaagaaaact	1500
gtttgggaaa	atacgttgag	ggagagaaga	ccttggggcca	agatgctaaa	tgggaatgca	1560
aagcttgagc	tgctctgcaa	gagaaaataa	gcaggacaga	ggatttgctc	tgcacagaga	1620
tggaagagcc	gggaacagag	aagtgtgggg	aagagatagg	aaccagcagg	atggcagggg	1680
caaaggggtc	aagggtgagg	aggccagtgg	gacccacag	agttggggag	ataaagggaac	1740
attggttgct	ttggtggcac	gtaagctcct	tgtctgtctc	cagcaccag	aatctcatta	1800
aagcttattt	attgtacctc	cagcggctgt	gtgcaatggg	gtcttttggt	gaaatcaagg	1860
agcagacagg	tttcatgtgt	actgtcacca	cgtgggatgg	aaccagaggc	atggaagcaa	1920
gacgctaaat	gaagagggcc	ataagggctg	ggattcccag	gctccttagg	aacagcttgt	1980
cttttttttt	ttcctctcca	aaaaaaaaat	gtaaggagac	gtgacaagag	tgagactctg	2040
tctccaaaaa	aaaaaaaaaa	aaaaaaaaaa				2069

<210> 49  
 <211> 924  
 <212> DNA  
 <213> Homo sapiens

<400> 49		
ggcagcagag	acctccagac aatcccagaa gactctattg acttattctg tectgtttct 60	
ctttctaagc	atgaaaatcc agcaacacgg tttccacagg ctcttgaaag tgcctcggga 120	
gctcggttct	tagctcacct ctgtgacct tectgagttt gcttttcacc catgggttgc 180	
tgacctattt	cacccattcg gggatgatag ataactaagc caagtaaaag gggcataatt 240	
tactgcctgc	ccctgctttt ccaattatcc cattgagcc tcgctaattc tttcctcacc 300	
tctctcacct	ctcctcacct caccgagttc ttccatttgc tctgtcagac cactgggtat 360	
agtgatgata	acctgctttc actccgggtg tcatctcaaa caaaggcctg cttcaccaaaa 420	
tgggggtgtt	cagcagcgag cagctcacct ctcaccaca gctgctctgc acgtggctca 480	
gggagagtct	ctgagcacag atgtggaatg cagagtcccc ggcctcatgc tcacccttct 540	
tttagctgta	catcagcaaa ttctagttgg cttacctgtg caagttgggt ggagtctctg 600	
taacactgat	ggtcctaaat tgctctgtgg aagacaagg ctcatgcttc tcacaggaca 660	
tcattgccaa	gcaagtaaac ataagtcaca aggtctttga aaatttgcta ggtactctgg 720	
ccatgagctc	cactagactt cctccaagg atgacatcca gctgtatgag atagtttaaa 780	
gagatgcaaa	tgcacccaaa caggattatg cacaggattt taatttgct gtgcctaaac 840	
agttactcta	agaaaatttt caaatcaaca ctttgggtgt attctctgat atgggtttgac 900	
tctgtgtccc	cacccaaatc tcat	924

<210> 50  
 <211> 2520  
 <212> DNA  
 <213> Homo sapiens

<400> 50	
acgagcgcct	tgaggaggat gagtccctgg agctgggtcc tgctgcagac cctctgcctc 60
ctgcccacgg	gcgcagcttc gcggcgcggg gcgcccggca ccgccaactg cgagctcaag 120
ccccaaacaa	gcgagctgaa ttccttcttg tggaccatta agcgagacct accatcttac 180
ttctttggca	caatccatgt cccgtacacc cgagtttggg acttcatccc cgacaactct 240
aaggaggctt	tcctgcagag cagcattgtg tactttgagt tggatctcac agacccttat 300
accatctcag	ctctcaccag ctgtcagatg ctgccacagg gcgagaacct ccaagatgtg 360
ctccccagg	acatctactg ccgctcaag cgccacctgg agtatgtcaa gctcatgatg 420
cccttgtgga	tgaccccaga ccagcgcggc aaggggtctc acgcagacta cctcttcaat 480

<400> 47  
ggcacgagaa caatttccct tgtacataat atacttatgt acttatacca ttgactctgt 60  
aagataaaag tcttagaaat ggggttgcca agtcaaaggg tctatgcatt taacacaggg 120  
aatgagtact gtcacgtggc ttctgaaact gtttaccag tttatgttcc caccaacagt 180  
gtctaattcc catabctgtg ctaggtatta tgtctttaat ttttgtctga ttatttcatt 240  
taattttaat ttccattatc actggtgagg ttgggcttct gttcagtttt tttgtcattt 300  
atgtttcttt tgtgaattgc cttttcctat gctttgtgca tttttctctt ggggtttgtc 360  
tttttaaaat tgatatacag gtgttctcta taatatagat attctgccac tatatgcaa 420  
tgatcttcca atttatttat ttatttgaaa cagagtttca ctcttgtcac caggttgag 480  
tgcagagggt cgatcttggc tcactgcaac ctccacctcc caagttcaag cgattttcct 540  
gctcagcct ccctagtaac tgggattaca ggtgacctgc caccatgcc ggctaatttt 600  
tgtatttttg gtagagacgg ggttttgcca tgttgcccg gctggcctcg aactcctgac 660  
ttcaggtgat ctgcccacct cagcctcca aagtgtcggg attacaggcc tgagctaccg 720  
caccggcccc aatttatttc ttttaactta gtttatggtg ccttttagctg tacaaaagtt 780  
actaattttt agtcaaatat ccagcttttc ctttagggct tcttatatgt cctgatccaa 840  
ggattatttt ttaaaaattc ttccgtattt tctctataa tattcatagg ttactttaca 900  
attagatttt taatacatct cctaactttt tcatatagta tgaggatatcc atttttaaaa 960  
aatggatata cagttgtgcc catatgtctt ttccactcat ctgaaatgcc accattatca 1020  
tattttcaat ttctcatgtc acgtgggtct gttttcaaac ttggagattc tcttccactg 1080  
atataatgtc attcttgtgc cagtgggtta actgctattg ctttatagta tattttgata 1140  
tcttcttttc aaaaggatac tcttgtgtat tcttttttct atcttgtgta ttctcatcca 1200  
ttttccagaa aaccacagaa tcaactttaa gtttcatttc attaatgcag attagtgaga 1260  
gctgattttc tgtgtatcat gttcattcag aaacatagtc tatctctcca tttaggggca 1320  
cttggtttat attttcttct taacacgtat tttgttgggt ttattgtacc tttttttttt 1380  
ttaacttcag attcaggggg gtgcacgtgc aggtttgtta cctgagtata cgatatgata 1440  
ctgaggttgg agtatgaatg atgccattac ccaggtagct ggcataatac ccaatagtta 1500  
gtttttcaac ccttgccctt ctccctctct cctccctcta gtagtcccca gtttctaata 1560  
ctgccatctc catgttcatg agaaccaggt gtttagctcc cacttataag tgagagcatg 1620  
ttgcatattg ttttctgttc ctgccatata cttttagagg acatggatga aattggaaaa 1680  
catcattctc agtaaaactat cgcaagaaca aaaaaccaa caccacatat tctactcat 1740  
aggtgggaat tgacaatggg aacacatgga cacaggaagg ggaacatcac actctgggga 1800  
ctgttgtggg gttggcggag gggggaggga tagcattggg agatatacct aatgctagat 1860  
gacgagttag tgggtgcagt gcagcagcat ggcacatgta tacatatgta actaacctgc 1920  
acaatgtgca catgtaccct aaaacttaaa gtataatata aaaaaaaaaa agaacaaaaa 1980  
ttaaaaaaaaa aaaaaaaa

<210> 48  
<211> 2069  
<212> DNA  
<213> Homo sapiens

<400> 48  
ggcacgaggg ctctactccg ggcacagcat gcaggcccag ttctgctgct ctgctgtttg 60  
ttctgctttc ctccacatat tggcatcacc ctctggtgcc aagatggctg ctgcattcca 120  
ggcatcacat ccagactcag acccagagaa gctgcccac cctacctggg tgagcctttg 180  
taggaacgag aaaccgcata cagcagcaga aacctcacc agcagcgtct tttccggtct 240  
cattcaccag cgccgccac cgtcaacca atccctggcc aaaagaatgg gaccgcctgg 300  
aaggctggac caaacaggac ctgccctctg gggctgggga gagggccaga tgaaggctgc 360  
aggacaggat ggactcctag acctctgtta ccagcagtga ctacctctgt ctgggtggtt 420  
ggaacatggt tgaattttat tctaagtact gtctacaagt tctgcaataa accttgactc 480  
ttcttttaat aatgcaaaag gaatcgaagt gattgtttga aaggagagg aagaaagaga 540  
gaaggaggga gggagaatg ggggaggga cagagagagt cagagagagt agaattcagc 600  
caccggaaaa tccagaatag ctggccttgc ttaatccatg cctggaaata actgctgggt 660  
ttgcaacaac ttctctccc gagacagacc aaggaaacta caaaactgca ggaaggattg 720  
aagggccggg acagtggctc acgcctgtaa tcccaaagtg ctgaattaa cagctacca 780  
tccacacggc tgacctcata catcaagcca ataccgtgtg gcccaagacc cccaccataa 840  
atcacatcat tagcatgaac caccagagt ggcccaagac tcccagatca gctaccaggc 900  
aggatattcc aagggttag agatgaatgc ccaggagctg aggataaagg gcccgatctt 960

tttctgtttc	agatgctcaa	acaagagatg	gagcaggggc	aggggttggg	gttaaattggg	2760
ctggaggtga	gattggcccc	cctaaggtgt	tgaggacact	tggggtgaaa	gtcgttaggg	2820
tatatgtagg	tcagagccag	ggccgctgcg	tgacacagagg	tctgtcatgg	agcggccagt	2880
aggcaccaaa	atccagccaa	agctcggcca	tgagagctgg	gtagcggcag	gggtgacaac	2940
agtggccacc	ctggttaaggt	taaggtcaga	cttgggttag	tctaagctgt	cagagggtgt	3000
tcatcatttt	tcttaccttt	ccaatagtga	ccctattcca	aaggccttgt	ttcttgtgcc	3060
agagaagaaa	ctaaagtata					3080

<210> 46  
 <211> 2204  
 <212> DNA  
 <213> Homo sapiens

<400> 46						
ccacgcgtcc	gctttccccc	acattttcca	agctctgggc	agctggagta	actgtgtgta	60
cagacttttc	tatgtgcgtg	tgtgggtgca	tgtatgagtg	tgtgtgtgtg	tttgtgtgtc	120
tgtgtattta	taggggaatg	agagtgcctt	gggtgtgcac	tttagatatt	cctctgtaca	180
tctgtgtgtg	gcttacatgg	acacattctg	tgtacttata	ctgtgtgtat	acacatgtgc	240
agcccatatg	tccatacata	ggtgtgtgtg	tatactatgt	gtgtactttg	tccacttatg	300
gatgtgtgtg	tgtaccattg	agtccatata	taggagagag	agagaatgtg	tgtgtgtgtg	360
tgtccatgta	tggatgtgtg	gatattctat	gtctgtattt	agagtgcagg	tatatggatg	420
tcatgtgtgt	gtgtgtgtgt	gtgcgcacac	acactctgcc	tctttgtgtg	tgtgcatgtg	480
tgtaccttgt	gtgcccatgt	atcgggggtg	tgtgtaccct	gcttgtctat	gtatggggga	540
gcacatgtag	cctgtgagtc	ttattctgct	gggcagtgtg	tggagtgggtg	gggaggctga	600
gcatgaaagg	ccacttgtgc	cagttggagg	aggggtgggc	gctgctgcct	gctgcctcag	660
gacttgggtg	gcctgtggga	ggcggggctc	cacccaccag	ccttccctgt	tctcggtccc	720
cagtttaaga	ggcaggttca	ggagtccacg	caggtgctac	gggagctgga	gacctccctg	780
aggaccaacc	acattgggtg	agtgagggct	cagatcttcc	tctctggggc	taggaaggct	840
ctgcttccag	gcagctcctg	gagcttcccc	ttcctactcc	ccctgcccc	tgacaaaggc	900
tgtgcttgtg	gaccacctcc	tggaggtgtc	caggacagct	tcccctcccc	ttcctgcccc	960
tgtcttgact	ggcaccttga	ggcatggctg	ggctgtggga	cccacctgag	tctcccagaa	1020
tcttttggtg	tcattgggtc	tttgggggtt	gaaagggcac	cccaggggtc	cttgcgtgtc	1080
ctgttctgtg	cccatgtggg	gcaggacctc	ctttctggct	ggagctcagg	gagccctgtg	1140
cccacagggtg	ggtgcaggag	ttcctcaatg	aagagaaccg	tggcctggat	gtgctgtctg	1200
agtacctggc	ctttgcccag	tgtctgttca	cgtaagcccc	ctgctcccag	ccctcatgcc	1260
gctcctcaga	gctttgatcc	cgtctcctcc	gcatctcacc	cactccctcg	gccagtttca	1320
agccaggcag	ccgagcctac	cctggaaccc	tccacttggc	cttgagcgat	gctccttcca	1380
gaaggcctgc	ccccgacagg	gaggggtggc	tctcttccac	cactatgttc	agcacagtgc	1440
caagaacaca	gcctcctcct	cctgctcctt	agtctcacct	gcaggtctgt	ctctccttgc	1500
gtttcctctg	ccccctttta	agtggcccc	gcagtgttgg	cctccagccc	cattgcatcc	1560
tgtccccagg	tatgacatgg	agagcacaga	caacgggggt	ccaactcaga	gaaaaacaag	1620
ccccctggagc	agtctgtgga	agacctcagc	aaggggtccac	cctcctccgt	gccccaaagc	1680
cgccacctga	ccatcaagta	tgtggggccac	aaagtggggg	gggtgggagaa	cagagaattc	1740
agccccccaca	ctgctgcatc	tagccagccc	accccggggc	cttgggggtg	gcgagagggg	1800
tagccatgca	ttaggggtcc	gagtaaggga	ctcatacaga	gtttgggaca	ccagtatgtt	1860
aagaagccat	caggggtggg	gctgggtgct	gtggctcatg	cctgtaatcc	cagcactttg	1920
ggagactgag	gtgggcagat	catttgagga	catgagtttg	agaccagcct	ggctaaccatg	1980
gtaaaccccca	tctctactaa	atacaaaaat	agccgggttg	gtggtgcacg	ccttaatcct	2040
agctactcag	gaagctgagg	tgggagaatc	gctggagccc	aggggatgga	ggttgcatgtg	2100
agctgagatc	gcaccactgc	actgcagcct	gggtgacaga	gtgagaccct	tctcaaaaaa	2160
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa		2204

<210> 47  
 <211> 1998  
 <212> DNA  
 <213> Homo sapiens

atcaaggagc	ccatcgaagg	agactgtgga	gccaggactc	tgcccaacaa	agacttagct	1260
aagcagtgac	cagaacccac	caaaaactag	gctgcattgc	tttgaagagg	caatcatttt	1320
gccatttgtg	aaagttgtgt	tggatttagt	aaaaatgtga	ataagctttg	tacttatttt	1380
gagaactttt	taaatgttcc	aaaataccct	attttcaaag	ggtaatcgta	agatgttaac	1440
ccttggtatt	tagaaaatta	aaaccttata	atatttttct	awmaaaaaaa	aaaaaaaaaa	1500
aagggcggcc	gctctag					1517

&lt;210&gt; 45

&lt;211&gt; 3080

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

ccctctaacc	tccagagcta	tgggtctcaga	tgttctcttt	tagagagaag	gtcatttagtc	60
caccaagaag	ccaaatgaca	acaggaaaagg	tgtatgggaag	atgaaaacaa	aggaagggtgg	120
acttttgggt	atatgttata	gccatgtatg	tatgtcttct	ttttctctatt	ttctcttgtt	180
cttcacttta	actgtcctca	atctgcccc	caccaaccct	gtgtcactcc	cagcacacat	240
aagacagagc	agaagacccc	atccttgagc	tgggtctcccc	tggttatggg	ctgagggtaac	300
atcccacaca	ccaggacgat	cttccctgcc	tcccatcggt	cacattaaga	cattttcaaa	360
gtgtaatat	ataaatggac	ctacctctaa	atattgactt	tacagttatt	ttatgaggca	420
ctcaatttat	agctaagggt	tttcagtcta	gtgtcatgaa	agagataaaa	gggtgttcac	480
agattattta	agacataagg	ctgggtcaggg	atgagtcaga	gagtcattct	ccatgaagtc	540
acccctggcc	aactttgaaa	ggaagaatgt	ttaactgcac	tttgggctga	aatgacaagc	600
atctggggacc	ctcccccttc	ctgatccctg	ccaccaccac	tcaatcgggc	agataatcaa	660
ttgtttctga	ggtcactttc	acataatctt	ggcaacttta	gttgttgaaa	gcatgcatgc	720
aggggcaaca	tggtgttacc	tgtttgcttt	tttttcccc	ttctaagctc	cttaccagag	780
agcagatcta	aggatactgt	gtaacttgaa	ataaccggca	ttttcagact	ttgccatttc	840
atagtccata	gggcaagcca	cttttcaggg	atatccacat	ggtgggaggg	aaatcttgac	900
attggcttct	cagaaaatat	ctgcctagtc	acacctggga	attcactaaa	cacccaaatg	960
cagtgtttga	tgtggcctta	cctgtctcct	gtatcttatt	ggattgaatg	agaacagatg	1020
caaaacaagt	atgtacagaa	atgccaggaa	aactactgtc	ttccaatggg	gttcaacagt	1080
tcaaagccct	ccattgatgg	agccacttag	gaggtttcag	tgtcttaatt	cttttagatt	1140
ttgacagttt	tagaaaacta	aaaaaaaaaa	aaacaagttt	ttatcgtgaa	atttgattac	1200
aaaagatttt	gagagaaatg	ataagaacca	gatctgaaga	atttgaaatt	tgaaaattca	1260
gcagagcatt	tttttaaatg	tatcttgtac	aagatgaact	aaataaatgt	ttttaaactg	1320
acttcttttt	ggtggatttc	aaaagttaac	cttcagactt	atttagaggg	ttttcataaa	1380
gcaagttttt	ttctgttgct	gctcaatttc	tttcttttct	ttctatctct	ttcttttctc	1440
ttccttttgc	tgttccctgt	gtgtgaagca	ggaggggcag	ctgaaatgct	ttgcatactc	1500
accctgggtca	ttttccagtt	aggacaagct	caaagggaga	gcacagctca	gaagggtggc	1560
ctcatgactc	aggaataaat	ttgtggctca	tttgaaagca	gcatcttcta	agtggtgtgc	1620
aaaatagaga	aaaatcaaca	gggtgttggg	gtgtttattt	tccccactgc	gtatgaaagc	1680
tggtgtctgt	gccctttgat	ggccaagagg	agctcctggc	agccgtggcc	atgtgtcccg	1740
gggtgtgtgg	ggcaggcggc	agttcttggc	agccttctct	gcagggtgc	ttcctgacct	1800
tgcttcaaag	ccttctgggc	tgtagaccac	acagagctca	ccctcaagca	gccacgctgg	1860
accacattgc	tttcaactgat	tttgactcat	ctccccata	gtgcagtgtg	tccaagggtg	1920
gtgtgtgggtg	acacagccgt	gtgttcgtgc	tgtacggcac	tgtgggtcatg	ggggtgacgc	1980
tggagctcct	gattagtctt	agttcaaate	ccagcctcgc	tggtgggcat	gcttagaaca	2040
gaccctagca	ggcgccaagc	cccagtaagt	ggtggagtca	ttggtaaagg	ataatgctga	2100
atgcaggaca	tttatatgga	tgaaagagta	tgggaaaggg	aatttcagtg	atatgaattc	2160
caaagcgtgt	tagtatattt	tataagaaac	aaaaagggtat	tcaccagcac	caccaaactc	2220
catcatcagt	cacaggcaac	caagaattga	tcactctccc	agaactttgg	gaggccgagg	2280
caggcagatc	acgaggctcag	gagatcgaga	ccatcctggc	taacacggtg	aaaccccgctc	2340
tgtactaaaa	atacaaaaaa	aaaaaaagaa	aaatttagccg	ggcatggtgg	cgggagggtg	2400
aggcaggaga	atggcgtgaa	cccgggaggc	ggagcttgca	gtgagccgag	atcacgccac	2460
tggactcctg	cctgagtgac	agagggagac	gccgtctcaa	aaaaaaaaaa	aaaaaaaaaa	2520
gaattgagca	ctcaagtcgg	tcttctaaac	tgctgaacc	tcttgagatg	agaagaacaa	2580
aacaaacctg	cgtgtgctgt	atgtagggtta	ccctaattgga	gcttccctggg	ttctcctctc	2640
cctgtcacat	ctcagggact	ccaccttatt	ttaaagctgt	cttactagca	ctgttggact	2700

tgcttcaagt	gttgttggaa	gtggaggcag	cagtgacaag	gggaagcttt	ccctgcagga	960
tgtagctgag	ctgattcggg	ccagagcctg	ccagaggggtg	gtgggtcatgg	tgggggcccg	1020
catcagcaca	cccagtgcca	ttccagactt	cagatcgccg	gggagtgggc	tgtacagcaa	1080
cctccagcag	tacgatctcc	cgtaccccga	ggccattttt	gaactcccat	tcttctttca	1140
caacccaag	ccctttttca	ctttggccaa	ggagctgtac	cctggaaact	acaagcccaa	1200
cgtaactcac	tactttctcc	ggctgcttca	tgacaagggg	ctgcttctgc	ggctctacac	1260
gcagaacatc	gatgggcttg	agagaggagt	cctgccaaagc	ccagaagttg	tgctcttggc	1320
cttgctgct	catctcggag	gcggcagcaa	cacttcgctt	tggcttgaat	ttcagtgtcg	1380
ggcatccctg	cctcaaagct	ggttgaagct	catggaacct	ttgcctctgc	cacctgcaca	1440
gtctgccaaa	gacccttccc	aggggaggac	attcgggctg	acgtgatggc	agacaggggt	1500
ccccgctgcc	cggctctgcac	cggcgttggtg	aagcccgaca	ttgtgttctt	tgggagccgc	1560
tgccccagag	gttcttgctg	catgtggttg	atttcccat	ggcagatctg	ctgtcatcc	1620
ttgggacctg	cctggagggtg	gagccttttg	ccagcttgac	cgaggccgtg	cggagctcag	1680
ttccccgact	gctcatcaac	cgggacttgg	tggggccctt	ggcttggcat	cctcgcagca	1740
gggacgtggc	ccagctgggg	gacgtggttc	acggcgtgga	aagcctagt	gagcttctgg	1800
gctggacaga	agagatgcgg	gaccttgtgc	agcgggaaac	tgggaagctt	gatggaccag	1860
acaaatagga	tgatggctgc	ccccacacaa	taaattggtaa	cataggagac	atccacatcc	1920
caattctgac	aagacctcat	gcctgaagac	agcttgggca	ggtgaaacca	gaatatgtga	1980
actgagtggg	cacccgaggc	tgccactgga	atgtcttctc	aggccatgag	ctgcagtgc	2040
tggtagggct	gtgtttacag	tcagggccac	cccgtcacat	atacaaaagg	gctgcctgcc	2100
tgtttgtgtg	gttgaactct	tcactctgct	gaagctccta	atggaaaaag	ctttcttctg	2160
actgtgacct	tcttgaactg	aatcagacca	actggaatcc	cagaccgagt	ctgcttctctg	2220
tgcctagtgt	aacggcaagc	tcggcatctg	ttggttacaa	gatccagact	tgggcccagc	2280
ggtccccagc	cctcttcatg	ttccgaagtg	tagtcttgag	gccctggtgc	cgcacttcta	2340
gcatgttggg	ctcctttagt	ggggctatct	ttaatgagag	aaaatctggt	ctttccagca	2400
tgaataacat	ttagtctcct	caaaaaaaaa	aaaaaaaaaa	aaaaactcga	ggggggggccc	2460

&lt;210&gt; 44

&lt;211&gt; 1517

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (144)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 44

gttagtctct	tgggtgtgct	tttaattggtc	tctctgcctc	ttccttaggt	gtcaggctgc	60
tctacctgtt	tctagacgct	cttcttttcc	cccttccaaa	cctcttttct	tccttgctgc	120
tttctatct	tctgtggcta	gganatcagg	taatcaagcc	tgtgttttct	gtaatgagta	180
agtgggttgc	cagcgagggtc	tctgtggatg	ctcctgtgag	tcaagtgcac	gagctttagt	240
gcatggactt	tggggctcttg	gttcccacag	cttatatgtt	ttgggggctg	ctttcttgct	300
ctttaccac	attctgtgtc	atgagtgtgc	cgggtagggtg	gcctcctgcc	cgatggaggc	360
tgagcatctt	ggcagtgtcc	atcatgcctt	gcgtgtgcct	ggcctctttg	ctgcagatac	420
tatggaccgg	cagctcatcc	cctgctcacc	acctggcctc	tccttttctc	tgtgtgcaga	480
tctggcagtg	tgggtgggkt	ctggaaacac	acccatgttc	ccatgttggc	catgttttcc	540
ccaagcaagc	tcctacttcc	cgcaacaagg	ctctggccaa	cagtgttcgt	gcagctgaag	600
tatggatgga	tgaatttaaa	gagctctact	accatcgcaa	cccccggtgc	cgttgggaac	660
cttttgggga	tgtgacagag	aggaagcagc	tccgggacaa	gctccagtgt	aaagacttca	720
agtggttctt	ggagactgtg	tatccagaac	tgcattgtgc	tgaggacagg	cctggcttct	780
tcgggatgct	ccagacaac	ggactaacag	actactgctt	tgactataac	cctcccagtg	840
aaaaccagat	tgtgggacac	caggtcattc	tgtacctctg	tcatgggatg	ggccagaatc	900
agtttttcga	gtacacgtcc	cagaaagaaa	tacgtataaa	caccaccag	cctgagggtc	960
gcattgctgt	ggaagcagga	atggataccc	ttatcatgca	tctctgcgaa	gaaactgccc	1020
cagagaatca	gaagtccatc	ttgcaggagg	atggatcttt	atttcacgaa	cagtcacaaga	1080
aatgtgtcca	ggctgcgagg	aaggagtcca	gtgacagttt	cgttccactc	ttacgagact	1140
gcaccaactc	ggatcatcag	aaatggttct	tcaaagagcg	catgttatga	agcctcgtgt	1200



ccacccgctg ga

1692

<210> 42  
 <211> 1605  
 <212> DNA  
 <213> Homo sapiens

<400> 42  
 ccacgcgtcc gaattttcttc agtttggtta aggggaatttt tttaaaacta attcagaact 60  
 tatgattcct ttttcacctc agaagttaac cctatggaaa atgtggcaat gtttctgaga 120  
 tttgcaaaat attgtgatag tatctatgtc ttattgtctc agatctaaac tcttatgttt 180  
 gggagtaggg gtttgcgtgtg tatgtgtgta ttttttttta acatcttggc ctacacagtgt 240  
 aaagtataaa gctcaggagg aatgttgtgc tgcagaacgc ctacattact agattactta 300  
 cggcaacact ttctttaatg aggatctctg tgaaaccatc tttttttcca cttacagttt 360  
 caataagagg agatcagtat gaaattaagt aggagagaac aatatgagag agagagagaa 420  
 gagttcagca ttctctctca agctagctaa tatttttaaa atgtcgacac tgttccagga 480  
 actctgcttt ttaggcaaaag attctgccct ggtcttcgtc ctctccacac cccagcatc 540  
 tcgtgggctg acacatcaac agggtttgag aaagagacac aaaagggtcag acgcatgaca 600  
 cagcaggaac ccaggaggac gtccctgcag cctgctctct tctaatagat ctccccagc 660  
 cccagttcc cagcctctga cccagtcct acctttataa tgtccctttc tctctatttt 720  
 ctctccggtg ccacttttcc ctccatttag cctctctct catccctcc tgttatcaca 780  
 gctgagctct acaactgagc tgagcaatat atacaaaact caagcctggt ttaggcaggc 840  
 ctgacccctg ggatagggtc gggcgggtgt tcttgggag aattcctgct tgatgagatg 900  
 gaagggtccaa gtcaatagcc tcatgggtccc cccaagtctg acagtctgct attctacaca 960  
 cctgtccaca ggctgcagac ttataaagggt aaatgttcag gtattagaaa atattcaaag 1020  
 aattctcaat gttcaaaatt ctgaaaagca aatctatgct gaatgtgtgg tggaggcatt 1080  
 ctaaaagata aaaaatgatg gctacaaaaa gccaaagtata aaaagaaaca cgtacatata 1140  
 cacacacata cacctacaca tgtacattcg aagaggcaga ggagagacag agaaaataat 1200  
 taagacagca ttagttccta aatagccttt tctataaact ccatgacaac aaaggacaat 1260  
 gagtaaaactg cagtatctaa agatttaaat ctcagaaatc ctgccagatg ccaggcatgg 1320  
 tggttcacac ctataatccc agcactttgg gaggccaagg cgggtgaatg gcttgagttc 1380  
 aggagttcga gaacagcttg ggcaacatgg cgaaaccctg tctctacaaa aaatacaaaa 1440  
 attagctgag catggtagcg cacacctgta gtcacagcta cttgagaggc tgaggcagga 1500  
 gggtcaccta tgcccaggaa gtcaaggctg cagttagctg tgatcacacc actgcactcc 1560  
 agcctgggtg acagagcaag accttgtctc aaaaaaaaaa aaaaa 1605

<210> 43  
 <211> 2460  
 <212> DNA  
 <213> Homo sapiens

<400> 43  
 actgcaggaa ttccggcacag gaggcatagg gctgcgtgtg aggagtgggc cattgcatgg 60  
 gcttctccca gtttggtctt ggatttttga gctctctgaa tttgttgttt gtgtcctttg 120  
 cacagtgtcc ctcccagggt gcacccatgc ctgcccctca ggggtcccca ctcccagtga 180  
 atttcacacc atgcagcatg tactttaagc catacatctt acgtatgttc cagacatttg 240  
 gtaaaacgcc gtttatgtgt ttttcagtga ctcacaaaac ttttatttac gtagatgagg 300  
 aatgtactca ggcacccttc gtgatacctt gccctcagca ggcactcaac agcaataata 360  
 actttcattc cttttgtgct tctcttaaca gttcgtgttt agtaggagca cagtagctgt 420  
 ttggggaaac accttaagtg aatagatgtc tgaaatgctg tgtgaagtgg ggcgcttaat 480  
 aggtggtgag atggttttag aaccagggtt ttccctcttt gcttcttgac tcttaacca 540  
 gttttcatta ggagaccctt ttggagggtt gcagtcagtc agagttgagt gcctactgag 600  
 tgtactgaat tatgaaatga gcacagttcc cattaacctg aattttttgc tcccaagtaa 660  
 gtcttgattt ctgatttatg actgcttttt gttgtaccoc aatagtcgtc taagaaagg 720  
 gattattttg agaggcctgg ggagacacac atgtctattc tcgagggtgg cgggtggtgca 780  
 gagggcagag ccatgctcgt tcttgctatc ctgagattgg ttgctatctg tttcctttgc 840  
 tgctgtgttt ttttctgtca gtattaaagg tggaagaagg tccatatctt tttctgtggg 900

tacagaatta	cgcatattcca	cttctaataga	caccatcatc	cgagcagtat	tgatttttgc	1260
agaaggaatt	tttacagggtg	aaagccacgt	ggtacatccc	agcatccaca	acctctccag	1320
ttccatctgc	atccctattg	tgccctccaa	agatgtccct	gtggatctgc	acttgaaggc	1380
attcgtgggt	tacagaagca	gcacccagtt	tcatgtatgt	gaatcgacaa	gacagctccc	1440
tcgattctcc	atgtatgcgc	tgaccagcct	ggaccctgcc	agtgaagcaa	tcagttatgt	1500
taactttacc	attgcagaac	gggcacagag	gtaaaactag	aaagaaggag	aactcttccc	1560
tcaagaatgg	ctgtaccttc	atatctagag	gcacattaaa	aaaaagaacg	tctgtacctt	1620
aaaaaatggg	gtcatttcat	tgtgttcatt	ttcaagggtg	ttgtatggct	cggtcagaac	1680
tttctgttac	cagaagacac	tcacattcag	aatgctccat	ttcaagtgtg	tttcacatct	1740
ttacggaatg	gcggccacct	gcataataaaa	ataaaactta	gtggagagat	cactataaat	1800
actgatgata	ttgatttggc	tggtgatatc	atccagtcaa	tggcatcatt	ttttgctatt	1860
gaagaccttc	aagtagaagc	ggattttcct	gtctattttg	aggaattacg	aaaggtgcta	1920
gttaagggtg	atgaatatca	ttcagtgcat	cagaagctca	gtgctgatat	ggctgatcat	1980
tctaatttga	tccgaagttt	gctggtcgga	gctgaggatg	ctcgtctgat	gagggacatg	2040
aaaacaatga	agagtcgtta	tatggaactc	tatgacctta	atagagactt	gctaaatgga	2100
tataaaattc	gctgtaacaa	tcacacagag	ctggtgggaa	acctcaaagc	agtaaatcag	2160
caattcaaag	agcaggtcgt	ctgcggtgtg	gaaaaccaaa	gaaccagggtg	atcactgctt	2220
gtcgggatgc	aattcgaagc	aataacatca	acacactgtt	caaaatcatg	cgagtgggga	2280
cagcttcttc	ctaggggcca	agaaatgaag	cttcaggcct	gtgaagtgtg	agagcagcaa	2340
gaatagtgc	tcagagcgaa	ataacttcat	gcactccttc	aatatctcag	gaagcttact	2400
ctcctcagct	ttctcataaa	acctgaaaaa	cagcaatgtc	aagttgttca	tcaaaagcac	2460
agatgtaaaa	tgactcacag	aataaaagct	gatcgttaaa	aaaaaaaaaa	aaaaaaaaaa	2520
aaaaaaaa						2528

&lt;210&gt; 41

&lt;211&gt; 1692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

ccacgcgtcc	ggccgcgggg	cgggcgggcg	cggcggcggg	ggcggccggg	accagcggg	60
ccaggtgggg	acggcgcgga	gcggtgctgg	gagatgcctg	gcgggactgg	ggccacctga	120
gccgcccggc	tcgtccccgc	cttctgtggg	aaggatgtgc	gcgcggatgg	ccggtcgcac	180
aacagcggcc	cctcgggggc	cctacggccc	ctggctctgc	ctcctggtgg	ccctcgccct	240
ggacgtcgtg	agagtggact	gtggccaggc	tcccctggac	cctgtctacc	tgccggcagc	300
cctggagctc	ctagacgccc	ctgaacactt	ccgtgtgcag	caggtggggc	actaccacc	360
tgccaactcc	tctctgagct	cccgatctga	gacctttctg	ctctacagc	cctggcccag	420
ggcccagcca	cttctccggg	cctcctaccc	accttttgcc	actcagcagg	tggtccccc	480
tcgagtcact	gagccccacc	aacggccagt	cccatagggac	gtgcggggccg	tttcagtgga	540
agcggctgtg	actccagcag	agccctacgc	ccgggttctc	ttccacctca	aagggcagga	600
ttggccacca	gggtctggca	gcctgccctg	tgcccggctc	catgccacac	accctgcccg	660
cactgctcac	caagcctgcc	gcttccagcc	atccctgggc	gcctgcgtgg	tggagctgga	720
gcttccctcg	cactggttct	cacaggcctc	caccacacgg	gccgagctgg	cctacacgct	780
tgagcctgca	gctgagggcc	ctgggggctg	tggtctccgg	gaggagaacg	accctgggga	840
gcaggccctc	ccagtggggg	gtgtggagct	gcgcccagca	gacccccgc	agtaccagga	900
gttacctctg	gacgaggctg	tgactctcgc	ggtgcctgac	atgccagtgc	ggcccggcca	960
gctctttagt	gctaccctcc	tgcttcggca	caacttcaca	gccagcctcc	tgacctgctg	1020
gatcaagggtg	aagaaggggc	tgcatgtgac	agccgcccgc	ccagcccagc	ccacactctg	1080
gactgccaaag	ctggaccgct	tcaagggtc	caggcaccac	accacctca	tcacctgcc	1140
ccgtgctggg	ctcacagagc	cagattccag	cagtccccct	gaactgtctg	agttectatg	1200
ggtggacttt	gtggtggaga	atagcactgg	tgggggcgta	gcggtcactc	gcccgcgtac	1260
gtggcagctg	tgtatcccag	gccaggcccc	tgaagcagag	aaggacaaaa	tggtgtggga	1320
aatcctgggtg	tcctgagcggg	acatcagagc	ccttatccca	ctggccaagg	tgctctgaggc	1380
ctgtgatgcc	gtgttcctgg	ctggcaagga	gagccggggc	gcccgggggg	tgagagtgg	1440
cttctggtgg	cgccggctcc	gcgcctcgc	gcggctgacc	gtgtggggcc	ccctgctacc	1500
gctgcgtatc	gagctcaccg	acaccacct	cgagcaggtc	cgcggtgga	gggtacctgg	1560
ccctgctgaa	gggcctgcgg	aaccgcgtgc	agaggcgctg	gatgaggccg	agcggcgccg	1620
ccgtggctgc	cacctgcagt	accagcgggc	cggtgtgcgc	ttctcgcgcc	ccttcgcggc	1680

gaacgggcct ctccctcctg caggccgtct gggcgactca ttagtgcccc ctgcagtcg 719

<210> 39  
 <211> 1269  
 <212> DNA  
 <213> Homo sapiens

<400> 39  
 ggcacgagca gggctaagcc tcctgtaaaa tgctctttaa gattattgta gcaagaacag 60  
 aaatgctgca tggctggggg tgggggagaga atgccaacga gacagctgca tttcaaacag 120  
 ttacagctgc aaggattact catagtaata gcagtgacag acaactgttt gagctttagt 180  
 gtaaaaggca atttggggac ttgccctgtc agaatttttag tagcaagctt ctgtgtgcac 240  
 gtgtgtgtgc atgtgcgtgt gtatttttatt caaattagtt tgtgtctgaa gagtgggaagg 300  
 aaatatttta aatttttact tctcaattgt gctaattgtt aaatcagtag ttgactcatc 360  
 tttattaaaa tcattgtcct agaggaagtt tataaaatgt ttattttag caatgatgaa 420  
 tttaaatgta tatgttctaa ctgaatcaca tgtctgcttt tccgtctcaa aatttatctt 480  
 gtgatgattc ctgtttttaa aatatgtgtt ttccttgtaa tityctgaaca tacagccttg 540  
 tytaatatag gatccttatt ttaaaaattt atttcaaata tgatgtmagc ttataaaagt 600  
 aatgcctgtc atgaaatctg gaaaatactc aaagaggtaa aggagaaaac aatcattatt 660  
 ctagcagaga taactgtcaa ttttaaatacc ttctggaccc ttgtttatgc attctagagc 720  
 atattaagag catgttaatc atkttaaagg ttaaaaatgg taatcatttt aaaaaatatt 780  
 tggagaaggt agcaaattgg gacaaatttg gttttgagaa gtcaataaca gccattgtgc 840  
 aagatttctt tttcagtggt cagctattaa agtaacattg cagcctgttt tctgtagcag 900  
 ttgtcttttg aaggccttgt acagtttatc tcgaaattta gttttatggt ttccttcaat 960  
 ttaaagtttg ctggctttac agggagtcct gtgatccatt gaaatgctaa cttgggtcgt 1020  
 gtctcaactg ctacaatgct gtgtagaaac tgtcattaaa attctggtta tcttgcaact 1080  
 ggcagagaac ccatgctgat tccttaggaa gatagtacac tgttaaaatt ttgaatcgca 1140  
 attgtgcttc tgtctgcaa atattatcaa tatttgaat cacttaaggt tgaaatagtt 1200  
 tgaataaat ggaacgtttt agtatgtatc ttctaaaaaa aaaaaaaaaa aaaaaaaaaa 1260  
 aaaaaaaaaa 1269

<210> 40  
 <211> 2528  
 <212> DNA  
 <213> Homo sapiens

<400> 40  
 ccacgcgtcc ggtcagctgt ctgactgcag gcgtattgaa ccctgagctt ggctatgatg 60  
 ccccttttagt ggggacacag actaatcttt tggcttatga tgtctacaat aattcggatt 120  
 tgttctacag agaggtagca gatggggcaa atgcaattgt gctggggaca ttgggagaca 180  
 tttcttcccc tcttgcgatt attggtggca attgtgctct gcaagggtttc aatcatgaag 240  
 gaagtgatct cttttggacg gttactggag acaatgttaa ttccttggcc ttgtgtgact 300  
 ttgatggtga tggaaagaaa gagcttcttg ttggatctga ggattttgat atccgagttt 360  
 ttaagggaaga tgagattgtg gcagaaatga cagaacaga gatagtcacc tctctttgtc 420  
 ccatgtatgg cagtcgattt ggttatgccc tttccaatgg cacagtggga gtttatgaca 480  
 aaacatcccg atactggaga attaaatcga aaaatcatgc catgagcatt catgtttttg 540  
 accttaattc tgatggagtg aatgaactga taactggttg gtccaatggg aaggttgatg 600  
 ctggaagtga ccgaactggg gaggtcatct ttaaggacaa tttttcttct gcaattgccg 660  
 gtgtggtaga gggagattac cggatggatg gccacataca gttaactctgc tgcctagtg 720  
 atggggaaaag taaattggga tgagaaaaat ccttaaaaag tcacgttttc catttgattg 780  
 ggtcaaaaata tcaggaaatt tcacctgaag tatttgtacc gagatcctgt agttctaata 840  
 aattcaccaa agttggggag aacttaggtt tttgttttaa gagcaggtaa ttgatgacct 900  
 aaaagtatac ctggttatac ttgctgtttt ttccttctgt tcagtcgggg gctacctgcc 960  
 tggcacggct gagatgaggg gcaacctcat ggacaccagt gcagagcagg acctgatccg 1020  
 agagctgagt cagaagaagc agaactctgt gctggaactc cgtaactatg aggaaaatgc 1080  
 caaggctgaa ttggccagtc cactgaacga ggctgatggg catcggggca taatcccagc 1140  
 caataccagg ctccacacca cgctctcagt cagcctgggg aatgagaccc aaactgctca 1200

gtaatatatta	aaattacaaa	atagattgtt	aactgttaca	ctgtggcatt	ggaattttaa	660
ctctttgtat	ttactggtat	gagagggcta	tctacaagg	taatatctt	gattaccctg	720
gtttacagaa	acctccagca	gtctttgaaa	catctcacat	gactctagtt	attgattgct	780
tttaattggt	ttatggtact	gttgatagtc	atagtggctg	cctatagaac	aatcttcaa	840
ctgagccatg	cttttagggga	gggaaagggg	ctaaagtctc	ttctgttggg	aatttattag	900
ttactcttga	aacagtaaaa	tccaacagaa	aggaagagat	agctactgta	tattacagta	960
aagaaagctg	catagttatt	ttaaatttaa	tggagatgaa	tatgggttaa	atatataact	1020
actgctgctt	gagaatagca	agagtattgt	tttaaaacat	attccacca	acttgagagt	1080
tcttttaaaa	tgattggcca	tatgaacatt	tgtaatcttg	ccattagggt	tggacctgcc	1140
atattttgtt	ttattctgtg	atcctaacta	gttcctttta	ataggctaaa	atatttatca	1200
atactgatca	gacttttaaag	aaattacttt	gtaaacctgc	tgactacctg	tatgtattgt	1260
atataatta	tatattaagt	atataatata	ttgagattat	aaaagatgaa	aattattgaat	1320
ccttataata	ttttaagttg	cagaatgtat	gttaaaaagt	gacttgaatg	agatgtattt	1380
gtatctagaa	atttttattt	tttttggaat	gagattaaaa	tacattttga	aagttcaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	aaaaa				1465

&lt;210&gt; 37

&lt;211&gt; 985

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

ggcacgagcg	gcgccacgag	gcggccggac	ccgcagcccc	gatgctgctg	acgctggccg	60
ggggcgcgct	cttcttcccc	gggtctctcg	cgctctgcac	ctgggcgctg	cgccgctccc	120
agcccgatg	gagccgcacc	gactgctga	tgatcagcac	caggctggtt	tcctcggtgc	180
acgccgtgct	ggccaccggc	tcggggatcg	tcatcattcg	ctcctgcgac	gacgtgatca	240
ccggcaggca	ctggcttgcc	cggaatatg	tgtggtttct	gattccatac	atgatctatg	300
actcgtacgc	catgtacctc	tgtgaatggg	gccgaaccag	agaccagaac	cgtgcgccct	360
ccctcactct	togaaacttc	ctaagtcgaa	accgcctcat	gatcacacat	catgcggtca	420
ttctctttgt	ccttgtgcca	gtcgcacaga	ggctccgggg	agacctggg	gacttctttg	480
tcggctgcat	cttcacggca	gaactgagca	ctccgtttgt	gtcgctgggc	agggttctga	540
ttcagctaaa	gcagcagcac	acccttctgt	acaagggtgaa	tggaatcctc	acgctggcca	600
ccttcctttc	ctgcgggac	cttctcttcc	ccttcatgta	ctggctctat	ggccgccagc	660
agggactaag	cctgctccaa	gtacccttca	gcacccatt	ctactgcaac	gtggccaatg	720
ccttcctcgt	agctcctcag	atctactggg	tctgtctgct	gtgcagggaag	gcagtcgggc	780
tctttgacac	tccccaagcc	aaaaaggatg	gctaaatgct	cctgggagtc	agggcgagcc	840
tcacaccagc	tgctcctctc	actcagcatt	ccatggacca	aattgtgccc	tgggtagcct	900
cagactttgg	gtattgataa	gccgatggat	ttgagttttt	ctaaagaata	ttcatattac	960
ctccttaaaa	aaaaaaaaaa	aaaaa				985

&lt;210&gt; 38

&lt;211&gt; 719

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

ggcacgagcc	tttcttggcc	ttcatcttct	cttcttacac	tgctcctggg	tgctatctgc	60
tttttgagtt	ttagtcatga	cctgtttccc	tacgcgcttg	gggtcagct	gccccaaacc	120
tgccttctct	cttgtacccc	tggccctggc	ccagtgtgtg	gtgccagctg	ggttcttggg	180
gaagtgtctg	ctgctgggga	gactgatgtg	tgcagagtgt	attgggacgt	actcatggga	240
tcagccccgt	agaagggaag	agatggaggc	gagactggac	agtgggagaa	gctgggcctc	300
agtgtatat	ggacacaggc	ctcagctgca	cggggagccc	tgcaactgcc	tggcctgcag	360
acgtgtccca	tgttgttctg	agggggccgg	gccattctcc	tccctcactg	accagcagtt	420
gaatgcagtc	taccctgggt	gatgtggttc	tcttcagcaa	ggagacaagg	cttctgctga	480
cccagcaggg	cctgtgcagc	tgggaagccg	tcggagagat	ctctggcgat	gggagggccg	540
gggttctctg	tccctgtgcc	agggcctggg	tgctcactgc	tcccaggaaa	gggtagggtc	600
ttgatgaagg	gctcttgccc	gtcaaggaca	acttctgggg	aggcagcact	ctccctggg	660

<221> SITE  
 <222> (1840)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1851)  
 <223> n equals a,t,g, or c

<400> 35

ctgcaggaat	tcggcacgag	cacctataaa	gaatctcaac	ccacttccca	ctcaaaagca	60
ctgtgtat	ctcatggcct	gcctgggagc	ccccatctcc	agcctgctgt	gctggctact	120
tctggcactt	atagcccttg	agatagtacc	gccagcagct	ccctgtgaag	tgctaacacc	180
ccttcaaaagc	agcaccaacc	caattgtgaa	caagctagga	gtaaaagacg	taaatgaatt	240
ggtcacccca	atgcagggga	tacagacttg	ttttaatat	aaaaagaagt	ggccttaacc	300
gtgcagggct	tgaggcctt	tgtaggcagt	ggagcatgct	gtgatccctg	gttctgtgct	360
aaacactcaa	aagggtcttc	tgactcaagt	ggaggtgata	aaccttttca	atagtaacag	420
gagagagtgt	gatatacaag	tgccmgaasy	cctcacggac	caacatttag	cacagacatt	480
caaactgctg	aaagawccaa	wcagaactca	actgaaaaaa	acagaccttt	taagaaaagc	540
aatagatctt	aatttggtgg	caagatccct	ggtttacctt	ttgaagtcaa	aatgttcaat	600
acatcacccg	agcttgactt	ttgagcactt	ggcaagattg	ttttttgcca	cttgacacaa	660
gtatgatgtc	cagctatgca	aaatgactgt	ttgatctgcc	ttttcagtgt	atttgtgtgg	720
cgatgtctgt	aaaatgccag	aagcctctta	tgtttattgt	gctgctgcta	ccagccagca	780
actgcagagg	ccatgctgag	gtgcctcctt	gccaccagcc	gttgggaaat	gcctaccatg	840
ctgccccgga	tgacacaagt	caaaacgctg	cagaagttac	acaactgctc	ccataatctg	900
gactctccaa	aaccgtgatg	ccacgaagga	agggtcaagt	ttaaaatgtt	aaagactgct	960
tgcctctgtt	cctgagacta	aacagtatac	atactaacta	cattgacaaa	gaaatcctat	1020
ctgataatgt	agcccgtga	cgaattttga	agcctcggtt	accctaacca	atatgtagct	1080
tttaatttgc	atcaaaaactt	ttacaaaagt	gttttgctat	tgtttctata	tacttcaaga	1140
atgttcattt	ttacaaataa	gttgaacaag	acagcctaag	ttagatgcac	cgaagtacta	1200
gaaatatcgc	tagcctctgt	tctccagttt	agctttcaaa	accaaagtga	ccatgtataa	1260
aggagttgag	aaacttaatt	tttaaatgtt	tcatttgtag	agttttatat	ccattaagtg	1320
cctttgaaag	tttccagttg	tgtgggctgc	tgtctcacct	cccaccaatt	tctcctttct	1380
ccttatgggtg	ctaaaacctc	aaagctgagg	agggctgtag	gaccttagc	agattcagtg	1440
tgtcacccct	gtcctgtgtt	cacgccaaag	cttccataat	gaaagacatc	ggttacctgc	1500
ttatgggaag	actcttcatg	ctgatcggat	cttgcatgta	aataaccatg	tggaagaaca	1560
atgaatcgat	taatgatgac	atgtacaacc	atattttaaag	agcaatagtg	tccgtgtgtc	1620
atgaaaaact	tatttgtaaa	cgtttatatg	gtatgatttt	gattttatgt	atgttcataa	1680
atcctgcact	gtatgatata	tgtgagttaa	aacattgggtg	catgaattta	ttttcaaaagt	1740
ataaaaacaca	tcacttaaac	attttatgtg	tcaaaataaaa	tttgattatg	taaaaaaaaa	1800
aaaaaaaaaac	tcgagggggg	gcccggrrcc	aattcgccan	atggagatcc	naa	1853

<210> 36  
 <211> 1465  
 <212> DNA  
 <213> Homo sapiens

<400> 36

ccacgcgtcc	gaagaaagaa	gcggggcgaa	taagcacggt	tgagctacag	aaaatggtgg	60
ctcgagtctt	ttattatctt	tgtgtcattg	cactgcagta	tgtgggcct	ctggtaatgc	120
tgtttcacac	aactctgctt	ttgaaaacac	taggtaatca	ttcctggggg	atttatccag	180
aatctatctc	taccttacca	gtggataata	gtctactgtc	caattctgtt	tactctgaat	240
taccatcagc	tgaagggaaa	atgaaggtaa	ctgttacaca	aataacagtg	gcactgagca	300
gcttaaaaaa	tatttttact	cctcttcttt	ttcgaggact	tctgtctttt	ctgacctggt	360
ggattgctgc	ttgcctcttt	tctacaagcc	tttttgggct	tttctatcac	cagtatctga	420
ctgtggcatg	aatctcagtt	aacaaaaaag	cataatccaa	atcacctttt	aaattaaaaa	480
atctgtgccc	ttaaagggct	gatgaaaacc	agaagaaagc	aaatacaatg	ggaaaaaaa	540
aacatatcag	aatgtcttgt	attaaatgtt	tctctgtat	tctcaggggtg	aattaatgta	600

<210> 34  
 <211> 2235  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (867)  
 <223> n equals a,t,g, or c

<400> 34  
 gagcggaccg ggcgctcgca ggccgggggt gtatgggggt cccgcgcggg tcgttcttct 60  
 ggctgtgct cctgctcacg gctgcctgct cggggctcct ctttgccctg tacttctcgg 120  
 cggcgcagcg gtacccgggg ccagcggccg gagccaggta ggggctgccg agcgcagagc 180  
 ggggagggcg caggggcgac cagggcgcg ggagggtccc cagcccaggg ctccccggcg 240  
 gccgcagcg ctcagcccaa cctccgcgtg gaccctctg gggcagctct cagcgaggac 300  
 tcggccgcgg ccctttgtcg ccagaacct ctcccagcct tgacctygcg mtgcccggac 360  
 cccgmggcct ttrcctgggt ccaaggaaga mctcgcccc gtkeactggm gamccgcccc 420  
 ggtgccccct gttggtgaag tcctccccgg cctgataagt acactttcta ttgtcgaaat 480  
 ctggctgggt ccccgaagca gataaaaact tccttttttg tcgggaactc tcctcggta 540  
 acgtcagatt ctgctttttg ggcagggggc caagtctccg gtttccaact tcgcgggggam 600  
 cctccgtcgg gccgcggcca gtgccttttc ccgcccgtg cggctctctgt ccgccccgcg 660  
 cccgctccct tctccccggc ttccgctcgc cgtgtctgga taagcccagt gcgggcgcga 720  
 tccgcgaaga ggcggggcgc cgwgggaaag aggggygact cctgggtcca tccgcgttct 780  
 cctccccgcg ccgctcctg cgctccactc cctcctctc cctaggcact ttcctgggtg 840  
 tcccacgagg agaacctggg agccggntc tagcagggtg wggttccggg gactgaagaa 900  
 gccgcaaac gatttcgctt agcttaagaa aggcggacca agcctgtcga agtctgggtt 960  
 tgggaggagg gaaggggccc gcagcctcag ggagaggcct ycagccccag cctttccctt 1020  
 cctggagctt ttccatctgc gcacccccca ccaaccttgc tgggggggcta acgggatgaa 1080  
 aacaaaataa gkatctggtc tycacaratg ctgtcaagg rtacaccaa agttgcagaa 1140  
 caatgtgaaa cagcttgcca gtgatcagga gtccagcact cttagaacaa aggggtgctt 1200  
 ccccgccacg tgacttaacg cctgtagtcc aagcactctg ggaggcggag gtgggaggat 1260  
 agcttgaggc caggwtttcg aggctgtgag ctgtgattgc actactgcat tccagcctgg 1320  
 ttgacagagc gagaccctgt ctcaaaagaa aaggaatcct tgtcactttt atgtaaagat 1380  
 gtttaaaaca caaagtatct caatgcaaa aaataatata tgtttgatat aagcctgggc 1440  
 aacatggcga aacctcgtct ctacaaaaaa tacaaaactt atccggggat ggtggtgcat 1500  
 gtctgtgctt ccatctatct attccgggag ctgaccaaga agatcccttg agtctgggag 1560  
 gtcgaggctg cagtgaagctg tgatcgcgcc actgcactcc agcctgggca atacagcaag 1620  
 gtcctgtctc cagaaaaaaa aaaaaaaaaa gttcgagggt atggatatgc taattagctg 1680  
 gtttgattat tacacattac atacacgtat tgaaatatca cactgtggcc gggcgcggtg 1740  
 gctcacgcct gtagtctcag cattttggga ggccgargca ggccgatcac gargtcagga 1800  
 gatccagacc atcctggcta acatggtgaa acccgttct actaaaaat mcaaaaaatt 1860  
 agctggggcg ggtggcgggc acctgtagtc ccagctactc gggaggctga ggcaggagaa 1920  
 tggcgtgaac ctgggagggt gagcttgagc tgagccaaga tcgcgccact gcactccagc 1980  
 ctggtgacag agcgagactc catctcaaaa aaaaaaaaaa agaaatatca cactgtaccg 2040  
 tatacatatg tgcaagtatg tgacaattaa aaataatttt acaaaaagga agagacctga 2100  
 tctagcaact cagccccact ctgcatgtga cgtcctgccc caccaacacc aaggccctct 2160  
 ggctgccctg gaccactgcc tatggggtag cctgctcca caaggagcag aaaaaaaaaa 2220  
 aaaaagggcg gccgc 2235

<210> 35  
 <211> 1853  
 <212> DNA  
 <213> Homo sapiens

<220>

agctgcagga	tatggagaag	aaagcaaacc	ccagctcact	tgttctggaa	aggagagagg	540
tggagcaaca	aggctttttg	catttggggg	aacatgatgg	cagtcttgac	ttgcatccta	600
gaagatcagt	tcaagaaggt	aatccaaggg	cctgatgact	cttttggtta	ccagacacca	660
atcaataaag	gggaggagac	gaaaatggaa	tgatttcttc	catgccacct	gtgcctttag	720
gaactgcccc	gaagaaaatc	caaggcttta	gccaggagcg	gaaactgact	accatgtaat	780
tatcaaagta	aaattgggca	ttccatgcta	tttttaatac	ctggattgct	gatttttcaa	840
gacaaaatac	ttgggggttt	ccaataaaga	ttgttgtaat	attgaaatga	gcctacaaaa	900
acctaggaag	agataactag	ggaataatgt	atattatctt	caagaagtgt	gtgcaggaat	960
gattggttct	tagaaatctc	tcctgccaga	cttcccagac	ctggcaaagg	tttagaaact	1020
gttgctaaga	aaagtgggtc	atcctgaata	aacatgtaat	actccagcag	ggatatgaag	1080
cctctgaatt	gtagaacctg	catttatttg	tgactttgaa	ctaaagacat	cccccatgtc	1140
ccaaagggtg	aatacaacca	gagggtctcat	ctctgaactt	tcttgctgac	tgattacatg	1200
agtcttttga	gtcgggggat	gaggagggtc	tgcccctgtg	agggtgtata	catgaccatc	1260
aaagtcctac	gtcaagctag	ctttgcagtg	gcagtaccgt	agccaatgag	atttatccga	1320
gacgcgatta	ttgctaattg	gaaattttcc	caatacccca	ccgtgatgac	ttgaaatata	1380
atcagcgctg	gcaatttttg	acagtcctta	cggagactga	ataagaaaaa	aaaaaaaaaa	1440
aaactcgagg	ggggggccccg	g				1461

<210> 33  
 <211> 1114  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1073)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1102)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1105)  
 <223> n equals a,t,g, or c

<400> 33						
ttattaaatg	aatatagcat	ttcttagcaa	cttcttttga	tttgtgagta	tatatattct	60
tggcctcaaa	attaaagtaa	aaagtatcct	cttactcagw	ggaggacagg	ggcaagagcc	120
tgggmccctta	tttgctaatt	aaaatgcaca	cacacacaca	cacacacaga	aattttgaga	180
gccatttttaa	tataattgcc	tccttagaaa	catacctttt	agggaatttt	tatcactaaa	240
ccacatgtta	tttaaatacg	tacatgttta	acataaatac	atacataaaa	ttcacatgca	300
tacttaacac	ttatgttaaa	tatatccaat	gtatatacat	atgtacacaa	tatatgcata	360
tatacatgtg	ggtatgtggt	atgtgtgcat	gtgtgtgtat	ggccagctac	ataatttgtg	420
ggactaaggg	caaaatgaaa	ctgtacggcc	ctcgttcaaa	aattaggtgt	ggggtgcttc	480
taagcacagt	cttgtgcaac	tgacacaggt	gcattgtccat	gaagccatcc	tgtgtgtgtg	540
cacatatgtg	tatgaatatg	tattttatat	aatacatata	tatgcatgta	tgtatctgag	600
aagaaatgtt	taaaaggcta	catacaagct	tttccaggct	tctactatct	gktaactaac	660
tagagacata	actcacaata	tgacgtcccc	actgagtgtt	caccataatt	tgagattctt	720
ggcatgktaa	cttttcatta	tggaatattg	aataatttca	atattattca	tacatttctt	780
gatgttcaaa	catacacaaa	aatagaataa	tgaactctta	cccatacccc	agctgcaaca	840
aatatcaata	ctttaccgkt	cttaawacat	ctaaccctt	actttttgtt	tgtttctttt	900
ggtgaagtat	ttaattgtaa	tttttttttt	aagagacagg	atctcactck	gtcaccaggg	960
ccagagtaca	gtggtacgat	cacttgagcc	taggagggtca	aggccgcagt	gagccgtgat	1020
cgtgttactg	cattccagcc	tgggtgacag	agtgaatca	tatctaaata	agnataataa	1080
tcaaaaagag	caacagagca	tnccngttag	aagg			1114

<220>  
 <221> SITE  
 <222> (1701)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1792)  
 <223> n equals a,t,g, or c

<400> 31  
 gatcctatta cagctgccta cttccctgat gactagaggg caccgccaag cagtgtttac 60  
 caaaatcaac aggccagagc acagctgraa gatttctgca tgaatcccca gacagtgtctg 120  
 ctctctgctggg tcctctgctggc cttctgtttc ctgggcatcc tgtgtagtct ctccgctttc 180  
 cttctgggatg tctttggggc gaagcatcct gctctgaaga tcaactgctc ctatgccttc 240  
 gcccatatcc taacggttct gcagtgtgcc accgtcattg gcttttctta ttgggcttct 300  
 gaactcatct tggcccagca gcagcagcat aagaagtacc atggatccca ggtctatgtc 360  
 accttcgctg ttagcttcta cctgggtggc ggagctggtg gagcctcaat cctggccacg 420  
 gcagccaacc tcctgcgcca ctaccccaca gaggaagagg agcaggcgct ggagctgctc 480  
 tcagagatgg aagagaacga gccctaccgc gcggaatatg aggtcatcaa ccagttccag 540  
 ccaccccttg cttacacacc ctaatgccag ccctgggctc tcttctcgg cagccctcc 600  
 ctcaactctg cagctcctct cgcacccaga ggagctcctt tccccagcag gcctcactgg 660  
 taggatcctg accatcttct ccaaaccctc cccaggagag actctgcctt tagggtcate 720  
 caagtatccc tgctctcaga accggagggtc cactgggttt ctataatgta ctctttccct 780  
 yctgccacat cctgccccct tcacattcac gagtattac cagccaggga aggtcatcca 840  
 agtttctctc agcatgggctg atatctttgg gaccgagact ttccttggag agctgctgag 900  
 agcggacagt cccaaaaaca agtgtcaaag ggcccaaggg aaaggggact gtgccctgga 960  
 ggctcacttc acagggatca gtgtttgctc cacagctgta gctctgggct gacgcccccc 1020  
 agaccccttc cttctcggag tgaccgcgcc ccaggccacc tgctccgggg agttctgtgc 1080  
 actttactct ttggacttct cctcacgtgt gccctgggtt tatggggaga gggaatcgct 1140  
 gttgggaagg cagagcagtt gcaaccctct ctgcccttgc ttcattgtggc tggagcccag 1200  
 gcaaggagag caggagccag cgtgagactg agggccctg gtgcctatca aggaccagag 1260  
 tgaaggggac tacatctccc agcccttcac cttttaaata tgagtgggtt taaaaggaaa 1320  
 aaaatgaaac caggcaacag caacaatatt ctgtttttaa aatagggaca agactgttgt 1380  
 cacttttttag acatgtatcc cattcctttt ggctctgcaa tatttggggc tgtagctcct 1440  
 tccaagccca tggtagtccc tccccagatc tctcccagta gaatgcagcc tcccttccct 1500  
 ggcccccttc ctctcagtga cggtgactcc ctggggcctt ctctgtggaac ccagaggggg 1560  
 tgaggactgt ggctggctg gcgggccagc gtnggtgctc ctcaggactg cagcactgag 1620  
 atggaacctg gcctcagttt aggaacaggg gccacaacag ggcaggaacc caccacctc 1680  
 cacataggaa tacaaccagt nggggccaca tcatgtgagg catyagacct acamtktiyag 1740  
 ccagcaaggc gggstktgtt cttyaaacca ktgytgccta rattytgatt tnggggattt 1800  
 ccag 1804

<210> 32  
 <211> 1461  
 <212> DNA  
 <213> Homo sapiens

<400> 32  
 aattcggcac gagccaaatg attatccttt taatcatgtt ctactccaaa aatatcagcc 60  
 tgaatgatgaa tttccagcct ccagacaaag cctggcgggc ctcacagatg atgactttct 120  
 tcatcttctt gctctttttc ccatctttca ccgggggtct gtgcaccctg gccatcacca 180  
 tctggagatt gaagccttca gctgactgtg gcccttttct aggtctgcct ctcttcattc 240  
 actccatcta cagctggatc gacaccctaa gtacacggcc tggctacctg tgggtgtgtt 300  
 ggatctatcg gaacctcatt ggaagtgtgc acttcttttt catcctcacc ctcatgtgc 360  
 taatcatcac ctatctttac tggcagatca cagaggggaag gaagattatg ataaggctgc 420  
 tccatgagca gatcattaat gagggcaaaag ataaaatgtt cctgatagaa aaattgatca 480



agtttgtcct	aatcatgcc	tgtgtagaca	acacccttac	aaggatccgc	agggctggga	1080
aaggaactca	aaacactaga	aaaagcattg	aatggaaaat	caatatatta	aacaaagtgc	1140
aatttagctg	gatttctgaa	ctatggtttt	gaatgtttta	agaagaatga	tgggtacagt	1200
taggaaagtt	tttttcttac	accgtgactg	agggaaacat	tgcttgcttt	tgagaaattg	1260
actgacatac	tggaagagaa	caccatttta	tctcaggtta	gtgaagaatc	agtgcaggtc	1320
cctgactctt	attttccag	aggccatgga	gctgagattg	agactagcct	tgtgggtttca	1380
cactaaagag	tttccttggt	atgggcaaca	tgcatgacct	aatgtcttgc	aaaatccaat	1440
agaagtattg	cagcttcctt	ctctgggtca	agggctgagt	taagtgaag	gaaaaacagc	1500
acaatgggtga	ccactgataa	aggctttatt	aggtatatct	gaggaagtgg	gtcacatgaa	1560
atgtaaaaag	ggaatgaggt	ttttgttggt	ttttggaagt	aaaggcaaac	ataaatatta	1620
ccatgatgaa	ttctagtga	atgacctt	gactttgctt	ttcttaatac	agatattttac	1680
tgagaggaac	tatttttata	acacaagaaa	aattttacaat	tgattaaaag	tatccatgtc	1740
ttggatacat	acgtatctat	agagctggca	tgtaattctt	cctctataaa	gaataggtat	1800
aggaaagact	gaataaaaaat	ggagggatat	ccccttggat	ttcacttgca	ttgtgcaata	1860
agcaaagaag	ggttgataaa	agttcttgat	caaaaagttc	aaagaaacca	gaatttttaga	1920
cagcaagcta	aataaatatt	gtaaaattgc	actatattag	gttaagtatt	atttagggtat	1980
tataatatgc	tttgtaaaatt	ttatatccca	aatatgtctc	aatatttttc	atctattaaa	2040
ttaattttcta	gtgtaaaaaa	aaaaaaaaaa	agggcgccgc	c		2081

&lt;210&gt; 30

&lt;211&gt; 1262

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

gaaaaaaaaa	aacaaaacaa	aaacatacta	catggtgttc	tttacttgct	tgtgggttttt	60
aaatgaacat	atattagtat	gcaattgtag	taatgtttca	ctttgttatt	ctctacctct	120
taaagaaaaa	attaccttct	tttacaatct	aacacactac	ttttttaaca	ggtgttttaa	180
gcactctgtt	gtatttgttg	aacaaatatt	tcttaacatt	gtatatacca	ggaacctaat	240
tgtatacttt	tcagagttaa	actatgcaat	ctgttcttca	gtaaatgaag	ctttgaccgt	300
gcagtcaaat	ccattaaaag	ttcttccatg	ggaaattagg	agagtttcaa	actcacagtg	360
tcttagtttg	atttctgttc	cttataacaa	tacctgaac	tgggtaatta	ataaagaaaa	420
ggaattttatt	tctttgttat	ggaggctggg	aagtctaagg	tcaaaggggtg	gcactctgtga	480
gagccttctt	gctggtgggg	actctgcagt	gtcctggggc	agcgcaggca	ctacatggta	540
agggggtaag	tgagctagt	tgttcgccca	ggtctgtctt	cctcatctta	tgaagccacc	600
agttctcttc	ctgtaataat	ccattaatcc	actaatccat	tgagggactg	atggcagagc	660
tctcatgatc	caggttgagg	attaagtttc	aacatgagtt	ttggaggggga	cattttaaacc	720
atagcacata	gtaacaaagc	tactttttct	tacaggaatt	tcagtaatca	gagatttggg	780
gggaagctat	gtggctatta	ttataaaaact	gagttctaac	agggcaaatc	cagagttgaa	840
ttacttctaa	ctctgttacc	acagcagttg	cctttttttc	accactaaca	aactttctta	900
aatatacgta	cgaaatattt	aaagcaccag	ccaccccaac	aaagagctgc	ttatggctgg	960
gcgtgggtgct	gacgcctgta	atcccaacag	tttgggaggc	tgaggcaggt	ggatcacctg	1020
gtcaggagat	cgagaccatc	ctggctaaca	cagtgaiaacc	ccatctctac	taaaaataca	1080
aaaaattagc	cgggcatggg	ggtggggcgc	tgtagtccca	gctactcaga	gaggctgagg	1140
caggagaatg	gcgtgaaccc	aggaggcgga	gcttgacgtg	agccaagatc	gtgtcactgc	1200
acttctgcct	gggcgacaga	gcaagactct	gtctcacaaa	aaaaaaaaaa	aaggcgccgc	1260
gc						1262

&lt;210&gt; 31

&lt;211&gt; 1804

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1593)

&lt;223&gt; n equals a,t,g, or c

agccttcagt	tgaaccggtg	agggcaggca	atgggatggg	agggcaaaga	gggaaggcaa	900
cttaggtctt	cagagctggg	gtgggggtgc	cctctggatg	ggtagcgagg	aggcaggcgt	960
ggcctccac	agccctggg	cctcccaagg	gggctggacc	agctcctctc	tgggaggcac	1020
ccttccttct	ccagctctct	caggatctgt	gccctattct	ctgctgcccc	taactccaac	1080
tctgccctat	ttgggtcttt	tatgccacct	tgtctaagac	aactctgccc	tcttaacctt	1140
gattccccct	ctttgtcttg	aacttccccct	tctattcttg	cctacccctt	ggttcctgac	1200
tgtgcccttt	ccctcttccct	ctcaggattc	ccctggtgaa	tctgtgatgc	ccccaatgtg	1260
gggtgcagcc	aagcaggagg	ccaagggggc	ggcacagccc	ccatcccact	gagggtgggg	1320
cagctgtggg	gagctggggc	cacaggggct	cctggctcct	gccccttgca	caccaccggg	1380
aacactcccc	agccccacgg	gcaatcctat	ctgctcgccc	tctgcagggt	gggggacctca	1440
catactctgtg	acttcgggtc	cctgtcccca	cccttgtgca	ctcacatgaa	agccttgac	1500
actcacctcc	accttcacag	gccatttgca	cacgctcctg	caccctctcc	ccgtccatac	1560
cgctcgcctc	agctgactct	catgtttctct	cgctcacaat	ttgcaactctc	tccttcccac	1620
attctgtgtc	cagctcactc	agtggtcagc	gtttcctgca	cactttacct	ctcatgtgcg	1680
tttcccggcc	tgatgttgtg	gtgggtgtgcg	gcgtgctcac	tctctccctc	atgaacaccc	1740
accacactcg	tttccgcagc	ccctgcgtgc	tgctccagag	gtgggtggga	ggtagcttg	1800
gggtcctctg	ggccctcatc	ggtcattggc	tcgtcccatt	ccacaccatt	tgtttctctg	1860
tctcccacac	ctactccaag	gatgccggca	tcaccctgag	ggctccccct	tgggaatggg	1920
gtagtgaagg	cccagacttc	acccccagcc	cactgctaaa	atctgttttc	tgacagatgg	1980
gttttgggga	gtcgctgctc	gcactacatg	agaaaggagc	tcccatttgc	ccttcccttt	2040
ctctacagct	cccttttgtc	ttgtctgtcc	tggctgtctg	tgtgtgtgce	attctctgga	2100
cttcagagcc	ccctgagcca	gtccctccctt	cccagcctcc	ctttgggctc	ccctaactcc	2160
acctaggtcg	ccagggaccg	gagtcagctg	gttcaaggcc	atcgggagct	ctgcctccaa	2220
gtctaccctt	cccttcccgg	actccctcct	gtccctcctc	ttcctccctc	cttccttcca	2280
ctctccttcc	ttttgtcttc	ctgccctttc	ccctcctcca	ggttcttccc	tccttctcac	2340
tggtttttcc	accttccctc	ttcccttctt	ccctggctcc	taggctgtga	tatatatttt	2400
tgtattatct	ctttcttctt	cttgtgggtga	tcactctgaa	ttactgtggg	atgtaagtct	2460
caaaattttc	aaataaagcc	tttgcaagat	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2520
aaaaaaa						2527

&lt;210&gt; 29

&lt;211&gt; 2081

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (538)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 29

gggttctcaa	tggaataata	ttggtagaca	tcagcaacaa	cctcaaaatc	aatcaatatc	60
cagaatctaa	tgcagagtac	cttgcctcatt	tggtgccagg	agcccacgtg	gtaaaagcat	120
ttaacaccat	ctcagcctgg	gctctccagt	caggagcact	ggatgcaagt	cggcaggtgt	180
ttgtgtgtgg	aaatgacagc	aaagccaagc	aaagagtgat	ggatattgtt	cgtaactctg	240
gacttactcc	aatggatcaa	ggatcactca	tggcagccaa	agaaattgaa	aagtaccccc	300
tgcagctatt	tccaatgtgg	aggttccctt	tctatttgtc	tgctgtgctg	tgtgtcttct	360
tgtttttcta	ttgtgttata	agagacgtaa	tctaccctta	tgtttatgaa	aagaaagata	420
atacatctcg	tatggctatt	tccattccaa	atcgtatctt	tccaataaca	gcacttacac	480
tgettgtctt	ggtttactcc	ctgggtgttat	tgctgccatt	ctacaactgt	accgaggnca	540
caaaataccg	tcgaattcca	gactggcttg	accactggat	gctttgccga	aagcagcttg	600
gcttggtagc	tctgggattt	gccttccctc	awgtcctctm	cmcaactgtg	attcctatct	660
gatattatgt	acgatgraga	ttgggaaact	taaccgttac	ccagscaata	ctcaagaagg	720
agaatccatt	tagcacytcy	tcagcctggc	tcagtgatcc	atatgtggct	ttgggaatac	780
ttgggttttt	tctgtttgta	ctcttgggaa	tcacttcttt	gccatctgtt	agcaatgcag	840
tcaactggag	agagttccga	tttgtccagt	ccaaactggg	ttatttgacc	ctgatcttgt	900
gtacagccca	caccctgggtg	tacggtggga	agagattcct	cagcccttca	aatctcagat	960
ggatctcttc	tgcagcctac	gtgttagggc	ttatcattcc	ttgcaactgtg	ctgggtgatca	1020

agagcactgt	gtatgactga	aatttcttga	ataactgtaa	atgggttatgt	taatggaata	1140
aaacacaaat	gttgaataat	gtaaaatata	tatacataga	ttcaaatcct	tatatatgta	1200
tgcttgtttt	gtgtacagga	ttttgttttt	tctttttaag	tacaggttcc	tagtggttta	1260
ctataactgt	cactatgtat	gtaactgaca	tatataaata	gtcatttata	aatgaccgta	1320
ttacaacatt	taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa		1362

&lt;210&gt; 27

&lt;211&gt; 1381

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

ggacgagatt	tccttatct	ccttcgcagt	gcagctcctt	caacctcgcc	atggcctctg	60
ccggaatgca	gatcctggga	gtcgtcctga	cactgctggg	ctgggtgaat	ggcctggctt	120
cctgtgccct	gcccatgtgg	aaggtgaccg	ctttcatcgg	caacagcatc	gtgggtggcc	180
aggtgggtgtg	ggagggcctg	tggatgtcct	gcgtggtgca	gagcaccggc	cagatgcagt	240
gcaaggtgta	cgactcactg	ctggcgctgc	cacaggacct	gcaggctgca	cgtgccctct	300
gtgtcatcgc	cctccttgtg	gccctgttcg	gcttgcgtgg	ctaccttgct	ggggccaagt	360
gtaccacctg	tttttatata	aggattccaa	ggcccgcctg	gtgctcacct	ctgggattgt	420
ctttgtcatc	tcaggggtcc	tgacgcta	ccccgtgtgc	tggacggcgc	atgccatcat	480
ccgggacttc	tataaccccc	tggtggctga	ggcccaaaag	cgggagctgg	gggcctccct	540
ctacttgggc	tggcggcct	caggcctttt	gttgcgtggg	gggggggtgc	tgtgctgcac	600
ttgccccctg	gggggtccc	agggccccag	ccattacatg	gcccgtact	caacatctgc	660
ccctgccatc	tctcgggggc	cctctgagta	ccctaccaag	aattacgtct	gacgtggagg	720
ggaatggggg	ctccgctggc	gctagagcca	tccagaagtg	gcagtgccca	acagctttgg	780
gatgggttcg	taccttttgt	ttctgcctcc	tgctattttt	cttttgactg	aggatattta	840
aaattcattt	gaaaactgag	ccaaggtgtt	gactcagact	ctcacttagg	ctctgctgtt	900
tctcaccctt	ggatgatgga	gccaaagagg	ggatgctttg	agattctgga	tcttgacatg	960
cccatcttag	aagccagtca	agctatggaa	ctaattcgga	ggctgcttgc	tgtgctggct	1020
ttgcaacaag	acagactgtc	cccaagagtt	cctgctgctg	ctgggggctg	ggcttcccta	1080
gatgtcactg	gacagctgcc	ccccatccta	ctcaggtctc	tggagctcct	ctcttcaccc	1140
ctggaaaaac	aaatgatctg	ttaacaaagg	actgccacc	tccggaactt	ctgacctctg	1200
tttcctccgt	cctgataaga	cgccaccccc	ccaggccag	gtcccagcta	tgtagacccc	1260
cgccccacc	tccaacactg	cacccttctg	ccccgcccc	ctcgtctcac	cccccttaca	1320
ctcacatttt	tatcaataaa	agcatgtttt	gttagtgcaa	aaaaaaaaaa	aaaaaaaaaa	1380
a						1381

&lt;210&gt; 28

&lt;211&gt; 2527

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

ggcacgagtc	acagctgagg	aagacctcag	acatggagtc	caggatgtgg	cctgcgctgc	60
tgctgtccca	cctcctccct	ctctggccac	tgctgttgct	gccccctcca	ccgcctgctc	120
agggctcttc	atccccccct	cgaaccccac	cacccccagc	ccgccccccg	tgtgccaggg	180
gaggccccct	ggccccacgt	catgtgtgcg	tgtgggagcg	agcacctcca	ccaagccgat	240
ctcctcgggt	cccaagatca	cgtcggcaag	tcctgcctgg	cactgcaccc	ccagccaccc	300
catcaggctt	tgaggagggg	ccgcctcat	cccaataccc	ctgggctatc	gtgtggggtc	360
ccaccgtgtc	tcgagaggat	ggaggggacc	ccaactctgc	caatcccga	tttctggact	420
atggttttgc	agccctcat	gggctcgcaa	ccccacacc	caactcagac	tccatgcgag	480
gtgatggaa	gggcttatcc	ttggagaggc	acctgccacc	ctgcgggtcat	tcctgttcgg	540
gggcccgtgg	gaaggtgtgg	acccccagct	ctatgtcaca	attaccatct	ccatcatcat	600
tgttctcgtg	gccactggca	tcatcttcaa	gttctgctgg	gaccgcagcc	agaagcgacg	660
cagaccctca	gggcagcaag	gtgccttgag	gcaggaggag	agccagcagc	cactgacaga	720
cctgtccccg	gctggagtca	ctgtgctggg	ggccttcggg	gactcaccta	ccccacccc	780
tgaccatgag	gagccccgag	ggggaccccc	gtctgggatg	ccccaccca	agggggctcc	840

ctttcctatg	tggtttttct	ttgtcttccc	caaggettag	tgtcccagtt	ttatctgctc	1380
ctgagactga	gcccagatcc	ccaaatctaa	tctgatttac	agttcaagga	agctgatggg	1440
gagctgggcc	ttaccctga	tgtaggaggg	gcacacagct	gggggtgcag	agcccacctg	1500
ggtacctgac	ccccagggga	tgaaaatgca	aggatgagtc	tgcttggggc	tgagagtgtg	1560
atctgcaggg	gcaggctcat	cttttctctc	ccctgccttc	tcctccttct	ctccccagag	1620
cccccttgag	ccccctctgc	tatgtccctc	tgccctctcc	ccatgcccc	agttgctgtg	1680
gcttgattct	gctaccctga	ccccaccatg	tgccaggtgg	catctgcctt	actgccttcc	1740
ctgaggagct	gggacatgct	gggcagttgt	cagatgtaaa	ggcacagctg	gagcagaggg	1800
catgtcagta	atgattggtc	cctggggaag	gtctggctgg	ctccagcaca	gtgaggcatt	1860
taggtatctc	tcggtgaccg	ttggattcct	ggaagcagta	gctgttctgt	ttggatctgg	1920
taggacaggg	ctcagagggc	taggcagcga	gggaaggtca	gaggagaagg	caggcagggc	1980
ccagtgcagag	gggagcatgc	cttccccac	cctggcttgc	tcttggtcac	agggcggttc	2040
tgggcacttg	aactcagggc	ccaagcagaa	gcacaggccc	agtcctggct	gcaagcacia	2100
tagcctgaat	gggatttcag	gttaggcagg	gtgggagggg	aggctctctg	gctttagttt	2160
tgttttgttt	tccaaatcaa	ggttaacttg	tcccttctgc	ctacaggcct	tggtcttggc	2220
ttgtcctcac	ccagtcggaa	ctccctacca	ctttcaggag	agtgggttta	ggcccgtggg	2280
gctgttctgt	tccaagcagt	gtgagaacat	ggctggtaga	ggctctagct	gtgtgcgggg	2340
cctgaagggg	agtgggttct	cgcccaaaga	gcactctgcc	atttcccacc	ttcccttctc	2400
ccaccagaag	cttgccctgag	ctgtttggac	aaaaatccaa	acccacttg	gctactctgg	2460
cctggcttca	gcttgggaacc	caatacctag	gcttacaggc	catcctgagc	caggggcctc	2520
tggaatttct	cttcctgatg	gtcctttagg	tttgggcaca	aaatataatt	gcctctcccc	2580
tctcccatct	tctctcttgg	gagcaatggg	cacagtccct	ggtacctgaa	aaggtactag	2640
gtctaggccc	ttcttccctt	tccttctctc	tccttctccc	cagaactttg	gctcccttct	2700
ccttctctct	ctggtagctc	caggaggcct	gtgatccagc	tccttgccct	gcattccatga	2760
cctgttggat	gttacctcca	atcagtttcc	tgctctacct	gcctctttgg	cttggagccta	2820
tatggccatg	ctctggctct	acccttggga	agcctgatcc	cgggtgtgtg	cccagcttgt	2880
tcaggccctg	ggatgctgca	tctccaggca	actatgcact	ttcccgggga	gagaaccagt	2940
atgagaagtg	ggggcagggc	acacattcat	ctttgtagga	aggctctggc	tggggtcggg	3000
tgaaggaggg	cccagggtcag	ttctgggggt	ccagtgcact	gctttgccat	tctcctgggt	3060
ccgctgctgc	tccctgtttc	tggagctgga	tggtccccag	ctggcagttg	agctgcctga	3120
gccaatgtgt	ctgtcttttg	taactgagtg	aaccataata	aaggggaaca	tttggccctg	3180
tgaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3240
anncc						3244

&lt;210&gt; 26

&lt;211&gt; 1362

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

ggcacgagaa	tcctccaaca	tggagcctct	tgcagcttac	ccgctaaaat	gttccggggc	60
cagagcaaa	gtattttgag	ttttgctgtc	tatagttcta	tgcacagtaa	cgctatttct	120
tctacaacta	aaatttctca	aacctaaaa	caacagcttt	tatgcctttg	aagtgaagga	180
tgcaaaagga	agaactgttt	ctctggaaaa	gtataaaggc	aaagtttcac	tagttgtaaa	240
cgtggccagt	gactgccaac	tcacagacag	aaattactta	gggctgaagg	aactgcacaa	300
agagtttggg	ccatccact	tcagcgtgtt	ggcttttccc	tgacaatcag	tttgagaaat	360
cggagccccg	cccaagcaag	gaagtagaat	cttttgcaag	aaaaaactac	ggagtaactt	420
tccccatctt	ccacaagatt	aagattctag	gatctgaagg	agaacctgca	tttagatttc	480
ttgttgattc	ttcaaagaag	gaaccaaggt	ggaatttttg	gaagtatctt	gtcaaccctg	540
agggccaagt	tgtgaagtct	tggaggccag	aggagcccat	tgaagtcata	aggcctgaca	600
tagcaagctc	ggttagacaa	gtgatcataa	aaaagaaaga	ggatctatga	gaatgccatt	660
gcgtttctaa	tagaacagag	aaatgtctcc	atgagggttt	ggtctcattt	taaacatttt	720
ttttttggag	acagtgtctc	actctgtcac	ccaggctgga	gtgcagtagt	gcgttctcag	780
ctcattgcaa	cctctgcctt	tttaaaccatg	ctattaaatg	tggcaatgaa	ggattttttt	840
ttaatgttat	cttgctatta	agtggtaatg	aatgttccca	ggatgaggat	gttaccctaa	900
gcaaaaatca	agagttagcca	aagaatcaac	atgaaatata	ttaactactt	cctctgacca	960
tactaaagaa	ttcagaatac	acagtgacca	atgtgcctca	atatcttatt	gttcaacttg	1020
acattttcta	ggactgtact	tgatgaaaat	gccaacacac	tagaccactc	tttggattca	1080

ctgtgcctgg	cctgccagat	ttcacaaatga	acaatgacaa	tgcataatgtg	ggaactacta	1740
ggctctcaat	atgtgggaac	tatattaata	atcatagaaa	ttatgactgt	aaggccatct	1800
gaggtgtct	ccagggtggag	aatcatgagt	ccatgcctgg	agaatcccag	gggttgatgg	1860
ttggggagaa	atgaactttg	aaactatagc	tgacatcggt	attctttcag	aggttacctt	1920
aatatgtaag	cctgcacact	tcactctact	aagtttccac	tgggtctgag	ttattctgta	1980
tttctctctt	cctctccaat	acaacagagc	ccttgggtata	cttgaattgc	ccattgaact	2040
cttctcaata	tttgtcttgc	atatagaggt	ttagttacag	atttccttga	aacatagagt	2100
ttttctaagt	catgttctgt	acttactata	atttctttca	ccccacactt	tcccttttcc	2160
tcttgctgga	gtgcctccca	taataatcct	ttatagaggg	agtgatgggt	gttttgatg	2220
tctgaaaatt	cctctatttt	gctctttctt	ttctgtaata	ggcataggta	gatattttat	2280
ttgaaggtct	ctgtttttca	tttccaagat	ttcgatttgg	ttctttttta	tttcattttt	2340
gaaatggttg	tgaaatgggt	gcatttttgc	ctttcccagc	agttcttgag	tggttacggt	2400
gggtctctc	cctctcagca	gccaccagcc	caggtgccc	cactctctgc	ccaccccttt	2460
ccaggctcac	cgaggcctct	ccttcctaac	aggtg			2495

&lt;210&gt; 25

&lt;211&gt; 3244

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (30)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3242)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3243)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 25

gcgcgcgcac	gctcgggtgc	agcgcaactcn	agcgcaagct	gcggcctttc	ggcagccgaa	60
cgccgcgcgc	agttcaggac	aaagaggtgt	gggcaggcca	ctgggcccagc	tggtaacatc	120
atggcagaga	aagtgaacaa	cttcccacca	ttgccc aaat	tcaccccgcct	gaagccatgt	180
ttctaccaag	acttcgaggc	agatattcct	ccccagcatg	tcagcatgac	caagcgccctc	240
tactacctct	ggatgtgact	gacagctcct	tcagtttcat	ggcattcttc	tttaccttca	300
tggctcagtt	ggtcatcagc	atcatccagg	ccgtgggcat	cccaggctgg	ggcgtctgag	360
gctggattgc	taccatctcc	ttcttcggaa	cgaacattgg	ctcggcggtg	gtgatgctaa	420
ttcccactgt	catgttcaca	gtgatggccg	tcttttccct	catcgccctc	agcatgggtc	480
ataaatttta	ccggggaggt	ggggggagtt	tcagcaaagc	tcaggaggag	tggaaccacag	540
gggcctggaa	gaatccacat	gtgcagcagg	cagcccagaa	cgcagccatg	ggggcagccc	600
aggggtgcat	gaatcagcct	cagactcagt	attccgccac	cccccaattac	acgtactcca	660
atgagatgtg	aaccagccac	gcctaccagg	tggcagagct	ggggccattg	ggacaggggg	720
ctcaagccac	atcgtcattt	gtggttacca	agcagggttc	ccccctccct	tttctccttc	780
cctactttgt	acaaaggacc	agagttatat	atatatatat	atgtatatgt	ctgtacccca	840
gccccacct	ttcagattct	gctcttggca	ctcagctgtg	ggctgcacgt	ggagctgtcc	900
cgtgcggtag	tagctgtgtc	tgtgtccctt	cgtgaaatag	tgtgcagtgg	aggtctcttg	960
tgggtgctaga	tgtgtgttta	gagctaaacc	agccccacc	cccaccctcc	acctgcccct	1020
cttgccctcg	gccccctctga	ccctggccca	gggacccctc	acggggccag	gggaggcata	1080
gcagaaaagac	tggcccttcc	ctaggggttat	gagctggaac	tgtttctact	ttcagttctc	1140
ctgggaagta	acagtactta	gcactcttgg	tgggtgggtg	gaggggtggg	acaggccagg	1200
gatattccct	tgtctttttg	atccctccag	gcctcgccctc	cttcagcttc	ctcctccctc	1260
atctgttccc	tgatgtcaca	ttccctgtgc	aatcttccct	tgcccatggt	ctgtctatct	1320

tttactccac	ctgggtccgc	ccttgacatg	tgggtgttat	tacaatttaa	ggtgagattt	1200
gggtggggac	acagagccaa	accatatcac	aaggctttct	cctccttgct	gggattgtac	1260
ccatagcctc	tttctgagtc	ctctctcttt	tagcctcttt	atgcctgcag	tgcatcctta	1320
taccatttct	agagtcctct	ttataaaact	tatactctcc	gtatgactca	taaatcctgt	1380
tttttttttt	gcacagtata	ttaagtataa	atttgttaaa	gtctttaatg	gtctgcccc	1440
aagctacatt	tccattttgt	atgtctttca	gttcctttct	actttgtatt	tggctgttga	1500
gttaactgaa	tttttgccat	tccattaacc	catcccatgc	ttttcccat	tctagatttc	1560
acttttcttg	taggctagaa	tgtcttgact	gggatctgac	tggagataat	gagaacaaaa	1620
actggttcaa	agagccagga	tgttgcataa	aagtcctaag	attgtatcta	agcaggtaaa	1680
ataaaaaatt	taggcaatta	cttaaatgtg	aaatgctcac	atttattaat	aaggcatgta	1740
acatctacat	gagccatcat	ttgctttttt	aattccacat	tgattaggag	ccaaaccttc	1800
agggcaggta	tccggtagag	cgccctggag	agggcctgga	taggcacagg	cgctgtcag	1860
ggggctcttc	acatgctgtg	tgctgctgct	gggagaagag	ggggccagag	actagggggc	1920
ttctaagaag	aggtggcatt	tctgcctcag	tgttgaagga	tgaataactt	tgacaggctg	1980
gaaaaagggtg	acatttcagg	tagagcgtgt	cacatggatg	taaataccaa	aggtcaagga	2040
catgggcttg	agagatgggtg	agaaggatgg	aggtgactgt	ggcttgcat	ctatccgtat	2100
cactattaat	taccttctaa	tgctttggc	tctaggtggt	ggaacaagta	aagtaatgga	2160
caataacttt	ttctaccaat	atttagtgac	caaatgcaga	gttatggaga	gggccaggga	2220
cctcatgaac	catactcttt	ctagtctagg	gacataactc	caatgccttt	cctgtcccag	2280
taagaggcca	tggatttcaa	gaagccagac	aatccattct	ttcagataat	gataaaaaag	2340
aaaccattta	ttttatttct	aagtatagaa	tgaacatttt	atagttgccc	aaattttggt	2400
accttttagg	agaaaaatac	agattttttt	gttggttaaaa	ataaacttaa	aaaaaaaaaa	2460
aaaaaa						2466

&lt;210&gt; 24

&lt;211&gt; 2495

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

aagagcctgg	ggccagaggg	ccagacagcc	acagagctcc	tggcgtgggc	aaggctggcc	60
aaggatggcg	acgccaggg	gcctgggggc	cctgctcctg	ctcctcctgc	tcccagacctc	120
aggtcaggaa	aagccaccg	aagggccaag	aaacacctgc	ctggggagca	acaacatgta	180
cgacatcttc	aacttgaatg	acaaggcttt	gtgcttcacc	aagtgcaggc	agtcgggcag	240
cgactcctgc	aatgtggaaa	acttgcagag	gttccgaggc	aggtgatgaa	ggacgaggac	300
aagccccctg	acagagtgcg	acttcccaag	agcctttttc	gatccctgcc	aggcaacagg	360
tctgtgtgcc	gcttggccgt	caccattctg	gacattggtc	cagggactct	cttcaagggc	420
ccccggctcg	gcctgggaga	tggcagcggc	gtgttgaaca	atcgccctgt	gggtttgagt	480
gtgggacaaa	tgcattgtcac	caagctggct	gagcctctgg	agatcgtctt	ctctcaccag	540
cgaccgcccc	ctaactatgac	cctcacctgt	gtattctggg	atgtgactaa	agggaccgtg	600
tgctcctgag	acccaccttg	gaccagtcca	cggtgcatat	cctcacacgc	atctcccagg	660
cgggctgtgg	ggtctccatg	atcttctctg	ccttcaccat	tattctttat	gcctttctga	720
ggcctgcccc	ccctgatggg	catcggcact	gggagtggca	acagctacgg	cctctacacc	780
atccgtgata	gggagaaccg	cacctctctg	gagctatgct	ggttccgtga	agggacaacc	840
atgtacgccc	tctatatcac	cgctccacggc	tacttctcca	tcaccttct	ctttggcatg	900
gtggctcctg	ccctggtggg	ctggaagatc	ttcaccctgt	cccgtgctac	agcgggtcaag	960
gagcggggga	agaaccggaa	gaagggtgct	acctgctggg	gcctctcgag	cctgggtgggt	1020
gtgacatggg	ggttggccat	cttcaccccg	ttgggcctct	ccaccgtcta	catctttgca	1080
cttttcaact	ccttgcaagc	ccagagaggc	atcacagtct	gactgtgaga	gaaacagcca	1140
agacaggagt	gacgagactc	aacctgttca	gggaagtcac	tagaaaccca	ggcgtcctag	1200
atgcagcggg	tataagcccc	caagaccagg	actggctccc	agcgccccat	gagagatgtg	1260
tggcttagtg	gctagggcca	ggcagccctg	ggtccaaatc	ctagccccat	ccctgaccca	1320
gcaagtcact	cagctccttc	cgctcctcatt	catcgcgaaa	ttgggataat	cccgtactta	1380
tctcaccagc	tttttttttt	tttttaattg	agatggagtc	ttgctctgtc	acccaggctg	1440
gagtgcagtg	gcacgatctc	agctcactgc	gacctccacc	tcctgggttc	aagtaattct	1500
tctgggttca	gcctcctgag	tagctggaac	tacaggcaca	tgccaccatg	cccagctaata	1560
ttttgaattt	tttagtagaaa	tgggggtttca	ccatactggt	caggctggtc	tcaaaactct	1620
gacctcagat	gatctacctg	cctcagccctc	cgaaagtgtc	gggattacag	gcgtgagcca	1680

ccatgttgct	caggctaate	tcaaactcct	ggacgtgagc	aagatcttcc	caattgctga	840
gattgcagag	gaaagctccc	cagaggtagt	accggtggaa	ctcttggtga	tgctttctcc	900
tgctctcaa	ggggacctgc	atacgaagcc	tttggggact	gacgatgact	tctggggccc	960
cacggggcct	gtggctactg	aggtagttga	caaagaaaag	aacttgtagc	gagttcactt	1020
cctgtagct	ggctcctacc	gctggcccaa	cacgggtctc	tgctttgtga	tgagagaagc	1080
ggtgaccgtt	gagattgaat	tctgtgtgtg	ggaccagttc	ctgggtgaga	tcaaccacac	1140
gcacagctgg	atggtggcag	ggcctctgct	ggacatcaag	gctgagcctg	gagctgtgga	1200
agctgtgcac	ctccctcact	ttgtggctct	ccaagggggc	catgtggaca	catccctgtt	1260
ccaagtggcc	cactttaaag	aggaggggat	gctcctggag	aagccagcca	gggtggagct	1320
gcatacacata	gttctggaaa	accccagctt	ctcccccttg	ggagtccctc	tgaaaatgat	1380
ccataatgcc	ctgcgcttca	ttcccgtcac	ctctgtggtg	ttgctttacc	accgctcca	1440
tcctgaggaa	gtcaccttcc	acctctacct	gaccccaagt	gactgtcca	ttcggaagga	1500
actggagctc	tgctatcgaa	gccctggaga	agaccagctg	ttctcggagt	tctacgttgg	1560
ccacttggga	tcagggatca	ggctgcaagt	gaaagacaag	aaagatgaga	ctctggtgtg	1620
ggaggccttg	gtgaaaccag	gagatctcat	gcctgcaact	actctgatcc	ctccagcccg	1680
catatccgta	ccttcacctc	tggatgcccc	gcagttgtctg	cactttgtgg	accagtatcg	1740
agagcagctg	atagcccag	tgacatcggt	ggaggttgtc	ttggacaaac	tgcatggaca	1800
ggtgctgagc	caggagcagt	acgagagggt	gctggctgag	aacacgaggc	ccagccagat	1860
gcggaagctg	ttcagcttga	gccagtcctg	ggaccggaag	tgcaaagatg	gactctacca	1920
agccctgaag	gagaccatc	ctcactcatt	atggaactct	gggagaaggg	cagcaaaaag	1980
ggactcctgc	cactcagcag	ctgaagtatc	aacactagcc	cttgaccctt	gagtcctggc	2040
tttggtgac	ccttcttttg	gtctcagttt	ctttctctgc	aaacaagttg	ccatctggtt	2100
tgctttccag	cactaaagta	atggaacttt	gatgatgcct	ttgctgggca	ttatgtgtcc	2160
atgccaggga	tgccacaggg	ggccccagtc	caggtggcct	aacagcatct	cagggaatgt	2220
ccatctggag	ctggcaagac	ccctgcagac	ctcatagagc	ctcatctggt	ggccacagca	2280
gcacaagcct	agagcctccg	gatcccatcc	aggcgcaaag	aggaatagga	gggacatgga	2340
accatttgcc	tctggctgtg	tcacaggggtg	agccccaaaa	ttgggggttca	gcgtgggagg	2400
ccacgtggat	tcttggcttt	gtacaggaag	atctacaaga	gcaagccaac	agagtaaagt	2460
ggaaggaagt	ttattcagaa	aataaaggag	tatcacagct	cttttagaat	ttgtctagca	2520
ggctttccag	tttttaccag	aaaaccctta	taaattaaaa	attttttact	taaatttaag	2580
aattaaaaaa	atacaaaaaa	gaaaaaatga	aaataaagga	ataagaagtt	acctactcca	2640
aaaaaaaaaa	aaaaaaa					2657

&lt;210&gt; 23

&lt;211&gt; 2466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

ggcacgagca	ggggcttaga	tgctgctgag	ccatccctta	cctgtctggt	tctgtttctc	60
cttctgtccc	ttcccagctc	cagcactgag	tctcttgccc	attggcctgg	tgagggaagg	120
agctgccagc	cccacccaac	agctcaggtt	acagagagag	tcactttctt	ccattactca	180
cagagtaaac	atcaaggaag	gccactgatt	gattgacagt	gtctgggtca	gatgtctatc	240
cttaggccag	tcctgtgaa	caaggggatg	ggtgtctgag	tggaaccagat	ctgaagcaca	300
ggcccatgcc	tggggccagg	ggtgggaact	atggacctct	ctccccactg	agaaccccag	360
ggagcaggtg	aggtgaaatt	cctctagggg	aagaggggca	aaattgacaa	gatagcagat	420
gtctaccata	ctgctgtggg	gcctggtccc	tcccagaagg	aaaaacatag	taacaataga	480
gtgggtctca	ccctccacct	gggtctcaag	tagggtgtgg	atgaggacaa	tggaaatgaa	540
ggaaaggtta	gaaggcctgt	ggtaccggtt	ggtaaatagc	tcttcgtgct	ttctccatat	600
ggagtggag	tgcttggatg	tgattccttc	aaagtcaggt	ctaggagact	caggatgcct	660
aatctagagg	taagaacatt	gtgaggaaag	ccagtgaatt	cagtcttgtg	catgctgact	720
ttgaagtact	tttggaaag	ccaagtggaa	ttatccacag	gacaggacca	aatcttacct	780
ggttcttccc	caggccgact	agtcacaca	aggaataaaa	aagagttgcc	ccgataccaa	840
gttgtagtag	tacttctcca	cactgctatg	gggaaatacc	tgagactggg	taatttataa	900
agggaaaagg	tttaattgac	tcacagttct	agatggctgg	ggaggcttca	ggaaacttac	960
aatcatggca	gaaggcacca	cttcacaggg	tgccggggaga	gagaatgagt	gccagcgcaa	1020
gggagaagct	ccttataaaa	ccatctgttc	tccttataaa	gatctcttaa	taaaaccgtc	1080
agagaactat	ctcattcact	atcaggagaa	gagcatgggg	gaaccgcccc	catgattcag	1140

aggtcagtaa	tttccaatgg	gcgaggaggca	ttaagcaccg	accctgggtc	cctaggcccc	1980
gcctggcact	cagccttgcc	agagattggc	tccagaattt	ttgccaggct	tacagaacac	2040
ccactgccta	gaggccatct	taaaggaagc	aggggctgga	tgcccttcat	cccaactatt	2100
ctctgtggta	tgaaaaagaa	aaaaaaaaaa	aaaaaa			2136

&lt;210&gt; 21

&lt;211&gt; 1547

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

ggcagagccc	agttcatctc	attgggactg	gttagacagt	gggtgcagcc	cacagagggg	60
gagcagaagc	aggggtgggg	gttgccctcac	ctgggaagcg	caaggggttg	aggaactccc	120
tcctctagcc	aaggcaagcc	atgaaggact	gtgccgtgag	ggacgggtgct	atctgaccca	180
catactacgc	ttttccgatg	gttttcacaa	cccacagacc	aaaagattcc	cttgggtgcc	240
tatacaacca	gggccctggg	tatcaagcat	aaaactggat	ggccgtttgg	ggagacaccg	300
agctggctgc	aggagttttt	tgtttttttt	tgtttttttg	ttttttgtac	ctcagtggca	360
cctggaatgc	cagcaagaca	gaactgttca	ctcctctgga	aaggagctg	aagccagggc	420
acccgagtgg	tatgctcagc	ggatcccacc	cccacggagc	ccaacaagct	aatccactg	480
gcttgaaaact	ctcgctgcct	gcacagcagt	ctgaagtga	cctgggatgc	tcaagcttgg	540
tggtggggagg	ggcatctgcc	attactgagg	ctttgtaaac	aaagctgaca	gaaagtgtga	600
actgggtgca	gaaccaaca	cagcatggca	aagccgctgt	agccagaatc	tagagaggca	660
tctctagatt	cctcctctct	gggcagggca	tctctgaaag	aaaggtagca	gccccagtca	720
ggagcttata	gaaaaaactc	ccatgtccct	gggacagagc	acctggggga	aggggcagct	780
gtgggcacag	cttcaacaga	cttaaacctt	cctgcctgct	ggctctgaag	agaggaacag	840
atctctcacc	acagcgctca	agatctgcta	agggacagac	tgctcttcc	agtggattct	900
tgacccccgt	gcctctgact	gggagacacc	ttccagcagg	ggacgacaga	cacctcaaac	960
aggagaactt	cagctggcat	ctggcggtg	cctctctcg	acgaagcttc	cagaggaagg	1020
atcaggcagc	aatatttgct	gttctgcagc	ctccactgga	gataccagg	caaacaggg	1080
ctggaatgga	acttcagtaa	attccagcag	acctgcagaa	gaggggcctg	actgttagaa	1140
ggaaaactaa	caaccagaaa	gcaatagcat	caacatcaac	aaaaaggaca	cccaagcaaa	1200
aaccccatcc	aaaggtcacc	aacatcaaag	accaaaggta	gataaattca	cgaagatgag	1260
gaaaaaccaa	cgcaaaaagg	ctgaaaattc	ccaaaaccag	aatgcctctt	ctcctccaaa	1320
gtatcacaa	tccttgccag	taagggaaca	aaactggacg	gagaatgagt	ttgatgaatt	1380
gacagaagta	ggcttcagaa	ggtgggtaat	aacaaactct	caagctaaag	gagtgtgttt	1440
taacccaatg	caaggaagct	aagaaccttg	ataaaaagtt	acaggaacta	tcactagaat	1500
accagttatg	agaacaacat	aaatacctga	tggagctgaa	gccaaagg		1547

&lt;210&gt; 22

&lt;211&gt; 2657

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ggcacgagga	agaagcttca	gctgattgag	ggcaggcagc	acagatcaac	atggagcccc	60
accatggtag	tcctgttcag	gtgggtccca	gtcacagatg	cctattggca	gattctcttc	120
tcctcctca	aggtcaccag	aaacctgaag	gagctggacc	taagtggaaa	ctcgctgagc	180
cactctgcag	tgaagagtct	ttgtaagacc	ctgagacgcc	ctcgctgcct	cctggagacc	240
ctgcggttgg	ctggctgtgg	cctcacagct	gaggactgca	aggaccttgc	ctttgggctg	300
agagccaacc	agaccttgac	cgagctggac	ctgagcttca	atgtgtcac	ggatgctgga	360
gccaaacacc	tttgccagag	actgagacag	ccgagctgca	agctacagcg	actgcagctg	420
gtcagctgtg	gcctcacgtc	tgactgctgc	caggacctgg	cctctgtgct	tagtgccagc	480
cccagcctga	aggagctaga	cctgcagcag	aacaacctgg	atgacgttgg	cgtgcgactg	540
ctctgtgagg	ggctcagcat	cctgcctgca	aactcatacg	cctggggctg	gaccagacaa	600
ctctgagtga	tgagatgagg	caggaactga	gggccctgga	gcaggagaaa	cctcagctgc	660
tcactctcag	cagacggaaa	ccaagtgtga	tgacctctac	tgaggcctgg	atacgggaga	720
gatgagtaat	agcacatcct	cactcaagcg	gcagagactc	ggatcagaga	gggcggcttc	780



cctgagaaca	ccaagccccc	cgaccccggg	cccacgcccc	cccaccaccc	agcctcgga	420
gcgctttccc	aggattcaca	tggtaatgaa	ggcatccatc	ttctcccaga	cacacactgg	480
gccctgcgac	cctcccagg	cccacacaat	ggcccacagc	gccgcggccc	caccacctgt	540
tggattttcc	cagggaaagg	agtgaggggg	tggaggggaa	gggcagtccg	tctcttccca	600
gccccagcc	ccatttgac	cctggtcgca	agagtcagtc	agcgagggca	cccatgtcct	660
cggactctca	gtccatcctc	agcaccctgt	ttcctcatcc	tcaaactgca	aggtggttgg	720
gaggattcta	atgggaatgg	tagtaaggac	acgctcagga	actgtggatt	gccagacaaa	780
gagagcaaaa	ggctgggctt	acaggcgtga	gccacaacgt	ccggccaggc	taatttttta	840
atatttttgt	agagacggga	tctcactgta	ttgcccaggc	tgggtctcaa	ctcctatcct	900
caagcagtc	tccttcctca	gcctcccaga	gtgctgggat	tgcaggcatg	agaccccgca	960
cagtctgttt	ctacagcggc	ctctctcgcc	cttctctctt	tctggcctca	tggagaaacc	1020
ccagaaagag	catagactct	ggaattagag	aaacagggtt	tgggaattctg	tgccattctc	1080
tccctgtgtg	gtttggccaa	ctgattcaaa	ggctgtttcc	tcatattgaa	aatggagata	1140
tatagtcagt	ggctctgttt	attatctccc	tgctacctgc	cccttcccca	aacaccagcc	1200
agtcttctct	gctctggcca	aattgataat	agcttttgtt	tttcaagcct	aaaaccagct	1260
tcttccagtt	tgctcagcag	ctatttgcta	atcatccaga	gtgacctagg	acgtatttac	1320
atgagcggaa	gagccactcg	gggagagtgc	tgctgggaat	gcctccacag	agatgctgat	1380
tgtacgcag	ctgcgtaagc	ctcagatttt	tctgttcagg	cccaaatgcg	cagcacaatc	1440
tgtgggaaag	ttgcaacaga	gaaagcaaaa	aaaaaaaaaa	aaaactcgag	ggggggcccc	1500

&lt;210&gt; 20

&lt;211&gt; 2136

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggacgagcag	ccgcagtcgc	cactggctgc	ctgaggtgct	cttacagcct	gttccaagtg	60
tggtttaatc	cgctccacc	accagatctt	tctccgtgga	ttcctctgct	aagaccgctg	120
ccatgccagt	gacggtaacc	cgcaccacca	tcacaaccac	cacgacgtca	tcttcggggc	180
tggggteccc	catgatcgtg	gggtcccttc	gggcccgtgac	acagccctg	ggctctcttc	240
gcctgtgca	gctgggtgtt	acctgcgtgg	ccttctcgct	gggtgctagc	gtgggcgctt	300
ggacggggtc	catgggcaac	tggtccatgt	tcacctgggtg	cttctgcttc	tccgtgaccc	360
tgatcatcct	catcgtggag	ctgtgcgggc	tccaggcccc	cttccccctg	tcttggcgca	420
acttccccat	caccttcgcc	tgctatggcg	ccctctctctg	cctctcgccc	tccatcatct	480
acccaccacc	ctatgtccag	ttcctgtccc	acggccgttc	gcgggaccac	gccatcgccg	540
ccaccttctt	ctcctgcac	gcgtgtgtgg	cttacgccac	cgaagtggcc	tggaccgggg	600
cccggccccg	cgagatcact	ggctatatgg	ccaccgtacc	cgggctgctg	aaggtgctgg	660
agaccttcgt	tgctgcac	atcttcgcgt	tcacagcgca	ccccaacctg	taccagcacc	720
agccggccct	ggagtgggtg	gtggcggtgt	acgcatctctg	cttcatccta	gcggccatcg	780
ccatcctgct	gaacctgggg	gagtgcacca	acgtgctacc	catccctctc	ccagcttctc	840
tgtcggggct	ggccttgctg	tctgtcctcc	tctatgccac	cgccttggtt	ctctggcccc	900
tctaccagtt	cgatgagaag	tatggcggca	gcctcggcgc	tcgagagatg	taagctgcag	960
ccgcagccat	gcctactacg	tgtgtgcctg	ggaccgccga	ctggctgtgg	ccatcctgac	1020
ggccatcaac	ctactggcgt	atgtggctga	cctgggtgac	tctgcccacc	tgggttttgt	1080
caaggtctaa	gactctccca	agaggctccc	gttccctctc	caacctcttt	gttcttcttg	1140
cccagagttt	ctttatggag	tacttctttc	ctccgccttt	cctctgtttt	cctcttctctg	1200
tctccccctc	ctccacacct	tttctttctt	tcccaattcc	ttgcactcta	accagttctt	1260
ggatgcattc	tcttcttctc	ctttcctctt	gctgtttctt	tctgtgtgtg	ttttgttgcc	1320
cacatcctgt	tttccacctt	gagctgtttc	tcttttcttt	ttctttcttt	tttttttttt	1380
tttttaagac	ggattctttac	tctgtggccc	aggctggagc	gcagtgggtg	gatctcgact	1440
cactgcaacc	cccgcctcct	gggttcaagc	gattctcctg	ccccagcctc	ccaagtagct	1500
gggaggacag	gtgtgagctg	ccgcacccag	cctgtttctc	tttttccact	cttctttttt	1560
ctcatctctt	ttctgggttc	ctgtcggctt	tcttatctgc	ctgttttgca	agcaccttct	1620
cctgtgtcct	tgggagccct	gagactctct	tctctccttg	cctccaccca	cctccaaagg	1680
tgtgagctc	acatccacac	cccttgacgc	cgtccatgcc	acagcccccc	aaggggcccc	1740
attgccaaag	catgcctgcc	caccctcgct	gtgccttagt	cagtgtgtac	gtgtgtgtgt	1800
gtgtgtgttt	gggggtggg	gggtgggtag	ctggggattg	ggccctcttt	ctcccagtg	1860
aggaaggtgt	gcagtgtact	tcccccttaa	attaaaaaac	atatatatat	atatattttg	1920

tctacatccc	tgacggctcc	ttcaccaaca	tctggttcta	cttcggcgctc	gtgggctcct	540
tcctcttcat	cctcatccag	ctggtgctgc	tcatygactt	tgcgcaactcc	tgggaaccagc	600
ggtggctggg	caaggccgag	gagtgcgatt	cccgtgcctg	gtacgcaggc	ctcttcttct	660
tcactctcct	cttctacttg	ctgtcgatcg	cggccgtggc	gctgatgttc	atgtactaca	720
ctgagcccag	cggctgccac	gagggcaagg	tcttcatcag	cctcaacctc	accttctgtg	780
tctgcgtgtc	catcgctgct	gtcctgcccc	aggtccagga	cgcccagccc	aactcgggtc	840
tgctgcaggc	ctcggtcac	accctctaca	ccatgtttgt	cacctgggtca	gccctatcca	900
gtatccctga	acagaaatgc	aacccccatt	tgccaaccca	gctgggcaac	gagacagttg	960
tggcaggccc	cgagggctat	gagacccagt	ggtgggatgc	cccagcatt	gtgggctca	1020
tcattctcct	cctgtgcacc	ctcttcatca	gtctgcgctc	ctcagaccac	cggcaggtga	1080
acagcctgat	gcagaccgag	gagtggccac	ctatgctaga	cgccacacag	cagcagcagc	1140
agcaggtggc	agcctgtgag	ggccgggcct	ttgacaacga	gcaggacggc	gtcacctaca	1200
gctactcctt	cttccacttc	tgctggtgct	tgccctcact	gcacgtcatg	atgacgtca	1260
ccaactggta	caagcccggg	gagacccgga	agatgatcag	cacgtggacc	gccgtgtggg	1320
tgaagatctg	tgccagctgg	gcagggctgc	tctctacct	gtggaccctg	gtagcccac	1380
tcctcctgcg	caaccgcgac	ttcagctgag	gcagcctcac	agcctgccat	ctggtgcctc	1440
ctgccacctg	gtgcctctcg	gctcggtgac	agccaacctg	ccccctcccc	acaccaatca	1500
gccaggtga	gccccaccc	ctgccccagc	tccaggacct	gcccctgagc	cgggccttct	1560
agtcgtatg	cgttcagggt	ccgaggagca	tcaggctcct	gcagagcccc	atccccccgc	1620
cacaccacaca	cgggtggagct	gcctcttctc	tccccctctc	cctgttgccc	atactcagca	1680
tctcggatga	aagggtctcc	ttgtcctcag	gctccacggg	agcggggctg	ctggagagag	1740
cggggaactc	ccaccacagt	ggggcatccg	gcactgaagc	cctggtgttc	ctggtcacgt	1800
cccccagggg	accctgcccc	cttcctggac	ttcgtgcctt	actgagtctc	taagactttt	1860
tctaataaac	aagccagtgc	gtgtacaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1920
a						1921

&lt;210&gt; 18

&lt;211&gt; 692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgagtg	ttcttcagca	accctacctg	cttctccaaa	ctgcctaaag	agatccagta	60
ctgatgacgc	tgttcttcca	tctttactcc	ctggaaacta	accacgttgt	cttcttttct	120
tcaccaccac	ccaggagctc	agagatctaa	gctgctttcc	atcttttctc	ccagccccag	180
gacactgact	ctgtacagga	tggggccgctc	ctcttgcttc	cttctcatcc	taatccccct	240
tctccagctg	atcaacctgg	ggagtactca	gtgttctcta	gactccgtta	tggataagaa	300
gatcaaggat	gttctcaaca	gtctagagta	cagtcctctc	cctataagca	agaagctctc	360
gtgtgctagt	gtcaaaaagcc	aaggcagacc	gtcctcctgc	cctgctggga	tggctgtcac	420
tggctgtgct	tgtggctatg	gctgtggttc	gtgggatgtt	cagctggaaa	ccacctgcca	480
ctgccagtgc	agtgtggtgg	actggaccac	tgcccgtgc	tgccacctga	cctgacaggg	540
aggaggctga	gaactcagtt	ttgtgaccat	gacagtaatg	aaaccagggt	cccaaccaag	600
aaatctaact	caaacgtccc	acttcatttg	ttccattcct	gattcttggg	taataaagac	660
aaactttgta	cctcaaaaaa	aaaaaaaaaa	aa			692

&lt;210&gt; 19

&lt;211&gt; 1500

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ccccgggct	gcaggaattc	ggcagagcg	agtttttact	tccttaataa	aattgggtttt	60
ggtgctcact	ttggcagcac	atatactaaa	attggaacta	gacagagatt	ggcattgccc	120
ccgagcaaga	atgacacgca	aattcgtgaa	gccttcaata	aaaaataaaa	taattttgtt	180
ttcccaatct	gtgtctcttt	taagccccac	aggatagaaa	tgtcctaaaa	taagaaatta	240
aataagaggg	gaagcccat	gatctgttct	ggtttttttg	ggtggtggtg	gtggtggtgt	300
tttttaattg	gtctctcagg	attccaccag	accacttcc	cagccgctgt	gtggtctggg	360

tggttggggc	agccgagagc	ctgggggttca	ttggtgaagg	ggccttggag	ttgtgactgc	1620
cggggcccgt	tcaggaaacgt	acgggtaaac	gtgtgttttc	tggaaaaaaa	aaaaaaaaaa	1680
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	tcgag	1735

<210> 16  
 <211> 1274  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1258)  
 <223> n equals a,t,g, or c

<400> 16						
ctacnccgga	caaaatctgg	agctccaccc	gcggtggcgg	ccgctctaga	actagtggat	60
cccccgggct	gcaggaaattc	ggcacgagga	gccatcttgc	agccgtccat	atggcagcct	120
gggtcttccc	gttgctttca	gtcatccaca	cargtctgcc	acaggccagt	cctgaaatct	180
gggtaactca	gtcagaagggt	ggatgatcagg	gcgtagcttg	tgaarggggt	gggggtgtgt	240
tragcacact	ggatcgatt	gaattgtgtt	tcctaagtga	ccgtgctagc	tcaggctgca	300
rtgacaaaac	accacagact	ggggtcttat	tcctgggggc	tgccatttgc	catgaagggtg	360
tgggcagggc	tggttcctcc	cgagccctct	ctcctggggc	tgcargtgcc	gtctttccgt	420
cttttcctcg	tgccttcccg	gggccatcct	gcgtgtgtct	gtgtcctcgg	ctctcctgga	480
ramcctaccg	ttctcaagga	ccctgggtcat	attggatcag	ggccacccta	atggcctcat	540
gtcactgcag	ttacctytaa	aggccgttaa	agtcccmagc	tccaagtata	wtcmcattec	600
aaggcactgg	ggtcgggatt	tcaacttwcg	aactctgagc	ggragatcaa	ttcaggccat	660
ggcaggctaa	agtataatac	taaaatcaca	aatgtagcag	cctgcttttc	cgtagaatgt	720
tgctgtgtgt	attttttgtt	ttctgtggca	aaataaaaagt	gggtcactct	tgtaaaattt	780
ggcagttttt	aatggagaaa	gcaacttaat	tttgctagcc	tttaagaaat	ggcatcttga	840
catatcaggt	cttcatttta	ttccaacaag	aatgcagaat	atgttttaaa	aataaccaag	900
aatccctcta	gtgcttcata	aaataagtga	aaacctgacc	ctgatttttg	tagcaaaaaa	960
tgaagtaaac	gtggaaaatg	aagaggaaat	tctagtagga	gacgatgggg	tcataagtca	1020
gaaattaaag	agttgtttgc	tccccaccct	cccggccagc	ctcacctcac	ccctgctgtg	1080
gggcctctgc	ccagcctggg	ccaaggccgt	ggctccccctg	gtgccatcct	gtccgcagtc	1140
ggctccctgt	ccacggcggtg	tggtctcttc	aggacatcag	tcacctgttg	tccatgtggc	1200
acatccctgt	gccgaattcg	atatcaagct	tatcgatacc	gtcgacctcg	aggggggncc	1260
ggaaccggg	tcga					1274

<210> 17  
 <211> 1921  
 <212> DNA  
 <213> Homo sapiens

<400> 17						
cgccccggcg	cgggcgcccc	aagccgggag	ccgcccgcct	gggggcctgc	ctgggagcct	60
gtcctctgct	cagctgcgcg	tcctgcctct	ggggtcttgc	cccctgcac	ctgtgcagct	120
gctgccccgc	cagccgcaam	tccaccgtga	gccgcctcat	cttcacgttc	ttcctcttcc	180
tggggggtgct	gggtgccatc	attatgtgta	gcccgggctg	ggagagtcag	ctctacaagc	240
tgccctgggt	gtgtgaggag	ggggccggga	tccccaccgt	cctgcagggc	cacatcgact	300
gtggctccct	gcttggttac	cgcgctgtct	accgcatgtg	cttcgccacg	gcggccttct	360
tcttcttttt	cacctgtctc	atgctctgct	tgagcagcag	ccgggacccc	cgggctgcca	420
tccagaatgg	gttttggttc	tttaagttcc	tgatcctggt	gggccycacc	gtgggtgcct	480

gccggagacg	ccggaaccag	gatcgacccc	agctgwccaa	gaagttctgt	gaggccagct	60
ggaggtttct	cttctacctg	tcctccttcg	tgggcggcct	ctcggtcctg	taccacgagt	120
catggctgtg	ggcaccagta	atgtgctggg	acaggtaccc	aaaccagact	ctgaagccat	180
ccctgtactg	gtggtacctc	ttggagctgg	gtttctacct	ctcactgcta	atcaggctgc	240
cctttgatgt	caagegcaag	gatttcaagg	agcaggtgat	acaccacttc	gtggcggcca	300
tcctgatgac	cttctcctac	agtccaacc	tgctgcgcac	tggctctctg	gtgctgctgt	360
tacaygattc	ctctgactac	ctgctggagg	cctgtaagat	ggtcaactac	atgcagtatc	420
agcaagtgtg	cgacgctctc	ttcctcatct	tctcctttgt	cttcttctac	acccgactgg	480
tcctctttcc	caccagatc	ctctacacca	catactacga	gtccatcagc	aacaggggcc	540
ccttcttcgg	ctactacttc	ttcaacgggc	ttctgatgtt	gctgcagctg	ctgcacgtgt	600
tctggctctg	cctcattctg	cgcatgctct	atagcttcat	gaagaagggc	cagatggaga	660
aggacatttg	tagtgatgta	gaagaatcag	actccagtga	ggaggyggcg	gcggcccagg	720
aacctctgca	gctaaagaac	gggrcagctg	gagggcccag	gccagcccc	actgatggcc	780
ctcggagccg	ggtggccggg	cgtctgacca	acaggcacac	aacagccaca	tagccgggcg	840
gggctggctg	taaggggttg	cccccccgcc	agtgccttgg	atatttcttg	ggtgactgga	900
ctggcgcccc	tgggccacct	ttctggagac	agggaggggc	ccaccggggg	tgggtgggaa	960
ggctgatgat	ctgtctccag	ccccttcctt	ctgccacccc	rcccttcttc	cctctgggca	1020
actggacaga	tctggsagcc	agcagctgga	tgctgtggct	ggccagagac	acctccaggc	1080
tgtgcctgga	gggctggggg	gagccccagg	ctgaaaaggg	tccaattaaa	acaaatggag	1140
ccaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaactcgag		1190

&lt;210&gt; 15

&lt;211&gt; 1735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1002)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 15

tcgacccacg	cgctccggcg	ggatcagctt	ccagcccagt	cggcccggcc	cgggggcmat	60
ggagctccga	gcggcggatc	gcgagcctcc	tgccaacccc	agcctgcacg	cccggttagc	120
attcgcccg	gagatgcggc	agtggaaatc	ggaagggcgg	tgaaaaacct	acgtcctgcc	180
ctcgcccggc	ctctccattc	gtcccccggg	tagagagggt	cccggctccc	accccttccc	240
agccccagcg	ctggagacag	cagcccctag	actactgagg	gacagcgaca	gcatgaaggc	300
tcggggtcgg	ctcgtgctca	tcacctctgt	ctccgtggtc	ttctctgccg	tctacatcct	360
cctgtgctgc	tgggcccggc	tgccccctct	cctggccacc	tgcctggacc	accacttccc	420
cacaggctcc	aggcccaact	tgccgggacc	cctgcacttc	agtggatata	gcagtgtgcc	480
agatgggaag	ccgctgggtc	gcgagccctg	ccgcagctgt	gccgtgggtg	ccagctccgg	540
ccaaatgctg	ggctcaggcc	tgggtgctga	gatcgacagt	gccgagtgcg	tgttccgcat	600
gaaccaggcg	cccaccgtgg	gctttgaggc	ggatgtgggc	cagcgagca	ccctgcgtgt	660
cgtctcacac	acaagcgtgc	cgctgctgct	gcgcaactat	tcacactact	tccagaaggc	720
ccgagacacg	ctctacatgg	tgtggggcca	gggcaggcac	atggaccggg	tgctcggcgg	780
ccgcacctac	cgcacgctgc	tgacgtcac	caggatgtac	cccggcctgc	aggtgtacac	840
cttcacggag	cgcagatggg	cctactgcga	ccagatcttc	caggacgaga	cgggcaagaa	900
ccggaggcag	tccgggtcct	tcctcagcac	cggtcgggtc	accatgatcc	tgcgctgga	960
gctgtgtgag	gagatcgtgg	tctatgggat	ggtcagcgac	anctactgca	gggagaagag	1020
ccaccctca	gtgccttacc	actactttga	gaagggccgg	ctagatgagt	gtcagatgta	1080
cctggcacac	gagcaggcgc	cccgaagcgc	ccaccgcttc	atcactgaga	aggcggctct	1140
ctcccgtcgg	gccaaagaaga	ggcccatcgt	gttcgcccac	ccgtcctgga	ggactgagta	1200
gcttccgtcg	tcctgccagc	cgccatgccg	ttgcgaggcc	tccgggatgt	cccattccaa	1260
gccatcacac	tcacaaaaaa	catttaattt	atggatcctg	cctcctgcc	cgtgctgggt	1320
ggacctaaag	ttccttccca	ccccattst	ggcgacaytt	ggagccatct	caggcctcca	1380
ctccctgagt	aattcatggc	atttgggggc	tcacccaccc	tcccaggctc	gtcaagtgcc	1440
ctttgtccct	gggctgatgg	cccccaactc	accagcatca	tgacctgtgt	ccagtcctgg	1500
tcctccctcc	ccagccggcc	ctaccacctt	ttggtgccac	acttctcagg	ctggccgccc	1560

gtgggctgt	cacctgtccc	aggttcccag	caagtctgca	gctgtgcagt	cctgggggtcc	2400
ctgaccctgt	cgcccagggg	gcgtgctgtc	cagcaggggc	cctgccttgc	aaggaacgtc	2460
tcttccggcg	gctggggccg	tcctgectgg	tctgggctgt	gtgtggcgcc	ctttcctcct	2520
tgtttgttcc	tctgtgttct	gtgtgcgtct	taagcaataa	agcgtggccg	tggctcgcga	2580
aaaaaaaaaa	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2640
aaaaaaaaaa	aaaaaaaaaa	aaaaaaa				2667

&lt;210&gt; 13

&lt;211&gt; 2170

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ggcagcaggt	ccgggtcccaa	aggtgggaac	gcgtccgccc	cgccccgcac	catggcacgg	60
ttcggcttgc	ccgcgcttct	ctgcaccctg	gcagtgtca	gcgccgcgct	gctggctgcc	120
gagctcaagt	cgaaaagtgt	ctcggaagtg	cgacgtcttt	acgtgtccaa	agggctcaac	180
aagaacgatg	ccccctcca	cgagatcaac	ggatgatcatt	tgaagatctg	tccccagggg	240
tctacctgct	gctctcaaga	gatggaggag	aagtacagcc	tgcaaagtaa	agatgatattc	300
aaaagtgtgg	tcagcgaaca	gtgcaatcat	ttgcaagctg	tctttgcttc	acgttacaa	360
aagtctgatg	aattcttcaa	agaactactt	gaaaatgcag	agaaatccct	gaatgatatg	420
tttgtgaaga	catatggcca	tttatacatg	caaaattttg	agctatttaa	agatctcttc	480
gtagagttga	aacgttacta	cgtggtggga	aatgtgaacc	tggaagaaat	gctaaatgac	540
ttctgggctc	gcctcctgga	gcggatgttc	cgccctggga	actcccagta	ccactttaca	600
gatgagtatc	tggaatgtgt	gagcaagtat	acggagcagc	tgaagccctt	cggagatgtc	660
cctcgcaaat	tgaagctcca	ggttactcgt	gctttttag	cagcccgtac	tttcgctcaa	720
ggcttagcgg	ttgcggggaga	tgtccgtgag	caaggtctcc	gtggtaaaac	ccacagccca	780
gtgtacccat	gccctgttga	agatgatcta	ctgctccac	tgccgggggtc	tcgtgactgt	840
gaagccatgt	tacaactact	gctcaaacat	catgagaggc	tgtttgccca	accaagggga	900
tctcgatttt	gaatggaaca	atttcataga	tgctatgctg	atggtggcag	agaggctaga	960
gggtcctttc	aacattgaat	cggtcatgga	tcccatcgat	gtgaagattt	ctgatgctat	1020
tatgaacatg	caggataata	gtgttcaagt	gtctcagaag	gttttccagg	gatgtggacc	1080
ccccagccc	ctcccagctg	gacgaatttc	tcgttccatc	tctgaaagtg	ccttcagtgc	1140
tcgcttcaga	ccacatcacc	ccgaggaacg	cccaaccaca	gcagctggca	ctagtttgga	1200
ccgactgggt	actgatgtca	aggagaaact	gaaacaggcc	aagaaattct	ggtcctccct	1260
tccgagcaac	gtttgcaacg	atgagaggat	ggctgcagga	aacggcaatg	aggatgactg	1320
ttggaatggg	aaaggcaaaa	gcaggtaact	gtttgcagtg	acaggaaatg	gattagccaa	1380
ccagggcaac	aaccagagg	tccaggttga	caccagcaaa	ccagacatac	tgatccttcg	1440
tcaaatcatg	gctcttcgag	tgatgaccag	caagatgaag	aatgcataca	atgggaaacga	1500
cgtggacttc	tttgatatca	gtgatgaaag	tagtggagaa	ggaagtggaa	gtggctgtga	1560
gtatcagcag	tgcctttcag	agtttgacta	caatgccact	gaccatgctg	ggaagagtgc	1620
caatgagaaa	gcccagagt	ctgggtgccg	tcctggggca	caggcctacc	tcctcactgt	1680
ctctgcatc	ttgttcctgg	ttatgcagag	agagtggaga	taattctcaa	actctgagaa	1740
aaagtgttca	tcaaaaagtt	aaaaggcacc	agttatcact	tttctaccat	cctagtgtact	1800
ttgcttttta	aatgaatgga	caacaatgta	cagtttttac	tatgtggcca	ctggtttaag	1860
aagtgtgtac	tttgtttctc	attcagtttt	gggaggaaaa	gggactgtgc	attgagttgg	1920
ttcctgtctc	ccaaaccatg	ttaaactgtg	ctacagtgtg	ggtacagaac	tatagttagt	1980
tgtgcatttg	tgattttatc	actctattat	ttgtttgtat	gtttttttct	catttcgttt	2040
gtgggttttt	ttttccaact	gtgatctcgc	cttgtttctt	acaagcaaac	caggggtccct	2100
tcttggcacg	taacatgtac	gtattttctga	aatattaaat	agctgtacag	aaaaaaaaaa	2160
aaaaaaaaaa						2170

&lt;210&gt; 14

&lt;211&gt; 1190

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

tttgatttga	tttttctaaa	ctatctacca	tattttaagt	gtagcagctt	tgactttgca	1140
ataacgtggc	aagtatctga	tttctccttt	gaggcagagg	tttaagtgt	ggcctgttac	1200
acttgtttga	tacctttttc	atgacagtct	cagtatagat	cagttggtac	agaaatacat	1260
gaacacattt	tgatagggtc	tatttcacac	aaagaagttt	atgggtattt	gtgtggggtg	1320
gtgttggtat	atattattgt	ctttaaggga	aaagaagcta	taagattcgc	tgacagccaa	1380
agtatcattt	agaaaagtga	agcaacaaga	tttaggttga	tgaaagatac	atgagtttgc	1440
attttgacct	gttcagtgtc	tgtcttcacg	cacggtgtgt	acacttcttc	aaaattgtac	1500
acagtttgct	aattagaaat	atcttggaaa	gcctcatggt	cactaatttt	caactagcat	1560
caggtatttt	gaaaacgtgt	gtctggatat	taactcttgt	ttaaactgaa	tgtatgat	1620
tttgtttagaa	tggaaaagta	ctatcttggt	aatttaagta	ttttaaatat	agttgtatat	1680
ttttcttaaa	aaaaaaaaaa	aaaaaaaaaa	aaagggcggc	cgctctagag	gatcccgcca	1740
ggggccccan	attacgcgtg	agcggt				1766

&lt;210&gt; 12

&lt;211&gt; 2667

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

ccccgggtcga	cccacgcgtc	cgcccacgcg	tccgaccgag	ccctttgtga	gggctgtgag	60
ctgcgcctga	cggtggcacc	atgagcagct	caggtggggc	gcccggggcg	tccgccagct	120
ctgcgcgcgc	cgcgaggaa	gagggcatga	cggtgtggta	ccgctggctg	tgtcgcctgt	180
ctgggggtgct	gggggcagtc	tcttgcgcca	tctctggcct	cttcaactgc	atcaccatcc	240
accctctgaa	cattgcggcc	ggcgtgtgga	tgatgatggc	ggtcgttccc	atcgtcatca	300
gcctgacctt	gaccacgctg	ctgggcaacg	ccatcgccct	tgctacgggg	gtgctgtacg	360
gactctctgc	tctgggcaaa	aagggcgatg	cgatctccta	tgccaggatc	cagcagcaga	420
ggcagcaggc	ggatgaggag	aagctcgccg	agaccctgga	gggggagctg	tgaagggctg	480
ggcgccccct	cctccctgtc	ccctcttctg	gctctgtgtg	ggtccaagtg	aggcctggac	540
tgtccacgct	gaggcacagc	ctggagaggg	gcctttgcac	gtgtccctac	acctggagtc	600
ctctgctcct	ttctccagac	tggcttaagc	caggagccac	tggctgctgg	tgtgagggtc	660
tgggctgctg	gacttgaggc	agagcctgca	gcagctgtgt	ggacactacc	cagccctact	720
cctctgctgg	gtgggtctgc	agatctcaca	ccacagacag	ggctgcctgt	gacctgctgt	780
gacctgggag	cagcttcccc	tggagatgct	ggctctggct	tgaggggagg	ggcaagtggg	840
accctgccac	ctgggcactg	agcagaggga	cctccccag	ctctcttagc	agggtggagc	900
ccagggcctg	ggacagcctg	ccgctgccag	caacctccca	ctgctgccta	gggtgcagcg	960
cccactgtca	ccctgccttc	tggagaagcc	cacagggtc	ctaagggtga	ccccgggtacc	1020
tggaaactga	gccttggcag	tgactggaca	gctgggtggg	ggatgctccc	tgctggccct	1080
gggaaccttg	gagagccac	ctcaaggccc	ctcggtgcc	cctcctccct	gggcctgctg	1140
gggccccctag	gttctgcccc	tcaccccccg	cccctgctgg	ccttggtgct	aagggaagtgg	1200
ggagagcagg	ctctccctgg	caccgagggt	gcccaccctc	tccctggtgt	ggccccgtca	1260
acatcagcca	cagcccagcc	ccattagtgg	gttagtgggt	ctgacctcag	ccccactcag	1320
gtgctcctgc	tggcctgccc	aagccctgcc	ctcagggagc	ttctgccttt	taagaactgg	1380
gcagaggcca	cagtcacctc	cccacacaga	gctgtcccca	ctgccctggg	tgccaggctg	1440
tccggagcca	ggcctaccca	gggaggatgc	agagagctgg	tgcccaggat	gtgcaccccc	1500
atattccctc	tgccctgtgg	cctcagcccc	ctggcctctc	tgacctgag	gctggctctc	1560
agccatcggg	caggtgcctg	gtcgggcctg	gcttagccca	gggtgggttt	ggcagaagcg	1620
ggcggtgtg	gaagatatc	catctggggc	caaccccagg	ctgggcctgc	gctgagcttc	1680
tggagcgcag	gtactgggtc	ttgctaagtg	aactgtttcc	caggaacacc	tctcgggccc	1740
atctgcgtct	gaggctggga	gtggcatctg	aggccgggag	tggcatctga	ggccaggagt	1800
ggcaggctgg	tgggctgggc	gtgggggttt	ctggggcctg	cccagtactg	ccctggggac	1860
ttggtgggct	cctgggtcag	cagcatccca	ccctgggag	tctggccagc	tgagccccag	1920
ggtggcagg	gcattatagc	ctgggtggaca	tgtgccttca	gggttcctcc	ggggccacct	1980
tcctcaggcc	agtgtgtggg	tcaaagggtc	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	2040
gtatgtatat	gtgtgtgggt	gcacacatct	gtcccatgta	tgcatgaga	cctgtctacc	2100
tcccacaagg	agcaagggtc	ctgcccgcgc	tctgtctatt	cctaccagg	tagtgggacc	2160
ccgggcccc	ttctgcctgg	cttgccctgt	tctgcccctt	ccagaggggt	ctcactgaca	2220
gccagagaca	gcaggagaag	ggttggctgt	ggatcaagga	aggctgcccc	tgtaccctgt	2280
ggggaaatgg	tgggtgcatg	gctggatgca	gaggtggaag	gccctgggcc	acaggcgaga	2340

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

gcggcctcga ggggactttc ccgggggactt tccggggact ttccgggact ttccatcctg	60
ccatctcaat tag	73

&lt;210&gt; 10

&lt;211&gt; 256

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct	60
caattagtca gcaaccatag tcccggccct aactccgccc atcccggccc taactccgcc	120
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga	180
ggcgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg	240
cttttgcaaa aagctt	256

&lt;210&gt; 11

&lt;211&gt; 1766

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (14)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1750)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 11

acgggggctt taangggaaa cccttcccgg aatttncggg tcgaccacag cgtccggttt	60
tgtttatgga ggggtccagta agtgcaaaaca accattgcct ggtcctaagg gttcagagtc	120
cccgaattcc ttcttgagacc aggaaagccg gagacgaaga ttcaccattg cagactcgga	180
tcagttgcct gggtactcgg tggaacacaa cattctgccc acaaaaatga gagagaaaac	240
accatcttat ggcaagccac ggcctttgtc catgcctgct gatgggaact ggatggggat	300
tgtggaccct tttgccagac ctcgaggtca tggcaggaaa ggggaggatg ccctttgccg	360
gtatttcagt aacgagcgga ttctccgat cattgaagag agctcctctc ccccataccg	420
gttctccaga cccacgaccg agcggcatct ggtccggggg gcggactaca tccgaggaag	480
caggtgctac atcaactcag atctccacag cagcgccacg attccattcc aggaggaagg	540
gacaaaaaag aaatctggct cctcagctac gagtcctcgt ccacagaacc gtccctcctg	600
gtcagctggt ttacgcgcct caaactgttg actcactgag agggaccctg ctcaggccac	660
ctgcctggct cctgscacca gtgccttgct tttacagtgg acagcctctt ctcgtttcag	720
cctcagtatt atgtagggac cttatgcaat ttctttttct tttgaaaagt tatctactgc	780
ccttcttgga agtttgacagg attggatggg aacaaattca gaggatctta ggtgctggct	840
tgtaggagaca aaaggaggga aatgggtaga gcctgtttgt cttgcttccc cagagataga	900
atgtgaagac acgcgctaga aatcgcatgc ctggccagag acgttatggt cattgtgagg	960
gactggtggc attgttcctt tttgaggggc tggggggact caaattgggt gctgttttca	1020
cacagatgtg ttggttttgt gtccaacttc tttatctgaa aaagccagtg agaaaacatt	1080

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccg<sup>a</sup>aat gatttccccg aaatgatttc 60  
ccccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcgggcaagct ttttgcaaag cctaggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc ccctaactc cgcccatccc 120  
gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc ggcactcccc ggatccgcct c 31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc 12

<210> 9

<211> 73

<212> DNA



<110> Human Genome Sciences, Inc.

<120> 47 Human Secreted Proteins

<130> PZ035.PCT

<140> Unassigned

<141> 1999-12-15

<150> 60/112,809

<151> 1998-12-17

<150> 60/113,006

<151> 1998-12-18

<160> 230

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgaccggtca	gtcttctctt	tcccccaaaa	acccaaggac	accctcatga	120
tctcccggtg	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	accccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccgaagaac	acaggtgtac	accctgcccc	420
catcccggtg	tgagctgacc	aagaaccagg	tcagcctgac	ctgectggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctt	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

<212> DNA

23. The product produced by the method of claim 20.

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

15 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

20

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

25 (c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and  
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 5 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 10 10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence  
15 included in ATCC Deposit No:Z;
- (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 20 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in  
25 ATCC Deposit No:Z;
- (g) a variant of SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

5

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

10

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

20

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
- 5 consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a
  - 10 polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
  - 20 having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.



**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>115</u> , line <u>n/a</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution <i>(including postal code and country)</i> <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>01 December 1998</u>	Accession Number <u>203499</u>
<b>C. ADDITIONAL INDICATIONS</b> <i>(leave blank if not applicable)</i> <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> <i>(if the indications are not for all designated States)</i>	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> <i>(leave blank if not applicable)</i>	
The indications listed below will be submitted to the International Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>	

<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> This sheet was received with the international application </div> <div style="border: 1px solid black; padding: 5px; min-height: 40px;"> Authorized officer </div>	<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; min-height: 40px;"> Authorized officer </div>
---	--

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>115</u> , line <u>n/a</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>10 December 1998</u>	Accession Number <u>203517</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<u>Europe</u> In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For receiving Office use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received with the international application</div> <div style="border-top: 1px solid black; height: 40px; margin-top: 5px;"></div> <div style="text-align: center; border-top: 1px solid black; margin-top: 5px;">Authorized officer</div>	<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">For International Bureau use only</div> <div style="padding: 5px;"><input type="checkbox"/> This sheet was received by the International Bureau on:</div> <div style="border-top: 1px solid black; height: 40px; margin-top: 5px;"></div> <div style="text-align: center; border-top: 1px solid black; margin-top: 5px;">Authorized officer</div>
---	--

the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [ 5 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the 10 invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

15 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both 20 incorporated herein by reference in their entireties.

medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNNP reagent must then be added to each of

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM



Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

- 5       Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema  
10 software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

- Limb Weight Comparison: After drawing blood, the animal is prepared for tissue  
15 collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

- Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped  
20 into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
25 invention.

Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are  
5 used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The  
10 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ  
15 Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which  
20 typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are  
25 evaluated at 2 places. Analysis is performed in a blind manner.

treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

5        The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10    **Example 51: Lymphadema Animal Model**

or        The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system  
15    in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

      Prior to beginning surgery, blood sample is drawn for protein concentration  
20    analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The  
25    intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's

calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups  
5 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

10 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing  
15 the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

20

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the  
25 healing process and the morphologic appearance of the repaired skin is improved by

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

5        Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*  
10 *libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of  
15 wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the  
20 testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement  
25 on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a

cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by  
5 establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

10

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the  
15 healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

20 Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

25 Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon

Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of  
5 wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-  
10 thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of  
15 surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses,  
20 from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral  
25 buffered formalin in tissue cassettes between biopsy sponges for further processing.



contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal  
5 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al. Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375  
10 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,  
15 *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of*  
20 *Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All  
25 manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- 5        b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- 10       e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15       invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

##### ***A.        Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is  
25       dependent on formation of granulation tissue and re-epithelialization rather than

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after  
10 coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is  
15 delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the  
20 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 49: Rat Corneal Wound Healing Model**

25

a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

c) Topical treatment with a polypeptide of the invention of the excisional wounds  
5 (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 47: Peripheral Arterial Disease Model**

15       Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

20       b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention  
25 and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the  
5 ability of polypeptides of the invention to affect the blood pressure in spontaneously  
hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900  
mg/kg) of the polypeptides of the invention are administered to 13-14 week old  
spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM.  
Statistical analysis are performed with a paired t-test and statistical significance is defined  
10 as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the  
invention. However, one skilled in the art could easily modify the exemplified studies to  
test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
invention.

15

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor  
VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of  
20 polypeptides of the invention, during the skin ischemia, is studied using in situ  
hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- 25 c) Normal wounds

The experimental protocol includes:

femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* 5 *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a 10 hydrogel-coated balloon catheter as described (Riessen *et al. Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al. J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these 15 rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of 20 collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and 25 polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative  
5 Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the  
10 abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug  
15 are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

25 To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one

**Example 42: Angiogenic Effect n Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese qual (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old qual embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

25

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine



**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of  
5 endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a  
10 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Cord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an  
15 additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.


Commercial (R&D) VEGF (50 ng/ml) is used as a positive control.  $\beta$ -estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also  
20 utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after

mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After  
5 counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV  
10 fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

### **Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the  
20 invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours  
25 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

5           For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight.

10   After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is

15   subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

          The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20   invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

25           HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6

proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

5       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10       **Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16  
15       units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is  
20       determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25       test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

5           It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J.  
10   Neuroscience, 1990).

          Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential  
15   effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium  
20   containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

25           Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are

medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity



outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA

cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems  
5 (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine  
10 and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the  
15 reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies  
20 to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays**

25 Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite

activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

20

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the

25

measure the IL-12 release as follows. Dendritic cells ( $10^6/\text{ml}$ ) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA  
5 kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on  
10 monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic  
15 activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled  
20 monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or  
25 alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or

test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC**

5 **Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control  
10 mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4/\text{well}$ ) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium  
15 alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored  $-20$  degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5  $\mu\text{Ci}$  of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of  
20 proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse  
5 (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and  
10 various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and  
15 proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

20 Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are  
25 compared between buffer and polypeptide-treated mice.

ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).



with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect *E. coli* HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective

fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immuntubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification

(See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268  
5 (1985).)

b) Isolation Of Antibody Fragments Directed

Against XXX From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a  
10 library of antibody fragments which contain reactivities against XXX to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage  
15 displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture  
20 incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

25 M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody

serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the XXX polypeptide.

Alternatively, additional antibodies capable of binding to XXX polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the XXX protein-specific antibody can be blocked by XXX. Such antibodies comprise anti-idiotypic antibodies to the XXX protein-specific antibody and are used to immunize an animal to induce formation of further XXX protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein.

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10 **Example 31: Production of an Antibody**

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing XXX are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of XXX protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for protein XXX are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with XXX polypeptide or, more preferably, with a secreted XXX polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine

engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

5    **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by  
10   reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express  
15   polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be  
20   used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

25       In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically

inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening  
5 may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse  
10 transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding  
15 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given  
20 integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

25 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of



such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
5 enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., *Nature* 380:64-66 (1996); Wilmut et al., *Nature* 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their  
10 cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., *Proc. Natl. Acad. Sci. USA* 89:6232-6236 (1992)). The regulatory  
15 sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the  
20 endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., *Science*  
25 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

5    **Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a  
10   specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of  
15   transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci.,  
20   USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent  
25   stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of

condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
5 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
10 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
15 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

20 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
25 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the

or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al., 5 *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial 10 space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the 15 cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those 20 skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies 25 techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120  $\mu\text{g/ml}$ . 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 5 960  $\mu\text{F}$  and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

10 Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a 15 further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

20

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. 25 The polynucleotide of the present invention may be operatively linked to a promoter

<220>  
 <221> SITE  
 <222> (1028)  
 <223> n equals a,t,g, or c

<400> 56  
 gggaaccaaa gctggagctc caccgcggtg gcggccgctc tagaactagt ggatcccccg 60  
 ggctgcagga attcggcacg aggtggactg gattagctgc ggaggccctg gaagctgcct 120  
 gtccttctcc ctgtgcttaa ccagagggtgc ccatgggttg gacaatgagg ctggtcacag 180  
 cagcactgtt actgggtctc atgatgggtg tcaactggaga cgaggatgag aacagcccgt 240  
 gtgcccataga ggccctcttg gacgaggaca ccctcttttg ccagggcctt gaagttttct 300  
 acccagagtt ggggaacatt ggctgcaagg ttgttcctga ttgtaacaac tacagacaga 360  
 agatcacctc ctggatggag ccgatagtca agttcccggg ggccgtggac ggcgcaacct 420  
 atatcctggt gatgggtgat ccgatgccc ctagcagagc agaaccaga cagagattct 480  
 ggagacattg gctggtaaca gatatcaagg gcgccgacct gaagraaggg aagattcagg 540  
 gccaggagtt atcagcctac caggctccct cccaccggc acacagtggc ttccatcgct 600  
 accagtctct tgtctatctt caggaaggaa aagtcattct tctccttccc aaggaaaaca 660  
 aaactcgagg ctcttggaat atggacagat ttctgaaccg tttccacctg ggcgaacctg 720  
 aagcaagcac ccagttcatg acccagaact accaggactc accaaccctc caggctccca 780  
 gagaaggggc cagcgagccc aagcacaaaa accaggcgga gatagctgcc tgctagatag 840  
 ccggtcttgc catccgggca tgtggccaca ctgcycacca ccgacgatgt gggtatggaa 900  
 cccctcttgg atacagaacc ccttcttttc caaataaaaa aaaaatcatc caggaaaaaa 960  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020  
 anaaannnn 1028

<210> 57  
 <211> 1854  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (57)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1844)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1853)  
 <223> n equals a,t,g, or c

<400> 57  
 gctgcggact gcagccccac tcccgcacct ccccatcgct gctgcatgat ctccacncac 60  
 gcacgtccag ggacagactg gaatgtatgt catttggggt cttgggggag ggctcccacg 120  
 aggccatcct cctcttcttg gmcctccttg gctgaccca ttctgtggg aaaccgggtg 180  
 cccatggagc ctcaaaaatg ccaccgggtg ggttggcatg gcctggggca ggaggcagag 240  
 gcaggagacc aagatggcag gtggaggcca ggcttaccac aacggaagag acctcccgt 300  
 ggggccgggc aggcctggct cagctgccac aggcataatg tggagagggg ggtaccctgc 360  
 ccaccttggg gtggtggcac cagagctctt gtctattcag acgctggtat gggggctcgg 420  
 acccctcact ggggacaggg ccagtgttgg agaattctga ttctttttt gttgtctttt 480  
 acttttgttt ttaacctggg ggttcgggga gaggccttgc ttgggaacat ctacagagct 540  
 ttctacatc ttccgtgggt cccagcacag cccaagatta ttggcagcc aagtggatgg 600  
 aactaacttt cctggactgt gtttcgcat cggcggtatc tggaaagtgg actgaacgga 660  
 atcaagctct gagcagaggg ctgaagcgga agcaccacat cgtccctgcc catctcactc 720

tctcccttga	tgatgcccc	agagctgagg	ctggagaaga	caccagggct	gactttgacy	780
gagggccatg	gacgcgacag	gcctgtggcc	ctgcgcagtc	tgaaataact	ggaacccagc	840
ctctctctct	acaccggcct	acctatctgg	gccccagagc	tgacttcaca	ctcctacaac	900
gaaggacaaa	ctgtccaggt	cggagggatc	acgagacaca	gaacctggag	gggtgtgcac	960
gctggcargt	ggcctctgcg	gcaattgcct	cacctgagg	acatcagcag	tcagcctgct	1020
cagagcgggg	gtgctggagc	gcgtgcagac	acagctcttc	cggagcagcc	ttcaccttct	1080
ctctgggata	agtgtccggc	tggccgacgt	ggcatttgc	gaccgaatgc	tcatagaggt	1140
tgacccccac	agggtcacgc	aggactcggg	cactgccttg	gaaacatgga	tggaacaagg	1200
cttttggcca	caggtgtggg	tgtcctgttg	gaggagggct	tgtttggaga	aggagggctg	1260
gctgggggag	aaacccggat	cccgtgcat	ctccgcgct	gtgggtgcat	gtcgcgtgct	1320
catctgttgc	acacagctca	ctcgtatgtc	ctgcactggt	acatgcatct	gtaatacagt	1380
ttctacgtct	atttaaggct	aggagccgaa	tgtgccccat	tgtcagtggg	tccacgtttc	1440
tccccggctc	ctctgggcta	aggcagtgtg	gcccaggct	taaaaagtta	ctcggtagctg	1500
tttttaagaa	cacttttata	gagttagtgg	aaggcaagtt	aagagccaat	cactgatccc	1560
caagtgtttc	ttgagcatct	ggtctggggg	gaccactttg	atcggaccca	cccttgga	1620
gctcaggggt	aggccaggt	gggatgctca	ccctgtcact	gagggttttg	gttggcatcg	1680
ttgtttttga	atgtagcaca	agcgatgagc	aaactctata	agagtgtttt	aaaaatatac	1740
ttcccaggaa	gtgagttaaa	aacaataaaa	gccctttctt	gagttaaaaa	gaaaaaaaaa	1800
aaaaaaaaaa	aacccggggg	ggggcccggg	accaaattcg	ccnnaagg	ggn	1854

&lt;210&gt; 58

&lt;211&gt; 1349

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

ctccaacatg	gagcctcttg	cagcttacc	gctaaaatgt	tccggggccca	gagcaaagg	60
atttgcagtt	ttgtgtcta	tagttctatg	cacagtaacg	ctatttcttc	tacaactaaa	120
attcctcaaa	cctaaaatca	acagctttta	tgcctttgaa	gtgaaggatg	caaaaggaa	180
aactgtttct	ctggaaaagt	ataaaggcaa	agtttcta	gttgtaaagc	tgccagtg	240
ctgccaactc	acagacagaa	attacttagg	gctgaaggaa	ctgcacaaag	agtttggacc	300
atcccacttc	agcgtgttgg	cttttccctg	caatcagttt	ggagaatcgg	agccccggcc	360
aagcaaggaa	gtagaatctt	ttgcaagaaa	aaactacgga	gtaactttcc	ccatcttcca	420
caagattaag	attctaggat	ctgaaggaga	acctgcattt	agatttcttg	ttgattcttc	480
aaagaaggaa	ccaaggtgga	atttttggaa	gtatcttgtc	aaccctgagg	gtcaagttgt	540
gaagtctctg	aggccagagg	agccattga	agtcatcagg	cctgacatag	cagctctggt	600
tagacaagtg	atcataaaaa	agaaagagga	tctatgagaa	tgccattg	tttctaata	660
aacagagaaa	tgtctccatg	agggtttggt	ctcattttaa	acattttttt	tttgagaca	720
gtgtctcact	ctgtcaccca	ggctggagtg	cagtagtcg	ttctcagtc	attgcaacct	780
ctgccttttt	aaacatgcta	ttaaattgtg	caatgaagga	ttttttttta	atgttatctt	840
gctattaagt	ggtaatgaat	gttcccagga	tgaggatgtt	acccaaagca	aaaatcaaga	900
gtagccaaag	aatcaacatg	aaatatatta	actacttctt	ctgaccatac	taaagaattc	960
agaatacaca	gtgaccaatg	tgcctcaata	tcttattgtt	caacttgaca	ttttctagga	1020
ctgtacttga	tgaaaatgcc	aacacactag	accactctt	ggattcaaga	gcactgtgta	1080
tgactgaaat	ttctggaata	actgtaaatg	gttatgttaa	tggaataaaa	cacaaatgtt	1140
gaaaaatgta	aaatatatat	acatagattc	aaatccttat	atatgtatgc	ttgttttgtg	1200
tacaggattt	tgttttttct	ttttaagtac	agggttcctag	tgtttttacta	taactgtcac	1260
tatgtatgta	actgacatat	ataaatagtc	atttataaat	gaccgtatta	taacatttaa	1320
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1349

&lt;210&gt; 59

&lt;211&gt; 1072

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE



&lt;222&gt; (374)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 59

ggcasagccc	ttatctcctt	cgcagtgcag	ctccttcaac	ctcgccatgg	cctctgccgg	60
aatgcagatc	ctgggagtcg	tcctgacact	gctgggctgg	gtgaatggcc	tggctcctg	120
tgcctgccc	atgtggaagg	tgacygcttt	catcggaac	agcatcgtgg	tggcccagg	180
ggtgtgggag	ggcctgtgga	tgtcctgcgt	ggtgcagagc	accggccaga	tgcaagtcaa	240
ggtgtacgac	tcactgctgg	cgctgccaca	ggacctgcag	gctgcacgtg	ccctctgtgt	300
catcgccctc	cttgtggccc	tgttcggctt	gctgggtctac	cttgctgggg	ccaagtgtac	360
cacctktttt	tatnataagg	attccaaggc	ccgcctggtg	ctcacctctg	ggattgtcct	420
tgtcatctca	ggggtcctga	cgctaatacc	cgtgtgctgg	acggcgcatg	ccatcatccg	480
ggacttctat	aacccccctg	tggctgargc	ccaaaagcgg	gagctggggg	cctccctcta	540
cttgggctgg	gcggcctcag	gccttttgtt	gctgggtggg	gggttgcctg	gctgcacttg	600
ccccctcggg	gggtcccagg	gccccagcca	ttacatggcc	cgctactcaa	catctgcccc	660
tgccatctct	cgggggccct	ctgagtaccc	taccaagaat	tacgtctgac	gtggagggga	720
atgggggctc	cgctggcgct	agagccatcc	agaagtggca	gtgccaaca	gcttgggat	780
gggttcgtac	cttttgtttc	tgctcctgct	tattttctct	ttgactgagg	atatttaaaa	840
ttcatttgaa	aactgagcca	aggtgttgac	tcagactctc	acttaggctc	tgctgtttct	900
caccttggga	tgatggagcc	aaagagggga	tgctttgaga	ttctggatct	tgacatgccc	960
atcttagaag	ccagtcaagc	tatggaacta	atgaggaggc	tgcttgcctg	gctggccttg	1020
caacaagaca	gactgtcccc	aagagtctct	gctgctgctg	ggggctgggc	tt	1072

&lt;210&gt; 60

&lt;211&gt; 2508

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

tcacagctga	ggaagacctc	agacatggag	tccaggatgt	ggcctgcgct	gctgctgtcc	60
cacctcctcc	ctctctggcc	actgctgttg	ctgccccctc	caccgcctgc	tcagggtctct	120
tcatectccc	ctcgaacccc	accaggccca	gccccccccc	cgtgtgccag	gggagggccc	180
tcggccccac	gtcatgtgtg	cgtgtgggag	cgagcacctc	caccaagccg	atctcctcgg	240
gtcccaagat	cacgtcggca	agtccctgcc	ggcactgcac	ccccagccac	cccatcaggc	300
tttgaggagg	ggccgccttc	atcccaatac	ccctgggcta	tcgtgtgggg	tcccaccgtg	360
tctcgagagg	atggagggga	ccccaaactc	gccaatcccg	gatttctgga	ctatggtttt	420
gcagccccct	atgggctcgc	aacccccacac	cccaactcag	actccatgcg	aggtgatgga	480
gatgggctta	tccttgagga	ggcacctgcc	accctgcggt	cattcctgtt	cgggggccgt	540
gggggaagggt	tggaccccc	gctctatgtc	acaattacca	tctccatcat	cattgttctc	600
gtggccactg	gcatcatctt	caagtctctg	tggaccgca	gccagaagcg	acgcagacc	660
tcagggcagc	aagggtgccct	gaggcaggag	gagagccagc	agccactgac	agacctgtcc	720
ccggctggag	tcactgtgct	gggggccttc	ggggactcac	ctacccccac	ccctgaccat	780
gatgagcccc	gagggggacc	ccggcctggg	atgccccacc	ccaagggggc	tccagccttc	840
cagttgaacc	ggtgagggca	ggggcaatgg	gatgggaggg	caaagagggga	aggcaactta	900
ggtcttcaga	gctgggggtg	gggtgccctc	tggatgggta	gcgaggaggc	aggcgtggcc	960
tcccacagcc	cctgggcctc	ccaagggggc	tggaccagct	cctctctggg	aggcaccctt	1020
acttctccca	gtctctcagg	atctgtgccc	tattctctgc	tgcccataac	tccaactctg	1080
ccctattttg	tctttttctc	tgccaccttg	tctaagacaa	ctctgccctc	ttaaccttga	1140
ttccccctct	ttgtcttgaa	cttccccctc	tattctggcc	taccctctgg	ttcttgactg	1200
tgccttttcc	ctcttctctt	caggattccc	ctggtgaatc	tgtgatgccc	ccaatgtttg	1260
ggtgcagcca	agcaggaggc	caagggggcc	gcacagcccc	catccactg	agggtggggc	1320
agctgtgggg	agctggggcc	acaggggctc	ctggctcctg	ccccttgca	accaccgga	1380
acactcccca	gccccacggg	caatcctatc	tgtctgccc	cctgcagggt	ggggcctcac	1440
atatctgtga	cttcgggttc	ctgtccccac	ccttgcacac	tcacatgaaa	gccttgcaca	1500
ctcacctcca	ccttcacagg	ccatttgcac	acgtctctgc	accctctccc	cgtccatacc	1560
gctccgctca	gctgactctc	atgttctctc	gtctcacatt	tgcactctct	ccttcccaca	1620
ttctgtgctc	agctcactca	gtggtcagcg	ttctctgcac	actttacctc	tcattgtcgt	1680
ttccccgcct	gatgttgtgg	tgggtgtcgg	cgtgctcact	ctctccctca	tgaacaccca	1740

cccacctcgt	ttccgcagcc	cctgcgtgct	gctccagagg	tgggtgggag	gtgagctggg	1800
ggctcccttg	gcccctcatc	gtcatggtct	cgteccattc	cacaccattt	gtttctctgt	1860
ctccccatcc	tactccaagg	atgccggcat	caccctgagg	gctccccctt	gggaatgggg	1920
tagtgaggcc	ccagacttca	ccccagccc	actgctaaaa	tctgttttct	gacagatggg	1980
ttttggggag	tgcctgctg	cactacatga	gaaagggact	cccatttgcc	cttccccttc	2040
tcctacagtc	ccttttgtct	tgctgtcct	ggctgtctgt	gtgtgtgcca	ttctctggac	2100
ttcagagccc	cctgagccag	tcctcccttc	ccagcctccc	tttgggcctc	cctaactcca	2160
cctaggctgc	cagggaccgg	agtcagctgg	ttcaaggcca	tcgggagctc	tgccccaag	2220
tctacccttc	ccttcccggg	ctccctcctg	tcctcctcct	tcctccctcc	ttcctccac	2280
tctccttcct	tttgcttccc	tgccctttcc	ccctcctcag	gttcttccct	ccttctcact	2340
ggtttttcca	ccttctcct	tccttctctc	cctggctcct	aggctgtgat	atatattttt	2400
gtattatctc	tttcttcttc	ttgtggtgat	catcttgaat	tactgtggga	tgtaagtttc	2460
aaaattttca	aataaagcct	ttgcaagata	aaaaaaaaaa	aaaaaaaa		2508

<210> 61  
 <211> 952  
 <212> DNA  
 <213> Homo sapiens

<400> 61						
gaattcggca	cgaggccctg	gaagctgcct	gtccttctcc	ctgtgcttaa	ccagaggtgc	60
ccatgggttg	gacaatgagg	ctggtcacag	cagcactggt	actgggtctc	atgatgggtg	120
tcactggaga	cgaggatgag	aacagcccgt	gtgcccata	ggccctcttg	gacgaggaca	180
ccctcttttg	ccagggcctt	gaagttttct	acccagagtt	ggggaacatt	ggctgcaagg	240
ttgttcctga	ttgtaacaac	tacagacaga	agatcacctc	ctggatggaa	gccgatagtc	300
aagttcccgg	gggcccgtgga	cggcgcaacc	tataatcctg	gtgatgggtg	atccagatgc	360
ccctagcaga	gcagaaccca	gacagagatt	ctggagacat	tggtggttaa	cagatatcaa	420
gggcgcgcag	ctgaagaaaag	ggaagattca	gggccaggag	ttatcagcct	accaggctcc	480
ctccccaccg	gcacacagtg	gcttccatcg	ctaccagttc	tttgtctatc	ttcaggaagg	540
aaaagtcatc	tctctccttc	ccaaggaaaa	caaaactcga	ggctcttgga	aaatggacag	600
attttctgaac	cgtttccacc	tgggcgaacc	tgaagcaagc	acccagttca	tgaccagaaa	660
ctaccaggac	tcaccaaccc	tccaggctcc	cagagaaaag	gccagcgagc	ccaagcacaa	720
aaaccaggcg	gagatagctg	cctgctagat	agccggcttt	gccatccggg	catgtggcca	780
cactgcccac	caccgacgat	gtgggtatgg	aacccctctc	ggatacagaa	ccccttcttt	840
tccaaataaa	aaaaaaaaatca	tccacccaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa	952

<210> 62  
 <211> 207  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (143)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (207)  
 <223> Xaa equals stop translation

<400> 62  
 Met Ala Ser His Gly Leu Cys Pro Cys Leu Leu Met Gly Thr Gly Trp  
 1 5 10 15

Gly Leu Trp Thr Leu Leu Pro Asp Leu Glu Val Met Ala Gly Lys Gly

40

20 25 30  
 Arg Met Pro Phe Ala Gly Ile Ser Val Thr Ser Gly Phe Leu Arg Ser  
 35 40 45  
 Leu Lys Arg Ala Pro Leu Pro His Thr Gly Ser Pro Asp Pro Arg Pro  
 50 55 60  
 Ser Gly Ile Trp Ser Gly Val Arg Thr Thr Ser Glu Glu Ala Gly Ala  
 65 70 75 80  
 Thr Ser Thr Gln Ile Ser Thr Ala Ala Pro Arg Phe His Ser Arg Arg  
 85 90 95  
 Lys Gly Pro Lys Arg Asn Leu Ala Pro Gln Leu Arg Val Leu Val His  
 100 105 110  
 Arg Thr Val Pro Pro Gly Gln Leu Val Tyr Ala Pro Gln Thr Val Asp  
 115 120 125  
 Ser Leu Arg Gly Thr Leu Leu Arg Pro Pro Ala Trp Leu Leu Xaa Gln  
 130 135 140  
 Val Pro Cys Phe Tyr Ser Gly Gln Pro Leu Leu Val Ser Ala Ser Val  
 145 150 155 160  
 Leu Cys Arg Asp Leu Met Gln Phe Leu Phe Leu Leu Lys Ser Tyr Leu  
 165 170 175  
 Leu Pro Phe Leu Glu Val Cys Arg Ile Gly Trp Glu Gln Ile Gln Arg  
 180 185 190  
 Ile Leu Gly Ala Gly Leu Trp Arg Gln Lys Glu Gly Asn Gly Xaa  
 195 200 205  
  
 <210> 63  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (109)  
 <223> Xaa equals stop translation  
  
 <400> 63  
 Met Thr Trp Trp Tyr Arg Trp Leu Cys Arg Leu Ser Gly Val Leu Gly  
 1 5 10 15  
 Ala Val Ser Cys Ala Ile Ser Gly Leu Phe Asn Cys Ile Thr Ile His  
 20 25 30  
 Pro Leu Asn Ile Ala Ala Gly Val Trp Met Met Met Ala Val Val Pro  
 35 40 45  
 Ile Val Ile Ser Leu Thr Leu Thr Thr Leu Leu Gly Asn Ala Ile Ala  
 50 55 60

Phe Ala Thr Gly Val Leu Tyr Gly Leu Ser Ala Leu Gly Lys Lys Gly  
65 70 75 80

Asp Ala Ile Ser Tyr Ala Arg Ile Gln Gln Gln Arg Gln Gln Ala Asp  
85 90 95

Glu Glu Lys Leu Ala Glu Thr Leu Glu Gly Glu Leu Xaa  
100 105

<210> 64

<211> 287

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (287)

<223> Xaa equals stop translation

<400> 64

Met Ala Arg Phe Gly Leu Pro Ala Leu Leu Cys Thr Leu Ala Val Leu  
1 5 10 15

Ser Ala Ala Leu Leu Ala Ala Glu Leu Lys Ser Lys Ser Cys Ser Glu  
20 25 30

Val Arg Arg Leu Tyr Val Ser Lys Gly Phe Asn Lys Asn Asp Ala Pro  
35 40 45

Leu His Glu Ile Asn Gly Asp His Leu Lys Ile Cys Pro Gln Gly Ser  
50 55 60

Thr Cys Cys Ser Gln Glu Met Glu Glu Lys Tyr Ser Leu Gln Ser Lys  
65 70 75 80

Asp Asp Phe Lys Ser Val Val Ser Glu Gln Cys Asn His Leu Gln Ala  
85 90 95

Val Phe Ala Ser Arg Tyr Lys Lys Ser Asp Glu Phe Phe Lys Glu Leu  
100 105 110

Leu Glu Asn Ala Glu Lys Ser Leu Asn Asp Met Phe Val Lys Thr Tyr  
115 120 125

Gly His Leu Tyr Met Gln Asn Phe Glu Leu Phe Lys Asp Leu Phe Val  
130 135 140

Glu Leu Lys Arg Tyr Tyr Val Val Gly Asn Val Asn Leu Glu Glu Met  
145 150 155 160

Leu Asn Asp Phe Trp Ala Arg Leu Leu Glu Arg Met Phe Arg Leu Val  
165 170 175

Asn Ser Gln Tyr His Phe Thr Asp Glu Tyr Leu Glu Cys Val Ser Lys  
180 185 190

Tyr Thr Glu Gln Leu Lys Pro Phe Gly Asp Val Pro Arg Lys Leu Lys  
195 200 205

Leu Gln Val Thr Arg Ala Phe Val Ala Ala Arg Thr Phe Ala Gln Gly  
 210 215 220

Leu Ala Val Ala Gly Asp Val Arg Glu Gln Gly Leu Arg Gly Lys Pro  
 225 230 235 240

His Ser Pro Val Tyr Pro Cys Pro Val Glu Asp Asp Leu Leu Leu Pro  
 245 250 255

Leu Pro Gly Ser Arg Asp Cys Glu Ala Met Leu Gln Leu Leu Leu Lys  
 260 265 270

His His Glu Arg Leu Phe Gly Gln Pro Arg Gly Ser Arg Phe Xaa  
 275 280 285

<210> 65

<211> 86

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (57)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (86)

<223> Xaa equals stop translation

<400> 65

Met Leu Leu Gln Leu Leu His Val Phe Trp Ser Cys Leu Ile Leu Arg  
 1 5 10 15

Met Leu Tyr Ser Phe Met Lys Lys Gly Gln Met Glu Lys Asp Ile Arg  
 20 25 30

Ser Asp Val Glu Glu Ser Asp Ser Ser Glu Glu Xaa Ala Ala Ala Gln  
 35 40 45

Glu Pro Leu Gln Leu Lys Asn Gly Xaa Ala Gly Gly Pro Arg Pro Ala  
 50 55 60

Pro Thr Asp Gly Pro Arg Ser Arg Val Ala Gly Arg Leu Thr Asn Arg  
 65 70 75 80

His Thr Thr Ala Thr Xaa  
 85

<210> 66

<211> 303

<212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (237)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (303)  
 <223> Xaa equals stop translation

<400> 66  
 Met Lys Ala Pro Gly Arg Leu Val Leu Ile Ile Leu Cys Ser Val Val  
     1                    5                    10                    15  
 Phe Ser Ala Val Tyr Ile Leu Leu Cys Cys Trp Ala Gly Leu Pro Leu  
                     20                    25                    30  
 Cys Leu Ala Thr Cys Leu Asp His His Phe Pro Thr Gly Ser Arg Pro  
                     35                    40                    45  
 Thr Val Pro Gly Pro Leu His Phe Ser Gly Tyr Ser Ser Val Pro Asp  
                     50                    55                    60  
 Gly Lys Pro Leu Val Arg Glu Pro Cys Arg Ser Cys Ala Val Val Ser  
     65                    70                    75                    80  
 Ser Ser Gly Gln Met Leu Gly Ser Gly Leu Gly Ala Glu Ile Asp Ser  
                     85                    90                    95  
 Ala Glu Cys Val Phe Arg Met Asn Gln Ala Pro Thr Val Gly Phe Glu  
                     100                    105                    110  
 Ala Asp Val Gly Gln Arg Ser Thr Leu Arg Val Val Ser His Thr Ser  
                     115                    120                    125  
 Val Pro Leu Leu Leu Arg Asn Tyr Ser His Tyr Phe Gln Lys Ala Arg  
     130                    135                    140  
 Asp Thr Leu Tyr Met Val Trp Gly Gln Gly Arg His Met Asp Arg Val  
     145                    150                    155                    160  
 Leu Gly Gly Arg Thr Tyr Arg Thr Leu Leu Gln Leu Thr Arg Met Tyr  
                     165                    170                    175  
 Pro Gly Leu Gln Val Tyr Thr Phe Thr Glu Arg Met Met Ala Tyr Cys  
                     180                    185                    190  
 Asp Gln Ile Phe Gln Asp Glu Thr Gly Lys Asn Arg Arg Gln Ser Gly  
                     195                    200                    205  
 Ser Phe Leu Ser Thr Gly Trp Phe Thr Met Ile Leu Ala Leu Glu Leu  
     210                    215                    220  
 Cys Glu Glu Ile Val Val Tyr Gly Met Val Ser Asp Xaa Tyr Cys Arg  
     225                    230                    235                    240

Glu	Lys	Ser	His	Pro	Ser	Val	Pro	Tyr	His	Tyr	Phe	Glu	Lys	Gly	Arg
				245					250					255	
Leu	Asp	Glu	Cys	Gln	Met	Tyr	Leu	Ala	His	Glu	Gln	Ala	Pro	Arg	Ser
			260					265					270		
Ala	His	Arg	Phe	Ile	Thr	Glu	Lys	Ala	Val	Phe	Ser	Arg	Trp	Ala	Lys
		275					280					285			
Lys	Arg	Pro	Ile	Val	Phe	Ala	His	Pro	Ser	Trp	Arg	Thr	Glu	Xaa	
	290					295					300				

<210> 67  
 <211> 150  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (15)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (39)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (64)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (67)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (99)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (124)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (125)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (150)  
 <223> Xaa equals stop translation

<400> 67

45

Met Ala Ala Trp Val Phe Pro Leu Leu Ser Val Ile His Thr Xaa Leu  
 1 5 10 15  
 Pro Gln Ala Ser Pro Glu Ile Trp Val Thr Gln Ser Glu Gly Gly Asp  
 20 25 30  
 Gln Gly Val Ala Cys Glu Xaa Val Gly Gly Val Leu Ser Thr Leu Asp  
 35 40 45  
 Arg Ile Glu Leu Cys Phe Leu Ser Asp Arg Ala Ser Ser Gly Cys Xaa  
 50 55 60  
 Asp Lys Xaa Pro Gln Thr Gly Val Leu Phe Leu Gly Ala Gly Ile Cys  
 65 70 75 80  
 His Glu Gly Val Gly Arg Ala Gly Ser Ser Arg Ala Leu Ser Pro Gly  
 85 90 95  
 Pro Ala Xaa Ala Val Phe Pro Ser Phe Pro Cys Ala Phe Pro Gly Pro  
 100 105 110  
 Ser Cys Val Cys Leu Cys Pro Arg Leu Ser Trp Xaa Xaa Tyr Arg Ser  
 115 120 125  
 Gln Gly Pro Trp Ser Tyr Trp Ile Arg Ala Thr Leu Met Ala Ser Cys  
 130 135 140  
 His Cys Ser Tyr Leu Xaa  
 145 150

&lt;210&gt; 68

&lt;211&gt; 358

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (44)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (358)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 68

Met Cys Phe Ala Thr Ala Ala Phe Phe Phe Phe Thr Leu Leu Met  
 1 5 10 15  
 Leu Cys Val Ser Ser Ser Arg Asp Pro Arg Ala Ala Ile Gln Asn Gly  
 20 25 30  
 Phe Trp Phe Phe Lys Phe Leu Ile Leu Val Gly Xaa Thr Val Gly Ala  
 35 40 45  
 Phe Tyr Ile Pro Asp Gly Ser Phe Thr Asn Ile Trp Phe Tyr Phe Gly  
 50 55 60



Val Val Gly Ser Phe Leu Phe Ile Leu Ile Gln Leu Val Leu Leu Ile  
 65 70 75 80  
 Asp Phe Ala His Ser Trp Asn Gln Arg Trp Leu Gly Lys Ala Glu Glu  
 85 90 95  
 Cys Asp Ser Arg Ala Trp Tyr Ala Gly Leu Phe Phe Phe Thr Leu Leu  
 100 105 110  
 Phe Tyr Leu Leu Ser Ile Ala Ala Val Ala Leu Met Phe Met Tyr Tyr  
 115 120 125  
 Thr Glu Pro Ser Gly Cys His Glu Gly Lys Val Phe Ile Ser Leu Asn  
 130 135 140  
 Leu Thr Phe Cys Val Cys Val Ser Ile Ala Ala Val Leu Pro Lys Val  
 145 150 155 160  
 Gln Asp Ala Gln Pro Asn Ser Gly Leu Leu Gln Ala Ser Val Ile Thr  
 165 170 175  
 Leu Tyr Thr Met Phe Val Thr Trp Ser Ala Leu Ser Ser Ile Pro Glu  
 180 185 190  
 Gln Lys Cys Asn Pro His Leu Pro Thr Gln Leu Gly Asn Glu Thr Val  
 195 200 205  
 Val Ala Gly Pro Glu Gly Tyr Glu Thr Gln Trp Trp Asp Ala Pro Ser  
 210 215 220  
 Ile Val Gly Leu Ile Ile Phe Leu Leu Cys Thr Leu Phe Ile Ser Leu  
 225 230 235 240  
 Arg Ser Ser Asp His Arg Gln Val Asn Ser Leu Met Gln Thr Glu Glu  
 245 250 255  
 Cys Pro Pro Met Leu Asp Ala Thr Gln Gln Gln Gln Gln Val Ala  
 260 265 270  
 Ala Cys Glu Gly Arg Ala Phe Asp Asn Glu Gln Asp Gly Val Thr Tyr  
 275 280 285  
 Ser Tyr Ser Phe Phe His Phe Cys Leu Val Leu Ala Ser Leu His Val  
 290 295 300  
 Met Met Thr Leu Thr Asn Trp Tyr Lys Pro Gly Glu Thr Arg Lys Met  
 305 310 315 320  
 Ile Ser Thr Trp Thr Ala Val Trp Val Lys Ile Cys Ala Ser Trp Ala  
 325 330 335  
 Gly Leu Leu Leu Tyr Leu Trp Thr Leu Val Ala Pro Leu Leu Leu Arg  
 340 345 350  
 Asn Arg Asp Phe Ser Xaa  
 355

&lt;210&gt; 69

<211> 112  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (112)  
 <223> Xaa equals stop translation

<400> 69

Met	Gly	Pro	Ser	Ser	Cys	Leu	Leu	Leu	Ile	Leu	Ile	Pro	Leu	Leu	Gln
1				5					10					15	
Leu	Ile	Asn	Leu	Gly	Ser	Thr	Gln	Cys	Ser	Leu	Asp	Ser	Val	Met	Asp
		20						25					30		
Lys	Lys	Ile	Lys	Asp	Val	Leu	Asn	Ser	Leu	Glu	Tyr	Ser	Pro	Ser	Pro
	35						40					45			
Ile	Ser	Lys	Lys	Leu	Ser	Cys	Ala	Ser	Val	Lys	Ser	Gln	Gly	Arg	Pro
	50					55						60			
Ser	Ser	Cys	Pro	Ala	Gly	Met	Ala	Val	Thr	Gly	Cys	Ala	Cys	Gly	Tyr
65					70					75					80
Gly	Cys	Gly	Ser	Trp	Asp	Val	Gln	Leu	Glu	Thr	Thr	Cys	His	Cys	Gln
				85					90					95	
Cys	Ser	Val	Val	Asp	Trp	Thr	Thr	Ala	Arg	Cys	Cys	His	Leu	Thr	Xaa
			100					105						110	

<210> 70  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (184)  
 <223> Xaa equals stop translation

<400> 70

Met	Ile	Cys	Ser	Gly	Phe	Phe	Gly	Trp	Trp	Trp	Trp	Trp	Cys	Phe	Leu
1				5					10					15	
Met	Gly	Leu	Ser	Gly	Phe	His	Gln	Thr	His	Phe	Pro	Ala	Ala	Val	Trp
		20						25						30	
Ser	Gly	Pro	Glu	Asn	Thr	Lys	Pro	Pro	Asp	Pro	Arg	Pro	Thr	Pro	Thr
		35					40					45			
His	His	Pro	Ala	Ser	Ala	Ala	Leu	Ser	Gln	Asp	Ser	His	Gly	Asn	Glu
	50					55						60			
Gly	Ile	His	Leu	Leu	Pro	Asp	Thr	His	Trp	Ala	Leu	Arg	Pro	Ser	Gln

```
<210> 71
<211> 254
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (254)
<223> Xaa equals stop translation
```

```

<400> 71
Met Ile Val Gly Ser Pro Arg Ala Leu Thr Gln Pro Leu Gly Leu Leu
  1              5              10              15
Arg Leu Leu Gln Leu Val Ser Thr Cys Val Ala Phe Ser Leu Val Ala
      20              25              30
Ser Val Gly Ala Trp Thr Gly Ser Met Gly Asn Trp Ser Met Phe Thr
      35              40              45
Trp Cys Phe Cys Phe Ser Val Thr Leu Ile Ile Leu Ile Val Glu Leu
      50              55              60
Cys Gly Leu Gln Ala Arg Phe Pro Leu Ser Trp Arg Asn Phe Pro Ile
      65              70              75              80
Thr Phe Ala Cys Tyr Ala Ala Leu Phe Cys Leu Ser Ala Ser Ile Ile
      85              90              95
Tyr Pro Thr Thr Tyr Val Gln Phe Leu Ser His Gly Arg Ser Arg Asp
      100              105              110
His Ala Ile Ala Ala Thr Phe Phe Ser Cys Ile Ala Cys Val Ala Tyr
      115              120              125

```

Ala Thr Glu Val Ala Trp Thr Arg Ala Arg Pro Gly Glu Ile Thr Gly  
 130 135 140

Tyr Met Ala Thr Val Pro Gly Leu Leu Lys Val Leu Glu Thr Phe Val  
 145 150 155 160

Ala Cys Ile Ile Phe Ala Phe Ile Ser Asp Pro Asn Leu Tyr Gln His  
 165 170 175

Gln Pro Ala Leu Glu Trp Cys Val Ala Val Tyr Ala Ile Cys Phe Ile  
 180 185 190

Leu Ala Ala Ile Ala Ile Leu Leu Asn Leu Gly Glu Cys Thr Asn Val  
 195 200 205

Leu Pro Ile Pro Phe Pro Ser Phe Leu Ser Gly Leu Ala Leu Leu Ser  
 210 215 220

Val Leu Leu Tyr Ala Thr Ala Leu Val Leu Trp Pro Leu Tyr Gln Phe  
 225 230 235 240

Asp Glu Lys Tyr Gly Gly Ser Leu Gly Ala Arg Glu Met Xaa  
 245 250

<210> 72  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (100)  
 <223> Xaa equals stop translation

<400> 72  
 Met Ala Val Trp Gly Asp Thr Glu Leu Ala Ala Gly Val Phe Cys Phe  
 1 5 10 15

Phe Leu Phe Phe Cys Phe Leu Tyr Leu Ser Gly Thr Trp Asn Ala Ser  
 20 25 30

Lys Thr Glu Leu Phe Thr Pro Leu Glu Arg Glu Leu Lys Pro Gly His  
 35 40 45

Pro Ser Gly Met Leu Ser Gly Ser His Pro His Gly Ala Gln Gln Ala  
 50 55 60

Lys Ser Thr Gly Leu Lys Leu Ser Leu Pro Ala Gln Gln Ser Glu Val  
 65 70 75 80

Asp Leu Gly Cys Ser Ser Leu Val Trp Gly Gly Ala Ser Ala Ile Thr  
 85 90 95

Glu Ala Leu Xaa  
 100

<210> 73

50

<211> 181  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (181)  
 <223> Xaa equals stop translation

<400> 73

Met	Val	Val	Leu	Phe	Arg	Trp	Val	Pro	Val	Thr	Asp	Ala	Tyr	Trp	Gln
1				5					10					15	
Ile	Leu	Phe	Ser	Val	Leu	Lys	Val	Thr	Arg	Asn	Leu	Lys	Glu	Leu	Asp
			20				25						30		
Leu	Ser	Gly	Asn	Ser	Leu	Ser	His	Ser	Ala	Val	Lys	Ser	Leu	Cys	Lys
		35					40					45			
Thr	Leu	Arg	Arg	Pro	Arg	Cys	Leu	Leu	Glu	Thr	Leu	Arg	Leu	Ala	Gly
	50					55					60				
Cys	Gly	Leu	Thr	Ala	Glu	Asp	Cys	Lys	Asp	Leu	Ala	Phe	Gly	Leu	Arg
65					70					75					80
Ala	Asn	Gln	Thr	Leu	Thr	Glu	Leu	Asp	Leu	Ser	Phe	Asn	Val	Leu	Thr
			85						90					95	
Asp	Ala	Gly	Ala	Lys	His	Leu	Cys	Gln	Arg	Leu	Arg	Gln	Pro	Ser	Cys
			100					105					110		
Lys	Leu	Gln	Arg	Leu	Gln	Leu	Val	Ser	Cys	Gly	Leu	Thr	Ser	Asp	Cys
		115					120					125			
Cys	Gln	Asp	Leu	Ala	Ser	Val	Leu	Ser	Ala	Ser	Pro	Ser	Leu	Lys	Glu
	130						135				140				
Leu	Asp	Leu	Gln	Gln	Asn	Asn	Leu	Asp	Asp	Val	Gly	Val	Arg	Leu	Leu
145					150					155					160
Cys	Glu	Gly	Leu	Ser	Ile	Leu	Pro	Ala	Asn	Ser	Tyr	Ala	Trp	Gly	Trp
			165						170					175	
Thr	Arg	Gln	Leu	Xaa											
			180												

<210> 74  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (63)  
 <223> Xaa equals stop translation

<400> 74

Met Leu Leu Arg His Pro Leu Pro Val Cys Phe Cys Phe Ser Phe Cys

51

1                      5                      10                      15  
 Pro Phe Pro Val Ser Ala Leu Ser Leu Leu Pro Ile Gly Leu Val Arg  
                          20                      25                      30  
 Glu Gly Ala Ala Ser Pro Thr Gln Gln Leu Arg Leu Gln Arg Glu Ser  
                          35                      40                      45  
 Leu Ser Ser Ile Thr His Arg Val Asn Ile Lys Glu Gly His Xaa  
                          50                      55                      60

<210> 75  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (74)  
 <223> Xaa equals stop translation

<400> 75  
 Met Ala Thr Pro Arg Gly Leu Gly Ala Leu Leu Leu Leu Leu Leu  
   1                      5                      10                      15  
 Pro Thr Ser Gly Gln Glu Lys Pro Thr Glu Gly Pro Arg Asn Thr Cys  
                          20                      25                      30  
 Leu Gly Ser Asn Asn Met Tyr Asp Ile Phe Asn Leu Asn Asp Lys Ala  
                          35                      40                      45  
 Leu Cys Phe Thr Lys Cys Arg Gln Ser Gly Ser Asp Ser Cys Asn Val  
                          50                      55                      60  
 Glu Asn Leu Gln Arg Phe Arg Gly Arg Xaa  
   65                      70

<210> 76  
 <211> 131  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (131)  
 <223> Xaa equals stop translation

<400> 76  
 Met Ala Phe Phe Phe Thr Phe Met Ala Gln Leu Val Ile Ser Ile Ile  
   1                      5                      10                      15  
 Gln Ala Val Gly Ile Pro Gly Trp Gly Val Cys Gly Trp Ile Ala Thr  
                          20                      25                      30  
 Ile Ser Phe Phe Gly Thr Asn Ile Gly Ser Ala Val Val Met Leu Ile  
                          35                      40                      45

Pro Thr Val Met Phe Thr Val Met Ala Val Phe Ser Phe Ile Ala Leu  
 50 55 60  
 Ser Met Val His Lys Phe Tyr Arg Gly Ser Gly Gly Ser Phe Ser Lys  
 65 70 75 80  
 Ala Gln Glu Glu Trp Thr Thr Gly Ala Trp Lys Asn Pro His Val Gln  
 85 90 95  
 Gln Ala Ala Gln Asn Ala Ala Met Gly Ala Ala Gln Gly Ala Met Asn  
 100 105 110  
 Gln Pro Gln Thr Gln Tyr Ser Ala Thr Pro Asn Tyr Thr Tyr Ser Asn  
 115 120 125  
 Glu Met Xaa  
 130

<210> 77  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (108)  
 <223> Xaa equals stop translation

<400> 77  
 Met Glu Pro Leu Ala Ala Tyr Pro Leu Lys Cys Ser Gly Pro Arg Ala  
 1 5 10 15  
 Lys Val Phe Ala Val Leu Leu Ser Ile Val Leu Cys Thr Val Thr Leu  
 20 25 30  
 Phe Leu Leu Gln Leu Lys Phe Leu Lys Pro Lys Ile Asn Ser Phe Tyr  
 35 40 45  
 Ala Phe Glu Val Lys Asp Ala Lys Gly Arg Thr Val Ser Leu Glu Lys  
 50 55 60  
 Tyr Lys Gly Lys Val Ser Leu Val Val Asn Val Ala Ser Asp Cys Gln  
 65 70 75 80  
 Leu Thr Asp Arg Asn Tyr Leu Gly Leu Lys Glu Leu His Lys Glu Phe  
 85 90 95  
 Gly Pro Ser His Phe Ser Val Leu Ala Phe Pro Xaa  
 100 105

<210> 78  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE

&lt;222&gt; (126)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 78

Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu Gly Trp Val Asn Gly  
 1 5 10 15

Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val Thr Ala Phe Ile Gly  
 20 25 30

Asn Ser Ile Val Val Ala Gln Val Val Trp Glu Gly Leu Trp Met Ser  
 35 40 45

Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys Lys Val Tyr Asp Ser  
 50 55 60

Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala Arg Ala Leu Cys Val  
 65 70 75 80

Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu Val Tyr Leu Ala Gly  
 85 90 95

Ala Lys Cys Thr Cys Phe Tyr Ile Arg Ile Pro Arg Pro Ala Trp  
 100 105 110

Cys Ser Pro Leu Gly Leu Ser Leu Ser Ser Gln Gly Ser Xaa  
 115 120 125

&lt;210&gt; 79

&lt;211&gt; 218

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 79

Met Glu Ser Arg Met Trp Pro Ala Leu Leu Leu Ser His Leu Leu Pro  
 1 5 10 15

Leu Trp Pro Leu Leu Leu Leu Pro Leu Pro Pro Pro Ala Gln Gly Ser  
 20 25 30

Ser Ser Pro Pro Arg Thr Pro Pro Pro Pro Ala Arg Pro Pro Cys Ala  
 35 40 45

Arg Gly Gly Pro Ser Ala Pro Arg His Val Cys Val Trp Glu Arg Ala  
 50 55 60

Pro Pro Pro Ser Arg Ser Pro Arg Val Pro Arg Ser Arg Arg Gln Val  
 65 70 75 80

Leu Pro Gly Thr Ala Pro Pro Ala Thr Pro Ser Gly Phe Glu Glu Gly  
 85 90 95

Pro Pro Ser Ser Gln Tyr Pro Trp Ala Ile Val Trp Gly Pro Thr Val  
 100 105 110

Ser Arg Glu Asp Gly Gly Asp Pro Asn Ser Ala Asn Pro Gly Phe Leu  
 115 120 125



Asp Tyr Gly Phe Ala Ala Pro His Gly Leu Ala Thr Pro His Pro Asn  
 130 135 140  
 Ser Asp Ser Met Arg Gly Asp Gly Met Gly Leu Ser Leu Glu Arg His  
 145 150 155 160  
 Leu Pro Pro Cys Gly His Ser Cys Ser Gly Ala Val Gly Lys Val Trp  
 165 170 175  
 Thr Pro Ser Ser Met Ser Gln Leu Pro Ser Pro Ser Ser Leu Phe Ser  
 180 185 190  
 Trp Pro Leu Ala Ser Ser Ser Ser Ala Gly Thr Ala Ala Arg Ser  
 195 200 205  
 Asp Ala Asp Pro Gln Gly Ser Lys Val Pro  
 210 215

<210> 80  
 <211> 233  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (36)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (67)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (70)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (71)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (82)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (92)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (233)  
 <223> Xaa equals stop translation

55

&lt;400&gt; 80

```

Met Ala Ile Ser Ile Pro Asn Arg Ile Phe Pro Ile Thr Ala Leu Thr
 1           5           10           15
Leu Leu Ala Leu Val Tyr Ser Leu Val Leu Leu Leu Pro Phe Tyr Asn
          20           25           30
Cys Thr Glu Xaa Thr Lys Tyr Arg Arg Phe Pro Asp Trp Leu Asp His
          35           40           45
Trp Met Leu Cys Arg Lys Gln Leu Gly Leu Val Ala Leu Gly Phe Ala
 50           55           60
Phe Leu Xaa Val Leu Xaa Xaa Leu Val Ile Pro Ile Arg Tyr Tyr Val
 65           70           75           80
Arg Xaa Arg Leu Gly Asn Leu Thr Val Thr Gln Xaa Ile Leu Lys Lys
          85           90           95
Glu Asn Pro Phe Ser Thr Ser Ser Ala Trp Leu Ser Asp Ser Tyr Val
          100          105          110
Ala Leu Gly Ile Leu Gly Phe Phe Leu Phe Val Leu Leu Gly Ile Thr
          115          120          125
Ser Leu Pro Ser Val Ser Asn Ala Val Asn Trp Arg Glu Phe Arg Phe
          130          135          140
Val Gln Ser Lys Leu Gly Tyr Leu Thr Leu Ile Leu Cys Thr Ala His
          145          150          155          160
Thr Leu Val Tyr Gly Gly Lys Arg Phe Leu Ser Pro Ser Asn Leu Arg
          165          170          175
Trp Tyr Leu Pro Ala Ala Tyr Val Leu Gly Leu Ile Ile Pro Cys Thr
          180          185          190
Val Leu Val Ile Lys Phe Val Leu Ile Met Pro Cys Val Asp Asn Thr
          195          200          205
Leu Thr Arg Ile Arg Arg Ala Gly Lys Gly Thr Gln Asn Thr Arg Lys
          210          215          220
Ser Ile Glu Trp Lys Ile Asn Ile Xaa
          225          230

```

&lt;210&gt; 81

&lt;211&gt; 122

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (122)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 81

```

Met Val Phe Phe Thr Cys Leu Trp Phe Leu Asn Glu His Ile Leu Val

```

56

1                      5                      10                      15  
 Cys Asn Cys Ser Asn Val Ser Leu Cys Tyr Ser Leu Pro Leu Lys Glu  
                          20                      25                      30  
 Lys Ile Thr Phe Phe Tyr Asn Leu Thr His Tyr Phe Phe Asn Arg Cys  
                          35                      40                      45  
 Phe Lys His Leu Phe Val Phe Val Glu Gln Ile Phe Leu Asn Ile Val  
                          50                      55                      60  
 Tyr Thr Arg Asn Leu Ile Val Tyr Phe Ser Glu Leu Asn Tyr Ala Ile  
                          65                      70                      75                      80  
 Cys Ser Ser Val Asn Glu Ala Leu Thr Val Gln Ser Asn Pro Leu Lys  
    85                      90                      95  
 Val Leu Pro Trp Glu Ile Arg Arg Val Ser Asn Ser Gln Cys Leu Ser  
    100                      105                      110  
 Leu Ile Ser Val Pro Tyr Asn Asn Thr Xaa  
    115                      120

<210> 82  
 <211> 155  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (155)  
 <223> Xaa equals stop translation

<400> 82  
 Met Asn Pro Gln Thr Val Leu Leu Leu Arg Val Ile Ala Ala Phe Cys  
   1                      5                      10                      15  
 Phe Leu Gly Ile Leu Cys Ser Leu Ser Ala Phe Leu Leu Asp Val Phe  
                          20                      25                      30  
 Gly Pro Lys His Pro Ala Leu Lys Ile Thr Arg Arg Tyr Ala Phe Ala  
                          35                      40                      45  
 His Ile Leu Thr Val Leu Gln Cys Ala Thr Val Ile Gly Phe Ser Tyr  
                          50                      55                      60  
 Trp Ala Ser Glu Leu Ile Leu Ala Gln Gln Gln Gln His Lys Lys Tyr  
                          65                      70                      75                      80  
 His Gly Ser Gln Val Tyr Val Thr Phe Ala Val Ser Phe Tyr Leu Val  
    85                      90                      95  
 Ala Gly Ala Gly Gly Ala Ser Ile Leu Ala Thr Ala Ala Asn Leu Leu  
    100                      105                      110  
 Arg His Tyr Pro Thr Glu Glu Glu Glu Gln Ala Leu Glu Leu Leu Ser  
    115                      120                      125

Glu Met Glu Glu Asn Glu Pro Tyr Pro Ala Glu Tyr Glu Val Ile Asn  
 130 135 140

Gln Phe Gln Pro Pro Pro Ala Tyr Thr Pro Xaa  
 145 150 155

<210> 83  
 <211> 191  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (191)  
 <223> Xaa equals stop translation

<400> 83  
 Met Met Asn Phe Gln Pro Pro Ser Lys Ala Trp Arg Ala Ser Gln Met  
 1 5 10 15

Met Thr Phe Phe Ile Phe Leu Leu Phe Phe Pro Ser Phe Thr Gly Val  
 20 25 30

Leu Cys Thr Leu Ala Ile Thr Ile Trp Arg Leu Lys Pro Ser Ala Asp  
 35 40 45

Cys Gly Pro Phe Arg Gly Leu Pro Leu Phe Ile His Ser Ile Tyr Ser  
 50 55 60

Trp Ile Asp Thr Leu Ser Thr Arg Pro Gly Tyr Leu Trp Val Val Trp  
 65 70 75 80

Ile Tyr Arg Asn Leu Ile Gly Ser Val His Phe Phe Phe Ile Leu Thr  
 85 90 95

Leu Ile Val Leu Ile Ile Thr Tyr Leu Tyr Trp Gln Ile Thr Glu Gly  
 100 105 110

Arg Lys Ile Met Ile Arg Leu Leu His Glu Gln Ile Ile Asn Glu Gly  
 115 120 125

Lys Asp Lys Met Phe Leu Ile Glu Lys Leu Ile Lys Leu Gln Asp Met  
 130 135 140

Glu Lys Lys Ala Asn Pro Ser Ser Leu Val Leu Glu Arg Arg Glu Val  
 145 150 155 160

Glu Gln Gln Gly Phe Leu His Leu Gly Glu His Asp Gly Ser Leu Asp  
 165 170 175

Leu Arg Ser Arg Arg Ser Val Gln Glu Gly Asn Pro Arg Ala Xaa  
 180 185 190

<210> 84  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<220>  
<221> SITE  
<222> (73)  
<223> Xaa equals stop translation

<400> 84  
Met His Ile Tyr Met Trp Val Cys Gly Met Cys Ala Cys Val Cys Met  
1 5 10 15  
Ala Ser Tyr Ile Ile Cys Gly Thr Lys Gly Lys Met Lys Leu Tyr Gly  
20 25 30  
Pro Arg Ser Lys Ile Arg Cys Gly Val Leu Leu Ser Thr Val Leu Cys  
35 40 45  
Asn Cys Thr Gly Cys Met Ser Met Lys Pro Ser Cys Val Cys Ala His  
50 55 60  
Met Cys Met Asn Met Tyr Phe Ile Xaa  
65 70

<210> 85  
<211> 43  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals stop translation

<400> 85  
Met Gly Leu Pro Arg Gly Ser Phe Phe Trp Leu Leu Leu Leu Thr  
1 5 10 15  
Ala Ala Cys Ser Gly Leu Leu Phe Ala Leu Tyr Phe Ser Ala Val Gln  
20 25 30  
Arg Tyr Pro Gly Pro Ala Ala Gly Ala Arg Xaa  
35 40

<210> 86  
<211> 75  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (75)  
<223> Xaa equals stop translation

<400> 86  
Met Ala Cys Leu Gly Ala Pro Ile Ser Ser Leu Leu Cys Trp Leu Leu  
1 5 10 15  
Leu Ala Leu Ile Ala Leu Glu Ile Val Pro Pro Ala Ala Pro Cys Glu

59

			20					25					30				
Val	Leu	Thr	Pro	Leu	Gln	Ser	Ser	Thr	Asn	Pro	Ile	Val	Asn	Lys	Leu		
			35				40					45					
Gly	Val	Lys	Asp	Val	Asn	Glu	Leu	Val	Thr	Pro	Met	Gln	Gly	Ile	Gln		
	50					55					60						
Thr	Cys	Phe	Asn	Ile	Lys	Lys	Lys	Trp	Pro	Xaa							
	65				70					75							

```
<210> 87
<211> 126
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (126)
<223> Xaa equals stop translation
```

```

<400> 87
Met Val Ala Arg Val Phe Tyr Tyr Leu Cys Val Ile Ala Leu Gln Tyr
 1          5          10          15
Val Ala Pro Leu Val Met Leu Leu His Thr Thr Leu Leu Lys Thr
      20          25          30
Leu Gly Asn His Ser Trp Gly Ile Tyr Pro Glu Ser Ile Ser Thr Leu
      35          40          45
Pro Val Asp Asn Ser Leu Leu Ser Asn Ser Val Tyr Ser Glu Leu Pro
 50          55          60
Ser Ala Glu Gly Lys Met Lys Val Thr Val Thr Gln Ile Thr Val Ala
 65          70          75          80
Leu Ser Ser Leu Lys Asn Ile Phe Thr Pro Leu Leu Phe Arg Gly Leu
      85          90          95
Leu Ser Phe Leu Thr Trp Trp Ile Ala Ala Cys Leu Phe Ser Thr Ser
      100          105          110
Leu Phe Gly Leu Phe Tyr His Gln Tyr Leu Thr Val Ala Xaa
      115          120          125

```

```
<210> 88
<211> 258
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (258)
<223> Xaa equals stop translation
```

<400> 88

Met Leu Leu Thr Leu Ala Gly Gly Ala Leu Phe Phe Pro Gly Leu Phe  
 1 5 10 15  
 Ala Leu Cys Thr Trp Ala Leu Arg Arg Ser Gln Pro Gly Trp Ser Arg  
 20 25 30  
 Thr Asp Cys Val Met Ile Ser Thr Arg Leu Val Ser Ser Val His Ala  
 35 40 45  
 Val Leu Ala Thr Gly Ser Gly Ile Val Ile Ile Arg Ser Cys Asp Asp  
 50 55 60  
 Val Ile Thr Gly Arg His Trp Leu Ala Arg Glu Tyr Val Trp Phe Leu  
 65 70 75 80  
 Ile Pro Tyr Met Ile Tyr Asp Ser Tyr Ala Met Tyr Leu Cys Glu Trp  
 85 90 95  
 Cys Arg Thr Arg Asp Gln Asn Arg Ala Pro Ser Leu Thr Leu Arg Asn  
 100 105 110  
 Phe Leu Ser Arg Asn Arg Leu Met Ile Thr His His Ala Val Ile Leu  
 115 120 125  
 Phe Val Leu Val Pro Val Ala Gln Arg Leu Arg Gly Asp Leu Gly Asp  
 130 135 140  
 Phe Phe Val Gly Cys Ile Phe Thr Ala Glu Leu Ser Thr Pro Phe Val  
 145 150 155 160  
 Ser Leu Gly Arg Val Leu Ile Gln Leu Lys Gln Gln His Thr Leu Leu  
 165 170 175  
 Tyr Lys Val Asn Gly Ile Leu Thr Leu Ala Thr Phe Leu Ser Cys Arg  
 180 185 190  
 Ile Leu Leu Phe Pro Phe Met Tyr Trp Ser Tyr Gly Arg Gln Gln Gly  
 195 200 205  
 Leu Ser Leu Leu Gln Val Pro Phe Ser Ile Pro Phe Tyr Cys Asn Val  
 210 215 220  
 Ala Asn Ala Phe Leu Val Ala Pro Gln Ile Tyr Trp Phe Cys Leu Leu  
 225 230 235 240  
 Cys Arg Lys Ala Val Arg Leu Phe Asp Thr Pro Gln Ala Lys Lys Asp  
 245 250 255

Gly Xaa

<210> 89  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE

&lt;222&gt; (122)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 89

```

Met Thr Cys Phe Pro Thr Arg Leu Gly Leu Ser Cys Pro Lys Pro Ala
 1           5           10           15

Phe Leu Leu Val Pro Leu Ala Leu Ala Gln Cys Val Val Pro Ala Gly
          20           25           30

Phe Leu Gly Lys Cys Cys Leu Leu Gly Arg Leu Met Cys Ala Glu Cys
          35           40           45

Ile Gly Thr Tyr Ser Trp Asp Gln Pro Arg Arg Arg Glu Glu Met Glu
          50           55           60

Ala Arg Leu Asp Ser Gly Arg Ser Trp Ala Ser Val Leu Tyr Gly His
 65           70           75           80

Arg Pro Gln Leu His Gly Glu Pro Cys Thr Ala Val Ala Cys Arg Arg
          85           90           95

Val Pro Cys Cys Ser Glu Gly Ala Gly Pro Phe Ser Ser Leu Thr Asp
          100          105          110

Gln Gln Leu Asn Ala Val Tyr Pro Gly Xaa
          115          120

```

&lt;210&gt; 90

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (88)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 90

```

Met Pro Thr Arg Gln Leu His Phe Lys Gln Leu Gln Leu Gln Gly Leu
 1           5           10           15

Leu Ile Val Ile Ala Val Thr Asp Asn Cys Leu Ser Phe Ser Val Lys
          20           25           30

Gly Asn Leu Gly Thr Cys Pro Val Arg Ile Leu Val Ala Ser Phe Cys
          35           40           45

Val His Val Cys Val His Val Arg Val Tyr Phe Ile Gln Ile Ser Leu
          50           55           60

Cys Leu Lys Ser Gly Arg Lys Tyr Phe Lys Phe Leu Leu Leu Asn Cys
          65           70           75           80

Ala Asn Val Glu Ile Ser Ser Xaa
          85

```



```

<400> 91
Met Gly Gln Met Gln Leu Cys Trp Gly His Trp Glu Thr Phe Leu Pro
  1              5              10              15

Leu Leu Arg Leu Leu Val Ala Ile Val Leu Cys Lys Val Ser Ile Met
  20              25              30

Lys Glu Val Ile Ser Phe Gly Arg Leu Leu Glu Thr Met Leu Ile Pro
  35              40              45

Trp Pro Cys Val Thr Leu Met Val Met Glu Arg Lys Ser Phe Leu Leu
  50              55              60

Asp Leu Arg Ile Leu Ile Ser Glu Phe Leu Arg Lys Met Arg Leu Trp
  65              70              75              80

Gln Lys Xaa

```

```
<210> 92
<211> 508
<212> PRT
<213> Homo sapiens
```

BNSDOCID: <WO\_\_0035937A1\_I\_>

Thr Pro Ala Glu Pro Tyr Ala Arg Val Leu Phe His Leu Lys Gly Gln  
 130 135 140  
 Asp Trp Pro Pro Gly Ser Gly Ser Leu Pro Cys Ala Arg Leu His Ala  
 145 150 155 160  
 Thr His Pro Ala Gly Thr Ala His Gln Ala Cys Arg Phe Gln Pro Ser  
 165 170 175  
 Leu Gly Ala Cys Val Val Glu Leu Glu Leu Pro Ser His Trp Phe Ser  
 180 185 190  
 Gln Ala Ser Thr Thr Arg Ala Glu Leu Ala Tyr Thr Leu Glu Pro Ala  
 195 200 205  
 Ala Glu Gly Pro Gly Gly Cys Gly Ser Gly Glu Glu Asn Asp Pro Gly  
 210 215 220  
 Glu Gln Ala Leu Pro Val Gly Gly Val Glu Leu Arg Pro Ala Asp Pro  
 225 230 235 240  
 Pro Gln Tyr Gln Glu Val Pro Leu Asp Glu Ala Val Thr Leu Arg Val  
 245 250 255  
 Pro Asp Met Pro Val Arg Pro Gly Gln Leu Phe Ser Ala Thr Leu Leu  
 260 265 270  
 Leu Arg His Asn Phe Thr Ala Ser Leu Leu Thr Leu Arg Ile Lys Val  
 275 280 285  
 Lys Lys Gly Leu His Val Thr Ala Ala Arg Pro Ala Gln Pro Thr Leu  
 290 295 300  
 Trp Thr Ala Lys Leu Asp Arg Phe Lys Gly Ser Arg His His Thr Thr  
 305 310 315 320  
 Leu Ile Thr Cys His Arg Ala Gly Leu Thr Glu Pro Asp Ser Ser Ser  
 325 330 335  
 Pro Leu Glu Leu Ser Glu Phe Leu Trp Val Asp Phe Val Val Glu Asn  
 340 345 350  
 Ser Thr Gly Gly Gly Val Ala Val Thr Arg Pro Val Thr Trp Gln Leu  
 355 360 365  
 Glu Tyr Pro Gly Gln Ala Pro Glu Ala Glu Lys Asp Lys Met Val Trp  
 370 375 380  
 Glu Ile Leu Val Ser Glu Arg Asp Ile Arg Ala Leu Ile Pro Leu Ala  
 385 390 395 400  
 Lys Val Ser Glu Ala Cys Asp Ala Val Phe Val Ala Gly Lys Glu Ser  
 405 410 415  
 Arg Gly Ala Arg Gly Val Arg Val Asp Phe Trp Trp Arg Arg Leu Arg  
 420 425 430  
 Ala Ser Leu Arg Leu Thr Val Trp Ala Pro Leu Leu Pro Leu Arg Ile

435                      440                      445  
 Glu Leu Thr Asp Thr Thr Leu Glu Gln Val Arg Gly Trp Arg Val Pro  
 450                      455                      460  
 Gly Pro Ala Glu Gly Pro Ala Glu Pro Ala Ala Glu Ala Ser Asp Glu  
 465                      470                      475                      480  
 Ala Glu Arg Arg Ala Arg Gly Cys His Leu Gln Tyr Gln Arg Ala Gly  
                     485                      490                      495  
 Val Arg Phe Leu Ala Pro Phe Ala Ala His Pro Leu  
                     500                      505

<210> 93  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals stop translation

<400> 93  
 Met Phe Gly Ser Arg Gly Leu Leu Cys Met Cys Val Phe Phe Phe Asn  
   1                    5                    10                    15  
 Ile Leu Ala Ser Gln Cys Lys Val Ile Ser Ser Gly Gly Met Leu Cys  
                     20                    25                    30  
 Cys Arg Thr Pro Thr Leu Leu Asp Tyr Leu Arg Gln His Phe Leu Xaa  
                     35                    40                    45

<210> 94  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (120)  
 <223> Xaa equals stop translation

<400> 94  
 Met Gly Phe Leu Gln Phe Gly Phe Gly Phe Leu Ser Ser Leu Asn Leu  
   1                    5                    10                    15  
 Leu Phe Val Ser Phe Ala Gln Cys Pro Ser Gln Val Ala Pro Met Pro  
                     20                    25                    30  
 Ala Pro Gln Gly Pro Pro Leu Pro Val Asn Phe Thr Pro Cys Ser Met  
                     35                    40                    45

65

Tyr Phe Lys Pro Tyr Ile Leu Arg Met Phe Gln Thr Phe Gly Lys Thr  
     50                    55                    60  
 Pro Phe Met Cys Phe Ser Val Thr His Lys His Phe Ile Tyr Val Asp  
     65                    70                    75                    80  
 Glu Glu Cys Thr Gln Ala Pro Phe Val Ile Pro Cys Pro Gln Gln Ala  
                     85                    90                    95  
 Leu Asn Ser Asn Asn Asn Phe His Ser Phe Cys Ala Ser Leu Asn Ser  
                     100                    105                    110  
 Ser Cys Leu Val Gly Ala Gln Xaa  
             115                    120

<210> 95  
 <211> 290  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (60)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (290)  
 <223> Xaa equals stop translation

<400> 95  
 Met Ser Val Pro Gly Arg Trp Pro Pro Ala Arg Trp Arg Leu Ser Ile  
     1                    5                    10                    15  
 Leu Ala Val Ser Ile Met Pro Cys Val Cys Leu Ala Ser Leu Leu Gln  
                     20                    25                    30  
 Ile Leu Trp Thr Arg Ser Ser Ser Pro Ala His His Leu Ala Ser Pro  
             35                    40                    45  
 Phe Leu Cys Val Gln Ile Trp Gln Cys Gly Gly Xaa Leu Glu Thr His  
     50                    55                    60  
 Pro Cys Ser His Val Gly His Val Phe Pro Lys Gln Ala Pro Tyr Ser  
     65                    70                    75                    80  
 Arg Asn Lys Ala Leu Ala Asn Ser Val Arg Ala Ala Glu Val Trp Met  
                     85                    90                    95  
 Asp Glu Phe Lys Glu Leu Tyr Tyr His Arg Asn Pro Arg Ala Arg Leu  
             100                    105                    110  
 Glu Pro Phe Gly Asp Val Thr Glu Arg Lys Gln Leu Arg Asp Lys Leu  
             115                    120                    125  
 Gln Cys Lys Asp Phe Lys Trp Phe Leu Glu Thr Val Tyr Pro Glu Leu  
     130                    135                    140

His Val Pro Glu Asp Arg Pro Gly Phe Phe Gly Met Leu Gln Asn Lys  
 145 150 155 160  
 Gly Leu Thr Asp Tyr Cys Phe Asp Tyr Asn Pro Pro Asp Glu Asn Gln  
 165 170 175  
 Ile Val Gly His Gln Val Ile Leu Tyr Leu Cys His Gly Met Gly Gln  
 180 185 190  
 Asn Gln Phe Phe Glu Tyr Thr Ser Gln Lys Glu Ile Arg Tyr Asn Thr  
 195 200 205  
 His Gln Pro Glu Gly Cys Ile Ala Val Glu Ala Gly Met Asp Thr Leu  
 210 215 220  
 Ile Met His Leu Cys Glu Glu Thr Ala Pro Glu Asn Gln Lys Phe Ile  
 225 230 235 240  
 Leu Gln Glu Asp Gly Ser Leu Phe His Glu Gln Ser Lys Lys Cys Val  
 245 250 255  
 Gln Ala Ala Arg Lys Glu Ser Ser Asp Ser Phe Val Pro Leu Leu Arg  
 260 265 270  
 Asp Cys Thr Asn Ser Asp His Gln Lys Trp Phe Phe Lys Glu Arg Met  
 275 280 285  
 Leu Xaa  
 290

<210> 96  
 <211> 49  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (49)  
 <223> Xaa equals stop translation

<400> 96  
 Met Tyr Val Phe Phe Phe Leu Phe Ser Leu Val Leu His Leu Asn Cys  
 1 5 10 15  
 Pro Gln Ser Ala Pro His Gln Pro Cys Val Thr Pro Ser Thr His Lys  
 20 25 30  
 Thr Glu Gln Lys Thr Pro Ser Leu Ser Trp Ser Pro Leu Gly Met Gly  
 35 40 45  
 Xaa

<210> 97  
 <211> 118  
 <212> PRT  
 <213> Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (118)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 97

Met Asp Thr Phe Cys Val Leu Ile Leu Cys Val Tyr Thr Cys Ala Ala  
 1 5 10 15

His Met Ser Ile His Arg Cys Val Cys Ile Leu Cys Val Tyr Phe Val  
 20 25 30

His Leu Trp Met Cys Val Cys Thr Ile Glu Ser Ile Ser Arg Arg Glu  
 35 40 45

Arg Glu Cys Val Cys Val Cys Val His Val Trp Met Cys Gly Tyr Ser  
 50 55 60

Met Ser Val Phe Arg Val Gln Val Tyr Gly Cys Ser Cys Ala Val Cys  
 65 70 75 80

Val Cys Ala His Thr His Ser Ala Ser Leu Cys Val Cys Met Cys Ile  
 85 90 95

Pro Cys Val Pro Met Tyr Arg Gly Cys Val Tyr Pro Ala Cys Leu Cys  
 100 105 110

Met Gly Glu His Met Xaa  
 115

&lt;210&gt; 98

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (49)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 98

Met Ser Thr Val Thr Trp Leu Leu Lys Leu Phe Thr Gln Phe Met Phe  
 1 5 10 15

Pro Pro Thr Val Ser Asn Ser His Thr Cys Ala Arg Tyr Tyr Val Phe  
 20 25 30

Asn Phe Cys Leu Ile Ile Ser Phe Asn Phe Asn Phe His Tyr His Trp  
 35 40 45

Xaa

&lt;210&gt; 99

&lt;211&gt; 124

&lt;212&gt; PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (124)

<223> Xaa equals stop translation

<400> 99

```

Met Gln Ala Gln Phe Cys Cys Ser Ala Val Cys Ser Ala Phe Leu His
 1             5             10             15

Ile Leu Ala Ser Pro Ser Gly Ala Lys Met Ala Ala Ala Phe Gln Ala
          20             25             30

Ser His Pro Asp Ser Asp Pro Glu Lys Leu Pro Ile Pro Thr Trp Val
          35             40             45

Ser Leu Cys Arg Asn Glu Lys Pro His Pro Ala Ala Glu Thr Ser Pro
          50             55             60

Ser Ser Val Phe Ser Gly Leu Ile His Gln Arg Arg Pro Pro Leu Asn
          65             70             75             80

Gln Ser Leu Ala Lys Arg Met Gly Pro Pro Gly Arg Leu Asp Gln Thr
          85             90             95

Gly Pro Ala Leu Trp Gly Trp Gly Glu Ala Gln Met Lys Ala Ala Gly
          100            105            110

Gln Asp Gly Leu Leu Asp Leu Cys Tyr Gln Gln Xaa
          115            120

```

<210> 100

<211> 132

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (132)

<223> Xaa equals stop translation

<400> 100

```

Met Ile Thr Lys Pro Ser Lys Arg Gly Ile Ile Tyr Cys Leu Pro Leu
 1             5             10             15

Leu Phe Gln Leu Ser His Leu Ser Leu Ala Asn Leu Phe Leu Thr Ser
          20             25             30

Leu Thr Ser Pro His Leu Thr Glu Phe Phe His Leu Leu Cys Gln Thr
          35             40             45

Thr Gly Tyr Ser Asp Asp Asn Leu Leu Ser Leu Pro Val Ser Ser Gln
          50             55             60

Thr Lys Ala Cys Phe Thr Lys Trp Gly Val Ser Ala Ala Ser Ser Ser
          65             70             75             80

```

Pro Leu Thr His Ser Cys Ser Ala Arg Gly Ser Gly Arg Val Ser Glu  
85 90 95

His Arg Cys Gly Met Gln Ser Pro Arg Pro His Ala His Pro Ser Phe  
100 105 110

Ser Cys Thr Ser Ala Asn Ser Ser Trp Leu Thr Cys Ala Ser Trp Leu  
115 120 125

Glu Ser Leu Xaa  
130

<210> 101

<211> 334

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (334)

<223> Xaa equals stop translation

<400> 101

Met Ser Pro Trp Ser Trp Phe Leu Leu Gln Thr Leu Cys Leu Leu Pro  
1 5 10 15

Thr Gly Ala Ala Ser Arg Arg Gly Ala Pro Gly Thr Ala Asn Cys Glu  
20 25 30

Leu Lys Pro Gln Gln Ser Glu Leu Asn Ser Phe Leu Trp Thr Ile Lys  
35 40 45

Arg Asp Pro Pro Ser Tyr Phe Phe Gly Thr Ile His Val Pro Tyr Thr  
50 55 60

Arg Val Trp Asp Phe Ile Pro Asp Asn Ser Lys Glu Ala Phe Leu Gln  
65 70 75 80

Ser Ser Ile Val Tyr Phe Glu Leu Asp Leu Thr Asp Pro Tyr Thr Ile  
85 90 95

Ser Ala Leu Thr Ser Cys Gln Met Leu Pro Gln Gly Glu Asn Leu Gln  
100 105 110

Asp Val Leu Pro Arg Asp Ile Tyr Cys Arg Leu Lys Arg His Leu Glu  
115 120 125

Tyr Val Lys Leu Met Met Pro Leu Trp Met Thr Pro Asp Gln Arg Gly  
130 135 140

Lys Gly Leu Tyr Ala Asp Tyr Leu Phe Asn Ala Ile Ala Gly Asn Trp  
145 150 155 160

Glu Arg Lys Arg Pro Val Trp Val Met Leu Met Val Asn Ser Leu Thr  
165 170 175

Glu Val Asp Ile Lys Ser Arg Gly Val Pro Val Leu Asp Leu Phe Leu  
180 185 190



Ala Gln Glu Ala Glu Arg Leu Arg Lys Gln Thr Gly Ala Val Glu Lys  
 195 200 205

Val Glu Glu Gln Cys His Pro Leu Asn Gly Leu Asn Phe Ser Gln Val  
 210 215 220

Ile Phe Ala Leu Asn Gln Thr Leu Leu Gln Gln Glu Ser Leu Arg Ala  
 225 230 235 240

Gly Ser Leu Gln Ile Pro Tyr Thr Thr Glu Asp Leu Ile Lys His Tyr  
 245 250 255

Asn Cys Gly Asp Leu Ser Ser Val Ile Leu Ser His Asp Ser Ser Gln  
 260 265 270

Val Pro Asn Phe Ile Asn Ala Thr Leu Pro Pro Gln Glu Arg Ile Thr  
 275 280 285

Ala Gln Glu Ile Asp Ser Tyr Leu Arg Arg Glu Leu Ile Tyr Lys Arg  
 290 295 300

Asn Glu Arg Ile Gly Lys Arg Val Lys Ala Leu Leu Glu Glu Phe Pro  
 305 310 315 320

Asp Lys Gly Phe Phe Phe Ala Phe Gly Ala Ala Ser Gln Xaa  
 325 330

<210> 102  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (63)  
 <223> Xaa equals stop translation

<400> 102  
 Met Thr Trp Thr Lys Cys Pro Leu Pro Leu Gly Pro Ala Phe Phe Thr  
 1 5 10 15

Gln Cys Cys Leu Ile Gly Leu Leu Val Pro Leu Leu Gly Trp Gly Asn  
 20 25 30

Gln Asn Thr Gln Trp Tyr Pro Thr Ser Lys Met Pro Asp Leu Lys Asp  
 35 40 45

Ser Lys Thr Thr Asp Leu Cys Gln His Val Lys His Met Val Xaa  
 50 55 60

<210> 103  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<220>

<221> SITE  
 <222> (100)  
 <223> Xaa equals stop translation

<400> 103

Met	Ser	Glu	Thr	Phe	Leu	Glu	Ser	Val	Asn	Leu	Leu	Leu	Val	Ile	Pro
1				5					10					15	
Val	Ala	Thr	Thr	Leu	Ile	Ser	Trp	Met	Ala	Pro	Arg	Lys	Lys	Glu	Ser
			20					25					30		
Phe	Gln	Glu	Leu	Ser	Arg	Gln	Val	Val	Pro	Cys	Gln	Met	Met	Leu	Leu
		35					40					45			
Ser	Thr	Val	Leu	Pro	Cys	Leu	Thr	His	Pro	Arg	Ile	Lys	Lys	Gly	Val
	50					55					60				
Leu	Arg	Phe	Pro	Gly	Val	Thr	Leu	Trp	Leu	Tyr	Leu	Arg	Pro	Phe	Gln
65					70					75					80
Phe	Tyr	Gln	Phe	Ile	Pro	Met	Asp	His	Arg	Ser	Leu	Asp	Ser	Gln	Phe
				85					90					95	
Arg	Met	Arg	Xaa												
			100												

<210> 104  
 <211> 87  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (87)  
 <223> Xaa equals stop translation

<400> 104

Met	Gly	Ala	Asn	Phe	Thr	Val	Phe	Leu	Gln	Tyr	Leu	Val	Phe	Pro	Ile
1				5					10					15	
Phe	Gly	Phe	Leu	Leu	Ile	Ile	Ser	His	Pro	Ser	Gln	Pro	Leu	Phe	Ser
			20					25					30		
Ser	Pro	Pro	Leu	Cys	Leu	Gln	His	Pro	Ile	Leu	Pro	Ser	Leu	Pro	Phe
		35					40					45			
Asn	Leu	Pro	Ile	Leu	Phe	Phe	Pro	Leu	Lys	Ser	His	Met	Ile	Leu	Gln
	50					55					60				
Ser	Ser	Phe	Val	Phe	Pro	Lys	Lys	Lys	Lys	Asn	Phe	Phe	Phe	Phe	Lys
65					70					75					80
Glu	Ser	Phe	Leu	Asp	Ser	Xaa									
				85											

<210> 105  
 <211> 83

<212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (83)  
 <223> Xaa equals stop translation

<400> 105  
 Met Val Leu Arg Thr Asp Ser Val Pro Ala Leu Phe Thr Tyr Leu Ser  
           1                  5                  10                  15  
 Thr Phe Trp Leu Ala Phe Ile Ser Gly Leu Ala Asp Ile Leu Thr Leu  
                   20                  25                  30  
 Cys Thr Lys Met Ala Asp Thr Ile Ile Phe His His Ile Leu Gln Lys  
                   35                  40                  45  
 Ile Leu Leu Leu Lys Asn Thr Leu Arg Asn Met Phe Tyr Gly Gln Ile  
           50                  55                  60  
 Ser Leu Gly Asn Ser Glu Leu Leu Phe Leu Leu Cys Arg Ile Thr Met  
           65                  70                  75                  80  
 His Cys Xaa

<210> 106  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (45)  
 <223> Xaa equals stop translation

<400> 106  
 Met Arg Pro Asn Val Leu Gln Val Ala Phe Pro Ile Ser Thr His Arg  
           1                  5                  10                  15  
 Cys Val Arg Pro Ser Cys Trp Leu Leu Phe Ile Leu Phe Arg Leu Leu  
                   20                  25                  30  
 Pro Ile Met Ile Ser Gln Pro Gly Cys Asn Ser Cys Xaa  
           35                  40                  45

<210> 107  
 <211> 227  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (125)  
 <223> Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 107

Met Gly Trp Thr Met Arg Leu Val Thr Ala Ala Leu Leu Leu Gly Leu  
 1 5 10 15

Met Met Val Val Thr Gly Asp Glu Asp Glu Asn Ser Pro Cys Ala His  
 20 25 30

Glu Ala Leu Leu Asp Glu Asp Thr Leu Phe Cys Gln Gly Leu Glu Val  
 35 40 45

Phe Tyr Pro Glu Leu Gly Asn Ile Gly Cys Lys Val Val Pro Asp Cys  
 50 55 60

Asn Asn Tyr Arg Gln Lys Ile Thr Ser Trp Met Glu Pro Ile Val Lys  
 65 70 75 80

Phe Pro Gly Ala Val Asp Gly Ala Thr Tyr Ile Leu Val Met Val Asp  
 85 90 95

Pro Asp Ala Pro Ser Arg Ala Glu Pro Arg Gln Arg Phe Trp Arg His  
 100 105 110

Trp Leu Val Thr Asp Ile Lys Gly Ala Asp Leu Lys Xaa Gly Lys Ile  
 115 120 125

Gln Gly Gln Glu Leu Ser Ala Tyr Gln Ala Pro Ser Pro Pro Ala His  
 130 135 140

Ser Gly Phe His Arg Tyr Gln Phe Phe Val Tyr Leu Gln Glu Gly Lys  
 145 150 155 160

Val Ile Ser Leu Leu Pro Lys Glu Asn Lys Thr Arg Gly Ser Trp Lys  
 165 170 175

Met Asp Arg Phe Leu Asn Arg Phe His Leu Gly Glu Pro Glu Ala Ser  
 180 185 190

Thr Gln Phe Met Thr Gln Asn Tyr Gln Asp Ser Pro Thr Leu Gln Ala  
 195 200 205

Pro Arg Glu Arg Ala Ser Glu Pro Lys His Lys Asn Gln Ala Glu Ile  
 210 215 220

Ala Ala Cys  
 225

&lt;210&gt; 108

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (66)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 108

Met Gly Ala Arg Thr Pro His Trp Gly Gln Gly Gln Cys Trp Arg Ile

74

1                      5                      10                      15  
 Leu Ile Pro Phe Leu Leu Ser Phe Thr Phe Val Phe Asn Leu Gly Val  
                          20                      25                      30  
 Arg Gly Glu Ala Leu Leu Gly Asn Ile Ser Arg Ala Phe Leu His Leu  
                          35                      40                      45  
 Pro Trp Phe Pro Ala Gln Pro Lys Ile Ile Trp Gln Pro Ser Gly Trp  
                          50                      55                      60  
 Asn Xaa  
 65  
  
 <210> 109  
 <211> 209  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 109  
 Met Glu Pro Leu Ala Ala Tyr Pro Leu Lys Cys Ser Gly Pro Arg Ala  
   1                      5                      10                      15  
 Lys Val Phe Ala Val Leu Leu Ser Ile Val Leu Cys Thr Val Thr Leu  
                          20                      25                      30  
 Phe Leu Leu Gln Leu Lys Phe Leu Lys Pro Lys Ile Asn Ser Phe Tyr  
                          35                      40                      45  
 Ala Phe Glu Val Lys Asp Ala Lys Gly Arg Thr Val Ser Leu Glu Lys  
                          50                      55                      60  
 Tyr Lys Gly Lys Val Ser Leu Val Val Asn Val Ala Ser Asp Cys Gln  
   65                      70                      75                      80  
 Leu Thr Asp Arg Asn Tyr Leu Gly Leu Lys Glu Leu His Lys Glu Phe  
                          85                      90                      95  
 Gly Pro Ser His Phe Ser Val Leu Ala Phe Pro Cys Asn Gln Phe Gly  
                          100                      105                      110  
 Glu Ser Glu Pro Arg Pro Ser Lys Glu Val Glu Ser Phe Ala Arg Lys  
                          115                      120                      125  
 Asn Tyr Gly Val Thr Phe Pro Ile Phe His Lys Ile Lys Ile Leu Gly  
                          130                      135                      140  
 Ser Glu Gly Glu Pro Ala Phe Arg Phe Leu Val Asp Ser Ser Lys Lys  
   145                      150                      155                      160  
 Glu Pro Arg Trp Asn Phe Trp Lys Tyr Leu Val Asn Pro Glu Gly Gln  
                          165                      170                      175  
 Val Val Lys Phe Trp Arg Pro Glu Glu Pro Ile Glu Val Ile Arg Pro  
                          180                      185                      190  
 Asp Ile Ala Ala Leu Val Arg Gln Val Ile Ile Lys Lys Lys Glu Asp  
                          195                      200                      205

Leu

<210> 110  
 <211> 215  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (102)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (105)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 110  
 Met Gln Ile Leu Gly Val Val Leu Thr Leu Leu Gly Trp Val Asn Gly  
   1                  5                  10                  15  
 Leu Val Ser Cys Ala Leu Pro Met Trp Lys Val Thr Ala Phe Ile Gly  
           20                  25                  30  
 Asn Ser Ile Val Val Ala Gln Val Val Trp Glu Gly Leu Trp Met Ser  
           35                  40                  45  
 Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys Lys Val Tyr Asp Ser  
       50                  55                  60  
 Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala Arg Ala Leu Cys Val  
   65                  70                  75                  80  
 Ile Ala Leu Leu Val Ala Leu Phe Gly Leu Leu Val Tyr Leu Ala Gly  
           85                  90                  95  
 Ala Lys Cys Thr Thr Xaa Phe Tyr Xaa Lys Asp Ser Lys Ala Arg Leu  
           100                  105                  110  
 Val Leu Thr Ser Gly Ile Val Phe Val Ile Ser Gly Val Leu Thr Leu  
       115                  120                  125  
 Ile Pro Val Cys Trp Thr Ala His Ala Ile Ile Arg Asp Phe Tyr Asn  
   130                  135                  140  
 Pro Leu Val Ala Glu Ala Gln Lys Arg Glu Leu Gly Ala Ser Leu Tyr  
  145                  150                  155                  160  
 Leu Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu Gly Gly Gly Leu Leu  
           165                  170                  175  
 Cys Cys Thr Cys Pro Ser Gly Gly Ser Gln Gly Pro Ser His Tyr Met  
           180                  185                  190  
 Ala Arg Tyr Ser Thr Ser Ala Pro Ala Ile Ser Arg Gly Pro Ser Glu  
       195                  200                  205

Tyr Pro Thr Lys Asn Tyr Val  
210 215

<210> 111  
<211> 277  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (277)  
<223> Xaa equals stop translation

<400> 111  
Met Glu Ser Arg Met Trp Pro Ala Leu Leu Leu Ser His Leu Leu Pro  
1 5 10 15  
Leu Trp Pro Leu Leu Leu Leu Pro Leu Pro Pro Pro Ala Gln Gly Ser  
20 25 30  
Ser Ser Ser Pro Arg Thr Pro Pro Gly Pro Ala Arg Pro Pro Cys Ala  
35 40 45  
Arg Gly Gly Pro Ser Ala Pro Arg His Val Cys Val Trp Glu Arg Ala  
50 55 60  
Pro Pro Pro Ser Arg Ser Pro Arg Val Pro Arg Ser Arg Arg Gln Val  
65 70 75 80  
Leu Pro Gly Thr Ala Pro Pro Ala Thr Pro Ser Gly Phe Glu Glu Gly  
85 90 95  
Pro Pro Ser Ser Gln Tyr Pro Trp Ala Ile Val Trp Gly Pro Thr Val  
100 105 110  
Ser Arg Glu Asp Gly Gly Asp Pro Asn Ser Ala Asn Pro Gly Phe Leu  
115 120 125  
Asp Tyr Gly Phe Ala Ala Pro His Gly Leu Ala Thr Pro His Pro Asn  
130 135 140  
Ser Asp Ser Met Arg Gly Asp Gly Asp Gly Leu Ile Leu Gly Glu Ala  
145 150 155 160  
Pro Ala Thr Leu Arg Ser Phe Leu Phe Gly Gly Arg Gly Glu Gly Val  
165 170 175  
Asp Pro Gln Leu Tyr Val Thr Ile Thr Ile Ser Ile Ile Ile Val Leu  
180 185 190  
Val Ala Thr Gly Ile Ile Phe Lys Phe Cys Trp Asp Arg Ser Gln Lys  
195 200 205  
Arg Arg Arg Pro Ser Gly Gln Gln Gly Ala Leu Arg Gln Glu Glu Ser  
210 215 220  
Gln Gln Pro Leu Thr Asp Leu Ser Pro Ala Gly Val Thr Val Leu Gly

225                      230                      235                      240  
 Ala Phe Gly Asp Ser Pro Thr Pro Thr Pro Asp His Asp Glu Pro Arg  
                                  245                      250                      255  
 Gly Gly Pro Arg Pro Gly Met Pro His Pro Lys Gly Ala Pro Ala Phe  
                                  260                      265                      270  
 Gln Leu Asn Arg Xaa  
                                  275

<210> 112  
 <211> 87  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (87)  
 <223> Xaa equals stop translation

<400> 112  
 Met Arg Leu Val Thr Ala Ala Leu Leu Leu Gly Leu Met Met Val Val  
   1                                  5                                  10                                  15  
 Thr Gly Asp Glu Asp Glu Asn Ser Pro Cys Ala His Glu Ala Leu Leu  
                                   20                                  25                                  30  
 Asp Glu Asp Thr Leu Phe Cys Gln Gly Leu Glu Val Phe Tyr Pro Glu  
                                   35                                  40                                  45  
 Leu Gly Asn Ile Gly Cys Lys Val Val Pro Asp Cys Asn Asn Tyr Arg  
   50                                  55                                  60  
 Gln Lys Ile Thr Ser Trp Met Glu Ala Asp Ser Gln Val Pro Gly Gly  
   65                                  70                                  75                                  80  
 Arg Gly Arg Arg Asn Leu Xaa  
                                   85

<210> 113  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<400> 113  
 Ala Ala Pro Asp Gly Gly Thr Met Ser Ser Ser Gly Gly Ala Pro Gly  
   1                                  5                                  10                                  15  
 Ala Ser Ala Ser Ser Ala Pro Pro Ala Gln Glu Glu Gly  
                                   20                                  25

<210> 114  
 <211> 191  
 <212> PRT  
 <213> Homo sapiens



&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 114

Arg	Arg	Arg	Arg	Asn	Gln	Asp	Arg	Pro	Gln	Leu	Xaa	Lys	Lys	Phe	Cys
1				5					10					15	
Glu	Ala	Ser	Trp	Arg	Phe	Leu	Phe	Tyr	Leu	Ser	Ser	Phe	Val	Gly	Gly
			20					25					30		
Leu	Ser	Val	Leu	Tyr	His	Glu	Ser	Trp	Leu	Trp	Ala	Pro	Val	Met	Cys
		35					40					45			
Trp	Asp	Arg	Tyr	Pro	Asn	Gln	Thr	Leu	Lys	Pro	Ser	Leu	Tyr	Trp	Trp
	50					55					60				
Tyr	Leu	Leu	Glu	Leu	Gly	Phe	Tyr	Leu	Ser	Leu	Leu	Ile	Arg	Leu	Pro
	65				70					75					80
Phe	Asp	Val	Lys	Arg	Lys	Asp	Phe	Lys	Glu	Gln	Val	Ile	His	His	Phe
				85					90					95	
Val	Ala	Val	Ile	Leu	Met	Thr	Phe	Ser	Tyr	Ser	Ala	Asn	Leu	Leu	Arg
			100					105					110		
Ile	Gly	Ser	Leu	Val	Leu	Leu	Leu	His	Asp	Ser	Ser	Asp	Tyr	Leu	Leu
		115					120					125			
Glu	Ala	Cys	Lys	Met	Val	Asn	Tyr	Met	Gln	Tyr	Gln	Gln	Val	Cys	Asp
	130					135					140				
Ala	Leu	Phe	Leu	Ile	Phe	Ser	Phe	Val	Phe	Phe	Tyr	Thr	Arg	Leu	Val
	145				150					155					160
Leu	Phe	Pro	Thr	Gln	Ile	Leu	Tyr	Thr	Thr	Tyr	Tyr	Glu	Ser	Ile	Ser
				165					170					175	
Asn	Arg	Gly	Pro	Phe	Phe	Gly	Tyr	Tyr	Phe	Phe	Asn	Gly	Leu	Leu	
			180					185					190		

&lt;210&gt; 115

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 115

Arg	Arg	Arg	Arg	Asn	Gln	Asp	Arg	Pro	Gln	Leu	Xaa	Lys	Lys	Phe	Cys
1				5					10					15	
Glu	Ala	Ser	Trp	Arg	Phe	Leu	Phe	Tyr	Leu	Ser	Ser	Phe	Val	Gly	Gly

20 25 30  
 Leu Ser Val Leu Tyr His Glu Ser Trp Leu Trp Ala Pro Val  
 35 40 45  
  
 <210> 116  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 116  
 Met Cys Trp Asp Arg Tyr Pro Asn Gln Thr Leu Lys Pro Ser Leu Tyr  
 1 5 10 15  
 Trp Trp Tyr Leu Leu Glu Leu Gly Phe Tyr Leu Ser Leu Leu Ile Arg  
 20 25 30  
 Leu Pro Phe Asp Val Lys Arg Lys Asp Phe Lys Glu Gln Val Ile His  
 35 40 45  
  
 <210> 117  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 117  
 His Phe Val Ala Val Ile Leu Met Thr Phe Ser Tyr Ser Ala Asn Leu  
 1 5 10 15  
 Leu Arg Ile Gly Ser Leu Val Leu Leu Leu His Asp Ser Ser Asp Tyr  
 20 25 30  
 Leu Leu Glu Ala Cys Lys Met Val Asn Tyr Met Gln Tyr Gln Gln  
 35 40 45  
  
 <210> 118  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 118  
 Val Cys Asp Ala Leu Phe Leu Ile Phe Ser Phe Val Phe Phe Tyr Thr  
 1 5 10 15  
 Arg Leu Val Leu Phe Pro Thr Gln Ile Leu Tyr Thr Thr Tyr Tyr Glu  
 20 25 30  
 Ser Ile Ser Asn Arg Gly Pro Phe Phe Gly Tyr Tyr Phe Phe Asn Gly  
 35 40 45  
  
 Leu Leu  
 50

<210> 119  
 <211> 43  
 <212> PRT  
 <213> Homo sapiens

<400> 119  
 Lys Thr Tyr Val Leu Pro Ser Pro Gly Leu Ser Ile Arg Pro Pro Gly  
           1                          5                          10                          15  
 Arg Glu Val Pro Gly Ser His Pro Phe Pro Ala Pro Ala Leu Glu Thr  
                           20                          25                          30  
 Ala Ala Pro Arg Leu Leu Arg Asp Ser Asp Ser  
                           35                          40

<210> 120  
 <211> 345  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (280)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 120  
 Lys Thr Tyr Val Leu Pro Ser Pro Gly Leu Ser Ile Arg Pro Pro Gly  
           1                          5                          10                          15  
 Arg Glu Val Pro Gly Ser His Pro Phe Pro Ala Pro Ala Leu Glu Thr  
                           20                          25                          30  
 Ala Ala Pro Arg Leu Leu Arg Asp Ser Asp Ser Met Lys Ala Pro Gly  
                           35                          40                          45  
 Arg Leu Val Leu Ile Ile Leu Cys Ser Val Val Phe Ser Ala Val Tyr  
           50                          55                          60  
 Ile Leu Leu Cys Cys Trp Ala Gly Leu Pro Leu Cys Leu Ala Thr Cys  
           65                          70                          75                          80  
 Leu Asp His His Phe Pro Thr Gly Ser Arg Pro Thr Val Pro Gly Pro  
                           85                          90                          95  
 Leu His Phe Ser Gly Tyr Ser Ser Val Pro Asp Gly Lys Pro Leu Val  
                           100                          105                          110  
 Arg Glu Pro Cys Arg Ser Cys Ala Val Val Ser Ser Ser Gly Gln Met  
           115                          120                          125  
 Leu Gly Ser Gly Leu Gly Ala Glu Ile Asp Ser Ala Glu Cys Val Phe  
           130                          135                          140  
 Arg Met Asn Gln Ala Pro Thr Val Gly Phe Glu Ala Asp Val Gly Gln  
           145                          150                          155                          160  
 Arg Ser Thr Leu Arg Val Val Ser His Thr Ser Val Pro Leu Leu Leu

```
<210> 121
<211> 966
<212> DNA
<213> Homo sapiens
```

<400>	121						
ACATGGTGTG	GGGCCAGGGC	AGGCACATGG	ACCGGGTGCT	CGGCGGCCGC	ACCTACCGCA		60
CGCTGCTGCA	GCTCACCAGG	ATGTACCCCG	GCCTGCAGGT	GTACACCTTC	ACGGAGCGCA		120
TGATGGCCTA	CTGCGACCAG	ATCTTCCAGG	ACGAGACGGG	CAAGAACCGG	AGGCAGTCGG		180
GCTCCTTCCT	CAGCACCGGC	TGGTTCACCA	TGATCCTCGC	GCTGGAGCTG	TGTGAGGAGA		240
TCGTGGTCTA	TGGGATGGTC	AGCGACACTA	CTGCAGGGAG	AAGAGCCACC	CCTCAGTGCC		300
TTACCACTAC	TTTGAGAAGG	GCCGGCTAGA	TGAGTGTGAG	ATGTACCTGG	CACACGAGCA		360
GGCGCCCCGA	AGCGCCCACC	GCTTCATCAC	TGAGAAGGCG	GTCTTCTCCC	GCTGGGCCAA		420
GAAGAGGCCC	ATCGTGTTTCG	CCCATCCGTC	CTGGAGGACT	GAGTAGCTTC	CGTCGTCCTG		480
CCAGCCGCCA	TGCCGTTGCG	AGGCCTCCGG	GATGTCCCAT	CCCAAGCCAT	CACACTCCAC		540

AAAAACATTT AATTTATGGT TCCTGCCCTC TGCCACGTGC TGGGTGGACC TAAGGTTCTT	600
CCCACCCATT CTGGCGACAC TTGGAGCCAT CTCAGGCCCC TCCACTCCCT GAGTAATTCA	660
TGGCATTGGG GGGCTCACCC CACCTCCAGG TCTGTCAAGT GGCCTTTGTC CCTGGGGCTG	720
ATGGCCCCCA ACTCACCAGC ATCATGACCT TGTGCCAGTC CTGGTCCTCC CTCCCCAGCC	780
GCCCCTACCA CCTTTTGGTG CCACACTTCT CAGGCTGGCC GCCCTGGTTG GGGCAGCCGA	840
GAGCCTGGGG TTCATTGGTG AAGGGGCCTT GGAGTTGTGA CTGCCGGGGC CGTATCAGGA	900
ACGTACGGGT AAACGTGTGT TTTCTGGAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	960
AAAAAA	966

<210> 122  
 <211> 185  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (51)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (75)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (100)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (103)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (135)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (160)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (161)  
 <223> Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 122

Thr Arg Asn Lys Ile Trp Ser Ser Thr Arg Gly Gly Gly Arg Ser Arg  
 1 5 10 15

Thr Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Ser His Leu  
 20 25 30

Ala Ala Val His Met Ala Ala Trp Val Phe Pro Leu Leu Ser Val Ile  
 35 40 45

His Thr Xaa Leu Pro Gln Ala Ser Pro Glu Ile Trp Val Thr Gln Ser  
 50 55 60

Glu Gly Gly Asp Gln Gly Val Ala Cys Glu Xaa Val Gly Gly Val Leu  
 65 70 75 80

Ser Thr Leu Asp Arg Ile Glu Leu Cys Phe Leu Ser Asp Arg Ala Ser  
 85 90 95

Ser Gly Cys Xaa Asp Lys Xaa Pro Gln Thr Gly Val Leu Phe Leu Gly  
 100 105 110

Ala Gly Ile Cys His Glu Gly Val Gly Arg Ala Gly Ser Ser Arg Ala  
 115 120 125

Leu Ser Pro Gly Pro Ala Xaa Ala Val Phe Pro Ser Phe Pro Cys Ala  
 130 135 140

Phe Pro Gly Pro Ser Cys Val Cys Leu Cys Pro Arg Leu Ser Trp Xaa  
 145 150 155 160

Xaa Tyr Arg Ser Gln Gly Pro Trp Ser Tyr Trp Ile Arg Ala Thr Leu  
 165 170 175

Met Ala Ser Cys His Cys Ser Tyr Leu  
 180 185

&lt;210&gt; 123

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Phe Leu Gly Val Leu Val Ser Ile Ile Met Leu Ser Pro Gly Val Glu  
 1 5 10 15

Ser Gln Leu Tyr Lys Leu Pro Trp Val Cys Glu Glu Gly Ala Gly Ile  
 20 25 30

Pro Thr Val Leu Gln Gly His Ile Asp Cys Gly Ser Leu Leu Gly Tyr  
 35 40 45

Arg Ala Val Tyr Arg  
 50

&lt;210&gt; 124

&lt;211&gt; 58

<212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 124  
 Pro Gly Ala Gly Arg Pro Lys Pro Gly Ala Ala Ala Met Gly Ala Cys  
           1                  5                  10                  15  
 Leu Gly Ala Cys Ser Leu Leu Ser Cys Ala Ser Cys Leu Cys Gly Ser  
                   20                  25                  30  
 Ala Pro Cys Ile Leu Cys Ser Cys Cys Pro Ala Ser Arg Xaa Ser Thr  
                   35                  40                  45  
 Val Ser Arg Leu Ile Phe Thr Phe Phe Leu  
           50                  55

<210> 125  
 <211> 468  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (155)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 125  
 Pro Gly Ala Gly Arg Pro Lys Pro Gly Ala Ala Ala Met Gly Ala Cys  
           1                  5                  10                  15  
 Leu Gly Ala Cys Ser Leu Leu Ser Cys Ala Ser Cys Leu Cys Gly Ser  
                   20                  25                  30  
 Ala Pro Cys Ile Leu Cys Ser Cys Cys Pro Ala Ser Arg Xaa Ser Thr  
                   35                  40                  45  
 Val Ser Arg Leu Ile Phe Thr Phe Phe Leu Phe Leu Gly Val Leu Val  
           50                  55                  60  
 Ser Ile Ile Met Leu Ser Pro Gly Val Glu Ser Gln Leu Tyr Lys Leu  
           65                  70                  75                  80  
 Pro Trp Val Cys Glu Glu Gly Ala Gly Ile Pro Thr Val Leu Gln Gly  
                   85                  90                  95  
 His Ile Asp Cys Gly Ser Leu Leu Gly Tyr Arg Ala Val Tyr Arg Met  
           100                  105                  110

Cys Phe Ala Thr Ala Ala Phe Phe Phe Phe Phe Thr Leu Leu Met Leu  
 115 120 125  
 Cys Val Ser Ser Ser Arg Asp Pro Arg Ala Ala Ile Gln Asn Gly Phe  
 130 135 140  
 Trp Phe Phe Lys Phe Leu Ile Leu Val Gly Xaa Thr Val Gly Ala Phe  
 145 150 155 160  
 Tyr Ile Pro Asp Gly Ser Phe Thr Asn Ile Trp Phe Tyr Phe Gly Val  
 165 170 175  
 Val Gly Ser Phe Leu Phe Ile Leu Ile Gln Leu Val Leu Leu Ile Asp  
 180 185 190  
 Phe Ala His Ser Trp Asn Gln Arg Trp Leu Gly Lys Ala Glu Glu Cys  
 195 200 205  
 Asp Ser Arg Ala Trp Tyr Ala Gly Leu Phe Phe Phe Thr Leu Leu Phe  
 210 215 220  
 Tyr Leu Leu Ser Ile Ala Ala Val Ala Leu Met Phe Met Tyr Tyr Thr  
 225 230 235 240  
 Glu Pro Ser Gly Cys His Glu Gly Lys Val Phe Ile Ser Leu Asn Leu  
 245 250 255  
 Thr Phe Cys Val Cys Val Ser Ile Ala Ala Val Leu Pro Lys Val Gln  
 260 265 270  
 Asp Ala Gln Pro Asn Ser Gly Leu Leu Gln Ala Ser Val Ile Thr Leu  
 275 280 285  
 Tyr Thr Met Phe Val Thr Trp Ser Ala Leu Ser Ser Ile Pro Glu Gln  
 290 295 300  
 Lys Cys Asn Pro His Leu Pro Thr Gln Leu Gly Asn Glu Thr Val Val  
 305 310 315 320  
 Ala Gly Pro Glu Gly Tyr Glu Thr Gln Trp Trp Asp Ala Pro Ser Ile  
 325 330 335  
 Val Gly Leu Ile Ile Phe Leu Leu Cys Thr Leu Phe Ile Ser Leu Arg  
 340 345 350  
 Ser Ser Asp His Arg Gln Val Asn Ser Leu Met Gln Thr Glu Glu Cys  
 355 360 365  
 Pro Pro Met Leu Asp Ala Thr Gln Gln Gln Gln Gln Gln Val Ala Ala  
 370 375 380  
 Cys Glu Gly Arg Ala Phe Asp Asn Glu Gln Asp Gly Val Thr Tyr Ser  
 385 390 395 400  
 Tyr Ser Phe Phe His Phe Cys Leu Val Leu Ala Ser Leu His Val Met  
 405 410 415  
 Met Thr Leu Thr Asn Trp Tyr Lys Pro Gly Glu Thr Arg Lys Met Ile  
 420 425 430



Ser Thr Trp Thr Ala Val Trp Val Lys Ile Cys Ala Ser Trp Ala Gly  
 435 440 445

Leu Leu Leu Tyr Leu Trp Thr Leu Val Ala Pro Leu Leu Leu Arg Asn  
 450 455 460

Arg Asp Phe Ser  
 465

<210> 126  
 <211> 44  
 <212> PRT  
 <213> Homo sapiens

<400> 126  
 Arg Cys Ser Ser Ile Phe Thr Pro Trp Lys Leu Thr Thr Leu Ser Ser  
 1 5 10 15  
 Phe Leu His His His Pro Gly Ala Gln Arg Ser Lys Leu Leu Ser Ile  
 20 25 30

Phe Ser Pro Ser Pro Arg Thr Leu Thr Leu Tyr Arg  
 35 40

<210> 127  
 <211> 155  
 <212> PRT  
 <213> Homo sapiens

<400> 127  
 Arg Cys Ser Ser Ile Phe Thr Pro Trp Lys Leu Thr Thr Leu Ser Ser  
 1 5 10 15  
 Phe Leu His His His Pro Gly Ala Gln Arg Ser Lys Leu Leu Ser Ile  
 20 25 30

Phe Ser Pro Ser Pro Arg Thr Leu Thr Leu Tyr Arg Met Gly Pro Ser  
 35 40 45

Ser Cys Leu Leu Leu Ile Leu Ile Pro Leu Leu Gln Leu Ile Asn Leu  
 50 55 60

Gly Ser Thr Gln Cys Ser Leu Asp Ser Val Met Asp Lys Lys Ile Lys  
 65 70 75 80

Asp Val Leu Asn Ser Leu Glu Tyr Ser Pro Ser Pro Ile Ser Lys Lys  
 85 90 95

Leu Ser Cys Ala Ser Val Lys Ser Gln Gly Arg Pro Ser Ser Cys Pro  
 100 105 110

Ala Gly Met Ala Val Thr Gly Cys Ala Cys Gly Tyr Gly Cys Gly Ser  
 115 120 125

Trp Asp Val Gln Leu Glu Thr Thr Cys His Cys Gln Cys Ser Val Val  
 130 135 140

Asp Trp Thr Thr Ala Arg Cys Cys His Leu Thr  
145 150 155

<210> 128  
<211> 41  
<212> PRT  
<213> Homo sapiens

<400> 128  
Ser Val Ser Thr Thr Arg Ser Phe Ser Val Asp Ser Ser Ala Lys Thr  
1 5 10 15  
Ala Ala Met Pro Val Thr Val Thr Arg Thr Thr Ile Thr Thr Thr Thr  
20 25 30  
Thr Ser Ser Ser Gly Leu Gly Ser Pro  
35 40

<210> 129  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 129  
Ser Thr Cys Val Ala Phe Ser Leu Val Ala Ser Val Gly Ala Trp Thr  
1 5 10 15

Gly

<210> 130  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 130  
Met Phe Thr Trp Cys Phe Cys Phe  
1 5

<210> 131  
<211> 6  
<212> PRT  
<213> Homo sapiens

<400> 131  
Ile Leu Ile Val Glu Leu  
1 5

<210> 132  
<211> 22  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 132

Phe	Pro	Leu	Ser	Trp	Arg	Asn	Phe	Pro	Ile	Thr	Phe	Ala	Cys	Tyr	Ala
1				5					10					15	

Ala	Leu	Phe	Cys	Leu	Ser
				20	

&lt;210&gt; 133

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Ser	Ile	Ile	Tyr	Pro	Thr	Thr	Tyr	Val	Gln	Phe	Leu
1				5					10		

&lt;210&gt; 134

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Arg	Asp	His	Ala	Ile	Ala	Ala	Thr
1				5			

&lt;210&gt; 135

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Ala	Tyr	Ala	Thr	Glu	Val	Ala	Trp	Thr	Arg	Ala	Arg	Pro	Gly	Glu	Ile
1				5					10					15	

Thr	Gly	Tyr	Met	Ala	Thr	Val	Pro	Gly	Leu	Leu	Lys	Val
			20					25				

&lt;210&gt; 136

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Glu	Thr	Phe	Val	Ala	Cys	Ile	Ile	Phe	Ala	Phe	Ile
1				5					10		

&lt;210&gt; 137

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

Ala	Leu	Glu	Trp	Cys	Val	Ala	Val	Tyr
1				5				

<210> 138  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 138  
 Cys Thr Asn Val Leu Pro Ile Pro Phe Pro  
     1                    5                    10

<210> 139  
 <211> 442  
 <212> PRT  
 <213> Homo sapiens

<400> 139  
 Gly Leu Asp Thr Gly Glu Met Ser Asn Ser Thr Ser Ser Leu Lys Arg  
     1                    5                    10                    15  
 Gln Arg Leu Gly Ser Glu Arg Ala Ala Ser His Val Ala Gln Ala Asn  
                     20                    25                    30  
 Leu Lys Leu Leu Asp Val Ser Lys Ile Phe Pro Ile Ala Glu Ile Ala  
                     35                    40                    45  
 Glu Glu Ser Ser Pro Glu Val Val Pro Val Glu Leu Leu Cys Met Pro  
     50                    55                    60  
 Ser Pro Ala Ser Gln Gly Asp Leu His Thr Lys Pro Leu Gly Thr Asp  
     65                    70                    75                    80  
 Asp Asp Phe Trp Gly Pro Thr Gly Pro Val Ala Thr Glu Val Val Asp  
                     85                    90                    95  
 Lys Glu Lys Asn Leu Tyr Arg Val His Phe Pro Val Ala Gly Ser Tyr  
                     100                    105                    110  
 Arg Trp Pro Asn Thr Gly Leu Cys Phe Val Met Arg Glu Ala Val Thr  
     115                    120                    125  
 Val Glu Ile Glu Phe Cys Val Trp Asp Gln Phe Leu Gly Glu Ile Asn  
     130                    135                    140  
 Pro Gln His Ser Trp Met Val Ala Gly Pro Leu Leu Asp Ile Lys Ala  
     145                    150                    155                    160  
 Glu Pro Gly Ala Val Glu Ala Val His Leu Pro His Phe Val Ala Leu  
                     165                    170                    175  
 Gln Gly Gly His Val Asp Thr Ser Leu Phe Gln Val Ala His Phe Lys  
                     180                    185                    190  
 Glu Glu Gly Met Leu Leu Glu Lys Pro Ala Arg Val Glu Leu His His  
     195                    200                    205  
 Ile Val Leu Glu Asn Pro Ser Phe Ser Pro Leu Gly Val Leu Leu Lys  
     210                    215                    220

Met Ile His Asn Ala Leu Arg Phe Ile Pro Val Thr Ser Val Val Leu  
 225 230 235 240  
 Leu Tyr His Arg Val His Pro Glu Glu Val Thr Phe His Leu Tyr Leu  
 245 250 255  
 Ile Pro Ser Asp Cys Ser Ile Arg Lys Glu Leu Glu Leu Cys Tyr Arg  
 260 265 270  
 Ser Pro Gly Glu Asp Gln Leu Phe Ser Glu Phe Tyr Val Gly His Leu  
 275 280 285  
 Gly Ser Gly Ile Arg Leu Gln Val Lys Asp Lys Lys Asp Glu Thr Leu  
 290 295 300  
 Val Trp Glu Ala Leu Val Lys Pro Gly Asp Leu Met Pro Ala Thr Thr  
 305 310 315 320  
 Leu Ile Pro Pro Ala Arg Ile Ser Val Pro Ser Pro Leu Asp Ala Pro  
 325 330 335  
 Gln Leu Leu His Phe Val Asp Gln Tyr Arg Glu Gln Leu Ile Ala Arg  
 340 345 350  
 Val Thr Ser Val Glu Val Val Leu Asp Lys Leu His Gly Gln Val Leu  
 355 360 365  
 Ser Gln Glu Gln Tyr Glu Arg Val Leu Ala Glu Asn Thr Arg Pro Ser  
 370 375 380  
 Gln Met Arg Lys Leu Phe Ser Leu Ser Gln Ser Trp Asp Arg Lys Cys  
 385 390 395 400  
 Lys Asp Gly Leu Tyr Gln Ala Leu Lys Glu Thr His Pro His Ser Leu  
 405 410 415  
 Trp Asn Ser Gly Arg Arg Ala Ala Lys Arg Asp Ser Cys His Ser Ala  
 420 425 430  
 Ala Glu Val Ser Thr Leu Ala Leu Asp Pro  
 435 440

<210> 140  
 <211> 64  
 <212> PRT  
 <213> Homo sapiens

<400> 140  
 Gly Leu Asp Thr Gly Glu Met Ser Asn Ser Thr Ser Ser Leu Lys Arg  
 1 5 10 15  
 Gln Arg Leu Gly Ser Glu Arg Ala Ala Ser His Val Ala Gln Ala Asn  
 20 25 30  
 Leu Lys Leu Leu Asp Val Ser Lys Ile Phe Pro Ile Ala Glu Ile Ala  
 35 40 45

Glu Glu Ser Ser Pro Glu Val Val Pro Val Glu Leu Leu Cys Met Pro  
 50 55 60

<210> 141  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<400> 141  
 Ser Pro Ala Ser Gln Gly Asp Leu His Thr Lys Pro Leu Gly Thr Asp  
 1 5 10 15  
 Asp Asp Phe Trp Gly Pro Thr Gly Pro Val Ala Thr Glu Val Val Asp  
 20 25 30  
 Lys Glu Lys Asn Leu Tyr Arg Val His Phe Pro Val Ala Gly Ser Tyr  
 35 40 45  
 Arg Trp Pro Asn Thr Gly Leu Cys Phe Val Met Arg Glu  
 50 55 60

<210> 142  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<400> 142  
 Ala Val Thr Val Glu Ile Glu Phe Cys Val Trp Asp Gln Phe Leu Gly  
 1 5 10 15  
 Glu Ile Asn Pro Gln His Ser Trp Met Val Ala Gly Pro Leu Leu Asp  
 20 25 30  
 Ile Lys Ala Glu Pro Gly Ala Val Glu Ala Val His Leu Pro His Phe  
 35 40 45  
 Val Ala Leu Gln Gly Gly His Val Asp Thr Ser Leu Phe Gln Val  
 50 55 60

<210> 143  
 <211> 65  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Ala His Phe Lys Glu Glu Gly Met Leu Leu Glu Lys Pro Ala Arg Val  
 1 5 10 15  
 Glu Leu His His Ile Val Leu Glu Asn Pro Ser Phe Ser Pro Leu Gly  
 20 25 30  
 Val Leu Leu Lys Met Ile His Asn Ala Leu Arg Phe Ile Pro Val Thr  
 35 40 45

Ser Val Val Leu Leu Tyr His Arg Val His Pro Glu Glu Val Thr Phe  
50 55 60

His  
65

<210> 144  
<211> 65  
<212> PRT  
<213> Homo sapiens

<400> 144  
Leu Tyr Leu Ile Pro Ser Asp Cys Ser Ile Arg Lys Glu Leu Glu Leu  
1 5 10 15

Cys Tyr Arg Ser Pro Gly Glu Asp Gln Leu Phe Ser Glu Phe Tyr Val  
20 25 30

Gly His Leu Gly Ser Gly Ile Arg Leu Gln Val Lys Asp Lys Lys Asp  
35 40 45

Glu Thr Leu Val Trp Glu Ala Leu Val Lys Pro Gly Asp Leu Met Pro  
50 55 60

Ala  
65

<210> 145  
<211> 65  
<212> PRT  
<213> Homo sapiens

<400> 145  
Thr Thr Leu Ile Pro Pro Ala Arg Ile Ser Val Pro Ser Pro Leu Asp  
1 5 10 15

Ala Pro Gln Leu Leu His Phe Val Asp Gln Tyr Arg Glu Gln Leu Ile  
20 25 30

Ala Arg Val Thr Ser Val Glu Val Val Leu Asp Lys Leu His Gly Gln  
35 40 45

Val Leu Ser Gln Glu Gln Tyr Glu Arg Val Leu Ala Glu Asn Thr Arg  
50 55 60

Pro  
65

<210> 146  
<211> 59  
<212> PRT  
<213> Homo sapiens

<400> 146  
Ser Gln Met Arg Lys Leu Phe Ser Leu Ser Gln Ser Trp Asp Arg Lys

93

1                      5                      10                      15  
 Cys Lys Asp Gly Leu Tyr Gln Ala Leu Lys Glu Thr His Pro His Ser  
                     20                      25                      30  
 Leu Trp Asn Ser Gly Arg Arg Ala Ala Lys Arg Asp Ser Cys His Ser  
                     35                      40                      45  
 Ala Ala Glu Val Ser Thr Leu Ala Leu Asp Pro  
                     50                      55

<210> 147  
 <211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 147  
 Ser Glu Gln Leu Pro Thr Ile Ala Gln Ile His Pro Ala Glu Ala Met  
   1                      5                      10                      15

Phe Leu

<210> 148  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 148  
 Tyr Ser Ser Pro Ala Cys Gln His Asp Gln Ala Pro Leu Leu Pro Leu  
   1                      5                      10                      15

Asp Val Thr Asp  
                     20

<210> 149  
 <211> 85  
 <212> PRT  
 <213> Homo sapiens

<400> 149  
 Ala Pro His Arg Ser Gly Ala Ala His Ser Ser Ala Arg Cys Gly Leu  
   1                      5                      10                      15

Ser Ala Ala Glu Arg Pro Arg Gln Phe Arg Thr Lys Arg Cys Gly Gln  
                     20                      25                      30

Ala Thr Gly Pro Ala Gly Asn Ile Met Ala Glu Lys Val Asn Asn Phe  
                     35                      40                      45

Pro Pro Leu Pro Lys Phe Ile Pro Leu Lys Pro Cys Phe Tyr Gln Asp  
                     50                      55                      60

Phe Glu Ala Asp Ile Pro Pro Gln His Val Ser Met Thr Lys Arg Leu  
   65                      70                      75                      80



Tyr Tyr Leu Trp Met  
85

<210> 150  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 150  
Gly Ala Ala His Ser Ser Ala Arg Cys Gly Leu Ser Ala Ala Glu Arg  
1 5 10 15

Pro Arg Gln Phe  
20

<210> 151  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 151  
Ala Thr Gly Pro Ala Gly Asn Ile Met Ala Glu Lys Val Asn Asn Phe  
1 5 10 15

Pro Pro Leu Pro Lys Phe Ile  
20

<210> 152  
<211> 13  
<212> PRT  
<213> Homo sapiens

<400> 152  
Ile Pro Pro Gln His Val Ser Met Thr Lys Arg Leu Tyr  
1 5 10

<210> 153  
<211> 184  
<212> PRT  
<213> Homo sapiens

<400> 153  
His His Gly Arg Glu Ser Glu Gln Leu Pro Thr Ile Ala Gln Ile His  
1 5 10 15

Pro Ala Glu Ala Met Phe Leu Pro Arg Leu Arg Gly Arg Tyr Ser Ser  
20 25 30

Pro Ala Cys Gln His Asp Gln Ala Pro Leu Leu Pro Leu Asp Val Thr  
35 40 45

Asp Ser Ser Phe Ser Phe Met Ala Phe Phe Phe Thr Phe Met Ala Gln  
50 55 60

Leu Val Ile Ser Ile Ile Gln Ala Val Gly Ile Pro Gly Trp Gly Val

65		70		75		80
Cys Gly Trp Ile Ala Thr Ile Ser Phe Phe Gly Thr Asn Ile Gly Ser						
	85			90		95
Ala Val Val Met Leu Ile Pro Thr Val Met Phe Thr Val Met Ala Val						
	100		105			110
Phe Ser Phe Ile Ala Leu Ser Met Val His Lys Phe Tyr Arg Gly Ser						
	115		120			125
Gly Gly Ser Phe Ser Lys Ala Gln Glu Glu Trp Thr Thr Gly Ala Trp						
	130		135			140
Lys Asn Pro His Val Gln Gln Ala Ala Gln Asn Ala Ala Met Gly Ala						
	145		150		155	160
Ala Gln Gly Ala Met Asn Gln Pro Gln Thr Gln Tyr Ser Ala Thr Pro						
	165		170			175
Asn Tyr Thr Tyr Ser Asn Glu Met						
	180					

<210> 154  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<400> 154  
 Ala Arg Glu Ser Ser Asn  
 1 5

<210> 155  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<400> 155  
 Arg Asn Cys Thr Lys Ser Leu Asp His Pro Thr Ser Ala Cys Trp Leu  
 1 5 10 15  
 Phe Pro Asp Asn Gln Phe Gly Glu Ser Glu Pro Arg Pro Ser Lys Glu  
 20 25 30  
 Val Glu Ser Phe Ala Arg Lys Asn Tyr Gly Val Thr Phe Pro Ile Phe  
 35 40 45  
 His Lys Ile Lys Ile Leu Gly Ser Glu Gly Glu Pro Ala Phe Arg Phe  
 50 55 60  
 Leu Val Asp Ser Ser Lys Lys Glu Pro Arg Trp Asn Phe Trp Lys Tyr  
 65 70 75 80  
 Leu Val Asn Pro Glu Gly Gln Val Val Lys Phe Trp Arg Pro Glu Glu  
 85 90 95  
 Pro Ile Glu Val Ile Arg Pro Asp Ile Ala Ala Leu Val Arg Gln Val

```

100              105              110

Ile Ile Lys Lys Lys Glu Asp Leu
      115              120

<210> 156
<211> 24
<212> PRT
<213> Homo sapiens

<400> 156
Ala Cys Trp Leu Phe Pro Asp Asn Gln Phe Gly Glu Ser Glu Pro Arg
 1              5              10              15

Pro Ser Lys Glu Val Glu Ser Phe
      20

<210> 157
<211> 22
<212> PRT
<213> Homo sapiens

<400> 157
Glu Gly Glu Pro Ala Phe Arg Phe Leu Val Asp Ser Ser Lys Lys Glu
 1              5              10              15

Pro Arg Trp Asn Phe Trp
      20

<210> 158
<211> 20
<212> PRT
<213> Homo sapiens

<400> 158
Lys Phe Trp Arg Pro Glu Glu Pro Ile Glu Val Ile Arg Pro Asp Ile
 1              5              10              15

Ala Ala Leu Val
      20

<210> 159
<211> 48
<212> PRT
<213> Homo sapiens

<400> 159
Val Leu Asn Gly Lys Ile Leu Val Asp Ile Ser Asn Asn Leu Lys Ile
 1              5              10              15

Asn Gln Tyr Pro Glu Ser Asn Ala Glu Tyr Leu Ala His Leu Val Pro
      20              25              30

Gly Ala His Val Val Lys Ala Phe Asn Thr Ile Ser Ala Trp Ala Leu
      35              40              45

```

<210> 160  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens

<400> 160  
 Gln Ser Gly Ala Leu Asp Ala Ser Arg Gln Val Phe Val Cys Gly Asn  
 1 5 10 15  
 Asp Ser Lys Ala Lys Gln Arg Val Met Asp Ile Val Arg Asn Leu Gly  
 20 25 30  
 Leu Thr Pro Met Asp Gln Gly Ser Leu Met Ala Ala Lys Glu Ile  
 35 40 45

<210> 161  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<400> 161  
 Glu Lys Tyr Pro Leu Gln Leu Phe Pro Met Trp Arg Phe Pro Phe Tyr  
 1 5 10 15  
 Leu Ser Ala Val Leu Cys Val Phe Leu Phe Phe Tyr Cys Val Ile Arg  
 20 25 30  
 Asp Val Ile Tyr Pro Tyr Val Tyr Glu Lys Lys Asp Asn Thr Phe Arg  
 35 40 45

<210> 162  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 162  
 Lys Lys Thr Asn Lys Thr Lys Thr Tyr Tyr  
 1 5 10

<210> 163  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (18)  
 <223> Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 163

Arg Ala Pro Pro Ser Ser Val Tyr Gln Asn Gln Gln Ala Arg Ala Gln  
1 5 10 15

Leu Xaa Asp Phe Cys  
20

&lt;210&gt; 164

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 164

Thr Thr Cys Tyr Leu Asn Thr Tyr Met Phe Asn Ile Asn Thr Tyr Ile  
1 5 10 15

Lys Phe Thr Cys Ile Leu Asn Thr Tyr Val Lys Tyr Ile Gln Cys Ile  
20 25 30

Tyr Ile Cys Thr Gln Tyr  
35

&lt;210&gt; 165

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 165

Cys Arg Asn Ser Ala Arg Ala Pro Ile Lys Asn Leu Asn Pro Leu Pro  
1 5 10 15

Thr Gln Lys His Cys Val Phe Leu  
20

&lt;210&gt; 166

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 166

Thr Arg Pro Lys Lys Glu Ala Gly Arg Ile Ser Thr Val Glu Leu Gln  
1 5 10 15

Lys

&lt;210&gt; 167

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 167

His Glu Arg Arg His Glu Ala Ala Gly Pro Ala Ala Pro  
1 5 10

<210> 168  
 <211> 153  
 <212> PRT  
 <213> Homo sapiens

<400> 168  
 Met Val Pro Asn Gln Arg Pro Glu Pro Cys Ala Leu Pro His Ser Ser  
           1                          5                          10                          15  
 Lys Leu Pro Lys Ser Lys Pro Pro His Asp His Thr Ser Cys Gly His  
                           20                          25                          30  
 Ser Leu Cys Pro Cys Ala Ser Arg Thr Glu Ala Pro Gly Arg Pro Trp  
                           35                          40                          45  
 Gly Leu Leu Cys Arg Leu His Leu His Gly Arg Thr Glu His Ser Val  
           50                          55                          60  
 Cys Val Ala Gly Gln Gly Ser Asp Ser Ala Lys Ala Ala Ala His Pro  
           65                          70                          75                          80  
 Ser Val Gln Gly Glu Trp Asn Pro His Ala Gly His Leu Pro Phe Leu  
                           85                          90                          95  
 Pro Asp Pro Ser Leu Pro Leu His Val Leu Val Leu Trp Pro Pro Ala  
                           100                          105                          110  
 Gly Thr Lys Pro Ala Pro Ser Thr Leu Gln His Pro Ile Leu Leu Gln  
                           115                          120                          125  
 Arg Gly Gln Cys Leu Pro Arg Ser Ser Ser Asp Leu Leu Val Leu Ser  
           130                          135                          140  
 Ala Val Gln Glu Gly Ser Pro Ala Leu  
           145                          150

<210> 169  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<400> 169  
 Cys Ala Leu Pro His Ser Ser Lys Leu Pro Lys Ser Lys Pro Pro His  
           1                          5                          10                          15  
 Asp His Thr Ser Cys  
                           20

<210> 170  
 <211> 24  
 <212> PRT  
 <213> Homo sapiens

<400> 170  
 Glu Ala Pro Gly Arg Pro Trp Gly Leu Leu Cys Arg Leu His Leu His

100

1 5 10 15  
 Gly Arg Thr Glu His Ser Val Cys  
 20

<210> 171  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 171  
 Gln Gly Ser Asp Ser Ala Lys Ala Ala Ala His Pro Ser Val Gln Gly  
 1 5 10 15  
 Glu Trp Asn Pro His Ala Gly His Leu  
 20 25

<210> 172  
 <211> 24  
 <212> PRT  
 <213> Homo sapiens

<400> 172  
 Ala Pro Ser Thr Leu Gln His Pro Ile Leu Leu Gln Arg Gly Gln Cys  
 1 5 10 15  
 Leu Pro Arg Ser Ser Ser Asp Leu  
 20

<210> 173  
 <211> 11  
 <212> PRT  
 <213> Homo sapiens

<400> 173  
 Ser Val His Ala Val Leu Ala Thr Gly Ser Gly  
 1 5 10

<210> 174  
 <211> 246  
 <212> PRT  
 <213> Homo sapiens

<400> 174  
 Thr Arg Pro Val Ser Cys Leu Thr Ala Gly Val Leu Asn Pro Glu Leu  
 1 5 10 15  
 Gly Tyr Asp Ala Leu Leu Val Gly Thr Gln Thr Asn Leu Leu Ala Tyr  
 20 25 30  
 Asp Val Tyr Asn Asn Ser Asp Leu Phe Tyr Arg Glu Val Ala Asp Gly  
 35 40 45  
 Ala Asn Ala Ile Val Leu Gly Thr Leu Gly Asp Ile Ser Ser Pro Leu  
 50 55 60

Ala Ile Ile Gly Gly Asn Cys Ala Leu Gln Gly Phe Asn His Glu Gly  
 65 70 75 80  
 Ser Asp Leu Phe Trp Thr Val Thr Gly Asp Asn Val Asn Ser Leu Ala  
 85 90 95  
 Leu Cys Asp Phe Asp Gly Asp Gly Lys Lys Glu Leu Leu Val Gly Ser  
 100 105 110  
 Glu Asp Phe Asp Ile Arg Val Phe Lys Glu Asp Glu Ile Val Ala Glu  
 115 120 125  
 Met Thr Glu Thr Glu Ile Val Thr Ser Leu Cys Pro Met Tyr Gly Ser  
 130 135 140  
 Arg Phe Gly Tyr Ala Leu Ser Asn Gly Thr Val Gly Val Tyr Asp Lys  
 145 150 155 160  
 Thr Ser Arg Tyr Trp Arg Ile Lys Ser Lys Asn His Ala Met Ser Ile  
 165 170 175  
 His Val Phe Asp Leu Asn Ser Asp Gly Val Asn Glu Leu Ile Thr Gly  
 180 185 190  
 Trp Ser Asn Gly Lys Val Asp Ala Arg Ser Asp Arg Thr Gly Glu Val  
 195 200 205  
 Ile Phe Lys Asp Asn Phe Ser Ser Ala Ile Ala Gly Val Val Glu Gly  
 210 215 220  
 Asp Tyr Arg Met Asp Gly His Ile Gln Leu Ile Cys Cys Ser Val Asp  
 225 230 235 240  
 Gly Glu Ser Lys Leu Gly  
 245

<210> 175  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<400> 175  
 Thr Arg Pro Val Ser Cys Leu Thr Ala Gly Val Leu Asn Pro Glu Leu  
 1 5 10 15  
 Gly Tyr Asp Ala Leu Leu Val Gly Thr Gln Thr Asn Leu Leu Ala Tyr  
 20 25 30  
 Asp Val Tyr Asn Asn Ser Asp Leu Phe Tyr Arg Glu Val Ala Asp Gly  
 35 40 45  
 Ala Asn Ala Ile  
 50

<210> 176  
 <211> 53



<212> PRT  
<213> Homo sapiens

<400> 176  
Val Leu Gly Thr Leu Gly Asp Ile Ser Ser Pro Leu Ala Ile Ile Gly  
1 5 10 15  
Gly Asn Cys Ala Leu Gln Gly Phe Asn His Glu Gly Ser Asp Leu Phe  
20 25 30  
Trp Thr Val Thr Gly Asp Asn Val Asn Ser Leu Ala Leu Cys Asp Phe  
35 40 45  
Asp Gly Asp Gly Lys  
50

<210> 177  
<211> 54  
<212> PRT  
<213> Homo sapiens

<400> 177  
Lys Glu Leu Leu Val Gly Ser Glu Asp Phe Asp Ile Arg Val Phe Lys  
1 5 10 15  
Glu Asp Glu Ile Val Ala Glu Met Thr Glu Thr Glu Ile Val Thr Ser  
20 25 30  
Leu Cys Pro Met Tyr Gly Ser Arg Phe Gly Tyr Ala Leu Ser Asn Gly  
35 40 45  
Thr Val Gly Val Tyr Asp  
50

<210> 178  
<211> 37  
<212> PRT  
<213> Homo sapiens

<400> 178  
Lys Thr Ser Arg Tyr Trp Arg Ile Lys Ser Lys Asn His Ala Met Ser  
1 5 10 15  
Ile His Val Phe Asp Leu Asn Ser Asp Gly Val Asn Glu Leu Ile Thr  
20 25 30  
Gly Trp Ser Asn Gly  
35

<210> 179  
<211> 50  
<212> PRT  
<213> Homo sapiens

<400> 179  
Lys Val Asp Ala Arg Ser Asp Arg Thr Gly Glu Val Ile Phe Lys Asp

103

1                      5                      10                      15  
 Asn Phe Ser Ser Ala Ile Ala Gly Val Val Glu Gly Asp Tyr Arg Met  
                          20                                      25                                      30  
 Asp Gly His Ile Gln Leu Ile Cys Cys Ser Val Asp Gly Glu Ser Lys  
                          35                                      40                                      45  
 Leu Gly  
                          50

<210> 180  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<400> 180  
 His Ala Ser Gly Arg Gly Ala Gly Gly Gly Gly Gly Gly Gly Arg  
                          1                                      5                                      10                                      15  
 Asp Pro Ala Gly Gln Val Gly Thr Ala Arg Ser Gly Cys Gly Arg Cys  
                          20                                      25                                      30  
 Arg Ala Gly Leu Gly Pro Pro Glu Pro Pro Ala Ser Ser Pro Pro Ser  
                          35                                      40                                      45  
 Val Gly Arg Met Cys Ala Arg  
                          50                                      55

<210> 181  
 <211> 287  
 <212> PRT  
 <213> Homo sapiens

<400> 181  
 Thr Thr Ser Pro Ser Trp Ala Thr Ser Leu Leu Arg Gly Cys Gln Ala  
                          1                                      5                                      10                                      15  
 Lys Gly Pro Thr Lys Ser Arg Leu Met Ser Ser Arg Gly Thr Glu Leu  
                          20                                      25                                      30  
 Arg Thr Ala Ser Val Lys Leu Ala Lys Gly Ser Thr Ser Arg Glu Val  
                          35                                      40                                      45  
 Pro Arg Met Ser Ser Arg Ser Ala Met Gly Lys Ser Thr Thr Cys Ser  
                          50                                      55                                      60  
 Lys Asn Leu Trp Gly Ser Gly Ser Gln Arg Thr Gln Cys Arg Ala Ser  
                          65                                      70                                      75                                      80  
 Gln Arg Arg Cys Arg Pro Gly Ser Gly Glu Pro Cys Leu Pro Ser Arg  
                          85                                      90                                      95  
 Gln Pro Glu Cys Pro Pro Leu Gly Arg Val Phe Gly Arg Leu Cys Arg  
                          100                                      105                                      110  
 Trp Gln Arg Gln Arg Phe His Glu Leu Gln Pro Ala Leu Arg Gln Gly

115	120	125
Cys Pro Thr Leu Lys Phe Lys Pro Lys Arg Ser Val Ala Ala Ala Ser		
130	135	140
Glu Met Ser Thr Gln Gly Gln Glu His Asn Phe Trp Ala Trp Gln Asp		
145	150	155
Ser Ser Leu Lys Pro Ile Asp Val Leu Arg Val Glu Pro Gln Lys Gln		
165	170	175
Pro Leu Val Met Lys Gln Pro Glu Lys Val Val Ser Asp Val Gly Leu		
180	185	190
Val Val Ser Arg Val Gln Leu Leu Gly Gln Ser Glu Lys Gly Leu Gly		
195	200	205
Val Val Lys Glu Glu Trp Glu Phe Lys Asn Gly Leu Gly Val Arg Glu		
210	215	220
Ile Val Leu Leu Glu Val Ala Val Gln Ala Thr Pro Arg Arg Ser Glu		
225	230	235
Val Trp Asn Ala Thr Gly Cys Ala Asp Ala Gly Pro His His Asp His		
245	250	255
His Pro Leu Ala Gly Ser Gly Pro Asn Gln Leu Ser Tyr Ile Leu Gln		
260	265	270
Gly Lys Leu Pro Leu Val Thr Ala Ala Ser Thr Ser Asn Asn Thr		
275	280	285

<210> 182  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens

<400> 182  
 Leu Leu Arg Gly Cys Gln Ala Lys Gly Pro Thr Lys Ser Arg Leu Met  
 1 5 10 15  
 Ser Ser Arg Gly Thr Glu Leu Arg Thr Ala  
 20 25

<210> 183  
 <211> 23  
 <212> PRT  
 <213> Homo sapiens

<400> 183  
 Met Gly Lys Ser Thr Thr Cys Ser Lys Asn Leu Trp Gly Ser Gly Ser  
 1 5 10 15  
 Gln Arg Thr Gln Cys Arg Ala  
 20

105

<210> 184  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 184  
Gly Ser Gly Glu Pro Cys Leu Pro Ser Arg Gln Pro Glu Cys Pro Pro  
1 5 10 15  
Leu Gly Arg Val Phe Gly Arg Leu Cys Arg  
20 25

<210> 185  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 185  
Pro Thr Leu Lys Phe Lys Pro Lys Arg Ser Val Ala Ala Ala Ser Glu  
1 5 10 15  
Met Ser Thr Gln Gly Gln Glu His  
20

<210> 186  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 186  
Trp Gln Asp Ser Ser Leu Lys Pro Ile Asp Val Leu Arg Val Glu Pro  
1 5 10 15  
Gln Lys Gln Pro Leu Val Met Lys Gln Pro  
20 25

<210> 187  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 187  
Val Ala Val Gln Ala Thr Pro Arg Arg Ser Glu Val Trp Asn Ala Thr  
1 5 10 15  
Gly Cys Ala Asp Ala Gly Pro  
20

<210> 188  
<211> 223  
<212> PRT  
<213> Homo sapiens

<400> 188  
Asp Trp Leu Leu Ser Val Ser Phe Ala Ala Val Phe Phe Ser Val Ser

```
<210> 190
<211> 23
<212> PRT
<213> Homo sapiens
```

&lt;400&gt; 190

Lys Leu Ser Leu Gln Asp Val Ala Glu Leu Ile Arg Ala Arg Ala Cys  
1 5 10 15

Gln Arg Val Val Val Met Val  
20

&lt;210&gt; 191

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

Tyr Ser Asn Leu Gln Gln Tyr Asp Leu Pro Tyr Pro Glu Ala Ile Phe  
1 5 10 15

Glu Leu Pro Phe Phe Phe His Asn  
20

&lt;210&gt; 192

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 192

Leu Tyr Pro Gly Asn Tyr Lys Pro Asn Val Thr His Tyr Phe Leu Arg  
1 5 10 15

Leu Leu His Asp Lys Gly Leu Leu  
20

&lt;210&gt; 193

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 193

Leu Pro Ser Pro Glu Val Val Leu Leu Ala Leu Arg Ala His Leu Gly  
1 5 10 15

Gly Gly Ser Asn Thr Ser Leu Trp Leu Glu Phe  
20 25

&lt;210&gt; 194

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 194

Arg Asp Gly Arg Gln Gly Ser Pro Leu Pro Gly Leu His Arg Arg Cys  
1 5 10 15

Glu Ala Arg His Cys Val Leu Trp Glu Pro Leu Pro Gln Arg Phe Leu  
20 25 30

Leu His Val Val Asp Phe Pro Met Ala Asp Leu Leu Leu Ile Leu Gly  
35 40 45

Thr Ser Leu Glu Val Glu Pro Phe Ala Ser Leu Thr Glu Ala Val Arg  
50 55 60

Ser Ser Val Pro Arg Leu Leu Ile Asn Arg Asp Leu Val Gly Pro Leu  
65 70 75 80

Ala Trp His Pro Arg Ser Arg Asp Val Ala Gln Leu Gly Asp Val Val  
85 90 95

His Gly Val Glu Ser Leu Val Glu Leu Leu Gly Trp Thr Glu Glu Met  
100 105 110

Arg Asp Leu Val Gln Arg Glu Thr Gly Lys Leu Asp Gly Pro Asp Lys  
115 120 125

<210> 195  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 195  
Leu Pro Gly Leu His Arg Arg Cys Glu Ala Arg His Cys Val Leu Trp  
1 5 10 15

Glu Pro Leu Pro Gln Arg Phe Leu  
20

<210> 196  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 196  
Val Val Asp Phe Pro Met Ala Asp Leu Leu Leu Ile Leu Gly Thr Ser  
1 5 10 15

Leu Glu Val Glu Pro Phe Ala Ser Leu  
20 25

<210> 197  
<211> 22  
<212> PRT  
<213> Homo sapiens

<400> 197  
Leu Val Gly Pro Leu Ala Trp His Pro Arg Ser Arg Asp Val Ala Gln  
1 5 10 15

Leu Gly Asp Val Val His

20

&lt;210&gt; 198

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 198

Val	Glu	Ser	Leu	Val	Glu	Leu	Leu	Gly	Trp	Thr	Glu	Glu	Met	Arg	Asp
1				5					10					15	

Leu	Val	Gln	Arg	Glu	Thr	Gly
				20		

&lt;210&gt; 199

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 199

Ile	Ser	Val	Ser	Gly	Ile	Pro	Ala	Ser	Lys	Leu	Val	Glu	Ala	His	Gly
1				5					10					15	

Thr	Phe	Ala	Ser	Ala	Thr	Cys	Thr	Val	Cys	Gln	Arg	Pro	Phe	Pro	Gly
			20					25					30		

Glu	Asp	Ile	Arg	Ala	Asp	Val	Met	Ala	Asp	Arg	Val	Pro	Arg	Cys	Pro
	35						40					45			

Val	Cys	Thr	Gly	Val	Val	Lys	Pro	Asp	Ile	Val	Phe	Phe	Gly	Ser	Arg
	50					55					60				

Cys	Pro	Arg	Gly	Ser	Cys	Cys	Met	Trp	Leu	Ile	Ser	Pro	Trp	Gln	Ile
65					70					75				80	

Cys	Cys	Ser	Ser	Leu	Gly	Pro	Pro	Trp	Arg	Trp	Ser	Leu	Leu	Pro	Ala
				85					90					95	

&lt;210&gt; 200

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 200

Glu	Ala	His	Gly	Thr	Phe	Ala	Ser	Ala	Thr	Cys	Thr	Val	Cys	Gln	Arg
1				5					10					15	

Pro	Phe	Pro	Gly	Glu	Asp	Ile	Arg	Ala	Asp	Val	Met	Ala	Asp	Arg	Val
			20					25					30		

Pro



110

<210> 201  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

<400> 201  
 Phe Phe Gly Ser Arg Cys Pro Arg Gly Ser Cys Cys Met Trp Leu Ile  
     1                    5                    10                    15  
 Ser Pro Trp Gln Ile Cys Cys Ser Ser Leu Gly  
                     20                    25

<210> 202  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<400> 202  
 Thr Arg Pro Leu Ser Pro Thr Phe Ser Lys Leu Trp Ala Ala Gly Val  
     1                    5                    10                    15  
 Thr Val Cys Thr Asp Phe Ser Met Cys Val Cys Gly Cys Met Tyr Glu  
                     20                    25                    30  
 Cys Val Cys Val Phe Val Cys Leu Cys Ile Tyr Arg Gly Met Arg Val  
                     35                    40                    45  
 Pro Trp Val Cys Thr Leu Asp Ile Pro Leu Tyr Ile Leu Cys Val Leu  
                     50                    55                    60  
 Thr Trp Thr His Ser Val Tyr Leu Tyr Cys Val Tyr Thr His Val Gln  
     65                    70                    75                    80  
 Pro Ile Cys Pro Tyr Ile Gly Val Cys Val Tyr Tyr Val Cys Thr Leu  
                     85                    90                    95  
 Ser Thr Tyr Gly Cys Val Cys Val Pro Leu Ser Pro Tyr Leu Gly Glu  
                     100                    105                    110  
 Arg Glu Asn Val Cys Val Cys Val Ser Met Tyr Gly Cys Val Asp Ile  
                     115                    120                    125  
 Leu Cys Leu Tyr Leu Glu Cys Arg Tyr Met Asp Val His Val Leu Cys  
                     130                    135                    140  
 Val Cys Val Arg Thr His Thr Leu Pro Leu Cys Val Cys Ala Cys Val  
     145                    150                    155                    160  
 Tyr Leu Val Cys Pro Cys Ile Gly Gly Val Cys Thr Leu Leu Val Tyr  
                     165                    170                    175  
 Val Trp Gly Ser Thr Cys Ser Leu  
                     180

<210> 203  
 <211> 55

111

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 203

Ala Ser Leu Ile Phe Ser Ser Pro Leu Ser Pro Leu Leu Thr Ser Pro  
 1 5 10 15

Ser Ser Ser Ile Cys Ser Val Arg Pro Leu Gly Ile Val Met Ile Thr  
 20 25 30

Cys Phe His Ser Arg Cys His Leu Lys Gln Arg Pro Ala Ser Pro Asn  
 35 40 45

Gly Val Phe Gln Gln Arg Ala  
 50 55

&lt;210&gt; 204

&lt;211&gt; 43

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 204

Ala His Leu Ser Pro Thr Ala Ala Leu His Val Ala Gln Gly Glu Ser  
 1 5 10 15

Leu Ser Thr Asp Val Glu Cys Arg Val Pro Gly Leu Met Leu Thr Leu  
 20 25 30

Leu Leu Ala Val His Gln Gln Ile Leu Val Gly  
 35 40

&lt;210&gt; 205

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 205

Leu Pro Val Gln Val Gly Trp Ser Leu Cys Asn Thr Asp Gly Pro Lys  
 1 5 10 15

Leu Leu Cys Gly Arg Gln Gly Leu Met Leu Leu Thr Gly His Cys  
 20 25 30

Gln Ala Ser Lys His Lys Ser Gln Gly Leu  
 35 40

&lt;210&gt; 206

&lt;211&gt; 140

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 206

Ala Ser Leu Ile Phe Ser Ser Pro Leu Ser Pro Leu Leu Thr Ser Pro  
 1 5 10 15

Ser Ser Ser Ile Cys Ser Val Arg Pro Leu Gly Ile Val Met Ile Thr

112

20 25 30  
 Cys Phe His Ser Arg Cys His Leu Lys Gln Arg Pro Ala Ser Pro Asn  
 35 40 45  
 Gly Val Phe Gln Gln Arg Ala Ala His Leu Ser Pro Thr Ala Ala Leu  
 50 55 60  
 His Val Ala Gln Gly Glu Ser Leu Ser Thr Asp Val Glu Cys Arg Val  
 65 70 75 80  
 Pro Gly Leu Met Leu Thr Leu Leu Leu Ala Val His Gln Gln Ile Leu  
 85 90 95  
 Val Gly Leu Pro Val Gln Val Gly Trp Ser Leu Cys Asn Thr Asp Gly  
 100 105 110  
 Pro Lys Leu Leu Cys Gly Arg Gln Gly Leu Met Leu Leu Thr Gly His  
 115 120 125  
 His Cys Gln Ala Ser Lys His Lys Ser Gln Gly Leu  
 130 135 140

<210> 207  
 <211> 219  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (169)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (211)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 207  
 Val Glu Ala Glu Trp Leu Gln Asp Val Gly Leu Ser Thr Leu Ile Ser  
 1 5 10 15  
 Gly Asp Glu Glu Glu Asp Gly Lys Ala Leu Leu Ser Thr Leu Thr Arg  
 20 25 30  
 Thr Gln Ala Ala Ala Val Gln Lys Arg Tyr His Thr Tyr Thr Gln Thr  
 35 40 45  
 Met Arg Lys Lys Asp Lys Gln Ser Ile Arg Asp Val Arg Asp Ile Phe  
 50 55 60  
 Gly Val Ser Glu Ser Pro Pro Arg Asp Thr Cys Gly Asn His Thr Asn  
 65 70 75 80  
 Gln Leu Asp Gly Thr Lys Glu Glu Arg Glu Leu Pro Arg Val Ile Lys  
 85 90 95  
 Thr Ser Gly Ser Met Pro Asp Asp Ala Ser Leu Asn Ser Thr Thr Leu

100	105	110
Ser Asp Ala Ser Gln Asp Lys Glu Gly Ser Phe Ala Val Pro Arg Ser		
115	120	125
Asp Ser Val Ala Ile Leu Glu Thr Ile Pro Val Leu Pro Val His Ser		
130	135	140
Asn Gly Ser Pro Glu Pro Gly Gln Pro Val Gln Asn Ala Ile Ser Asp		
145	150	155
Asp Asp Phe Leu Glu Lys Asn Ile Xaa Pro Glu Ala Glu Glu Leu Ser		
165	170	175
Phe Glu Val Ser Tyr Ser Glu Met Val Thr Glu Ala Leu Lys Arg Asn		
180	185	190
Lys Leu Lys Lys Ser Glu Ile Lys Lys Glu Asp Tyr Val Leu Thr Lys		
195	200	205
Phe Asn Xaa Gln Lys Thr Arg Phe Gly Leu Thr		
210	215	

<210> 208  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 208  
 Val Glu Ala Glu Trp Leu Gln Asp Val Gly Leu Ser Thr Leu Ile Ser  
     1                    5                    10                    15  
 Gly Asp Glu Glu Glu Asp Gly Lys Ala Leu Leu Ser Thr Leu Thr Arg  
             20                    25                    30  
 Thr Gln Ala Ala Ala Val Gln Lys Arg Tyr His Thr Tyr Thr Gln Thr  
             35                    40                    45  
 Met Arg  
     50

<210> 209  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<400> 209  
 Lys Lys Asp Lys Gln Ser Ile Arg Asp Val Arg Asp Ile Phe Gly Val  
     1                    5                    10                    15  
 Ser Glu Ser Pro Pro Arg Asp Thr Cys Gly Asn His Thr Asn Gln Leu  
             20                    25                    30  
 Asp Gly Thr Lys Glu Glu Arg Glu Leu Pro Arg Val Ile Lys Thr Ser  
             35                    40                    45  
 Gly Ser Met Pro Asp Asp

114

50

<210> 210  
<211> 52  
<212> PRT  
<213> Homo sapiens

<400> 210  
Ala Ser Leu Asn Ser Thr Thr Leu Ser Asp Ala Ser Gln Asp Lys Glu  
1 5 10 15  
Gly Ser Phe Ala Val Pro Arg Ser Asp Ser Val Ala Ile Leu Glu Thr  
20 25 30  
Ile Pro Val Leu Pro Val His Ser Asn Gly Ser Pro Glu Pro Gly Gln  
35 40 45  
Pro Val Gln Asn  
50

<210> 211  
<211> 63  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (13)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 211  
Ala Ile Ser Asp Asp Asp Phe Leu Glu Lys Asn Ile Xaa Pro Glu Ala  
1 5 10 15  
Glu Glu Leu Ser Phe Glu Val Ser Tyr Ser Glu Met Val Thr Glu Ala  
20 25 30  
Leu Lys Arg Asn Lys Leu Lys Lys Ser Glu Ile Lys Lys Glu Asp Tyr  
35 40 45  
Val Leu Thr Lys Phe Asn Xaa Gln Lys Thr Arg Phe Gly Leu Thr  
50 55 60

<210> 212  
<211> 32  
<212> PRT  
<213> Homo sapiens

<400> 212  
Leu Ala Gln Thr Val Thr Asp Met Pro Leu Thr Gly Thr Asn His Asp  
1 5 10 15

115

Arg Gln Gly His Leu Leu Arg Ser Gly Thr Thr Tyr Tyr Leu Leu Ala  
                   20                  25                  30

&lt;210&gt; 213

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 213

Leu Ser Phe Leu Glu Leu Asp Ser Glu Cys Ser  
       1                  5                  10

&lt;210&gt; 214

&lt;211&gt; 83

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 214

Trp Trp Ser Leu Glu Thr Arg Met Arg Thr Ala Arg Val Pro Met Arg  
       1                  5                  10                  15

Pro Ser Trp Thr Arg Thr Pro Ser Phe Ala Arg Ala Leu Lys Phe Ser  
                   20                  25                  30

Thr Gln Ser Trp Gly Thr Leu Ala Ala Arg Leu Phe Leu Ile Val Thr  
           35                  40                  45

Thr Thr Asp Arg Arg Ser Pro Pro Gly Trp Lys Pro Ile Val Lys Phe  
       50                  55                  60

Pro Gly Ala Val Asp Gly Ala Thr Tyr Asn Pro Gly Asp Gly Gly Ser  
       65                  70                  75                  80

Arg Cys Pro

&lt;210&gt; 215

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 215

Met Arg Thr Ala Arg Val Pro Met Arg Pro Ser Trp Thr Arg Thr Pro  
       1                  5                  10                  15

Ser Phe Ala Arg  
           20

&lt;210&gt; 216

&lt;211&gt; 21

&lt;212&gt; PRT

<213> Homo sapiens

<400> 216

Pro Gly Trp Lys Pro Ile Val Lys Phe Pro Gly Ala Val Asp Gly Ala  
1 5 10 15

Thr Tyr Asn Pro Gly  
20

<210> 217

<211> 149

<212> PRT

<213> Homo sapiens

<400> 217

Ser Ser Ser Arg Gly Pro Trp Thr Ala Gln Pro Ile Ile Leu Val Met  
1 5 10 15

Val Asp Pro Asp Ala Pro Ser Arg Ala Glu Pro Arg Gln Arg Phe Trp  
20 25 30

Arg His Trp Leu Val Thr Asp Ile Lys Gly Ala Asp Leu Lys Lys Gly  
35 40 45

Lys Ile Gln Gly Gln Glu Leu Ser Ala Tyr Gln Ala Pro Ser Pro Pro  
50 55 60

Ala His Ser Gly Phe His Arg Tyr Gln Phe Phe Val Tyr Leu Gln Glu  
65 70 75 80

Gly Lys Val Ile Ser Leu Leu Pro Lys Glu Asn Lys Thr Arg Gly Ser  
85 90 95

Trp Lys Met Asp Arg Phe Leu Asn Arg Phe His Leu Gly Glu Pro Glu  
100 105 110

Ala Ser Thr Gln Phe Met Thr Gln Asn Tyr Gln Asp Ser Pro Thr Leu  
115 120 125

Gln Ala Pro Arg Glu Arg Ala Ser Glu Pro Lys His Lys Asn Gln Ala  
130 135 140

Glu Ile Ala Ala Cys  
145

<210> 218

<211> 24

<212> PRT

<213> Homo sapiens

<400> 218

Pro Ile Ile Leu Val Met Val Asp Pro Asp Ala Pro Ser Arg Ala Glu  
1 5 10 15

Pro Arg Gln Arg Phe Trp Arg His  
20

<210> 219  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 219  
Lys Ile Gln Gly Gln Glu Leu Ser Ala Tyr Gln Ala Pro Ser Pro Pro  
1 5 10 15  
Ala His Ser Gly Phe His Arg  
20

<210> 220  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 220  
Ile Ser Leu Leu Pro Lys Glu Asn Lys Thr Arg Gly Ser Trp Lys Met  
1 5 10 15  
Asp Arg Phe Leu  
20

<210> 221  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 221  
Gln Glu Leu Ser Ala Tyr Gln Ala Pro Ser Pro Pro Ala His Ser Gly  
1 5 10 15  
Phe

<210> 222  
<211> 8  
<212> PRT  
<213> Homo sapiens

<400> 222  
Pro Glu Val Pro Met Gly Trp Thr  
1 5

<210> 223  
<211> 86  
<212> PRT  
<213> Homo sapiens

<400> 223  
Met Arg Leu Val Thr Ala Ala Leu Leu Leu Gly Leu Met Met Val Val  
1 5 10 15



```
<210> 224
<211> 84
<212> PRT
<213> Homo sapiens
```

```

<400> 224
Pro Ile Leu Trp Gly Asn Arg Val Pro Met Glu Pro Gln Lys Cys His
  1                               5                               10                               15
Pro Ala Gly Trp His Gly Leu Gly Gln Glu Ala Glu Ala Gly Asp Gln
                               20                               25                               30
Asp Gly Arg Trp Arg Pro Gly Leu Pro Gln Arg Lys Arg Pro Pro Ala
                               35                               40                               45
Gly Ala Gly Gln Ala Trp Leu Ser Cys His Arg His Met Val Glu Arg
                               50                               55                               60
Gly Val Pro Cys Pro Pro Trp Gly Gly Gly Thr Arg Ala Leu Val Tyr
  65                               70                               75                               80
Ser Asp Ala Gly

```

```
<210> 225
<211> 26
<212> PRT
<213> Homo sapiens
```

```

<400> 225
Pro Met Glu Pro Gln Lys Cys His Pro Ala Gly Trp His Gly Leu Gly
  1             5             10             15
Gln Glu Ala Glu Ala Gly Asp Gln Asp Gly
      20             25

```

```
<210> 226
<211> 28
<212> PRT
<213> Homo sapiens
```

&lt;400&gt; 226

Ala Gly Ala Gly Gln Ala Trp Leu Ser Cys His Arg His Met Val Glu  
 1 5 10 15

Arg Gly Val Pro Cys Pro Pro Trp Gly Gly Gly Thr  
 20 25

&lt;210&gt; 227

&lt;211&gt; 136

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 227

Ser Pro Xaa Thr His Val Gln Gly Gln Thr Gly Met Tyr Val Ile Trp  
 1 5 10 15

Gly Leu Gly Gly Gly Leu Pro Arg Gly His Pro Pro Leu Leu Gly Pro  
 20 25 30

Pro Trp Pro Asp Pro Phe Cys Gly Glu Thr Gly Cys Pro Trp Ser Leu  
 35 40 45

Arg Asn Ala Thr Arg Leu Val Gly Met Ala Trp Gly Arg Arg Gln Arg  
 50 55 60

Gln Glu Thr Lys Met Ala Gly Gly Gly Gln Ala Tyr His Asn Gly Arg  
 65 70 75 80

Asp Leu Pro Leu Gly Pro Gly Arg Pro Gly Ser Ala Ala Thr Gly Ile  
 85 90 95

Trp Trp Arg Gly Gly Tyr Pro Ala His Leu Gly Val Val Ala Pro Glu  
 100 105 110

Leu Leu Ser Ile Gln Thr Leu Val Trp Gly Leu Gly Pro Leu Thr Gly  
 115 120 125

Asp Arg Ala Ser Val Gly Glu Phe  
 130 135

&lt;210&gt; 228

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 228

Trp Gly Leu Gly Gly Gly Leu Pro Arg Gly His Pro Pro Leu Leu Gly  
 1 5 10 15

Pro Pro Trp Pro Asp Pro Phe Cys Gly  
 20 25

<210> 229  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 229  
Gln Arg Gln Glu Thr Lys Met Ala Gly Gly Gly Gln Ala Tyr His Asn  
1 5 10 15  
Gly Arg Asp Leu Pro Leu Gly Pro Gly Arg  
20 25

<210> 230  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 230  
His Leu Gly Val Val Ala Pro Glu Leu Leu Ser Ile Gln Thr Leu Val  
1 5 10 15  
Trp Gly Leu Gly  
20

## INTERNATIONAL SEARCH REPORT

International application No.  
US99/29950

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C07K 14/47; C12N 1/21, 15/12, 15/64; C12P 21/02

US CL : 536/23.5; 530/350; 435/69.1, 252.3, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 530/350; 435/69.1, 252.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

SEQUENCE DATABASE MPSRCH: EST, GenEmbl, N\_Geneseq\_36, SwissProt\_38, A\_Geneseq\_36, n-issued, a-issued, PIR62, SPTREMBL12 (SEQ ID NOS: 11 and 62).

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EST, WashU-NCI human EST Project, (St. Louis, MO USA), AN AA705532, HILLIER et al. zj92d09.s1 Soares fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:462353 3', mRNA sequence. December 1997.	1, 2, 5-10
X	WO 91/04328 A1 (THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION) 04 April 1991 (04/04/91), see Figure 2, amino acids 3438-3444, and claim 12.	1, 7-11, 14-16
A	US 5,958,731 A (YUE et al)28 September 1999 (28/09/99), see entire document.	1-12, 14-16 and 21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 MARCH 2000

Date of mailing of the international search report

11 APR 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EILEEN B. O'HARA

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992) \*

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/29950

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-12, 14-16 and 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992) \*

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-12, 14-16 and 21, in so far as they are drawn to polynucleotide of clone HLICQ90 having the nucleotide sequence of SEQ ID NO:11, gene, vector, host cell, method of producing a protein and encoded protein having the amino acid sequence of SEQ ID NO:62.

Groups II-XLVII (2-47), each group consisting of claim(s) 1-12, 14-16 and 21, drawn to the next forty six polynucleotides of distinct cDNA clones and encoded proteins listed in Table 1, pages 115-121.

Groups XLVIII-XCIV (48-94), claims 13 and 23, in so far as they are drawn to antibodies and binding compounds to one of the forty seven proteins listed in Table 1.

Groups XCV-CXLI (95-141), claim 17, in so far as it is drawn to a method of treating a medical condition comprising administering to a mammalian subject one of the forty seven proteins listed in Table 1.

Groups CXLII-CLXXXVIII (142-188), claim 18, in so far as it is drawn to a method of diagnosing a pathological condition by determining the presence or absence of a mutation in one of the forty seven polynucleotides listed in Table 1.

Groups CLXXXIX-CCXXXV (189-235), claims 19 and 20, in so far as they are drawn to a method of diagnosing a pathological condition or a method for identifying a binding partner to one of the forty seven proteins listed in Table 1, by binding assay.

Groups CCXXXVI-CCLXXXII (236-282), claim 22, in so far as it is drawn to a method of identifying an activity in a biological assay using one of the forty seven polynucleotides of distinct cDNA clones listed in Table 1.

The inventions listed as Groups I-CCLXXXII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I corresponds to the first invention wherein the first product is the polynucleotide and the first method of using is the method of making the protein. Note there is no method of making the polynucleotide. The invention also includes the protein made. Each of groups II-XLVII does not share the same or corresponding special technical feature because each group is drawn to a different polynucleotide and encoded protein, and each of groups XLVIII-CCLXXXII does not share the same or corresponding special technical feature because each group is drawn to different compounds or methods of using the forty seven polynucleotides and encoded proteins. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1